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ABSTRACT 
 
This present thesis focuses on compounds related to the epidithiodiketopiperazine 
(ETP) family of natural products, their synthesis and biological effects. The domain of 
natural products has long been recognized as an invaluable source of lead structures for 
the discovery and development of novel therapeutic agents, with the motif being one 
example that has long been recognized for its potent biological effects which are 
directly related to the disulfide bridge at the central core. 
The first chapter provides a detailed analysis of the ETP family of natural products with 
both the monomeric and dimeric family members being described to provide an 
overview of this diverse family of compounds and their corresponding biological 
effects. The second section in this chapter highlights the various synthetic strategies 
adopted by a number of different research groups and attempts to classify these into the 
varying approaches towards the central core. Finally the section closes with a 
description of dimeric natural products and their biological effects in relation to the 
potent activity observed from the dimeric ETP congeners. 
The results of our own approach towards the ETP core are described in the third chapter 
which commences with the synthesis of disubstituted ETPs and expands towards our 
efforts in synthesizing their tri and tetrasubstituted counterparts. Efforts to extend this 
chemistry towards dimeric ETPs are also described and our successful routes towards 
these complex compounds are discussed. The following section of this chapter outlines 
the successful biological evaluation of the ETP compounds that were synthesised with 
relevance to their effects in a surrogate model of tuberculosis, cancer cells via inhibition 
of the hypoxia pathway and activity against the feline immunodeficiency virus. 
The final chapter provides a formal description of the experimental results and 
procedures with full characterisation of the data for each compound. 
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1.1 Epi-3,6-dithio-2,5-diketopiperazines Overview 
 
This present thesis is concerned with the synthesis and biological activity of compounds 
known as the epi-3,6-dithio-2,5-diketopiperazines (ETPs). As such, this introduction 
outlines the diversity of these compounds with the structures of the natural products as 
well as the synthetic approaches to both the core structures and the parent natural 
products. 
To date, the ETP core has been reported in over 120 natural products, comprising a 
minimum of 14 different sub-classes with minor modifications to the primary ETP core 
structure. The ETP core is characterised by a diketopiperazine ring bridged by two 
sulfur atoms at the three and six positions. Variation amongst the natural products 
occurs at the remaining four positions around the ring – at the two bridgehead carbon 
atoms and the amidic nitrogens as shown below (Figure 1).
1
 
 
Figure 1 – ETP core 
The large array of interest in these compounds stems from their diverse potent reported 
antibacterial, antiviral, antifungal and anticancer activities. Studies by a number of 
groups have confirmed that the biological activity shown by the ETP family is a result 
of the unique disulfide bridge.
1
 As a result of this unique structure and potent activity, 
the ETP family are attractive targets for chemical synthesis and consequential 
pharmacological analysis.
2
 In order to define the different sub-families of natural 
products containing the ETP core, they were grouped firstly by the presence of one or 
more epidithiol core and secondly from the structure and biosynthetic origin. 
Accordingly, the ETPs can be divided into main groups of monomeric and dimeric 
ETPs. By definition, monomeric ETPs clearly contain one epidithiodiketopiperazine 
moiety in their basic structure. The dimeric ETP family of compounds contain more 
than one epidithiodiketopiperazine moiety or include one ETP core with structural 
similarity to family congeners as the original group member. Dimeric ETPs contain 
more variation in the ETP core with both tri- and tetra-sulfide bridges reported in one of 
the diketopiperazine motifs.  
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1.1.1 Monomeric ETPs 
 
1.1.1.1 Gliotoxin and dehydrogliotoxin 
Gliotoxin (1) is perhaps the most extensively studied member of the ETP family as a 
result of its widely studied biological activity in a number of areas and presumably in 
addition, its commercial availability (Figure 2).
3
 It was first isolated in 1936 by 
Weindbling and Emerson 
4
 from the fungus Gliocladium fimbriatum. 
 
Figure 2 – Gliotoxin 
It was also subsequently isolated from other fungal sources, namely Aspergillus 
fumigatus, Trichoderma viride, Gliocladium spp., Penicillium spp. and Candida 
albicans.
5, 6, 7, 8, 9, 10 
The Penicillium species were found to produce not only gliotoxin 
(1) but also dehydrogliotoxin (2) (Figure 3).
11, 12
 The first elemental analysis of 
gliotoxin (1) was reported in 1944 which produced its empirical formula: 
C13H14O4N2S2.1/2H2O.
13
 After further studies from Johnson and Woodward 
14
 to 
elucidate the correct absolute configuration of gliotoxin (1) it was Beecham et al, 
15
 that 
first reported the S configuration of the alcohol on the 1,3-cyclohexadiene moiety and 
the R,R configuration of the two disulfide bridgehead carbons. However, it took a 
further three years till Benedetti et al 
16
 demonstrated that the proposed rigid structure of 
ETPs was in fact flexible from its X-ray structure, which raised further interest in this 
family of natural products. 
 
Figure 3 – Dehydrogliotoxin 
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The enormous range of studies behind the characterization of gliotoxin (1) can only be 
matched by the wide variety of reported biological properties that it exhibits. Initial 
studies showed potent bacteriostatic activity against Bacillus subtilis, 
17
 however, both 
gliotoxin (1) and its related analogue, dehydrogliotoxin (2), also demonstrated the 
ability to block viral RNA replication by reverse transcriptase inhibition in infected 
cells. 
18, 19
 Infection deterrence against Plasmodium falciparum 
20
 was also seen by these 
compounds which demonstrated the great biological potential as both an antiviral and 
antimalarial agent. Despite widespread interest in gliotoxin (1) as a possible panacea 
therapeutic, its toxicity and allergic side effects when used in high concentrations 
proved to dampen the initial enthusiasm.
18
 Studies on gliotoxin (1) were later broadened 
to an enzymatic level in the works of Waring which concluded that inhibition of both 
alcohol dehydrogenase and creatine kinase activity in mammals could be observed from 
analysis of the effects of this natural product.
21
 Further studies were carried out on 
gliotoxin (1) which found it to be apoptotic, necrotic and immunosuppressive to cells.
22, 
23
 These results were found to be fundamental to its activity during in vitro and in vivo 
studies, due to the discovery of its immunosuppressive effects that led to the discovery 
of its inactivation and consequent decrease of T and B cells in rats.
23
 Studies by Pahl et 
al 
24
 highlighted the inhibition of nuclear factor-kappa B by gliotoxin, which acts as a 
regulator for transcription of inflammatory related cytokines that display crucial 
importance in inflammatory bowel disease. However, non-specific necrotic response 
occured at concentrations above 10 µM resulting in osmotic swelling and plasma 
membrane destruction due to an increase in intracellular calcium concentration.
25, 26, 27, 
28, 29 
 Gliotoxin (1) also activates Bak, a pro-apoptotic gene belonging to the Bcl-2 class 
of proteins. Activation of this gene leads to generation of reactive oxygen species and 
apoptosis, particularly of immunomodulating cells.
30
 Redox cycling reactions generate 
reactive oxygen species that cause single and double strand breakages in DNA, 
ultimately resulting in an apoptotic outcome.
 3, 31 
 
1.1.1.2 Sporidesmin 
The sporidesmin group of ETP natural products was first characterized by Synge and 
White 
32, 33
 when sporidesmin A (3) (Figure 4) was isolated from the fungi 
Sporidesmium bakeri (current denomination: Phytomyces chartarum). In 1962 
Fridrichsons et al 
34
 reported the X-ray structure of the natural product proving the 
absolute configuration at the disulfide bridge carbons as R,R. 
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Figure 4 – Sporidemisn A 
Related compounds were isolated by Ronaldson 
35, 36, 37, 38 
and Shannon, 
39
 with 
sporidesmin B (4) isolated as a derivative of sporidesmin A (3). Sporidesmin H (5) and 
sporidesmin J (6) were isolated by Taylor and co-workers in 1978 
40
 in which the first 
was described as an analogue of the original sporidesmin with the inclusion of a 3-
chloroindole moiety and the second as a N
6
-desmethylsporidesmin derivative, 
respectively (Figure 5). 
 
Figure 5 – Sporidesmins B, H and J 
The importance of the sporidesmin group of natural products arises from a pathological 
state known as facial eczema which affects sheep in New Zealand.
33, 34
 This type of 
infection caused early hepatic dysfunction which led to the animal’s death.41, 42 
Interestingly literature reports by Smith et al 
43
 demonstrated that the use of oral zinc 
sulfate for a period of five days protected sheep from the effects of sporidesmin. These 
results were later adapted by Towers 
44
 who carried out a similar test using sporidesmin 
poisoned rats, where zinc sulfate was added to their diets demonstrating that it protected 
them against the fungal metabolite. These findings would later prove crucial when 
determining the mechanism of action associated with ETPs. Much like gliotoxin (1), 
sporidesmin A (3) was also found to inhibit mitogen stimulation of T lymphocytes 
which showed the immunomodulating capability of these compounds.
45
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1.1.1.3 Aranotin 
In 1968 Nagarajan et al 
46, 47, 48, 49
 and Moncrief 
50
 were the first to characterize the 
antiviral metabolites aranotin (7) and acetylaranotin (8) from Arachniotus aureus and 
the pentacyclic structures are shown below (Figure 6). 
 
Figure 6 – Aranotin and Acetylaranotin 
In the same year, Nagarajan and Neuss 
49, 51
 identified two new members of this family 
of natural products: apoaranotin (9) and acetylapoaranotin (10) (Figure 7). The 
structures of these two metabolites were quite peculiar since one of the terminal parts of 
the molecules contained the already reported dihydrooxepin ring, with the other formed 
by a cyclohexadiene moiety similar to gliotoxin’s (1) structure. 
 
Figure 7 – Apoaranotin and Acetylapoaranotin 
In 1970 De Long et al 
52
 described the antiviral activity of aranotin (7) and its analogues 
and hypothesised that the mode of action was associated with inhibition of virus-
induced RNA-dependent RNA polymerase. In the same year Ho and co-workers 
53
 
assigned the antiviral action of these compounds to cellular DNA-dependent rather than 
viral RNA-dependent RNA polymerase. Another important conclusion from the same 
authors was acknowledgment that the reduced form of aranotin lacking the sulfur bridge 
was completely inactive. This important report indicated that the disulfide bond was 
essential for its inhibitory activity. Trown renamed acetylaranotin (8) to LL-S88α in 
1970 
54
 after isolating the metabolite from a different source, Aspergillus terreus. LL-
S88α (aranotin’s 5-acetate analogue) and showed that it exhibited antiviral properties 
with specific inhibition of viral RNA replication. In 1997 Hegde et al 
55
 identified SCH 
64874 (11) from an unknown source of fungi compound (Figure 8). The core structure 
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was identical to aranotin (7) and this new compound also showed anticancer properties. 
However, whilst the ester group stereochemistry was not assigned by the authors further 
studies on this sub-class of compounds have not been reported till date. 
 
Figure 8 – SCH 64874 
1.1.1.4 Emethallicin 
Kawahara et al 
56, 57
 isolated and characterized the emethallicin family of compounds 
from Emericella heterothallica which are structurally similar to the aranotin family of 
natural products. Amongst the reported examples, emethallicin A (12), E (13) and F 
(14) contain the dithiodiketopiperazine moiety (Figure 9).
58
 
 
Figure 9 – Emethallicins A, E and F 
These compounds were shown to have a potent anti-allergic effects from their inhibitory 
activity on histamine release.
59
 In 1995, Ueno et al 
60
 demonstrated that these same 
molecules could also induce apoptosis in cancer cell lines. 
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1.1.1.5 Epicorazine 
Baute 
61, 62
 and Deffieux 
63, 62
 were the first to identify two members from the 
epicorazine family of natural products: epicorazine A (15) and B (16) (Figure 10); 
isolated from the fungi Epicoccum nigrum. Later, in the works of Mallea, 
64
 epicorazine 
B (16) was also identified from a different species of fungi, Epicoccum purpurascens. 
More recently, Epicorazine A (15) was also found to be produced by Capnodium sp.
65
 
 
Figure 10 – Epicorazines A and B 
Studies by Deffieux defined the R,R configuration of the disulfide bridgehead carbons 
and the authors also concluded that the source of derivatization comes from the 
oxygenated indole moieties.
66, 67
 X-ray models showed that the only difference between 
these two epicorazines arises from the stereochemistry of one ring junction as can be 
seen above.
68
 The same author also reported the antibacterial activity of these molecules 
against Staphylococcus aureus.
62
 In 2001, Dornberger and co-workers 
69
 isolated 
epicorazine C (17) (Figure 11) as well as the other two already known epicorazines A 
(15) and B (16) from Stereum hirsutum fungi. This new compound was found to be 
active against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-
resistant Enterococcus faecalis (VREF) and Candida albicans. Epicorazine C (17) was 
later isolated by Lindequist et al 
70
 in cultures of the fungi Podaxis pistillaris. 
 
Figure 11 – Epicorazine C 
1.1.1.6 Hyalodendrin 
In 1973 Strunz et al 
71
 isolated hyalodendrin (18) (Figure 12) from the Hyalodendron 
sp. fungus which is perhaps the simplest structural member of the ETP family. The 
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same author defined the absolute configuration of the disulfide bridgehead carbons as 
S,S.
72, 73
 Hyalodendrin (18) has been studied for its antifungal and antibacterial activity 
in a number of models and has been shown to inhibit Staphylococcus pyogenes, 
Klebsiella pneumoniae and Candida albicans with 12.5 µg/mL, 50.0 µg/mL and 25.0 
µg/mL MIC’s, respectively.74, 75 
 
Figure 12 – Hyalodendrin 
1.1.1.7 Scabrosin 
In 1978, Begg et al 
76
 isolated several compounds from Xanthoparmelia scabrosa which 
they named scabrosin esters. Compounds (19) to (22) illustrate the examples of this 
group of natural products with differences lying in the ester alkyl substituents for each 
member of this ETP sub-family of compounds, as shown below (Figure 13).   
 
Figure 13 - Scabrosins 
These scabrosin derivatives previously isolated from Parmelia pulla by Culberson 
77
 
were reanalysed some years after their discovery by Helix and co-workers 
76,78
 who had 
also catalogued another member of this family, scabrosin butyrate hexanoate (23) 
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(Figure 14). These authors and others, were also responsible for establishing the potent 
cytotoxic activity against cancer lines that these products displayed.
76,79,80
 
 
Figure 14 – Scabrosin butyrate hexanoate 
In 1998 Williams et al 
81
 using the lichen Usnea sp. were able to isolate two identical 
products that shared the same structural complexity displayed by the scabrosins family. 
These were called Ambewelamides A (24) and B (25) (Figure 15) and both molecules 
possessed analogous properties exhibited by their former congeners.
82
 
 
Figure 15 – Ambewelamides’ A and B 
In 2004, studies by Chai 
83
 re-iterated the importance of the disulfide bridge in the 
biological activities of this class of natural products. They were clearly able to obviate 
the importance of the epoxide rings on the scabrosin esters anticancer activity. 
1.1.1.8 Sirodesmin 
In 1974, Broadbent et al 
84
 isolated sirodesmins from the Sirodesmium diversum fungi, 
which they described as being antiviral agents against rhinoviruses. Amongst these 
extracts, three compounds were found to incorporate the dithiodiketopiperazine moiety: 
sirodesmin A (26) and G (27). The difference between these two compounds lies in the 
stereochemistry of the methyl groups in the four position of the dyhidrofuran-one ring, 
as shown below (Figure 16). 
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Figure 16 – Sirodesmins A and G 
In 1977, Curtis and co-workers 
85
 characterised these compounds, establishing the 
configuration of the disulfide bridgehead carbons as R,R. In the same year, Ferezou et al 
86
 reported sirodesmin G (27) as sirodesmin PL. The name relates to the source of 
isolation, the fungi Phoma lingam.
87
 The same group also isolated deacetylsirodesmin 
PL (28) shown below, which is a biological precursor of sirodesmin E (Figure 17). 
 
Figure 17 – Deacetylsirodesmin PL 
Sirodesmins were also found in isolates of Leptosphaeria maculans and tests developed 
by Rouxel et al 
88
 in the early 1990s unveiled important information regarding their 
infectious role. The addition of zinc sulfide to Leptosphaeria maculans growth medium 
decreased the production of these toxic metabolites by 75%.
89
 Other studies by the same 
group reported the inhibition of RNA polymerase activity as an outcome of the 
antimetabolic activity induced by these compounds.
88
 Other sirodesmins were also 
isolated from the fungi Microsphaeropsis sp. by Funabashi and co-workers.
90
 These 
compounds TAN-1496 A (29), TAN-1496 B (identical to sirodesmin A (26)) and TAN-
1496 D (deacetylsirodesmin A derivative (30)) (Figure 18) were found to have 
anticancer activity suppressing tumour growth in various cell lines. 
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Figure 18 – TAN-1496 A and D 
1.1.1.9 Dithiosilvatin 
In 1987, Kawai et al 
56
 isolated dithiosilvatin (31) (Figure 19) from Aspergillus 
silvaticus. Its structural backbone led the authors to conclude that the biochemical 
synthetic pathway would have glycine, tyrosine and phenylalanine as intermediates in 
its biosynthetic origins. 
 
Figure 19 – Dithiosilvatin 
1.1.1.10 Emestrin 
Isolated from Emericella striata in 1985, emestrin (32) (Figure 20) was described as a 
macrocycle which incorporates a dithiodiketopiperazine motif in its core structure.
91
 
The configuration of both disulfide bridgehead carbons was identified as R,R.
92
 
 
Figure 20 – Emestrin 
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Later, emestrin (32) was also isolated from different sources: Emericella quadrilineata, 
Emericella foveolata, Emericella acristata and Emericella parvathecia.
92, 93, 94
 Works 
by Kawai on the cytotoxic effects of emestrin (32) showed that it inhibited ATP 
synthesis in mitochondria, restricting the respiratory process.
93
 However, it also showed 
potent antifungal as well as anticancer activity.
92, 60
 In 2004, Kanda et al 
95
 isolated three 
new compounds from Cladorrhinum sp. which contained the identical skeleton structure 
as emestrin (32): MPC1001 (33), MPC1001 B (34) and MPC1001 C (35) (Figure 21). 
 
Figure 21 – MPCs 1001 
These compounds proved to have highly potent anticancer activity and till now, are 
considered as important research models for both chemical and biological studies.
96, 97, 
98, 99 
1.1.1.11 Rostratin 
In 2004, Fenical et al 
100
 isolated four new examples of ETP containing molecules from 
Exserohilum rostratum which were named rostratins. Rostratins A (36), B (37), C (38) 
and D (39) (Figure 22) all demonstrated potent in vitro cytotoxicity against human 
colon carcinoma cell lines with IC50’s of 8.50, 1.90, 0.76, and 16.5 g/mL, respectively. 
In terms of absolute configuration the disulfide bridgehead carbons were reported as R, 
R’. 
Bruno Sil                                                                                                                  Introduction 
 
42 
 
 
Figure 22 – Rostratins A, B, C and D 
1.1.1.12 Epicoccin 
In 2007, Zhang et al 
101
 isolated a new class of natural products from Epicoccum nigrum 
which were named epicoccins. From this diverse group of products, one contained the 
epidithiodiketopiperazine moiety – epicoccin T (40) (Figure 23). This compound 
showed similar structural properties as rostratins A (36) and B (37) in terms of its 
absolute configuration.
102, 103
 
 
Figure 23 – Epicoccin T 
1.1.1.13 Glionitrin 
In 2009, Park et al 
104
 were able to isolate an unusual nitro-aromatic compound similar 
to gliotoxin (1) from the Sphingomonas bacterial strain KMK-001 and Aspergillus 
fumigatus fungal strain KMC-901, which was named Glionitrin A (41) (Figure 24). 
Studies proved the S,S configuration of the two disulfide bridgehead carbons. 
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Figure 24 – Glionitrin A 
The same group reported that the biological properties of this compound included 
antibiotic activity against methicillin-resistant Staphylococcus aureus (MRSA) and in 
vitro submicromolar cytotoxicity activity against four human cancer cell lines: HCT-
116, A549, AGS, and DU145.
105, 106
 
 
1.1.2 Dimeric ETPs 
 
1.1.2.1 Chaetocin 
In the early 1970’, Hauser et al 107, 108 isolated both chaetocin A (42) and 11α,11’α-
dihydroxychaetocin (43) from Chaetomiun minutum (Figure 25). Studies by Weber 
109
 
showed that the two disulfide bridgehead carbons configuration was S,S. Later that 
decade, chaetocin A (42) was also isolated from Chaetomiun thielavioideum.
110
 
 
Figure 25 – Chaetocin A and 11α,11’α-Dihydroxychaetocin 
In 1988, Saito et al 
111
 isolated chetocin B (44) from one of the Chaetomiun subspecies, 
Chaetomiun virescens thielavioideum (Figure 26). This family of compounds was 
widely studied for their biological activity that included antibacterial, antiviral and 
currently their more important anticancer activity.
112, 113, 114, 115, 116
 As anticarcinogenic 
agents, chetocins were proven to not only act as possible therapeutic agents against 
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cancer, but also in enviorments where oxygen levels are low such as seen in hypoxic 
cancer cells.
117
 
 
Figure 26 – Chetocin B 
1.1.2.2 Chaetomin 
In 1944, Bugie and Waksman 
118, 119
 isolated the first known natural product with two 
epidithiodiketopiperazine moieties present in the same structure from Chaetomium 
cochliodes and they named this compound chaetomin (45) (Figure 27). It was later 
renamed chetomin (45) 
120
 and this compound was found to have a related origin from 
the Chaetomium species, Chaetomium globosum.
121
 
 
Figure 27 – Chaetomin 
Chetomin (45) was shown to have potent antibacterial activity against Mycobacterium 
tuberculosis,
122
 as well as antiviral activity against the hepatitis C virus in rat models 
123
 
and anticancer activity.
124, 125
 Studies by Spirig et al demonstrated that chetomin (45) 
can also induce vasodilatation in in vitro human monocyte stimulation models.
 126
 
1.1.2.3 Chetracin 
In 2012, Zhu et al 
127
 characterised the only known example to date of the chetracin 
group of natural products with a trisulfide and disulfide bridged ETP in its structure and 
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it was named chetracin B (46) as shown below (Figure 28). It is structurally related to 
the chaetocin family, with an additional OH group. 
 
Figure 28 – Chetracin B 
Isolated from Oidiodendron truncatum, chetracin B (46) displayed potent cytotoxicity 
against cancer with IC50’s ranging from 0.003 µM for Bel-7402 cell lines to 0.028 µM 
for A2780 cell lines. 
1.1.2.4 Leptosin 
In 1994, Takahashi et al 
128
 were able to isolate several examples of the leptosin class of 
ETP containing natural products from Leptosphaeria sp.. Leptosins A (47), B (48), C 
(49) and D (50) (Figure 29) displayed antitumor activity for P-388 cancer cell line with 
activities ranging from 1.75 mg/mL for leptosin C (49) to 86.0 mg/mL for leptosin D 
(50).
129, 130
 
 
Figure 29 – Leptosins A, B, C and D 
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The same group was able to characterise two new compounds similar in structure to 
leptosins A (47) and B (48) that incorporated at least one epidithiodiketopiperazine 
moiety – leptosins G2 (51) and H (52) (Figure 30).
131
 
 
Figure 30 – Leptosins G2 and H 
In 1995, Takahashi and co-workers 
132
 introduced three new members of the leptosin 
family of natural products – leptosins K (53), K1 (54) and K2 (55) (Figure 31), in which 
leptosin K (53) was the only example that included two ETP cores. All these isolates 
were demonstrated to be cytotoxic metabolites. 
 
Figure 31 – Leptosins K, K1 and K2 
The leptosin sub-family of ETP natural products contain perhaps the largest number of 
members and to date, the last isolated leptosin from the Leptosphaeria species that 
contains an epidithiol bridged moiety is leptosin M1 (56) (Figure 32),
133
 which was 
shown to have potent anticancer activity. 
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Figure 32 – Leptosin M1 
1.1.2.5 Melinacidin 
Reusser 
134
 described the isolation of a mixture of compounds from Acrostalagmus 
cinnabarinus var. melinacidinus with antibacterial activity in 1968 which was named 
melinacidin. Later in 1977, Argoudelis 
135, 136, 137
 described the structures of 
melinacidins II (57) and III (58) as related forms of chaetocin A (42) and verticillins; 
and melinacidin IV (59) was considered to be identical to 11α,11’α-dihydroxychaetocin 
(43) (Figure 33). 
 
Figure 33 – Melinacidins II, III and IV 
Melinacidin III (58) and IV (59) were later isolated from Corollospora pulchella by 
Furuya et al.
138
 In the works of Feng,
139
 melinacidin IV (59) was also found in the 
isolates of Cladobotryum sp. 
1.1.2.6 Verticillin 
Verticillin A (60) (Figure 34) was isolated from Verticillium dahlia by Minato et al 
140
 
in 1970 and the authors demonstrated that this metabolite functioned as an antibacterial 
agent. In 2011, Liu 
141
 concluded that this compound was biologically active against 
different resistant human carcinoma cells with IC50’s ranging from 62 nM for HepG2 
hepatoma cell lines to 122 nM for HeLa cell cultures. 
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Figure 34 – Verticillin A 
Minato isolated two new compounds from this family of natural products – verticillins 
B (61) and C (62) (Figure 35).
142
 In contrast to verticillins A (60) and B (61) that 
contain two epidithiodiketopiperazines, verticillin C (62) possesses one 
epitrithiodiketopiperazine and one epidithiodiketopiperazine core. All verticillins were 
shown to possess antibacterial and anticancer activity.
142, 143
 
 
Figure 35 – Verticillins B and C 
In 1995, Chu et al 
144
 isolated two new members of this group of molecules, Sch52900 
(63) and Sch52901 (64) from Gliocladium sp. (Figure 36), as well as verticillin A (60), 
and reported that all compounds isolated possessed antitumorogenic activity when 
tested in vitro.
145
 
 
Figure 36 – Sch52900 and Sch52901 
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A marine isolate of the Penicillium sp. by Byeng and co-workers 
146
 led to the 
identification of two new compounds with identical core structures to verticillin A (60) 
– 11,11'-dideoxyverticillin A (65) and 11'-deoxyverticillin A (66) (Figure 37). 11,11'-
Dideoxyverticillin A (65) was later isolated from the herb Shiraia bambusicola.
147
 Both 
compounds demonstrated in vitro cytotoxicity against colon and human breast 
carcinoma cell lines.
146, 147
 
 
Figure 37 – 11,11'-Dideoxyverticillin A and 11'-Deoxyverticillin A 
From the same family, Joshi et al 
148
 isolated verticillins D (67), E (68) and F (69) 
(Figure 38) from the mycoparasite Gliocladium catenulatum. Stereochemistry for both 
the alcohol (67 and 69) and acetate groups (68 and 69) was not described by the authors. 
 
Figure 38 – Verticillins D, E and F 
A different species of the previous parasite isolates – Gliocladium roseum – by Zhang et 
al 
101
 led to the characterisation of three new examples of structurally related verticillin 
analogues: gliocladines A (70), B (71) and C (72) (Figure 39). These compounds 
showed antiparasitic activity against Caenorhabditis elegans and Panagrellus 
redivivus.
149, 
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Figure 39 – Gliocladines A, B and C 
Kim et al 
150
 isolated three new compounds from Bionectra byssicola with structural 
similarity to the verticillin group of natural products: bionectins A (73), B (74) and 
verticillin G (75) (Figure 40). These compounds were found to have potent activity 
against methicillin-resistant Staphylococcus aureus (MRSA) as well as the quinolone-
resistant species.
150, 151
  
 
Figure 40 – Bionectins A, B and G 
In 2011, Schenke et al contested the origin of the verticillin group of compounds by 
presenting data that suggested that verticillin A (60) is not produced by the Verticillium 
species but possibly from Gliocladium roseum, a known mycoparasite of the 
Verticillium sp.
152
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1.2 Synthetic approaches towards the epi-3,6-dithio-2,5-
diketopiperazine core and related natural products 
 
Despite their structural complexity, the ETP family of compounds all have a common 
origin, as amino acids have clearly been identified as their biosynthetic precursors, with 
cyclic dipeptides suggested as obvious reaction intermediates from radiolabelling 
experiments.
153, 154
 These biosynthetic pathways have clearly inspired ETPs synthetic 
approaches using amino acids as starting points for the synthetic process.
154
 Following 
the initial works by Trown in the late 1960’s,155 there have been a number of advances 
made to access either natural or synthetic ETPs using several different strategies as 
outlined below (Scheme 1).
156
 Incorporation of sulfur into a pre-formed 
diketopiperazine core or the introduction of sulfur in an initial pathway allows a 
classification of the numerous approaches. Rastetter and Williams 
157
 also highlighted 
the relevance and innovation that the work around the ETP core can bring to chemistry. 
Many authors attempted to find the best pathway to achieve a facile method towards the 
ETP core and synthesise structural analogues with the various approaches to this shown 
below (Scheme 1). 
 
Scheme 1 – Schematic representation of the different approaches used to achieve the ETP core including the 
corresponding authors 
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1.2.1 Trown’s approach 
In 1968 Trown et al 
54, 155, 158, 159, 160, 161
 was the first group that clearly introduced a 
synthetic methodology to access epi-3,6-dithio-diketopiperazines using the nucleophilic 
propensity of sulfur. According to their method, sarcosine anhydride (76) – a dimethyl 
substituted 2,5-piperazinedione – was first dibrominated at the 3- and 6- positions to 
form the 3,6-dibromo-1,4-dimethylpiperazine-2,5-dione intermediate (77). Treatment 
with potassium thioacetate led to the displacement of both bromine atoms to yield the 
resulting dithioacetate (78). Trown and co-workers already highlighted a concern at this 
stage of the synthesis which was to try to obtain the maximum yield of the cis isomer 
since it was the only one that could undergo the subsequent transformation to the 
disulfide. The next step involved the acidic hydrolysis of (78) in ethanol to remove the 
acetate groups giving compound (79). The disulfide bridged compound (1R,4R)-6,8-
dimethyl-2,3-dithiabicyclo[2.2.2]octane-5,7-dione (80) was achieved after oxidation 
with 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) (Scheme 2).162 
 
Scheme 2 – Trown’s approach 
1.2.2 Svokos’ approach 
In 1970 Svokos’ et al 163, 164 patented their approach to the ETP core. The first step of 
the synthesis followed the works of Meyer 
165
 and Halberkann 
166
 to achieve the 
functionalized 1,4-diphenyl-2,5-piperazinedione (82) from dimerization of the initial 
substituted 4-phenylamino acetic acid (81) at high temperatures followed by 
bromination in positions 3- and 6- giving (83) (Scheme 3). 
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Scheme 3 – Svoko’s approach (1) 
Treatment of (83) with thioacetic acid and sodium methoxide in methanol yielded the 
thiol intermediate in both the cis (85) and trans (84) isomeric forms. The cis (85) isomer 
was directly converted to (87) by treatment with hydroxylamine; whereas the trans 
isomer (84) had to be converted to the dithiol form (86) using hydrazine hydrate and 
was later oxidized with potassium ferricyanide to give the desired ETP (87) (Scheme 
4).
163
 
 
Scheme 4 - Svoko’s approach (2) 
1.2.3 Schmidt’s approach 
In 1971 Schmidt et al 
167, 168
 achieved an ETP synthesis by direct introduction of sulfur 
into the 2,5-piperazine ring using the same nucleophilic substitution principle as 
Trown.
155
 Treatment of 3,6-dibromo-1,4-dimethyl-2,5-piperazinedione with sodium 
tetrasulfide led to the stable compound (80). The epi-tetrasulfide (88) was then reduced 
using sodium tetrahydridoborate to the cis-dithiol compound (79) which could be 
dehydrogenated in a two-phase system of dithiol in chloroform / aqueous potassium 
iodide solution giving compound (80).
169, 170
 Schmidt developed this new method of 
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oxidation as they were unable to reproduce the system previously developed by Trown 
using Ellmans’s reagent.155 
 
Scheme 5 – Schmidt’s approach (1) 
Another method reported by Schmidt was nucleophilic introduction of sulfur using 
sulfones and hydroxy derivatives. The synthesis of epidithiopropyl-proline anhydride 
(94) involved the oxidation of compound (89) affording the corresponding 
hydroperoxide (90) which could be reduced to the corresponding hydroxide (91) using 
sodium sulfite and hydrogenation of (91) gave cis compound (92). Displacement of the 
hydroxides using zinc chloride and attack by hydrogen sulfide gave compound (93) that 
after oxidation led to the desired product (94) (Scheme 6).
167, 171, 172, 173, 174
 
 
Scheme 6 – Schmidt’s approach (2) 
Using the same principles as before, octahydrodipyrrolo[1,2-a:1',2'-d]pyrazine-5,10-
dione (95) was oxidised by lead tetraacetate to give intermediate (96) that led to the 
known compound (92) using dilute aqueous acid (Scheme 7). These new approaches 
were important as they introduced the ability to interconvert mixtures of isomeric 
intermediates to racemic ETPs.
172, 173, 175, 174
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Scheme 7 – Schmidt’s approach (3) 
However, despite these advances, this new methodology never led to highly 
functionalised ETPs. An alternative strategy developed by Schmidt was to incorporate 
both sulfurs as electrophiles into a 2,5-diketopiperazine scaffold using a strong base.
172, 
173, 175, 174
 Deprotonation of dione (95) with sodamide or lithium diisopropylamide 
(LDA) afforded anion (97). The reaction of elemental sulfur with (97) gave the 
polysulfide thiolate anion (98), thus repeating these steps led to (99) forming the 
polysulfide bridged product. Compound (100) was first reduced and further oxidized to 
give the disulfide bridged product (94) (Scheme 8). 
 
Scheme 8 – Schmidt’s approach (4) 
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1.2.4 Hino’s approach 
In 1971 Hino et al 
176, 177
 described a new way to achieve the ETP ring system in two 
steps. First, diethyl N-amino malonate (101) was heated to high temperatures to yield 
compound (102). Secondly, the diethoxy carbonyl precursor (102) was treated with a 
strong base to form the dicarbanion which, when treated with either disulfur dichloride 
or sulfur dichloride, gave ETP (103) (Scheme 9). 
 
Scheme 9 – Hino’s approach (1) 
Similar C-S bond formation was studied by Hino and co-workers using dicarboxylated 
salts.
178
 Hydrolysis of the already known (102) using potassium hydroxide led to the 
corresponding potassium salt (104) that was subsequently reacted with disulfur 
dichloride to yield the desired ETP (80) (Scheme 10). Intriguingly, the group noted that 
the decarboxylation process did not occur in boiling dioxane unless disulfur dichloride 
was added, indicating that the sulfur containing reactant was involved in the process. 
 
Scheme 10 – Hino’s approach (2) 
1.2.5 Kishi’s approach 
Kishi et al 
179
 in 1973 developed two methods in order to synthesise both natural and 
synthetic ETP containing products: one was to introduce a protected disulfide bridge at 
an early stage; the second complemented the other end of the synthesis introducing the 
disulfide bridge at a later stage. 
 
Bruno Sil                                                                                                                  Introduction 
 
57 
 
The starting and key point of the first synthetic route was to introduce a protected 
precursor of the ETP ring; this would enable functionalization of both 3- and 6- 
positions of the 3,6-dithio-2,5-diketopiperazine using carbanion chemistry.
179, 180
 The 
resulting intermediate would become useful since it was stable under acidic, basic or 
reductive conditions. In the first step of the proposed synthetic pathway it was 
interesting to note that both cis- and trans-dithiol materials (105) would react with para-
anisaldehyde in the presence of boron trifluoride etherate to produce the same thioacetal 
intermediate (106).
181
 Deprotonation on the bridge-head position of (106) was achieved 
using a strong base such as n-butyllithium (nBuLi) or LDA giving the carbanion. The 
next step involved alkylation using primary halides, acid halides and aldehydes to give 
mono-substituted thioacetals (107) and a small amount of disubstituted thioacetals. The 
disubstituted ETP precursor (108) could be obtained if the same procedure of 
deprotonation / alkylation was conducted once more under the same conditions. Kishi 
explained the need of this two-step reaction due to the differing acidities that both 
hydrogens on the 3- and 6- positions displayed depending on the position of the 
anisaldehyde residue.
179
 The disulfide was regenerated in two steps: reaction of the 
thioacetal with meta-chloroperbenzoic acid (m-CPBA) to give a sulfoxide intermediate 
followed by acid treatment, using Lewis or protic acids, leading to the ETP (109) 
(Scheme 11). According to Kishi, the para-methoxybenzene ring was proven to be of 
crucial importance since the cleavage of the sulfoxide did not take place using 
thioacetals derived from formaldehyde, acetaldehyde or benzaldehyde.
179
    
 
Scheme 11 – Kishi’s approach (1) 
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Although this synthetic route proved to be very useful to achieve a large variety of 
compounds, Kishi faced two problems: the short half-life of the bridgehead carbanion 
and the reaction conditions for acid cleavage of the thioacetal monosulfoxide (108). In 
order to overcome these potential problems, another methodology was developed in 
which the key intermediate, a dimethoxymethylthio compound (110), was prepared 
from (105) using potassium t-butoxide and chloromethyl methyl ether. This new 
compound (110) was functionalised in two separate stages since during alkylation 
studies, a difference in reactivity between both dicarbanion and carbanion formed from 
the monoalkylated derivative (111) was observed. When treated with a strong base, the 
cis-monoalkylated piperazinedione compound (111) was obtained in high yields. In 
light of these results, two approaches were used, based on the differences in reactivity 
associated with the alkylating agents to achieve unsymmetrically disubstituted 
dimethoxymethylthio compounds (112); or alkylation of the mono-substituted 
derivative (111) to give compound (112). After consecutive alkylation, compound (112) 
was converted to the corresponding cis-dithiol using boron trichloride which was then 
oxidized using iodine to yield the ETP (109) (Scheme 12).
182
  
 
Scheme 12 – Kishi’s approach (2) 
Using these two different synthetic pathways, Kishi and co-workers were able to 
synthesise natural products from the ETP family. Their accomplishments are described 
below. 
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1.2.5.1 Hyalodendrin 
Using the dimethoxymethylthio derivative (110), Kishi 
182
 was able to use different 
alkylating agents reactivity to form the unsymmetrical disubstituted compound (113). 
This was followed by cis-dithiol formation and oxidation to give a racemic mixture of 
hyalodendrin (18) (Scheme 13). 
 
Scheme 13 – Kishi’s synthesis of hyalodendrin 
In 1974 using thioacetal intermediate (106), Strunz and Kakushima 
73
 were able to 
synthesise a racemic mixture of hyalodendrin.
71, 72, 74
 Promoting carbanion formation 
using n-BuLi and treatment with chloromethyl methyl ether gave (113) which yielded 
(114) after alkylation with benzyl bromide. The resultant product was then treated with 
m-chloroperbenzoic acid and perchloric acid rendering (115). The last step involved 
reduction of the methyl ether to the corresponding alcohol using boron trichloride to 
give the desired racemic mixture of ETP (18) (Scheme 14). 
 
Scheme 14 – Strunz and Kakushima’s synthesis of hyalodendrin 
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1.2.5.2 Dehydrogliotoxin 
Using the previously described thioacetal intermediate chemistry, Kishi et al were able 
to synthesise (2).
179, 182, 183, 184
 The chosen starting material for this experiment was the 
piperazinedione (118) achieved by coupling 2-iodo-3-methoxybenzoic acid (117) to 
glycine-sarcosine anhydride (116) in the presence of cuprous iodide and potassium 
carbonate. The subsequent product of this reaction was treated with diazomethane to 
yield the esterified compound (118). Taking the previous product (118) in carbon 
tetrachloride and reacting it with N-bromosuccinimide and benzoyl peroxide gave 
Trown’s brominated intermediate analogue (119). Treatment with potassium thioacetate 
and displacement of both bromine atoms gave dithioacetate (120) in a 1:1 cis/trans 
mixture. Acid hydrolysis followed by treatment with para-anisaldehyde and boron 
trifluoride etharate gave thioacetals (121) in a 1:1 diastereomeric mixture (Scheme 15). 
 
Scheme 15 – Kishi’s synthesis of dehydrogliotoxin (1) 
The ester was then converted to the alcohol (122) using sodium hydroxide followed by 
triethylamine and ethyl chloroformate treatment. A methanolic solution of sodium 
borohydride was then added to form the desired compound (122). This thioacetal 
alcohol (122) was then converted to the corresponding thioacetal chloride (123) by 
treatment with triethylamine and methanesulfonylchloride. Conversion of this 
intermediate with lithium chloride gave the desired compound (123) in 89% yield 
(Scheme 16).
183
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Scheme 16 – Kishi’s synthesis of dehydrogliotoxin (2) 
The diastereomeric chloride (123) was regiospecifically metallated at the bridgehead 
position using phenyllithium to yield dihydroindole moiety (124) which was converted 
to (125) using the carbanion resulting from the addition of further phenyllithium and 
benzyl chloromethylether. The dehydrogliotoxin thioacetal (126) was obtained using 
boron trichloride and the product of this reaction treated with m-chloroperbenzoic acid 
and perchloric acid to render the racemic mixture of dehydrogliotoxin (2) (Scheme 
17).
183
  
 
Scheme 17 – Kishi’s synthesis of dehydrogliotoxin (3) 
1.2.5.3 Gliotoxin 
For the synthesis of gliotoxin (1), Kishi et al 
179, 182, 185 
commenced with the protection 
of known glycine-sarcosine anhydride (116) with a methoxymethyl group, using a 
strong base and chloromethyl methyl ether. Compound (127) was converted to the 
diastereomeric mixture of dithioacetates (128), followed by conversion to the 
corresponding methoxymethyl thioacetal (129) to form intermediate (130). The 
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methoxymethyl group was removed using a 1:1 ethanolic-acid mixture to form (131) 
and (132) (Scheme 18). 
 
Scheme 18 – Kishi’s synthesis of gliotoxin (1) 
Isomer (132) was found to be more reactive to N-benzoylation than (131) enabling them 
to be separated by silica gel chromatography. Treatment of the preferred diastereomer 
(131) with 4-carbo-t-butoxyoxepin (134) and Triton B yielded a mixture of Michael 
adducts (135 and 136). This reaction was found to be solvent dependent since the 
preferred configuration of product (136) could be achieved in a better ratio using 
dimethyl sulfoxide instead of dichloromethane as a solvent (Scheme 19).
179, 185
 
 
Scheme 19 – Kishi’s synthesis of gliotoxin (2) 
Compound (136) was subsequently treated with base and acetic anhydride to give 
acetate (137) followed by carboxylic acid formation using trifluoroacetic acid. The 
resultant product (138) was converted to the anhydride (139) by base and ethyl 
chloroformate treatment and further reduced to the alcohol (140) using sodium 
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borohydride. Mesylation and chlorination yielded the chloride acetate (141), which was 
reduced to chloride alcohol (142) on treatment with sodium methoxide (Scheme 20).
185
 
 
Scheme 20 – Kishi’s synthesis of gliotoxin (3) 
The decisive step that involved alkylation-cyclization of (142) was skilfully achieved by 
addition of a strong base and benzyl chloromethyl ether to give the desired product 
(143). The final steps of this synthesis are equivalent to the described route that 
achieved dehydrogliotoxin (2),
183
 with benzyl ether cleavage to give (144) followed by 
epidithiol formation that rendered racemic gliotoxin (1) (Scheme 21). 
 
Scheme 21 – Kishi’s synthesis of gliotoxin (4) 
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After separation of both isomeric forms of (131) and (132), Kishi and co-workers were 
able to synthesise optically active gliotoxin (1).
179, 182, 184, 185
 Compound (132) was 
recovered by exposing the N-benzoyl thioacetal (133) through treatment with ammonia 
solution. Thioacetal ureas (145 and 147) were obtained from compound (132) using α-(-
)-methylbenzyl isocyanate. The two diastereomers were separated by silica gel 
chromatography and the resolving agent removed by pyrolysis, yielding enantiomers 
(146) and (148) (Scheme 22). 
 
Scheme 22 – Kishi’s synthesis of gliotoxin (5) 
Use of the desired optically active thioacetal (146) by Kishi as starting material and the 
previously established synthetic route, enabled them to obtain optically active gliotoxin 
(1) as shown below (Scheme 23). 
 
Scheme 23 – Kishi’s synthesis of gliotoxin (6) 
1.2.5.4 Sporidesmin A 
Following the synthesis of gliotoxin (1),
185
 Kishi et al turned their attention to the total 
synthesis of sporidesmin A (3).
179, 186, 187
 This involved a thioacetal precursor (153) that, 
after treatment with the indole moiety (158), would give desired compound (159). 
Thioacetal intermediate synthesis started by treatment of 1,6-dimethylpiperazine-2,5-
dione (149) with base and chloromethyl methyl ether to give (150). Bromination / 
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dehydrobromination followed to give compound (151) and thioacetate formation 
afforded intermediate (152). The thioacetate was then transformed into the thioacetal 
(153) using a different method from the one described before since it used a trithiane 
derivative of p-anisaldehyde to form a syn- and anti- mixture of (153) to the 
anisaldehyde and methoxymethyl residues, respectively (Scheme 24). 
 
Scheme 24 – Kishi’s synthesis of sporidesmin A (1) 
6,7-Dimethoxyoxindole (154) chlorination was the first step in the indole moiety 
synthesis. This compound (155) was then N-methylated using methyl iodide in the 
presence of a strong base and reduced using diisobutylaluminium hydride (DIBAL) to 
give (156). Treatment of (156) with oxalyl chloride afforded the oxamic acid chloride 
(157) that when submitted to high temperatures yielded (158) (Scheme 25).
186
 
 
Scheme 25 – Kishi’s synthesis of sporidesmin A (2) 
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The next step in the synthesis gave the carbanion derived from (153) using a strong 
base. Alkylation in the presence of pre-formed acid chloride (158) gave a syn / anti 
mixture of (159). Acidic treatment afforded compounds (160) and (161) that were 
separated using preparative thin layer chromatography (TLC). Ketone (160) was 
stereoselectively reduced using DIBAL yielding alcohol (162) (Scheme 26). 
 
Scheme 26 – Kishi’s synthesis of sporidesmin A (3) 
Alcohol (162) was oxidized using acetic anhydride in a basic environment to give (163) 
that after treatment with iodosobenzene diacetate and dimethyl sulfide, yielded the 
cyclized diacetate (164). Using the previously described synthetic route (sodium 
hydroxide treatment; followed by m-chloroperbenzoic acid and boron trifluoride 
etherate reaction), a racemic mixture of sporidesmin A (3) was achieved (Scheme 27). 
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Scheme 27 – Kishi’s synthesis of sporidesmin A (4) 
1.2.5.5 Sporidesmin B 
Using the same acetate intermediate (163)
186
 used for the synthesis of racemic 
sporidesmin A (3) as starting material, Kishi et al 
179, 188
 were able to produce 
sporidesmin B (4) as a racemate. Reduction of (163) to the subsequent methylene 
derivative (165) followed by oxidation using benzoyl peroxide with traces of 4,4’-
thiobis(6-t-butyl-3-methylphenol) gave a mixture of both cyclized products (166) and 
(167). After purification, benzoate (167) was converted to alcohol (168) and reacted 
with m-chloroperbenzoic acid and boron trifluoride etherate to yield the desired 
monomeric ETP sporidesmin B (4) as a racemic mixture (Scheme 28). 
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Scheme 28 – Kishi’s synthesis of sporidesmin B (1) 
1.2.6 Ottenheym’s approach 
Before establishing a new route for ETP synthesis, Ottenheym et al 
189, 190, 191, 192, 193, 194 
made remarkable breakthroughs towards the ETP core structure. One of which was the 
synthesis of tetrachlorodioxopiperazine (171) reported in 1972,
195
 from the not expected 
instability of disubstituted sarcosyl chloride (169) which led to tetraketopiperazine 
(171) as the resulting decomposition product (Scheme 29). 
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Scheme 29 – Ottenheym’s approach (1) 
In 1973, and following Leuchs previous studies,
193
 Ottenheym attempted the 
nucleophilic displacement of 2-chloro substituted indolenines (174) by using sulfur 
nucleophiles. The idea was to create a sulfur adduct (173) that could undergo 
cyclization to form the dithiol-bridged diketopiperazine (172) (Scheme 30).
189
 
 
Scheme 30 – Ottenheym’s approach (2) 
Another model reaction reported by the author was the direct nucleophilic addition of 
sulfur to non-substituted Leuchs’ adducts (176) which could cyclize to give (175). In 
way of example, a desthiomethylene analogue of anhydrogliotoxin (177) was 
synthesised by ring closure of the free amine in an intramolecular aminolysis of (176) 
(Scheme 31).
189, 190, 191, 192
 
 
Scheme 31 – Ottenheym’s approach (3) 
Development of this chemistry led to the synthesis of a gliotoxin analogue (180). 
Indolenine-2-carboxamide (178) when treated with pyruvol chloride gave (179). This 
intermediate was converted to (180) by spontaneous ring closing after 80 minutes of 
stirring (Scheme 32).
191, 196, 197
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Scheme 32 – Ottenheym’s approach (4) 
After leaving (180) to stir for an extra 15 hours, products (181) and (182) were isolated. 
The chloroalkene (181) when bubbled with hydrogen sulfide yielded the 
mercaptoalkene (183), when either (180) or (183) were submitted to hydrogen sulfide 
and zinc chloride treatment and cis-dithiol (184) was formed. The cis configuration of 
this product was proven by disulfide formation after oxidation to yield the desired 
racemic ETP (185) (Scheme 33).
19, 198
 
 
Scheme 33 – Ottenheym’s approach (5) 
Although this synthetic pathway led to a racemic mixture of (185), chemical resolution 
was achieved by reduction of the disulfide bridge to give (184) which was consequently 
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reacted with a chiral bis-disulfenyl chloride (186) to yield diastereoisomers (187) and 
(188) (Scheme 34).
198, 199
 
 
Scheme 34 – Ottenheym’s approach (6) 
This diastereoisomeric mixture was separated using silica gel chromatography and the 
optically pure compounds (S-185) and (R-185) were subsequently obtained by 
reduction using sodium borohydride followed by the previously described oxidation 
process (Scheme 35).
198
 
 
Scheme 35 – Ottenheym’s approach (7) 
1.2.7 Matsunari’s approach 
In 1973, Nakamura et al 
200
 published their work on the synthesis and substitution of 
1,3,4,6-tetra-substituted-3,6-dihalogeno-2,5-diketopiperazines which served as a basis 
for Matsunari´s future work on the tetra-substitution of 2,5-diketopiperazines.
201
 In way 
of example, the synthetic pathway started by developing the N-methylated 3,6-dialkyl-
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2,5-piperazinedione precursor (189) using sodium hydride and methyl iodide. The 
resulting compound (190) was then treated with N-bromosuccinimide and 2,2’-
azobisiso-butyronitrile to yield 3,3α-dibromide (201) and 3,3α,6,6α-tetrabromide (200), 
both generated depending on the equivalents of brominating agent used for the 
procedure (Scheme 36). 
 
Scheme 36 – Matsunari’s approach (1) 
To avoid sulfenylation of both the 3α- and 6α-bromines, the 3,6-bromine atoms of 
compound (200) were converted to the correspondent dimethoxy intermediate (202) 
followed by reduction to give dimethyl compound (203). The resultant intermediate was 
then treated with hydrogen sulfide and zinc chloride yielding (204) which after 
oxidation gave the desired ETP (205) (Scheme 37).
202, 203
 
 
Scheme 37 – Matsunari’s approach (2) 
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1.2.8 Coffen’s approach 
In 1977, Coffen et al 
204
 were able to create synthetic analogues of aranotin’s. The 
synthetic process commenced with a copper-catalysed reaction to give (208) from 
glycine anhydride (206) and o-iodobenzoic acid (207). The diacid was then dissolved in 
methanol and reacted with diazomethane to yield (209), which after treatment with 
potassium tert-butoxide underwent cyclisation rendering the substituted indole moiety 
(210). The last step of the synthesis incorporated the disulfide bridge in the already 
known cyclic system by using disulfur dichloride in a basic environment to give the 
desired ETP (211) (Scheme 38). 
 
Scheme 38 – Coffen’s approach 
1.2.9 Rastetter and Williams’ approach 
The total synthesis of racemic gliovictin (212),
205, 157
 as well as the attempt for a 
putative gliotoxin precursor model (213),
206
 determined the initial steps for the ETP 
synthetic pathway development by Williams and Rastetter in 1979 (Figure 41). 
 
Figure 41 – Rastetter and Williams’ approach 
Gliovictin (212) synthesis started with monoformylation of sarcosine anhydride (76) to 
form the enolic aldehyde (214). Sulfenylation using methylsulfenyl chloride in a basic 
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environment yielded (215). This product was reduced to the corresponding alcohol 
(216) and thus protected as the tert-butyldimethylsilyl to give (217). The resultant 
compound was then treated with a strong base and alkylated using dimethyl disulfide 
and benzyl bromide to produce (218). Acid hydrolysis of the protecting silyl group 
yielded a racemic mixture of gliovictin (212) (Scheme 39). 
 
Scheme 39 – Rastetter and Williams’ synthesis of gliovictin 
The basis of this synthetic route was subsequently used to obtain the different sulfur 
containing molecules as shown below. 
1.2.9.1 Hyalodendrin 
The use of the same synthetic approach led to synthesis of hyalodendrin (18). The 
primary step involved similar intermediates from the previously discussed gliovictin 
synthesis in which the tert-butyldimethylsilyl protecting group was replaced by a tert-
butyldiphenylsilyl substituent. Alkylation of compound (219) using LDA with 
previously treated elemental sulfur and following acidic work up with sodium 
borohydride treatment yielded (220) (Scheme 40).
157
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Scheme 40 – Rastetter and Williams’ synthesis of hyalodendrin (1) 
Product (220) was treated with methylsulfenyl chloride followed by acid hydrolysis to 
give compound (221). Sulfenylation of the given product using triphenylmethyl 
chlorodissulfide in triethylamine rendered both diastereomers (222) and (223). 
Reduction of the desired isomer (222) followed by oxidation using Lugol’s iodine 
yielded hyalodendrin (18) as a racemic mixture (Scheme 41).
157
 
 
Scheme 41 – Rastetter and Williams’ synthesis of hyalodendrin (2) 
Rastetter’s studies continued towards developing models for ETPs biogenesis of arene 
oxides (213) and later for sym-oxepin oxides (224), initially planned to develop a partial 
synthetic route to the aranotin family of compounds as shown below (9) (Figure 42).
207
 
 
Figure 42 – Rastetter’s model for ETP synthesis 
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Williams work led to important achievements in the generation of bridgehead 
carbanions of the diketopiperazine ring that would be crucial for synthesis of the ETP 
cogenerate bicyclomycin (225).
208, 209, 210
 Other works reported by the author included 
the chiral right half synthesis of sirodesmin A (26) (Figure 43).
211
 
 
Figure 43 – Williams’ model for ETP synthesis 
These efforts were influential to the total synthesis of epidithiapiperazinedione – 
aspirochlorine (238). The synthetic route towards this compound is shown below.
212
 
1.2.9.2 Aspirochlorine 
The synthesis of this product started with formylation of 4-chloro-resorcinol (226) using 
zinc cyanide under acidic conditions to yield (227). The next step involved protection of 
the 4-hydroxyl group using chloromethyl methyl ether to give (228) followed by 
treatment with diethyl bromomalonate and potassium carbonate. Hydrolysis of the 
formed diester, rendered the desired coumarilic acid (229) (Scheme 42). 
 
Scheme 42 – Williams’ synthesis of aspirochlorine (1) 
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This derivative was coupled to o-(2-nitrobenzyl)glycine ethyl ester and the resulting 
intermediate, after acid hydrolysis using hydrochloric acid at high temperatures 
followed by acetylation, was converted to (230). The resulting product was treated with 
N-methylmorpholine and methoxylamine to afford (231) (Scheme 42).
212, 213, 214
 
Compound (231) was then treated with N-bromosuccinimide to form the desired 
tricyclic moiety with the required trans stereochemistry (232), followed by 
displacement of the bromide with silver triflate in methanol to give the methyl ether 
(233) as a mixture of diastereomers. Photolytic deprotection of the o-nitrobenzyl group 
under optimal conditions (10% water in the reaction mixture; five hours photolysis) led 
to (234) (Scheme 43).
212
 
 
Scheme 43 – Williams’ synthesis of aspirochlorine (2) 
Sulfenylation was achieved in three steps: oxidation of (234) to the corresponding 
bismethyl ether (235); removal of the acetate protecting group to give the free phenol 
(236); and bisthioacetate formation (237) using thiolacetic acid and boron trifluoride 
etherate. The final phase of the synthesis was difficult to achieve. However, optimal 
condition exploration demonstrated that treatment of (237) with excess methoxylamine 
and camphor sulfonic acid (CSA) under an aerobic environment led to a racemic 
mixture of aspirochlorine (238) (Scheme 44).
212, 213, 214
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Scheme 44 – Williams’ synthesis of aspirochlorine (3) 
1.2.10 Olsen’s approach 
In 1981, Olsen et al 
215
 tried to expand a model based on Kishi’s findings in which 
geminal dithiols were reacted with dibromo piperazinedione (77) to give intermediate 
compounds (239) substituted in both the 3- and 6- positions with the sulfides connected 
through a carbon bridging group. After introducing sulfide functions, attempts to 
remove the bridging group that after oxidation would render the desired ETPs were 
unsuccessful (Scheme 45). 
 
Scheme 45 – Olsen’s approach (1) 
These results followed previous results that started with bis N-methylation of 
unsaturated piperazinedione (240) to give (241). After treatment with thioacetic acid 
under strong acidic conditions, compound (242) was formed and further reduction using 
sodium borohydride to give the desired ETP (205) (Scheme 46).
215
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Scheme 46 – Olsen’s approach (2) 
1.2.11 Waring’s approach 
In 1993, Waring et al 
216
 used a very similar approach to the one developed by Trown 
and co-workers to obtain ETPs. The synthetic pathway, although having the same 
intermediates, was modified by different reaction conditions. In way of example, 
glycine anhydride (206) was bis alkylated in positions 1 and 4 using a strong base and 
benzyl bromide to give (243). The resulting product underwent bromination using N-
bromosuccinimide to render the desired dibrominated intermediate (244). Following 
treatment with potassium thioacetate yielded dithioacetate (245). Hydrolysis of (245) 
using boiling ethanol and hydrochloric acid gave the corresponding dithiol (246) that 
after oxidation rendered the desired ETP (247) (Scheme 47). 
 
Scheme 47 – Waring’s approach 
1.2.12 Danishefsky’s approach 
In 2000, Danishefsky et al 
213
 were able to synthesise an aspirochlorine analogue (254) 
using Kishi’s thioacetal (106) and Williams’ intermediate (227).179, 212 Following bis 
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methoxymethyl ether protection of (227) compound (248) was obtained which was used 
as the substituent’s left half of the natural product analogue precursor (Scheme 48). 
 
Scheme 48 – Danishefsky’s approach (1) 
The bicyclic moiety (106) was reacted with the aldehyde under strong basic conditions 
to give (249). The next step of the synthetic pathway elegantly yielded (253) on acid 
catalysis. The rationalization of this noteworthy rearrangement is illustrated from 
intermediate (250) to (252); the chain of events starts with protonation of the hydroxy 
group that aided by the phenolic oxygen gives the o-quinomethide compound (251). 
This product underwent subsequent stereospecific sulfur migration to yield (252). 
Treatment of (253) with m-chloroperbenzoic acid and perchloric acid in the presence of 
dimethyl sulfide rendered the desired aspirochlorine analogue (254) (Scheme 49). 
 
Scheme 49 – Danishefsky’s approach (2) 
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1.2.13 Hilton’s approach 
In 2004, Hilton et al 
1, 217
 developed a novel method to achieve the substituted 
diketopiperazine core by early introduction of one of the sulfur atoms necessary to form 
the disulfide bridge in the first reaction step. To achieve this, ethyl glyoxalate (256) was 
first premixed with benzylamine (255) and the resulting intermediate treated with a 
protected thiol substituent (257) to yield (258). The α-mercaptoamino acid ester was 
then reacted with diacetoxyacetyl chloride to give (259). This compound when treated 
with different amines and para-methoxybenzyl mercaptan in an acid environment 
elegantly rendered the protected dithiol diketopiperazines (260). The last stage on 
forming the desired ETPs consisted of a two phase one-pot process: thiol groups 
deprotection using a Lewis acid; followed by oxidation of the worked-up reaction using 
iodine to yield (261) (Scheme 50). 
 
Scheme 50 – Hilton’s approach 
1.2.14 Bräse’s approach 
In 2007, Bräse et al 
218
 synthesised various examples of both symmetrical and 
unsymmetrical diketopiperazines that could subsequently be thiolated using Schmidt’s 
methodology.
172
 The root method was based on a modified procedure from previous 
studies by Ugi et al 
219
 that described the one-pot synthesis of symmetrical 
diketopiperazines using amino acids and proline in the presence of dichloromethoxy 
phosphine. The use of functionalised prolines (262), hexahydroindolecarboxylic acid 
(265) and other substituted indole derivatives allied to enhanced reaction conditions 
enabled Bräse to obtain different examples of diketopiperazines (263) and (266). 
Introduction of the disulfide bridge was achieved via Schmidt’s synthetic pathway using 
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sodamide. Elemental sulfur and a final oxidation step yielded the desired ETP (264) 
(Scheme 51). 
 
Scheme 51 – Bräse’s approach (1) 
This unified methodology allowed Bräse and co-workers to create different building 
blocks that after dimerisation yielded the desired diketopiperazines. One of these was 
the core structure (276) of epicoccins A, C and D from a pre-formed cis-annelated 
cyclohexane (269) (Scheme 52).
220
 
 
Scheme 52 – Bräse’s approach (2) 
Former work by the author concerning the thiolation process of these compounds 
allowed a number of approaches to be considered for the enantioselective total synthesis 
of ETPs natural products.
221
 
1.2.15 Overman’s approach 
In 2007, Overman et al 
222, 223
 developed a method to construct tricyclic ETPs from 
dioxopiperazines containing a hydroxyproline unit. The synthetic process started with 
coupling of 3-hydroxyproline derivative (270) to acetylglycolic acid (271) to give (272). 
The resultant acetate was then cleaved yielding (273) that after Parikh-Doering 
oxidation and resultant cyclization rendered a mixture of (274) and (275) (Scheme 53). 
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Scheme 53 – Overman’s approach (1) 
Compound (275) was acetylated to give (276) and the tert-butylsilyl group removed 
upon treatment with tetra-n-butylammonium fluoride in acetic acid to render the 
corresponding alcohol (277). This secondary alcohol was then transformed into the 
(bromomethyl)dimethylsiloxy ether (278) derivative (Scheme 54).
222
 
 
Scheme 54 – Overman’s approach (2) 
Radical-promoted oxidation of (278) yielded the acetate species (279) that was next 
deprotected and acetylated to give (280). The resulting triacetate was treated with 
excess hydrogen sulfide and a catalytic amount of scandium triflate rendering the dithiol 
(281) that after exposure to oxygen, yielded ETP (282). The authors transformed the 
previous acetylated ETP to the given alcohol (283) (Scheme 55).
222
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Scheme 55 – Overman’s approach (3) 
1.2.15.1 (+)-Gliocladine C 
Using a different approach, Overman and co-workers developed a convergent method 
for constructing cyclotryptamine-fused polyoxopiperazines which led to the synthesis of 
gliocladine C (72).
149, 223
 Pre-constructed indole aldehyde (284) was coupled with 
trioxopiperazine (285) in the presence of a strong base followed by acid quenching that 
rendered (286). This compound, after treatment with boron trifluoride etharate, yielded 
cyclized intermediate (287) (Scheme 56). 
 
Scheme 56 – Overman’s synthesis of (+)-gliocladine C (1) 
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Trioxopiperazine (287) was treated with methylmagnesium chloride to give the 
corresponding tertiary alcohol that after protection rendered a siloxy epimeric mixture 
of (288). This mixture was then dihydroxylated and the resultant diol was acetylated 
yielding diacetate (289) (Scheme 57).
223
  
 
Scheme 57 – Overman’s synthesis of (+)-gliocladine C (2) 
Diacetate (289) was treated with hydrogen sulfide and boron trifluoride etherate 
followed by oxidation to give (290). This compound was heated in a methanolic 
solution of lanthanum(III) trifluoromethanesulfonate that rendered (+)-Gliocladine C 
(72) (Scheme 58).
223
 
 
Scheme 58 – Overman’s synthesis of (+)-gliocladine C (3) 
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1.2.16 Movassaghi’s approach 
In 2009 Movassaghi et al 
156, 224 
were able to very elegantly synthesise the dimeric ETP 
(+)-11,11-dideoxyverticillin A (65). The strategic synthetic pathway was developed to 
introduce the disulfide bridge at a late stage into the molecule core as shown below. 
1.2.16.1 (+)-11,11-Dideoxyverticillin A 
The synthesis started with cis-diketopiperazine (291) formation, with deprotection of 
amide (290) and morpholine treatment to give the diketopiperazine moiety. The 
resultant compound was treated with bromine in acetonitrile at 0 °C to give the desired 
monomeric tetracyclic bromide (292) that after reaction with methyl iodide and 
potassium carbonate yielded the tertiary benzylic bromide (293) (Scheme 59).
156
 
 
Scheme 59 – Movassaghi’s synthesis of (+)-11,11-dideoxyverticillin A (1) 
Compound (293) when treated with tris(triphenylphosphine)cobalt(I) chloride rendered 
the dimeric octacyclic intermediate (294) which was followed by oxidation using 
bis(pyridine)-silver(I) permanganate yielded the desired dimeric octacyclic tetraol (295) 
as a single diastereoisomer. This procedure avoided competing epimerisations that 
would result in complex mixtures.  After alcohol protection, treatment of (296) with 
monobasic sodium phosphate with sodium amalgam provided the dimeric intermediate 
(297). This was reacted with trithiocarbonate under acid conditions to give the 
bisdithiepanethione (298). Ethanolamine was then added rendering the diaminotetrathiol 
(299) that after mild oxidation yielded (+)-11,11-dideoxyverticillin A (65) (Scheme 
60).
156
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Scheme 60 – Movassaghi’s synthesis of (+)-11,11-dideoxyverticillin A (2) 
In 2010, Movassaghi and co-workers 
225
 were able to synthesise (+)-chaetocin A (42) by 
undertaking a similar strategy as reported for (+)-11,11-dideoxyverticillin A (65) which 
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enabled the synthesis of a modified intermediate of (291), proven to be crucial for the 
synthetic pathway. 
1.2.16.2 (+)-Chaetocin A 
Movassaghi et al used diketopiperazine construct (300) as the basis to form tetraol (301) 
that after exposal to hydrogen sulfide under acidic conditions formed bisthiohemiaminal 
(302). Addition of isobutyryl chloride gave (303) that after irradiation with a black-light 
phosphor-coated lamp with photosensitizer 1,4-dimethoxynaphthalene and L-ascorbic 
acid rendered (304) (Scheme 61).
225
 
 
Scheme 61 – Movassaghi’s synthesis of chaetocin A (1) 
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Hydrazinolysis of the thioesters yielded the dithiol (304) that was treated under basic 
conditions with trityl hypochlorothioite to give (305). Ionisation of the isobutyrates and 
cyclisation with triphenylmethyl cation loss rendered diacetate (306) that after mild 
methanolysis gave (+)-chaetocin A (42) (Scheme 62).
225
 
 
Scheme 62 – Movassaghi’s synthesis of chaetocin A (2) 
1.2.17 Iwasa’s approach 
In 2011, Iwasa et al 
115, 226, 227, 228 
developed an elegant synthetic route to achieve 
chaetocin A (42) as well as its corresponding enantiomer (ent-42). 
1.2.17.1 Chaetocin A 
The synthetic process to achieve chaetocin A (42) started by condensation of previously 
formed N-methyl-L-serine (307) and L-tryptophan methyl ester that when treated with 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and 1-
hydroxybenzotriazole monohydrate rendered dipeptide (308). The hydroxyl group and 
the nitrogen atom from the indole moiety were protected using tert-
butyldimethylchlorosilane and ditert-butyl dicarbonate respectively yielding (309). 
Reduction of the previously formed protected dipeptide gave (310) (Scheme 63).
226, 227
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Scheme 63 – Iwasa’s synthesis of chaetocin A (1) 
Compound (310) was reacted with ammonium hydroxide to afford cyclised product 
(311); that upon treatment with N-bromosuccinimide under mild conditions yielded the 
tetracyclic bromo compound (312) (Scheme 64).
226, 227
 
 
Scheme 64 – Iwasa’s synthesis of chaetocin A (2) 
In light of these results, the enantiomer of (312) was formed in order to continue the 
synthesis. This was achieved by using the D-amino acid derivative as starting material 
rendering ent-(313) (Scheme 65).
226, 227
 
 
Scheme 65 – Iwasa’s synthesis of chaetocin A (3) 
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Compound (313) was α-brominated to give (314) using 2,2’-azobis(4-methoxy-2,4-
dimethylvaleronitrile) as a radical initiator and N-bromosuccinimide as the halogenating 
agent. The use of a radical initiator was shown to be very important in this synthetic 
route since it supressed β-elimination of the alcohol protecting group. The next step 
formed diol (315) upon treatment with phosphate buffer which by using Movassaghi’s 
reductive coupling reaction yielded (316). This intermediate was then treated with 
hydrogen sulfide and boron trifluoride etharate to give (317) followed by oxidation to 
render chaetocin A (42). This established pathway enabled the synthesis of ent-(42) 
from L-amino acid derivatives when used as starting materials (Scheme 66).
226, 227
 
 
Scheme 66 – Iwasa’s synthesis of chaetocin A (4) 
1.2.18 Nicolaou’s approach 
In 2011, Nicolaou et al 
229, 230
 developed their own methodology to achieve the ETP 
core. The synthetic pathway started with the use of N-protected tyrosine (318) that after 
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proper cyclisation using excess iodobenzene diacetate rendered spirolactone (319).
231
 
This compound was then treated with methanol and sodium bicarbonate to yield (320). 
Formation of enone (321) was achieved by acetylation, zinc reduction and isomerization 
using 1,8-diazabicycloundec-7-ene. Reduction of the formed compound using 
cerium(III) chloride and sodium borohydride led to (322). Different treatment of the 
given product led to two dissimilar compounds; when exposed to trifluoroacetic acid, 
(322) was transformed into (323) whereas basic treatment of (322) gave (324) (Scheme 
67).
229
 
 
Scheme 67 – Nicolaou’s approach (1) 
Intermediates (323) and (324) were coupled using phosphoric acid bis(2-
oxooxazolidide) chloride affording N-Boc methyl ester amide (325) (Scheme 68).
229
  
 
Scheme 68 – Nicolaou’s approach (2) 
Amine deprotection of (325) followed by amine induced cyclisation gave (326). 
Diketopiperazine (328) was formed after treatment of (326) with trifluoroacetic 
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anhydride yielding (327) followed by elimination to render the desired product (Scheme 
69).
229
 
 
Scheme 69 – Nicolaou’s approach (3) 
Diketopiperazine sulfenylation step was well studied by Nicolaou and co-workers 
230
 
who concluded that optimal conditions required pre-treatment of elemental sulfur with 
three equivalents of sodium bis(trimethylsilyl) amide followed by addition of this to 
(328) with an extra two equivalents of the previously used base yielding (329). 
Reduction of (329) using sodium borohydride followed by oxidation gave ETP (331) 
and the corresponding 2,2’-epimer (330) (Scheme 70).230 
 
Scheme 70 – Nicolaou’s approach (4) 
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Having achieved a route to the ETP core, Nicolaou used previously formed ETP (330) 
to synthesise 8,8’-epi-ent-rostratin B (37).229 
1.2.18.1 8,8’-Epi-ent-rostratin B 
Photooxygenation of (330) followed by treatment with triethylamine gave (332) that 
after reduction of the olefinic bonds using cuprous hydride triphenylphosphine hexamer 
and subsequent oxidation yielded 8,8’-epi-ent-rostratin B (37) (Scheme 71).229 
 
Scheme 71 – Nicolaou’s synthesis of 8,8’-epi-ent-rostratin B 
1.2.19 Reisman’s approach 
In 2012, Reisman et al 
232
 were able to synthesise (-)-acetylaranotin (8), developing 
their own methodology to achieve ETP based natural products.  
1.2.19.1 (-)-Acetylaranotin 
The synthetic route started by reacting cinnamaldimine (333) with tert-butyl acrylate 
(334) using a catalytic amount of copper iodide and brucin-OL to give the endo-
pyrrolidine which after treatment with trifluoroacetic acid rendered (335). The next 
stage involved amine protection using trimethylsilyl carbamate and ozonolysis of the 
alkene to give the hydroxylactone (336) (Scheme 72).
232
 
 
Scheme 72 – Reisman’s synthesis of (-)-acetylaranotin (1) 
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Intermediate (336) was reacted with ethynylmagnesium bromide (337) that after acid 
work-up, triphenylphosphine and diisopropylazodicarboxylate treatment yielded lactone 
(338). Diol (339) formation was achieved by reduction using sodium borohydride 
followed by bis-silylation and selective cleavage of the primary silyl ether to give 
alcohol (340). Oxidation of the formed alcohol by Dess-Martin periodinane followed by 
treatment with N-chlorosuccinimide and pyrrolidine-trifluoroacetic acid and sodium 
borohydride reduction gave the desired alkynol (341) (Scheme 73).
232
 
 
Scheme 73 – Reisman’s synthesis of (-)-acetylaranotin (2) 
Compound (341) when reacted with cyclooctadiene rhodium chloride dimer and tris(4-
fluorophenyl)phosphine yielded (342). Treatment with tetrabutylammomium fluoride 
provided the free amine that when exposed to lithium chloride and lithium carbonate 
rendered dihydrooxepine (343). Using the same type of chloride elimination, compound 
(342) was converted to (344), which when treated with trimethyltin hydroxide gave 
(345) (Scheme 74).
232
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Scheme 74 – Reisman’s synthesis of (-)-acetylaranotin (3) 
Coupling of (343) and (345) under basic conditions yielded compound (346). 
Desilylation/cyclisation followed, to give diketopiperazine (347) (Scheme 75).
232
 
 
Scheme 75 – Reisman’s synthesis of (-)-acetylaranotin (4) 
Introduction of the tetrasulfide bridge was achieved using the previously reported 
method by Nicolaou,
230
 which used a pre-mixture of sodium bis(trimethylsilyl)amide 
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and elemental sulfur that was added to a solution of (347) in the same strong basic 
conditions to give (348). The formed compound was bisacetylated using acetyl chloride. 
The tetrasulfide bridge was further reduced using propanedithiol in a triethylamine 
mixture that was oxidized yielding (-)-acetylaranotin (8) (Scheme 76).
232
 
 
Scheme 76 – Reisman’s synthesis of (-)-acetylaranotin (5) 
1.2.20 Clive’s approach 
In 2012, Clive et al 
99, 233
 generated their own model to achieve ETPs. Studies regarding 
MPC1001 (33) led the author to examine several methods to introduce sulfur in 
different stages of the synthesis. For the purpose, reagent (350) was developed which 
enabled the conversion of (349) into a diastereomeric mixture of (351). 
 
Scheme 77 – Clive’s approach (1) 
Compound (351) was then reduced to the corresponding alcohol followed by silyl 
protection to give (352). The second sulfur atom was introduced after deprotonation and 
using the previously referenced reagent (350) to give compound (353). Treatment with 
sodium bis(trimethylsilyl)amide and hydrochloric acid yielded the single isomer (354) 
(Scheme 78).
99
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Scheme 78 – Clive’s approach (2) 
Having both sulfur atoms attached to the diketopiperazine moiety took Clive and co-
workers to the next stage of the synthetic pathway of sulfur deprotection and oxidation. 
This was achieved using tetra-n-butylammonium fluoride in a mixture of (354) in acetic 
acid followed by iodine treatment to give the desired ETP (355) (Scheme 79).
99
 
 
Scheme 79 – Clive’s approach (3) 
1.2.21 Overview and outlook on the synthetic approaches towards the epi-3,6-
dithio-2,5-diketopiperazine core and related natural products  
The increasing innovation in the field of synthetic chemistry allied to the quest for 
better pharmacological and medicinal outcomes led scientists to modernize and improve 
synthetic pathways to ETPs. Since the discovery of the first ETP based natural products 
much has been achieved in the synthetic chemistry field following Trown’s seminary 
approach that stimulated scientists like Svokos and Waring to the different pathways 
distinguished by Schmidt that led to amazing breakthroughs by other authors such as 
Bräse.
155, 164, 167, 216, 218
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1.3 Epi-3,6-dithio-2,5-diketopiperazines disulfide bridge and 
mechanism of action 
 
Following, it is clear that the development of a single and straightforward way to 
achieve the ETP core proved to be an exciting challenge to many authors. 
Understanding how these molecules behave and translating their structural components 
into biological outcomes led researchers to accept the importance of the disulfide bridge 
since depletion of it resulted in a loss of activity.
234
 In order to determine the 
characteristics behind the ETPs sulfur-sulfur bond, a number of physical techniques 
were used over the years that differentiated this connection from their simpler disulfide 
congeners. 
1.3.1 X-Ray studies 
X-Ray studies have demonstrated that the preferred conformation of the disulfide bridge 
is a helical twist where sulfur atoms are closer to the carbon atoms from the carbonyl 
groups than to the nitrogen atoms of the diketopiperazine ring.
235
 Bridged 
dithiodiketopiperazines also showed greater torsional strain compared to acyclic sulfur 
containing compounds.
236
 Dihedral angles (CSSC) vary between different ETPs and can 
go from 8° to 18°.
237
 When compared to simpler examples of acyclic disulfide bond 
containing molecules, i. e. HSSH and H3CSSCH3 the difference is noticeable since 
dihedral angles are shown to be approximately 90°.
238
 The conformation behind the 
disulfide bridge can be viewed as a repulsion of sulfur and nitrogen atoms lone pairs 
which can then involve the interaction in-between sulfur’s lone-pair electrons and the 
corresponding carbon atom from the amide bond (Figure 44).
239
 
 
Figure 44 – Schematic of the dissulfide bridge above the diketopiperazine ring 
1.3.2 Infra-red and Raman spectra studies 
Studies involving sporidesmin A (3) and its corresponding reduced form (356) showed 
relaxation of the disulfide bridge strain imposed on the carbonyls of the 
diketopiperazine core. Amide carbonyl stretching frequencies for sporidesmin A (3) 
indicated values of 1655 and 1680 cm
-1
, whereas the methylated reduced form of this 
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same molecule, sporidesmin D (356), presented frequencies of 1675 and 1700cm
-1
 
(Figure 45).
38,
 
240
 
 
Figure 45 – Sporidesmin A and Sporidesmin A disulfide reduced form 
Raman spectral studies performed by Scheraga and co-workers 
240
 showed similar 
conceptual results which confirmed the strained environment around the disulfide 
bridge. Sulfur-sulfur bonds for different natural products revealed stretching frequencies 
between 486 and 510cm
-1
 while simpler aliphatic disulfide compounds (ex. 1,2-
dithiane) showed values between 509 and 532cm
-1
. 
1.3.3 NMR studies 
The same examples previously used by Scheraga,
240
 sporidesmin A (3) and D (356), 
were used by Ronaldson 
36, 37
 in 1975 as NMR testing examples. Proton NMR studies 
showed a 0.16ppm (in CDCl3) downfield shift for the 3-methyl group of sporidesmin A 
(3) when compared to its reduced analogue. Carbon 13 NMR studies demonstrated 
again a downfield shift of 7.3ppm for the 3-methyl substituent as well as an upfield shift 
for the quaternary carbon atoms linked to sulfur of 4.6 – 4.8ppm now for sporidesmin D 
(356) when compared to sporidesmin A (3) (Figure 45). 
1.3.4 Epi-3,6-dithio-2,5-diketopiperazines mechanism of action 
The biological activity of ETPs is focused on the disulfide bridge moiety as previously 
discussed. The existing ideology is that one of the sulfur atoms can be involved in 
covalent modification through thiol disulfide interchange whilst the second thiol can be 
available for radical generation. In proteins, this effect results in conformational 
changes and altered activity when basic amino acids residues were coupled with thiol.
2, 
30
 Proof of the importance of the disulfide bridge came from the use of reducing agents, 
e.g. Cleland’s reagent, which resulted in loss of biological activity due to reduction of 
the disulfide bridge.
241
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From a different perspective, the reactive disulfide bridge of ETPs has been reported to 
cause DNA strand breakages in anaerobic conditions of oxidative stress by the 
formation of reactive sulfur species (Scheme 80).
 112, 113, 114, 241
 
 
Scheme 80 – Example of biological reduction of the ETPs dissulfide bridge 
Results demonstrated the importance of disulfide bridged compounds when compared 
to dithiol containing molecules for different biological outcomes. With former and 
current research, developments have led to the applicability of the knowledge extracted 
from the mode of action of ETPs to a wide range of biological areas. These areas 
include cancer, bacterial and viral drug discovery.
18, 141, 228
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1.4 Cancer, hypoxia and other targets 
Cancer is a disease caused by the uncontrolled growth of changed cells that result in the 
formation of a tumour. The spread of these masses to different sites throughout the body 
can cause death by vessel and organ obstruction, making surgical intervention 
impossible. In early stages of tumour growth, cancer cells usually resemble the original 
cells from which they derive; however, they can lose the appearance and function of 
their origin at a later stage.
242, 243 
Every year, more than 285,000 people are diagnosed with cancer in the United 
Kingdom and the current estimate is that more than one in three people will develop a 
form of cancer at some point in their lifetime. While numerous types of cancer are 
known, breast, lung, colorectal and prostate cancer, constitute over half of new cases 
diagnosed as seen in the chart below. In males, prostate cancer is the main cancer type 
with 36,000 new cases diagnosed in 2007, followed by lung cancer, ~22,000, and 
colorectal, ~21,000 new cases per year. In females, breast cancer continues to be the 
most common tumour type, accounting for nearly one in three female cancers, with over 
45,000 new cases diagnosed in 2007 (Chart 1).
242
 
 
Chart 1 – The 20 most commonly diagnosed cancers (excluding non-melanoma skin cancer), UK, 2007 
Tumour hypoxia, or tumour low oxygen tension, is frequently observed in solid 
tumours. This occurs when oxygenation levels decrease in malignant tissues forcing cell 
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death. Hypoxia is defined as a value of oxygenation below 2% in mammalian tissues 
with an average being in-between 2 and 9%. Its role in cancer treatment instigated 
studies that revealed a number of other crucial effects of hypoxia on tumour progression 
such as angiogenesis, increased metastatic potential, DNA replication and reduced 
protein synthesis.
244, 245
 
 
1.4.1 Hypoxia Inducible Factor 
Hypoxia Inducible Factor-1 (HIF-1) is a transcription factor that regulates the 
expression of a large number of genes, including those responsible for cell survival. The 
HIF complex is formed from one α and β subunit. Under normal oxygen conditions, 
levels of the hypoxia inducible factor-1α (HIF-1α) are tightly regulated, but in the 
deficient oxygen environment found in many tumours, HIF-1α accumulates causing 
transcription activation and hence tumour growth leading to poor patient prognosis. The 
role of HIF in cancer has become increasingly clear due to immunohistochemical 
techniques that have demonstrated the overexpression of HIF-1α in a broad range of 
human malignancies like early-stage cervical cancer, breast cancer, oligodendroglioma, 
ovarian cancer, endometrial cancer and oropharyngeal squamous cell carcinoma.
244, 246, 
247
  
As referred before, normoxia down-regulates the occurrence of HIF-1α by proteosomal 
degradation. This occurs by hydroxylation of two prolines on HIF-1α that enables the 
binding to the von Hippel-Lindau protein (pVHP) and consequently leads to 
ubiquitination. In a different but equally important pathway, hydroxylation of one 
asparagine aminoacid residue in HIF-1α disrupts the interaction between this protein 
and the p300 co-activator, crucial for HIF transcriptional activity. When oxygen levels 
decrease, the hypoxic-response is activated, leading to increased protein levels due to 
lack of HIF-1α hydroxylation. This enables the dimerisation of HIF-1α / HIF-1β (also 
known as aryl hydrocarbon receptor nuclear translocator, (ARNT) and the important 
p300 co-activator. This active transcriptional complex binds to the hypoxia response 
element (HRE) leading to the activation of hypoxic response proteins responsible for 
tumour survival and progression, as shown below (Figure 46).
247, 248, 249, 250
 
Bruno Sil                                                                                                                  Introduction 
 
104 
 
 
Figure 46 – Illustration of a normoxia and hypoxia state where HIF-1α is regulated. In normoxia, hydroxylation of 
one asparagine aminoacid residue in HIF-1α disrupts the interaction p300 leading to proteosomal degradation. 
Hydroxylation of two prolines on HIF-1α enables the binding to pVHP and ubiquitination. In hypoxia, dimerisation 
of HIF-1α / HIF-1β and p300 leads to the activation of this transcriptional complex which binds to the HRE leading 
to the activation of hypoxic response proteins. 
1.4.2 Epi-3,6-dithio-2,5-diketopiperazines as anticancer agents 
Although the role of the disulfide bridge in ETP activity has been known for some time, 
the mechanism by which the bridge confers anticancer activity was until recently 
unknown. It is now believed that the disulfide bridge disrupts the interaction between 
the HIF-1α C-terminal activation domain (C-TAD) and the cysteine-histidine rich 1 
(CH1) domain of the p300 co-activator. The CH1 region of p300 is formed by three 
main α-helices motifs which are zinc dependent to maintain their proper fold and, 
therefore, functionality (Figure 47).
251, 252
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Figure 47 – CH1 region of p300 formed by three main α-helices (green) and zincs (grey) 
ETPs are believed to cause zinc ejection from CH1 in a catalytic manner.
253
 This 
interaction alters p300 conformation hence leading to protein unfold and activity 
reduction (Scheme 81).
 251, 242
 
 
Scheme 81 – Schematic that illustrates the ETPs mode of action by zinc ejection from the p300 CH1 domain 
Studies demonstrated that the ETP core itself is both necessary and sufficient for 
biological activity as equally natural and synthetic ETPs cause zinc ion ejection from its 
natural site.
254, 255, 256, 257, 258, 259
 Cell based models furnished important information since 
addition of zinc to the culture environment eliminated the anti-proliferative effect of 
ETPs and drastically increased the percentage of viable cells.
253
 By way of example, the 
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addition of zinc restored the cell’s production of proteins responsible for 
neovascularization such as vascular endothelial growth factor (VEGF) during hypoxia.  
In vitro testing also confirmed that both natural and synthetic (mono and dimeric) ETPs 
inhibited the proliferation of cancer cell lines, proving their value for oncogenic 
treatment.
246, 248, 260, 261, 262
 
1.4.3 Epi-3,6-dithio-2,5-diketopiperazines and other biological targets 
Although it is probable that ETPs operate by more than one mechanism in cells, it is 
clear that proposed targets are either known, or associated, with zinc binding proteins. 
This suggested that the disruption of zinc binding may be one of the potential generic 
mechanisms of ETP action and, in part, their toxicity. Based on these findings other 
targets were defined as possible marks for ETP activity: matrix metalloproteinases and 
retroviruses. 
1.4.3.1 Matrix metalloproteinases 
Matrix metalloproteinases (MMPs) are a family of zinc depending proteins that play an 
important role in the physiological and pathological turnover of matrix components, 
tissue degradation and repair.
263
 They have been linked to angiogenesis in colorectal 
carcinomas, breast cancer and non-small-cell lung cancer.
264
 One of the most well 
known member of this group is the matrix metalloproteinase 9 (MMP-9) (Figure 48);
265
 
a VEGF modulator. Studies showed that MMP-9 plays an important role in the 
degradation and remodelling of damaged tissues and that its upregulation is induced by 
the HIF-1α/VEGF cascade of events.251, 263, 264 
 
Figure 48 – MMP9 
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1.4.3.2 Retroviruses 
ETP antiviral activity is related to inhibition of enzyme activity and viral RNA 
replication.
3
 Retroviruses belong to one of the viral groups where ETPs can biologically 
act, since one of its main constituents is the nucleocapsid protein. The nucleocapsid is 
the protection of the viral genome. Virus genomes removed from their capsids are more 
susceptible to inactivation. A secondary major function of the capsid is to recognize and 
attach to a host cell in which the virus can be replicated. Although the nucleocapsid 
must be stable enough to survive in the extracellular environment, it must also have the 
ability to alter its conformation so that, at the appropriate time, it can release its genome 
into the host cell.
266
 The nucleocapsid protein from human immunodeficiency virus 
type-1 (HIV-1) is highly basic (29 per cent of the amino acid residues are basic) and 
contains two zinc fingers associated (Figure 49).
266, 267, 268
 
 
Figure 49 – HIV-1 nucleocapsid (red and green) with zincs (grey) 
ETPs display anti-viral activity by zinc ejection which can render the protein inactive. 
Other sulfur containing molecules showed in vitro anti-retroviral activity against 
resistant strains of the nucleocapsid protein of the human immunodeficiency virus HIV-
1 NCp7 using similar intrinsic zinc ejection.
264
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1.5 Dimeric natural and synthetic molecules for diseases treatment 
As observed with monomeric and dimeric ETP natural products, the corresponding 
dimeric versions often display more potent biological activity when compared to their 
single entity congeners. As such, a brief discussion of other dimeric compounds will be 
described.
251
 It was Monod et al 
269
 that emphasized the argument that isologous 
associations usually result in a “closed structure” that maintains intrinsic symmetry and 
enhanced stability. In addition to this, Monod and co-workers 
269, 270
 suggested that a 
rapid organization of the monomeric units into an oligomeric species could potentially 
prevent the random association of its subunits with other cellular artifacts therefore 
increasing specificity of a compound.
271
 Genetic saving, functional gaining and 
structural advantages are some of the potential advantages in the dimerization of drugs 
such as artemisinin (357) (Figure 50), a clinically efficacious antimalarial agent isolated 
from Artemisia annua L. (Asteraceae).
272, 273
 
 
1.5.1 Dimeric artemisinin 
Artemisinin (357) sesquiterpene lactone contains a unique endoperoxide bridge system 
that is crucial for its activity.
272
 
 
Figure 50 – Artemisinin and dimeric analogue 
A synthetic campaign designed to improve the chemical stability of the parent natural 
product resulted in the identification of dimeric compounds that exhibited potent anti-
tumor activity. In way of example, three-carbon atom linked trioxane dimer alcohol 
(358) (Figure 50) acts as growth inhibitory towards aggressive prostate cancer cells 
(CH2) as the clinically used anticancer agent gemcitabine.
273
 More recent advances in 
the development of dimeric artemisinin analogues led to a series of hydrolytically stable 
derivates linked through a series of phthalate acids. Several of these compounds were 
found to be more active against malaria than its monomeric precursor since IC50 values 
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for (359), (360) and (361) (Figure 51) are correspondingly 2.9 nM, 1.6 nM and 0.77 nM 
compared with IC50 = 6.6 nM for artemisinin (357).
272
 
 
Figure 51 – Dimeric analogues of artemisinin 
Compound (360) proved to be not only active against its primary target but potent and 
selective against non-small cell lung carcinoma HOP-92 cells, melanoma SK-MEL-5 
cells and breast cancer BT-549 cells. In addition, dimer (360) exhibited potent activity 
against the human cervical cancer cell line, HeLa, while being nontoxic towards normal 
cervical cells.
269, 272
 
1.5.2 Protoberberine alkaloids 
Another example of the synergy behind monomeric coupling of identical molecules is 
represented by berberine (362) and the dimeric protoberberine alkaloids (363) (Figure 
52).
274
 
 
Figure 52 – Berberine and dimeric analogue 
Studies showed that berberine (362), as well as synthetic analogues of this product, 
exhibited minor inhibitory activity towards DNA Topoisomerase-I.
274
 DNA 
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topoisomerases are crucial for DNA replication, transcription and recombination. A 
distinction between the mono and dimeric forms of these alkaloids was seen clearly 
when compound (363) reported high active results in DNA Topoisomerase-I inhibition 
when compared to the corresponding monomeric species.
274
 
1.5.3 Bis(DACA) 
N-[(2-Dimethylamino)ethyl]acridine-4-carbomaxide (364) (Figure 53), also known as 
DACA, is a acridinecarboxamide derivative. DACA (364) proved to be biologically 
active on inhibiting DNA topoisomerase mutants showing excellent activity in 
experimental solid tumour models.
275
 
 
Figure 53 – DACA 
Studies by Denny et al 
276
 demonstrated that dimeric tricyclic aromatic carboxamides, 
bis(DACA) analogues such as compound (365) (Figure 54) showed an increase in 
cytotoxicity towards the same tumour type models. These results highlight the superior 
potency of dimeric conjugates towards the same target when compared with monomeric 
species. 
 
Figure 54 – bis(DACA) 
1.5.4 Bis(mitomycin C) 
A dimeric version of mitomycin C (366), the 7-N,7’-N’-(1’’,2’’-dithianyl-3’’-6’’-
dimethylenyl)bismitomycin C (367) (Figure 55), was developed by Kohn and Lee in 
2005.
277
 This new dimeric product was the result of bridging two mitomycin C (366) 
units by a dithiane linker. 
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Figure 55 – Mitomycin and dimeric analogue 
When compared to its monomeric predecessor, bis(mitomycin C) showed higher levels 
of DNA interstrand cross-links which demonstrated the increased potential of this new 
dimeric conjugate towards cancer treatment.
277
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As a result of the potent biological activity and structural complexities associated with 
the ETP family of compounds, there have been numerous efforts directed towards the 
obtention of both natural and synthetic congeners and examination of their biological 
efficacy. However, the need and difficulty associated with transferrring these products 
into therapeutically active molecules underlines the challenge associated with the ETP 
family of compounds. One of our key medicinal chemistry aims was therefore the 
development of a common precursor approach towards the ETP core structure. This 
would enable us to develop a full range of compounds, which after biological screening 
would enable us to explore their molecular prospects. Our proposed method was based 
on studies described by Hilton and co-workers.
1, 217
 Whilst current synthetic 
methodology developed by this author has led to efficient formation of the ETP core 
(260) from the diacetate (259), the final ring closure multi-component reaction requires 
the use of TFA, which is incompatible with a number of functional groups (Scheme 82). 
 
Scheme 82 – Methodology described by Hilton for the synthesis of the ETP core 
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As such, an additional aim of this project was to develop new methodology for the 
synthesis of the ETP core that would obviate the use of TFA. In addition, the current 
cyclisation / isomerisation protocol between the cis and trans-ETP requires long 
reaction times (average of 16 hours) and we therefore wanted to explore the effects of 
microwave acceleration of this step to reduce reaction times (Scheme 83). 
 
Scheme 83 – Trans and cis isomers of the protected ETP core 
We also could investigate the possibility of an in-situ base-catalysed deprotection of the 
diacetate (259) to the aldehyde (368). Using Hilton’s defined approach, we predicted 
that (259) should also react with 4-N,N-dimethylaminopyridine (DMAP) (371). This 
would unmask the aldehyde from (259) to form (368), which could then undergo a three 
component reaction with an amine, and para-methoxybenzyl mercaptan (257), followed 
by cyclisation to the diketopiperazine (260) (Scheme 84). 
 
Scheme 84 – Diacetate cyclisation procedure using DMAP 
One key aspect that would be investigated in detail was the cis/trans ratio of the ETP 
core formation (260). To carry this out, we would follow the reaction using HPLC and 
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NMR to determine the ratio for both cis/trans products. In the first instance, we could 
focus on the reaction between the diacetate (259) and n-butylamine to give the protected 
ETP (373) (Scheme 85). 
 
Scheme 85 – Diacetate cyclisation using n-butylamine 
After completing this step, we would next investigate which optimal conditions permit 
the introduction of different amine nucleophiles (Figure 56). These new groups would 
increase diversity when exploring the biological effects of the ETPs.
256
 
 
Figure 56 – Examples of different amino esters for diacetate cyclisation 
In conjunction with this phase of the research project, we would also explore the use of 
microwave acceleration of the reaction to try to optimise the ratio of the cis/trans 
products as well as reduce the reaction times that are currently used.
278, 279, 280
 
Another associated aim of this project would be the synthesis of tri-substituted ETPs. 
Using Hilton’s diacetate (259) we intended to develop a cyclisation pathway that would 
enable the later introduction of a tertiary substituent to the ETP core as shown below 
(Scheme 86). 
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Scheme 86 – Methodology for the synthesis of trisubstituted ETPs 
The next stage of the research programme would involve different approaches towards 
dimeric ETPs using our optimised conditions determined from the early investigational 
stages. As outlined before, dimeric ETPs often display more potent biological activities 
than their monomeric counterparts. We therefore intended to adapt our approach 
towards simplified dimeric ETP systems (Figure 57). 
 
Figure 57 – Disubstituted dimeric ETP 
Our proposed mechanistic approaches towards dimeric ETPs are outlined below. In the 
first instance we anticipate that reaction of one diamine linker with two equivalents of 
Hilton’s diacetate (259) and two equivalents of PMBSH (257) should facilitate the 
formation of simple dimeric ETPs (378) (Scheme 87). 
 
Scheme 87 – Synthesis of dimeric ETP using a diamine linker 
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In our second synthetic pathway we intended to use vinyl integrated ETP derivatives 
and form the dimeric molecules by olefin metathesis using Grubbs type catalysts 
(Figure 58).
281, 282, 283, 284
 
 
Figure 58 – Synthesis of disubstitued dimeric ETPs using Grubbs catalyst 
Following this research stage, we should be able to generate a library of ETPs and test 
them to see which are more biologically active against cancer cell lines and other 
targets; increasing their specificity and minimizing toxicity. 
To summarize, our objectives are as follows: 
 Cyclisation / isomerisation of the diacetate ETP precursor (259) using base-
catalysed deprotection. 
 Explore the effect of microwave acceleration to reduce reaction times for the 
formation of the protected ETP core. 
 Investigate the cis/trans ratio of the ETP core formation. 
 Introduce new amine nucleophiles to the ETP core. 
 Develop a modified route using Hilton’s diacetate (259) precursor to construct 
tri-substituted ETPs. 
 Synthesise dimeric ETPs using different approaches based on the initial studies 
towards their monomeric counterparts. 
 Produce a library of ETP based compounds and test their potency for different 
biological targets. 
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As outlined in the project aims, one of the main objectives was to synthesise the ETP 
core using our approach. The crucial step in our synthetic pathway is the formation of 
the diacetate intermediate (259). To achieve this we needed to synthesise 
diacetoxyacetyl chloride (379) in sufficient amounts in order to make a range of 
analogues (Scheme 88). 
 
Scheme 88 – 2-(Benzyl(2-ethoxy-1-(4-methoxybenzylthio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
synthesis 
However, when we attempted to synthesise diacetoxyacetyl chloride (379) on a large 
scale, the route used to prepare it on a multi-gramme scale often proved to be low 
yielding.
285
 To overcome this, our first step consisted of optimising the synthesis and 
purification of diacetoxyacetyl chloride (379) to avoid repeating the process multiple 
times, as this compound was an essential part of our synthetic strategy. 
 
3.1 Diacetoxyacetyl chloride synthesis 
The reported patented synthetic route to produce diacetoxyacetyl chloride (379) 
285
 
involves mixing acetic anhydride (381), acetic acid and glyoxylic acid monohydrate 
(380) and heating the reaction at 150 °C (Scheme 89) to give intermediate (382). This 
initial step was maintained in our synthetic protocol since we had found it to be 
straightforward and produced the intermediate (382) without any side products. 
 
Scheme 89 – Diacetoxyacetyl chloride synthesis (1) 
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The second step in the formation of diacetoxyacetyl chloride (379) required addition of 
thionyl chloride (383) to crude compound (382) in dichloromethane followed by heating 
the reaction under reflux conditions using an oil bath, followed by distillation (Scheme 
90). 
 
Scheme 90 – Diacetoxyacetyl chloride synthesis (2) 
However, on carrying out the same protocol in our laboratory, compound (379) could 
only be obtained in low yield (50%) and analysis of the crude material prior to 
distillation showed that considerable amounts of intermediate (382) could still be found. 
1
H NMR spectroscopy clarified the presence of the starting material (382) hydroxy 
group at 10.7 ppm (Figure 59) clearly indicating that we needed to optimise this 
reaction if we are to use this synthetic route. 
 
Figure 59 – 1H NMR showing the incomplition of diacetoxyacetyl chloride synthesis 
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In our laboratory, we had moved from oil bath heating used in previous laboratories to 
drysyn heating blocks to accomplish this reaction. However, following the previously 
reported protocol, only small amounts of diacetoxyacetyl chloride (379) were observed. 
We found this to be anomalous to the formerly described synthesis and thus decided to 
investigate it in more detail since diacetoxyacetyl chloride (379) was a key starting 
material for our work. Whilst it was clear that these differences are between the 
efficiency of an oil bath and drysyn heating, we considered it worthwhile to employ 
different conditions for the synthesis. This led us to use dimethylformamide (384) as a 
reaction catalyst which could promote chlorination and optimistically push the synthetic 
pathway towards completion (Scheme 91). 
 
Scheme 91 – Diacetoxyacetyl chloride synthesis (3) 
Whilst using dimethylformamide (384) we elected to follow the synthesis by NMR in 
which aliquouts of the mixture were removed at different time intervals. Throughout the 
experiment, three time periods (1.5, 3, and 5 hours) were studied in order to evaluate the 
conversion of the hydroxy group from compound (382) to the acid chloride (379). 
Using the previously described protocol in which oil bath heating conditions were used 
coupled with dimethylformamide (384), it can clearly be seen that after 1.5 hours 
(Figure 60, entry 1) the 
1
H NMR spectrum still showed the presence of the hydrogen of 
the carboxylic acid (10.7 ppm), leading to evaluation of the next 2 periods: 3 and 5 
hours. After 3 hours (Figure 60, entry 2), the presence of the carboxylic acid OH was 
still present in a 1:3 ratio to the desired acid chloride (379) product. Analysis of the 5 
hour aliquot showed complete conversion of the acid to the desired diacetoxyacetyl 
chloride (379) (Figure 60, entry 3). 
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Figure 60 – 1H NMRs of three time points collected during the synthesis of diacetoxyacetyl chloride: 1.5 hours (entry 
1), 3 hours (entry 2) and 5 hours (entry 3). 
Distillation of the crude reaction mixture led to the desired conversion of the starting 
material to the required diacetoxyacetyl chloride (379) in a much improved yield of 
75% (Figure 61). Allied to this yield increasing was the large amount of material (> 
30.0 g) obtained, which was ideal for our planned route to the ETP core.  
 
Figure 61 – 1H NMR of diacetoxyacetyl chloride synthesis 
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3.2 ETP diacetate formation 
With the essential diacetoxyacetyl chloride (379) reagent available in multi-gramme 
amounts using our adapted methodology, we next moved to the synthesis of ETPs. The 
first step in the synthetic pathway is the production of the diacetate precursor (259) 
following the previous synthetic pathway developed by ourselves.
1
 In order to 
synthesise diacetate precursor (259), benzylamine (255) was first reacted with ethyl 
glyoxalate (256) and para-methoxybenzyl mercaptan (257), in a three component 
reaction, to give amine (258) (Scheme 92).  
 
 Scheme 92 – Ethyl-2-(benzylamino)-2-((4-methoxybenzyl)thio)acetate synthesis (1)  
As shown below, this reaction proceeds with imine formation (386) and loss of water 
prior to addition of para-methoxybenzyl mercaptan (257) leading to the amine product 
(258) formation. Following this three-component reaction we obtained amine (258) as a 
colourless oil in 87% yield as well as > 7.00 g amounts (Scheme 93). 
 
Scheme 93 – Ethyl-2-(benzylamino)-2-((4-methoxybenzyl)thio)acetate synthesis (2) 
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Analogues of diacetate precursor (258) were also synthesised by the use of a number of 
different amines in the reaction, clearly demonstrating the procedure’s reproducibility. 
Using this same principle, we were able to synthesise allyl (388), cyclopropyl (391) and 
methyl (392) cyclisation precursors with the use of allylamine (387), cyclopropylamine 
(389) and methylamine (390) respectively. Hence, for example, reaction of ethyl 
glyoxalate (256) with allylamine (387) and para-methoxybenzyl mercaptan (257) gave 
the allyl substituted amine product (388) in a yield of 81% as a colourless oil (Scheme 
94).  
 
Scheme 94 – Ethyl-2-(allylamino)-2-(4-methoxybenzylthio)acetate synthesis 
The same type three component reaction using cyclopropylamine (389) and 
methylamine (390) gave the desired cyclopropane and methyl substituted amine 
products (391) and (392), as colourless oils in 68% and 37% yield, respectively 
(Scheme 95). We attributed the lower yield for the synthesis of intermediate (392) to 
both volatility of methylamine and the form by which this reagent is supplied as a 
tetrahydrofuran solution making water removal more difficult. 
 
Scheme 95 – Synthesis of different diacetate precursors  
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With amines (258), (388), (391) and (292) in hand, we next explored the formation of 
the corresponding diacetate cyclisation precursors (Scheme 96) using our previously 
synthesised diacetoxyacetyl chloride (379). 
 
Scheme 96 – Molecular mechanism for diacetate formation using diacetoxyacetyl chloride 
Amine (258) was reacted with diacetoxyacetyl chloride (379) under Schotten-Baümann 
conditions to give the diacetate cyclisation precursor (259) in 95% yield (Scheme 97).  
 
Scheme 97 – 2-(Benzyl(2-ethoxy-1-(4-methoxybenzylthio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
synthesis 
TLC analysis of the reaction mixture showed the presence of only the desired product 
(259) in amounts over 10.0 g with complete consumption of the starting amine (258). 
Analysis of the crude 
1
H NMR spectrum indicated that purification by flash column 
chromatography was not required, showing that this was a very efficient and clean 
reaction. Similarly, allyl (388), cyclopropyl (391) and methyl (392) containing amines 
were reacted in an analogous manner to provide cyclisation precursors (395), (396) and 
(397) in 97%, 78% and 97% yield, respectively (Scheme 98). 
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Scheme 98 – Synthesis of different diacetates 
3.2.1 Diacetate cyclisation – Base catalyse synthesis 
According to previous work developed by ourselves, cyclisation of the diacetate 
precursor to the protected ETP core involved the use of an acid catalyst (TFA) which 
has a number of drawbacks associated with its use. TFA is a strong acid that is 
unpleasant to use and incompatible with some functional groups such as esters and 
protected amines. Therefore we looked at the ability of a base (DMAP) to catalyse the 
cyclisation of the diacetate (398) to the protected dithiodiketopiperazine for the 
development of a new synthetic strategy for ETP production. 
DMAP (371) is a very good acylating agent for activation of anhydrides and carbamates 
and for group transfer reactions. For our ETP synthesis, we anticipated that DMAP 
could act by forming reactive acylating groups. We envisioned that it could unmask the 
aldehyde (399) by nucleophilic attack at the carbonyl group of one of the acetate groups 
of the diacetate (398), resulting in concommitant removal of the second acetate group 
and formation of the aldehyde. This would facilitate the formation of a site for the 
nucleophilic amine to attack and lead to formation of an iminium ion (400) where the 
nucleophilic sulfur of para-methoxybenzyl mercaptan can react, followed by cyclisation 
to produce the ETP precursor (402) (Scheme 99).  
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Scheme 99 – Synthesis of disubstituted protected ETPs using DMAP 
This reaction clearly required at least two equivalents of amine since after deprotection 
of the diacetate (398), DMAP (371) formed an inactive acetylpyridinium cation (372) 
due to donation of the acyl group from the diacetate (398) to DMAP, therefore disabling 
its purpose as a catalyst for the reaction. However, reaction of the acetylpyridinium 
cation (372) with another amine molecule would regenerate the active form of DMAP 
as a catalyst. DMAP could then undergo another reaction with the generation of a new 
amide by-product (403). For this reason, we first decided to use 0.5 equivalents of 
DMAP to catalyse the reaction (Scheme 100). 
 
Scheme 100 – By-products of DMAP catalysed cyclisation (1) 
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However, in order to determine the requirements for optimisation of our already 
published TFA mediated cyclisation procedure, we first needed to repeat classical 
reaction conditions (using acid catalysis) to provide a reference point for further 
investigations. 
Therefore, diacetate (259) was reacted with 1.5 equivalents of PMBSH, 3 equivalents of 
n-butylamine (404) and 1 equivalent of TFA in acetonitrile and the resulting mixture 
heated at 51 °C reflux for 16 hours (Scheme 101). 
 
Scheme 101 – (3S,6S)-1-benzyl-4-butyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione synthesis (1) 
TFA was used to catalyse the formation of the ETP precursor (260) by the formation of 
the aldehyde intermediate (368) which after nucleophilic attack by the amine resulted in 
the reactive iminium cation (405) (Scheme 102). 
 
Scheme 102 – (3S,6S)-1-benzyl-4-butyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione synthesis (2) 
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Following completion of the reaction, analysis of the crude NMR spectrum indicated 
complete conversion to the cis protected ETP following heating of the reaction 
overnight at reflux. Purification by flash column chromatography gave (273) as a 
colourless solid in 65% yield. 
With the pure cis protected compound in hand using TFA as a catalyst for the reaction, 
we next directed our attention towards optimising the procedure. For this purpose, we 
elected to use a base catalysed methodology combined with microwave assisted 
synthesis to try to reduce reactions times and increase product formation. 
3.2.2 Optimisation of Hilton’s diacetate cyclisation conditions 
In order to promote the cyclisation of the diacetate using the new developed conditions, 
a series of reactions were carried out towards the synthesis of the n-butyl ETP precursor 
(373). The results from our studies are shown below (Table 1). 
 
Method Entry Temperature (°C) Time Yield (%) 
Reflux 1 51 16h 81 
Microwave 
2 130 15min 48 
3 130 20min 50 
4 130 30min 47 
5 160 30min 23 
Table 1 – Conditions for (3S,6S)-1-benzyl-4-butyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione synthesis 
Conventional reaction methodology using DMAP as a catalyst with stirring for 16 hours 
under reflux conditions (entry 1, Table 1) gave the best yield for the reaction, with 81% 
of a cis/trans mixture of the product. 
The next step involved the use of a microwave reactor to accelerate the reaction. A 
Biotage™ microwave reactor was used in an attempt to accelerate the reaction rate so to 
reduce the time the synthesis took. Uniform heating as well as efficient heat transfer can 
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be obtained by this method leading to high reproducibility of results with both pressure 
and temperature control. In addition, the use of microwave heating allows experimental 
simplification and rapid optimisation of reaction conditions.
280
 Heating at 160 °C for 30 
minutes using the microwave (entry 5, Table 1) resulted in a reduced yield of 23% 
whilst heating at 130 °C for 20 minutes produced the best outcome of a 50% yield 
(entry 3, Table 1). 
The results clearly showed a greater yield was obtained using the conventional reflux 
method when compared to microwave assisted reactions. The optimum conditions for 
microwave usage were obtained for the formation of the n-butyl ETP precursor (373) 
using DMAP after 15 minutes pre-stirring and heating at 130 °C for 20 minutes. 
Possibly this was due to product degradation as a result of the increased reaction 
temperature. However, DMAP proved to be an effective catalyst for deprotection of 
diacetate (259) and formation of the ETP core using conventional heating. 
To determine the most advantageous reaction conditions for the synthesis of the 
protected ETP, cis/trans ratios of the reactions’ final products, using either TFA or 
DMAP as catalysts, were analysed by HPLC. HPLC is a useful analytical tool, 
providing rapid analysis and quantitative data directly from aliquots of the reaction 
mixture. However, after much analysis and effort we abandoned this method for 
determination of the selectivity of the reaction due to poor separation of the cis/trans-
isomers as shown below (Figure 62). 
 
Figure 62 – Separation of (3,6)-1-benzyl-4-butyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione isomers using 
HPLC 
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Although the HPLC chromatograph clearly showed two peaks, one representing the cis 
and the other the trans compound, these peaks overlapped and separation of the isomers 
proved to be too difficult due to the close similarity in both physical and chemical 
properties. TLC analysis was also used to study these reactions and to monitor their 
progress. The TLC showed reduction in the amount of starting material and an increase 
in the synthesis of the diketopiperazine product with increased heating time. Therefore 
we moved to 
1
H NMR spectrum analysis to follow the reaction and to determine the 
most favourable conditions using microwave assisted ETP synthesis, when compared to 
conventional synthesis (Figure 63). 
 
Figure 63 – 1H NMR ratio of the isomeric forms of (3,6)-1-benzyl-4-butyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione using different catalysts for diacetate cyclisation 
The 
1
H NMR spectrum of the product clearly showed a cis/trans ratio of 94:6 for TFA 
catalysed reaction (entry 4, Table 2) against 57:43 when DMAP was used (entry 3, 
Table 2). From these results we found that in the presence of TFA, there was virtually 
complete conversion to the cis n-butyl compound at 130 °C after 30 minutes indicating 
that these are the optimum conditions for its synthesis. This may be due to the presence 
of protons from TFA, which results in the conversion of the trans to cis isomer which is 
more thermodynamically stable. By using the Biotage™ microwave, the reaction rate 
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was accelerated resulting in more rapid conversion to the cis-butyl ETP precursor in 
reasonable yield. 
 
Method Entry 
Temperature 
(°C) 
Time 
(hours) 
Catalyst 
Ratio 
(cis/trans) 
Conventional 
1 51 16 DMAP N/D 
2 51 16 TFA N/D 
Microwave 
3 130 0.5 DMAP 57/43 
4 130 0.5 TFA 94/6 
Table 2 – Ratio of the isomeric forms of (3,6)-1-benzyl-4-butyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione 
using different catalysts for diacetate cyclisation 
It is known that this reaction initially occurs under kinetic control resulting in the most 
easily formed but least stable product.
1
 As it proceeds, the most stable thermodynamic 
isomer is formed as the major product. The most thermodynamically stable 
stereoisomer is the cis-ETP precursor.
1
 However, the cis/trans stereoisomers can only 
be converted to one another by the process of breaking and reforming of the carbon 
sulfur bond. TFA facilitates this conversion of the trans to cis compound apparently by 
two reasons: the loss of the mercaptan group from the ETP precursor (407) resulting in 
the formation of acyliminium cation (408) or by the inference of the thiocarbenium ion 
and cleavage of the diketopiperazine ring as proposed by Williams.
157
 Re-addition of 
nucleophilic sulfur to the intermediate (408) results in formation of the cis compound 
(373) (Scheme 103).
1
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Scheme 103 – (3S,6S)-1-benzyl-4-butyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione synthesis using an acid 
catalysed reaction 
However, this conversion from the trans to cis isomer requires the presence of protons 
which cannot be provided by DMAP. This may explain the lower yield compared to its 
analogous catalyst TFA. Nevertheless, a good yield was still achieved for cis-
diketopiperazines synthesis with the use of DMAP with purification being achievable 
by recrystallisation of the cis/trans mixture. This method is therefore useful for the 
synthesis of compounds that contain acid sensitive functional groups. 
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3.3 Monomeric ETP formation 
The next phase of the research project involved determining the optimum reaction 
conditions for the introduction of a number of amines into the ETP core. In order to 
synthesise these protected ETP precursors, changes were made in three areas to obtain 
the desired products: 
 Variation of the diacetate precursor. 
 Catalyst selection (TFA and DMAP). 
 Use of reflux and microwave heating conditions. 
Combinations of the above parameters facilitated the synthesis of a small library of 
monomeric compounds as described below. 
3.3.1 Monomeric disubstituted ETPs 
The first series used diacetate (259) to give the following protected ETPs (Table 3). It 
was noticeable that the use of reflux conditions to achieve protected ETP formation 
surpasses the use of microwave accelerated reactions. Only compound (416) gave a 
better reaction yield when microwave conditions were used. Base catalysed reactions in 
the example of protect 3-chlorobenzylamine substituted ETP (410) clearly highlighted 
the utility of this alternative method, since yields for both conditions (i. e. reflux and 
microwave) showed an increase in product formation. When comparing product 
formation under reflux conditions, compound (410) showed a 15% yield increase when 
a base catalyst was used compared to the analogous acid catalysed reaction. The same 
type of correlation was obtained using microwave accelerated conditions with a 17% 
difference in yields between both base and acid catalysed reactions. 
The production of compounds (411), (412), (413) and (414) demonstrated the 
importance of DMAP as an alternative catalyst for the cyclisation of ETP intermediates. 
Using this approach, we were able to introduce different carbon length ester groups in 
the ETP core avoiding acid hydrolysis. Reaction outcomes reflected the results and 
yields obtained with the use of reflux conditions clearly surpassing microwave usage. 
The optimum reaction conditions for ethyl 4-aminobutanoate (411) and aminocaproic 
methyl ester (412) protected ETP derivatives were to use reflux methodology which 
gave better yields in both cases. 
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R Group 
Compound Catalyst 
Conditions 
Yield (%) 
Temperature (°C) Time 
 
410 
TFA 51 (Reflux) 16h 60 
DMAP 51 (Reflux) 16h 75 
TFA 150 (MW) 5min 51 
DMAP 150 (MW) 5min 68 
 
411 
DMAP 51 (Reflux) 16h 70 
DMAP 130 (MW) 35min 28 
 
412 
DMAP 51 (Reflux) 16h 76 
DMAP 130 (MW) 25min 46 
 
413 DMAP 160 (MW) 16h 61 
 
414 DMAP 51 (Reflux) 16h 78 
 
415 
TFA 51 (Reflux) 16h 64 
TFA 150 (MW) 5min 60 
 416 
TFA 51 (Reflux) 16h 54 
DMAP 51 (Reflux) 16h 53 
DMAP 140 (MW) 30min 76 
 
417 TFA 51 (Reflux) 16h 64 
 
418 TFA 51 (Reflux) 16h 33 
 
419 TFA 51 (Reflux) 16h 58 
 
420 TFA 51 (Reflux) 16h 84 
Table 3 – Conditions for the synthesis of different protected disubstituted ETPs (1) 
Diacetate (395) was also used to produce different protected ETP intermediates (Table 
4). These two protected ETP examples share similar conditions as previously described 
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(i. e. reflux and microwave). However, unlike the previous examples, the best yield 
achieved in the synthesis of the allyl protected ETP precursor (421) was attained using 
microwave conditions. This clearly correlates with the previous result reported for this 
substituent to its N-benzyl analogue (416) which differed from the other results with an 
increased yield when compared to similar synthetic compounds using reflux conditions.  
Using the same base catalyse reaction methodology, benzyl protected ETP precursor 
(416) was synthesised under reflux conditions with a 72% yield. 
 
R Group 
Compound Catalyst 
Conditions 
Yield (%) 
Temperature (°C) Time 
 421 DMAP 140 (MW) 30min 72 
 
416 
TFA 51 (Reflux) 16h 80 
DMAP 51 (Reflux) 16h 72 
Table 4 – Conditions for the synthesis of different protected disubstituted ETPs (2) 
Diacetate (397) containing the N-methyl substituent enabled the synthesis of compound 
(423) (Table 5). The use of our approach to achieve cyclisation of the bis-N-methyl 
protected ETP (423) via acid catalysis with reflux conditions was the preferred method 
to attain the highest reaction yield. Dean and Stark conditions were also used for the 
synthesis of intermediate (423) as before for compound (392) to facilitate water removal 
from the reaction.  
 
R Group 
Compound Catalyst 
Conditions 
Yield (%) 
Temperature (°C) Time 
 
423 TFA 51 (Reflux) 24h 62 
Table 5 – Conditions for the synthesis of different protected disubstituted ETPs (3) 
Following the obtention of the ETP core, the last step for ETP synthesis was formation 
of the disulfide bridge. Conversion to the ETP core was achieved by the use of neat 
boron tribromide which as a Lewis acid, accepting a pair of electrons from the oxygen 
atom from the diketopiperazine core, which results in the loss of the PMB protecting 
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group from the ETP precursor via nucleophilic attack of the bromide anion as outlined 
below (Scheme 104). 
 
Scheme 104 – Molecular mechanism of ETP intermediate sulfur deprotection 
Protonation of the sulfur anion forming the dithiol intermediate followed by the addition 
of iodine, resulted in the concomminat oxidation and formation of the disulfide bridge 
(Scheme 105).
217
 
 
Scheme 105 – Molecular mechanism of ETP dissulfide bridge formation 
As part of the work-up procedure, sodium thiosulfate was added to the mixture to 
quench any excess iodine that might be present. Consequently, this reaction results in a 
one pot deprotection and oxidation of the ETP precursor leading to the final compound 
containing the disulfide bridge. 
However, variable yields were reported in the formation of the disulfide bridge showing 
that this reaction clearly requires optimisation regarding the number of steps involved in 
this transformation. We therefore decided to use different conditions during the reaction 
procedure to overcome previous difficulties encountered. In the dithiol deprotection 
step, changes were made by the use of either sodium hydrogen carbonate or 
hydrochloric acid instead of ammonium chloride as previously described by Hilton.
1
 
However, the use of iodine was maintained for the oxidation step. Compounds that were 
synthesised along with appropriate optimised conditions are shown below (Table 6). 
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R1 Group R2 Group Compound H
+
 Source Yield (%) 
 
 
424 NH4Cl 32 
 
425 NaHCO3 64 
 
426 NaHCO3 75 
 
427 NaHCO3 51 
 
428 NaHCO3 29 
 429 HCl 54 
 
430 NH4Cl 85 
 431 NH4Cl 60 
 
432 HCl 65 
 
433 NH4Cl 65 
 
434 NH4Cl 85 
 
435 NH4Cl 48 
  
436 NH4Cl 67 
  
437 NH4Cl 68 
Table 6 – Conditions for the ETPs dissulfide bridge formation 
The yields obtained from the deprotection / oxidation step leading to the desired ETPs 
vary between the substituted ETP examples that were used. Despite the variations, only 
three examples gave final yields below 50%: 3-chlorobenzyl (424), valeric methyl ester 
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(428) and para-methoxybenzyl substituted (435) ETPs. All other compounds gave 
yields that were consistently above 50% when the optimised conditions were used. 
3.3.2 Monomeric tri-substituted ETPs 
In order to extend the diversity of monomeric compounds developed, we decided to 
instigate the production of tri-substituted ETPs. With this objective in hand, a new 
approach for our diacetate precursor was developed. 
The idea behind the need to synthesise tri-functionalised ETPs arose from the need to 
produce a wider and more diversified library of ETP compounds than had previously 
been achievable with our methodology. Solubility of the final monomeric ETP 
molecules was another argument that compelled this work. This is a key molecular 
property that is crucial for both biological testing and drug formulation. The solution 
that we expected to overcome solubility difficulties rested on functionalising the 
available 3- and 6- positions that surround the ETP core. Hence, deprotonation / 
alkylation of the carbons adjacent to the sulfur atoms would give the desired 
compounds. This approach previously used by Kishi encountered regioselectivity 
problems, since both hydrogens present in the 3- and 6- positions of the 
diketopiperazine ring could easily be deprotonated in the same reaction step (Scheme 
106).
179,182
 The equal acidity of both these hydrogens coupled with molecular symmetry 
directed the alkylation of both positions in a nonspecific manner. The use of different 
alkylating groups with dissimilar reactivity also led to mixtures of tri and tetra-
substituted ETP precursors.
182
 
 
Scheme 106 – Kishi’s trisubstituted ETP synthesis 
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To overcome this, we decided to design a new cyclisation strategy for our diacetate with 
a different and easy exchangeable group introduced instead of the protected thiol as 
reported previously, leading to selective deprotonation / alkylation on the nonadjacent 
carbon. Alkylation should be more specific using this approach with different acidities 
being displayed by hydrogens in both the 3- and 6- positions. Following this, the new 
substitutent groups should be readily converted into the para-methoxybenzyl mercaptan 
group, leading to the desired protected ETP (Scheme 107). 
 
Scheme 107 – Protected trisubstituted ETP synthesis 
As described previously, the first step involved modifying our diacetate cyclisation 
procedure, by introducing a different substituent on the 3- position of the ETP precursor 
core to allow selective mono- alkylation. For this, different approaches were envisaged 
(Scheme 108) where cyclisation of our diacetate (398) would be altered by using one of 
the reactions by-products – water, as a nucleophile. This would give rise to a hydroxy 
intermediate (443) with differing acidities on both the 3- and 6- positions hydrogens of 
the diketopiperazine ring. Since the hydrogen closer to the sulfur protected substituent 
would be more readily removable, the synthesis of such an ETP precursor would enable 
alkylation on the 6- position of the diketopiperazine ring. However, substitution of the 
hydroxy group for PMBSH could prove to be extremely difficult as a strong acidic 
environment would be needed. We then intended to convert this newly tri-substituted 
intermediate (442) with acetic anhydride to form the correspondent acetate (441). 
Subsequent acid treatment followed by reaction with PMBSH would render the desired 
protected ETP core (440). 
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Scheme 108 – Retrosynthetic approach for the synthesis of protected trisubstituted ETPs (1) 
Although this new methodology could provide good overall results, it would also 
increase the number of steps. We therefore first decided to investigate the use of 
different nucleophiles for the initial diacetate cyclisation step. The idea was based on 
avoiding extra unnecessary steps which would reduce the efficiency of the synthetic 
pathway and therefore the overall yield. One of the reported steps which involved 
acetate (441) formation on diketopiperazine 6- position could be avoided by introducing 
a simpler removable group in the initial part of the synthesis (Scheme 109). Thus, the 
use of different reaction solvents that could also act as nucleophiles and change the 
reactivity of the two equidistant hydrogens were used for our diacetate cyclisation 
process. 
 
Scheme 109 – Retrosynthetic approach for the synthesis of protected trisubstituted ETPs (2) 
Experiments were carried out with a number of different alcohols as solvents. Imine 
formation followed and nucleophilic attack by the new substitutent group allowed for 
the formation of the new monothiol-protected products. As shown below (Figure 64), 
three compounds were synthesised by the use of methanol (Entry 1), ethanol (Entry 2) 
and isopropanol (Entry 3) as reaction solvents. All new compounds shared 
1
H NMR 
spectrum similarities with the dibenzyl protected ETP precursor (415) since the methyl 
group belonging to the para-methoxybenzyl mercaptan substituent was present in the 
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3.80ppm region. However, different shifts due to the introduction of dissimilar 
substituents could be seen in between the 1.05 and 1.30ppm region. 
 
Figure 64 – 1H NMR showing diacetate cyclisation using different solvents: methanol (entry 1), ethanol (entry 2), 
isopropanol (entry 3) and acetonitrile with para-methoxybenzyl mercaptan (entry 4) 
Though tert-butanol was also used as a nucleophile for the described reaction, no 
molecule that contained a tert-butoxy group was found. However, NMR analysis 
(Figure 65) showed the presence of a hydroxy product (450) as already described. This 
may have occurred due to the weak nucleophilicity of tert-butanol allowed the reaction 
of another nucleophile present in the reaction – water. Since one molecule of water is 
generated after the protonation of the aldehyde intermediate and with poor solubility of 
the reactions solvent, a nucleophilic attack by the formed water molecule might be the 
reason for the synthesis of this compound (450). 
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Figure 65 – 1H NMR of diacetate cyclisatio using tert-butanol 
After purification and analysis of the reaction yields, we decided to take the simplest 
product which was the methoxy intermediate (448) since it gave consistently higher 
cyclisation yields than other precursors (i. e. ethoxyde, isopropyl and hydroxide 
derivatives) as shown below (Table 7). 
 
Substituent Solvent Compound Yield (%) 
 
Methanol 448 79 
 
Ethanol 447 74 
 
iso-
Propanol 
446 60 
 
tert-Butanol 450 59 
Table 7 – Diacetate cyclisation using different solvents 
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Deprotonation of (448) was attempted using a number of basic conditions (Table 8) for 
the introduction of the vinyl halide.
210
 From these, lithium bis(trimethylsilyl)amide 
(LiHMDS) (Entry 1) was the base of choice to proceed with the synthetic pathway with 
a 79% yield. Other bases included lithium diisopropylamide (Entry 2), sodium hydride 
(Entry 3) and two different forms of butyllithium (Entries 4, 5) but all gave lower yields 
of alkylated product (453). 
 
Base Entry Yield (%) 
LiHMDS 1 79 
LDA 2 32 
NaH 3 22 
nBuLi 4 0 
secBuLi 5 0 
Table 8 – Conditions for alkylation of the methoxy trisubstituted ETP intermediate 
Substitution of the methoxy group for the desired para-methoxybenzyl mercaptan group 
was achieved using trifluoroacetic acid with an 83% yield after purification. The final 
step for ETP formation underwent the same procedure as described before giving 
compound (455) in 24% yield (Scheme 110). 
 
Scheme 110 – (±)-(1S,4S)-1-allyl-2,5-dibenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide synthesis 
The same methodology was used to obtain compound (459). Substituting the previously 
used allyl bromide for benzyl bromide gave intermediate (457) in 59% yield. The next 
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two synthetic steps involved para-methoxybenzyl mercaptan introduction (91% yield) 
and thiol deprotection / oxidation to form the desired ETP (459) in a 50% yield as 
shown below (Scheme 111). 
 
Scheme 111 - (±)-(1S,4S)-1,2,5-tribenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide synthesis 
Cyclisation of diacetate (259) using allyl amine and DMAP in a methanolic mixture 
gave compound (461) in a 76% yield. Benzyl bromide (456) was then reacted with the 
methoxy derivative (461) in the presence of LiHMDS to give (462) in a reduced 49% 
yield. Following the previously described procedure to introduce the protected thiol 
group gave intermediate (463) in 81% yield that after disulfide formation gave ETP 
(464) in 23% yield as shown below (Scheme 112). 
 
Scheme 112 - (±)-(1S,4S)-5-allyl-1,2-dibenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide synthesis 
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Both allyl tri-substituted ETP derivatives (i. e. compounds (455) and (464)) gave poor 
yields in the deprotection / oxidation synthetic steps when compared to the tri-benzyl 
substituted ETP (459). This may occur due to the increased lipophilicity of compound 
(459) which makes it more sterically protected facilitating the formation of the disulfide 
bridge. 
Our synthesis was then directed to the missing ETP analogue that would include two 
benzyl as well as one allyl substituents, compound (467). The uses of diacetate (395) 
facilitated the formation of desired precursor (465) and in addition enabled us to test the 
procedure reproducibility when using a different diacetate as a building block. We then 
decided to use different diacetate ETP intermediates to synthesise other molecules and 
prove the reproductibility of this new approach (Scheme 113).  
 
Scheme 113 – 2-(Allyl(2-ethoxy-1-(4-methoxybenzylthio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
cyclisation for the synthesis of trisubstituted ETPs 
The formation of compound (471) started with cyclisation of diacetate (395) using the 
above described conditions: methanol, DMAP and amine (255); with a 85% yield. 
Introduction of the benzyl group on the 3- position followed by methoxy substitution for 
para-methoxybenzyl mercaptan gave intermediate (470) in 64% yield. Thiol 
deprotection and disulfide bridge formation gave ETP (471) in a reduced 21% yield 
(Scheme 114) with similar yields achieved for the final synthetic step for ETPs (455) 
and (464) (Schemes 110 and 112). 
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Scheme 114 – (±)-(1S,4S)-2-allyl-1,5-dibenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide synthesis 
This approach that enabled selective alkylation of the ETP core directed our synthesis to 
different structures with the introduction of new cyclic systems. 
3.3.2.1 Bicyclic monomeric ETP 
Following the synthesis of a precursor that was readily alkylated on the ETP’s 3- 
position, we decided to attempt a new approach towards bicyclic ETPs, in order to 
synthesise more complex systems. As a result of the incorporation of an alkyl group on 
the ETP core, olefin metathesis seemed to be an ideal opportunity to achieve this. Olefin 
metathesis includes multiple features, from ring-closing metathesis (RCM) to cross 
metathesis (CM), and has become one of the most powerful and useful tools in organic 
synthesis for the formation of carbon-carbon double bonds.
286, 287
 Our primary objective 
was to make a terminal diolefin intermediate using our previously synthesised ETP 
precursor (468) in the presence of a strong base and allyl halide (472) addition. 
Introduction of the protected thiol group (474) followed by RCM using Grubbs catalyst 
would therefore give product (475) (Scheme 115). 
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Scheme 115 – Synthetic approach for the synthesis of 2-benzyl-3,9a-bis((4-methoxybenzyl)thio)-2,3,9,9a-tetrahydro-
1H-pyrido[1,2-a]pyrazine-1,4(6H)-dione 
RCM is a well known reaction that can be achieved in many cases under ambient 
conditions, using different types of Grubbs catalysts as shown below (Figure 66).
281
 
 
Figure 66 – Grubbs 2nd generation catalyst and Grubbs-Hoveyda 2nd generation catalyst 
Recently, it has been shown that RCM represents an important advance in the 
construction of functionalized heterocycles.
288
 Studies by Chai et al 
289
 demonstrated 
successful functionalisation of the piperazine-2,5-dione motif using this methodology 
(Scheme 116). Mono and dual functionalization was achieved using   piperazinedione 
(476) chemoselective N- and C-alkylation; the diallylated product (477) was then 
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submitted for ring-closing metathesis using a first generation Grubbs catalyst to give the 
cyclic alkene (478) in 82% yield. 
 
Scheme 116 – Chai’s synthetic functionalisation of the piperazine-2,5-dione core 
Our synthetic pathway started with formation of the previously described methoxy 
intermediate (468) followed by deprotonation and subsequent alkylation using allyl 
bromide to give compound (479) in a 68% yield. After acid treatment and para-
methoxybenzyl mercaptan addition, protected dithiol ETP precursor (480) was then 
reacted with Grubbs second generation catalyst under reflux conditions to give the 
bicyclic products (481 – (1)) and (481 – (2)) in 40% and 3% yields, respectively. 
Unfortunately, compound (482) disulfide bridge formation was inaccessible (Scheme 
117). 
 
Scheme 117 – (±)-(3S,9aS)-2-benzyl-2,3-dihydro-3,9a-epithiopyrido[1,2-a]pyrazine-1,4(6H,9H)-dione 10-sulfide 
synthesis 
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Our evaluation of the failure of this approach led us to consider whether the compound 
possessed a trans conformation (481 – (1)) (Figure 67). This conformer would not be 
able to form the desired ETP. The solution found to surpass this problem was to re-
arrange the synthetic route i. e. promote first, disulfide bridge formation, and second, 
RCM of the resulting diallyl ETP. 
 
Figure 67 – Protected dithiol probable conformation in the synthesis of 2-benzyl-3,9a-bis((4-methoxybenzyl)thio)-
2,3,9,9a-tetrahydro-1H-pyrido[1,2-a]pyrazine-1,4(6H)-dione 
Similar synthetic steps, as described before, were used to obtain intermediate (480). 
This was submitted to thiol deprotection and subsequent oxidation gave ETP (483) in a 
28% yield (Scheme 118). 
 
Scheme 118 – (±)-(1S,4S)-1,2-diallyl-5-benzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide synthesis 
Ring closing metathesis of ETP (483) required the study of different conditions since 
bicyclic ETP (482) formation was inaccessible using the same experimental 
methodology as for intermediate (481). As shown below (Table 9), the conversion of 
diallyl ETP (483) to the desired product (482) was achieved with the use of microwave 
accelerated reaction. Comparing both catalysing agents used, Grubbs-Hoveyda second-
generation catalyst showed the best result with a 40% yield (Entry 4). 
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  Conditions  
RCM catalyst Entry Temperature (°C) Time Yield (%) 
Grubbs second generation 1 160 (Reflux) 24h 0 
Grubbs second generation 2 80 (MW) 30min 8 
Grubbs-Hoveyda second-generation 3 160 (Reflux) 24h 0 
Grubbs-Hoveyda second-generation 4 80 (MW) 30min 40 
Table 9 – Conditions for the synthesis of (±)-(3S,9aS)-2-benzyl-2,3-dihydro-3,9a-epithiopyrido[1,2-a]pyrazine-
1,4(6H,9H)-dione 10-sulfide 
The synthesis of tri-substituted ETPs enabled us to not only increase the library of 
compounds produced, but to diversify the synthetic methodology behind cyclisation of 
our diacetate ETP precursors. Success in the synthesis of a bicyclic ETP molecule using 
a common building block allowed us to extend our research to the next objective where 
we elected to design a tri-cyclic ETP using a tetra-substituted ETP approach. 
3.3.3 Monomeric tetra-substituted ETPs 
In order to form a tri-cyclic ETP derivative we first needed to synthesise a tetra-
substituted symmetric ETP by adding two allyl groups on both the 3- and 6- positions. 
Formation of compound (485) commenced with the already described base induced 
cyclisation procedure of our diacetate (395), to give (421) in a 72% yield. 
Deprotonation / alkylation of (421) using allyl bromide in the presence of LiHMDS 
gave the protected tetra-substituted ETP (485) in 55% yield (Scheme 119). 
 
Scheme 119 – (3S,6S)-1,3,4,6-tetraallyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione synthesis 
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3.3.3.1 Tricyclic monomeric ETP 
Ring-closing of the previously synthesised tetra-vinyl protected ETP (485) using 
Grubbs second generation catalyst led to intermediate (486) in 28% yield. Deprotection 
/ oxidation of (486) did not however give rise to the desired tri-cyclic ETP (487) 
(Scheme 120). This result clearly highlighted the already demonstrated problem of 
synthesising an extra ring before disulfide bridge formation. 
 
Scheme 120 – Inital planned synthetic route for (±)-(6aS,12aS)-7,10-dihydro-6a,12a-epithiodipyrido[1,2-a:1',2'-d] 
pyrazine-6,12(1H,4H)-dione 13-sulfide synthesis 
We therefore decided to synthesise a tetra-substituted ETP which could then be 
submitted to RCM conditions. To this end, compound (485) was reacted with boron 
tribromide and oxidised using iodine to give (488) in 41% yield (Scheme 121). 
 
Scheme 121 – (±)-(1S,4S)-1,2,4,5-tetraallyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide synthesis 
The results shown below (Table 10) demonstrate that ring closing metathesis of ETP 
(488) using Grubbs-Hoveyda second generation catalyst under microwave conditions 
gave the best result to achieve the desired tri-cyclic ETP system (487) with a 39% yield 
(Entry 4). 
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  Conditions  
RCM catalyst Entry Temperature (°C) Time Yield (%) 
Grubbs second generation 1 160 (Reflux) 24h 0 
Grubbs second generation 2 80 (MW) 30min 7 
Grubbs-Hoveyda second-generation 3 160 (Reflux) 24h 0 
Grubbs-Hoveyda second-generation 4 80 (MW) 30min 39 
Table 10 – Conditions for the synthesis of (±)-(6aS,12aS)-7,10-dihydro-6a,12a-epithiodipyrido[1,2-a:1',2'-d] 
pyrazine-6,12(1H,4H)-dione 13-sulfide 
The formation of the tricyclic ETP (487) clearly demonstrated the diversity of 
compounds which can be created using different diacetate ETP precursors. Based on 
these results, our synthesis turned to the development of molecules that would 
incorporate two disulfide bridged cores, namely that of dimeric ETPs. 
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3.4 Dimeric ETP formation 
The dimeric ETPs that occur in Nature often display far more potent biological activity 
than those of their monomeric ETP counterparts. However, due to the greater 
complexity, these structures are often more difficult to synthesise. As a result of this, 
only a few dimeric ETP syntheses have been reported in the literature to date.
156, 225, 227
 
In way of example, Movassaghi’s elegant enantioselective synthesis of (+)-11,11-
dideoxyverticillin A (65) involved a number of steps that cannot be applicable towards 
the synthesis of a library of medicinally useful analogues.
156
 
We therefore decided to design different methods that could simplify the approach 
towards these dimeric constructs. By adapting the synthetic pathways described to build 
monomeric ETPs and extending this methodology towards their corresponding dimeric 
derivatives, we could vary our library of compounds. 
3.4.1 Diamino-tetra-acetate intermediate formation 
Our first approach to develop a simple method that could facilitate the formation of two 
ETP cores in the same molecule was to introduce a linker unit in the first step of the 
ETP synthesis (Scheme 122). This linker would include two amine motifs that could 
undergo a corresponding five component reaction, analogous to the previously 
described formation of the diacetate, in the presence of ethyl glyoxalate (256) and para-
methoxybenzyl mercaptan (257) (Scheme 122).
1
 
  
Scheme 122 – Model proposed for the synthesis of the diamino ETP intermediate based on a singular amine 
approach 
Using this methodology, diamine (490) was reacted with two equivalents of both ethyl 
glyoxalate (256) and PMBSH (257) to give intermediate (491) in 58% yield (Scheme 
123). 
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Scheme 123 – Ethyl 2-((6-((2-ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino) hexyl)amino)-2-((4-methoxy 
benzyl)thio)acetate synthesis 
Following the same approach, intermediate (493) was also produced in 79% yield. This 
was achieved using p-xylylenediamine (492) as a linker unit between the two esters 
elements as well as ethyl glyoxalate (256) and PMBSH (257) (Scheme 124). 
 
Scheme 124 – Diethyl 2,2'-((1,4-phenylenebis(methylene))bis(azanediyl))bis(2-((4-methoxybenzyl)thio)acetate) 
synthesis 
The second step towards the synthesis of a modified dimeric diacetate compound 
involved reaction of intermediates (491) and (493) with diacetoxyacetyl chloride (379) 
under double Schotten-Baümann conditions as before. This led to the formation of both 
diacetate cyclisation precursors (494) and (495) in 90 and 85% yield respectively 
(Scheme 125). 
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Scheme 125 – Synthesis of different diamino diacetate ETP intermediates 
The synthesis of these two diamino-didiacetate compounds led to the previously 
reported reaction model of ring closing using an amine, a protected thiol group and a 
catalyst. For this purpose, diacetates (494) and (495) were reacted with benzylamine 
(255) and para-methoxybenzyl mercaptan using our base catalysed reaction. Different 
conditions were used in order to achieve the protected tetra-thiol intermediates (496) 
and (497). Results showed no significant prevalence in yield for either reflux or 
microwave conditions (Table 11). 
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  Conditions   
R group Entry Temperature (°C) Time Yield (%) Compound 
 
1 51 (Reflux) 16h 43 
496 
2 130 (MW) 30min 48 
 
3 51 (Reflux) 16h 50 
497 
4 130 (MW) 30min 47 
Table 11 – Conditions for the cyclisation of different diamino diacetate ETP intermediates 
Unfortunately, the subsequent synthetic step which included deprotection / oxidation of 
the previously obtained protected thiol intermediates was found to be extremely difficult 
to achieve. This was due to the very low solubility of compounds containing four thiol 
deprotected groups (Scheme 126) as well as different by-products originating from the 
reaction. 
 
Scheme 126 – Inital planned synthetic route for dimeric ETP  thiol deprotection / oxidation 
To overcome this problem we decided to the use a 1M solution of boron tribromide 
instead of the neat form of this reagent, since dilution of this Lewis acid could lead to 
better solubility and hopefully a better outcome. In addition, we decided to incorporate 
methanol after reaction of boron tribromide. We envisioned that methanol would 
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increase the solubility of the suspension by dissolving the reaction products, by-
products and existing excess reagent. Treatment with sodium hydrogen carbonate and 
iodine would then enable the desired tetra-thiol compounds to be obtained. 
Using this new methodology, dimeric protected ETPs were deprotected using a 1M 
solution of boron tribromide in dichloromethane. Solubility difficulties were dissipated 
with the addition of methanol before treatment with aqueous sodium hydrogen 
carbonate. Oxidation using iodine to form the required disulfide bridge followed. 
Automatic column purification and HPLC separation of the reaction products rendered 
compounds (498) and (499) in 23 and 50% yields, respectively (Scheme 127). 
 
Scheme 127 – Different dimeric ETPs thiol deprotection / oxidation  
Using similar methodology as described previously for monomeric ETPs enabled the 
formation of molecules that included two ETP cores in the same structure. However, to 
simplify the approach towards dimeric compounds we decided to use our diacetate ETP 
precursors and link them by using one diamine as described below. 
3.4.2 Diacetate cyclisation using a diamino linker unit 
In order to synthesise dimeric ETPs, one possibility arose where one could potentially 
adapt the methodology for our monomeric ETPs. In our current protocol, primary 
amines were reacted with our diacetate (394) to furnish the required ETP core (402). If 
different diamines were to be used in its place, we could potentially access dimeric 
ETPs (500) via reaction of each amine with a diacetate precursor (Scheme 128).  
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Scheme 128 – Model proposed for the synthesis of different protected dimeric ETP intermediates based on a diamine 
linker unit approach 
The restructured methods developed to create these dimeric constructs require two 
diacetate molecules for every diamine linker, as shown above (Scheme 128). However, 
the use of a base catalysed reaction would obviously require the presence of another 
diamine molecule due to by-products formed during the catalyst’s regeneration (Scheme 
129). In addition, two para-methoxybenzyl mercaptan molecules were also required for 
the formation of the dimeric ETP molecule. This model defined the reaction’s ratio of 
2:2:2 diacetate, diamine and para-methoxybenzyl mercaptan in our initial attempts to 
form protected dimeric ETPs. 
 
Scheme 129 – By-products of DMAP catalysed cyclisation (2) 
Following the outlined protocol, different amine linkers were used to attempt 
cyclisation. 1,4-Diaminobutane (502) was the first diamine that was used for this 
purpose. This diamine nucleophile would potentially provide access to protected ETPs 
linked via four carbon atoms (Scheme 130). 
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Scheme 130 – Model for the synthetic route of (3S,3'S,6S,6'S)-4,4'-(butane-1,4-diyl)bis(1-benzyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione) 
Reaction of the diamine (502) with diacetate (259), para-methoxybenzyl mercaptan and 
DMAP under reflux conditions clearly showed the presence of two spots with low Rf 
values on the TLC plate, indicating the presence of extremely polar compounds. This 
was unexpected since we anticipated that the Rf of the desired compound (503) would 
be closer to that of the starting material. Following purification by flash column 
chromatography, two products (504) and (505) were isolated. The structures for these 
two compounds were established by 
1
H NMR and 
13
C NMR spectrum as shown below 
(Figure 68). 
 
Figure 68 – Isomeric forms of (8S,10a)-9-benzyl-8-((4-methoxybenzyl)thio) octahydropyrazino[1,2-a][1,3] 
diazepine-7,10-dione 
Following purification, 36% of the cis cyclised product (504) was obtained along with 
12% of the trans isomer (505), indicating that the cis compound was more favourable as 
a result of its higher stability compared to the trans form. NMR spectrum analysis of 
both cyclised products showed only one CH group next to the sulfur of the PMB group 
at 4.43 ppm (504) and 4.38 ppm (505), whereas two CH groups are normally found. The 
13
C NMR spectrum showed a shift in the position of one of the peaks representative of a 
CH group; this indicated that the CH group was next to the nitrogen atom rather than 
the sulfur as expected from the diketopiperazine synthesis. Therefore, the NMR 
spectrum showed two peaks representing the CH groups but with different shifts of 
72.06 (504), 72.48 (505) ppm and 58.08 (504), 57.02 (505) ppm representing the CHs 
next to nitrogen and sulfur respectively. Formation of these products was also 
confirmed with mass spectrometry data. The use of a short length carbon chain (four 
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carbon chain) resulted in an intramolecular cyclisation and consequently the protected 
dimeric ETP (503) synthesis was not successful. This may had arisen since cyclisation 
of the four carbon diamine with one diacetate intermediate (259) results in the formation 
of a seven membered ring which was perhaps more favourable than the synthesis of the 
dimeric prospect molecule (503). Scheme 131 below illustrates the proposed synthetic 
pathway for the formation of the intramolecular cyclised products. 
 
Scheme 131 – Molecular mechanism for the synthesis of (8S,10a)-9-benzyl-8-((4-methoxybenzyl)thio) 
octahydropyrazino[1,2-a][1,3] diazepine-7,10-dione 
Following this, we decided to use 1,6-diaminohexane (490) as the nucleophile to link 
two ETP cores. The reason behind the use of longer chain diamine comes from the 
reduced probability of an intramolecular cyclisation that would produce a nine 
membered ring, which is disfavoured when compared to the formation of desired 
protected dimeric ETP. 
This outlook led to the reaction of diacetate (259) with 1,6-diaminohexane (490) and 
para-methoxybenzyl mercaptan in the presence of DMAP. The reaction mixture was 
stirred at room temperature for 10 min and after heated at 130 °C for 30 minutes under 
microwave conditions (Scheme 132). 
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Scheme 132 – (3S,3'S,6S,6'S)-4,4'-(hexane-1,6-diyl)bis(1-benzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-
dione) synthesis 
Following purification by automatic flash column chromatography and recrystallisation, 
the dimeric ETP precursor (497) was obtained in a good yield of 33%. The following 
scheme outlines the proposed mechanistic pathway for the formation of the dimeric 
product (Scheme 133). 
 
Scheme 133 – Molecular mechanism for the synthesis of (3S,3'S,6S,6'S)-4,4'-(hexane-1,6-diyl)bis(1-benzyl-3,6-
bis((4-methoxybenzyl)thio)piperazine-2,5-dione) 
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After achieving our first protected dimeric ETP, we decided to synthesise a second 
dimeric ETP (512) (Scheme 135), which came from reaction of the cyclopropane 
substituted diacetate analogue (396) and a diamine linker. In the first instance, we 
synthesised cyclisation precursor (396) as described previously in 54% overall yield 
(Scheme 134). 
 
Scheme 134 – 2-(cyclopropyl(2-ethoxy-1-(4-methoxybenzylthio)-2-oxoethyl) amino)-2-oxoethane-1,1-diyl diacetate 
synthesis 
Reaction of this diacetate precursor (396) with 1,6-diaminohexane (490), para-
methoxybenzyl mercaptan and DMAP as catalyst followed. Conditions for this 
synthesis were similar to those used before for compound (497), stirring at room 
temperature for 10 min followed by heating at 130 °C for 30 minutes under microwave 
conditions. Following purification/recrystallisation, we observed efficient formation of 
the desired protected dimeric ETP (512) in a yield of 25% as the cis isomer, 
highlighting the relative ease with which dimeric ETP analogues may be synthesised 
using this synthetic approach (Scheme 135). 
 
Scheme 135 – (3S,3'S,6S,6'S)-4,4'-(hexane-1,6-diyl)bis(1-cyclopropyl-3,6-bis((4-methoxybenzyl)thio)piperazine-
2,5-dione) synthesis 
The next attempt led to the synthesis of another protected dimeric ETP analogue (514) 
by reaction of diacetate (529) and a different diamine linker, meta-xylylenediamine 
(513) (Scheme 136). 
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Scheme 136 – Model for (3S,6S)-1-benzyl-4-(3-(((2R,5R)-4-benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-
dioxopiperazin-1-yl)methyl)benzyl)-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione synthesis 
Following purification, analysis of the 
1
H NMR spectrum surprisingly indicated the 
formation of a symmetrical monomeric ETP precursor (415) which was obtained from 
the dimerisation of two amines (258) (Scheme 137). 
 
Scheme 137 – 1,4-dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione synthesis as a by-product of 
(3S,6S)-1-benzyl-4-(3-(((2R,5R)-4-benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-dioxopiperazin-1-yl)methyl)benzyl)-
3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione synthesis 
This led to the investigation of a possible mechanism by which this dimerisation may 
have taken place. With this, a two component reaction using amine (258) in the 
presence of a catalyst and acetonitrile as a solvent was carried out to attempt the 
synthesis of (415) (Scheme 138).  
 
Scheme 138 – 1,4-dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione synthesis using microwave 
conditions and different reaction catalysts from ethyl-2-(benzylamino)-2-((4-methoxybenzyl)thio)acetate as starting 
material 
As anticipated, the ETP (415) was obtained using both types of catalyst although only in 
trace quantities (<20%). 
Following the previous reaction using meta-xylylenediamine (513), we then tried to 
synthesise the same type of ETP precursor however using para-xylylenediamine (492). 
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The reasons for choosing this linker were due to the amine positions that may avoid the 
previous outcome as for the putative synthesis of compound (514). The equidistant 
position of the amines could determine a better positioning for both nucleophilic attacks 
(Scheme 139). The reaction gave an 18% yield of the cis isomeric form after 
recrystallisation. 
 
Scheme 139 – (3S,3'S,6S,6'S)-4,4'-(1,4-phenylenebis(methylene))bis(1-benzyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione) synthesis 
After achieving three different protected ETPs, deprotection and oxidation was carried 
out for compounds (497), (512) and (496) to achieve the final ETP forms (499), (515) 
and (498), respectively. For this, boron tribromide solution was used to form tetra-thiol 
intermediates which were treated with methanol to increase the solubility of each 
reaction derivative. Sodium hydrogen carbonate or Rochelle’s salt addition followed 
and oxidation using iodine enabled disulfide bridge formation for each final compound 
(Scheme 140). 
 
Scheme 140 – Thiol deprotection / oxidation of different dimeric ETPs 
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After reactions work up using sodium thiosulfate, purification using automated column 
chromatography and HLPC gave compounds (499), (515) and (498) in 50%, 20% and 
23% yields, respectively. HPLC results shown below (Figure 69) indicate the retention 
time for the three synthesised molecules. 
 
Figure 69 – HPLC separation of different examples of dimeric ETPs showing the correspondent retention times 
According to solvent rates throughout the separation, ETPs presented very similar 
solubility profiles with all molecules isolated from the reactions provingly to be 
extremely insoluble. 
Another approach towards the synthesis of dimeric ETPs focused our attempts on olefin 
metathesis. For this, different starting materials, catalysts and conditions were used as 
described below.  
3.4.3 Mono and disubstituted dimeric ETPs formation using cross metathesis 
As described before, synthesis of both bi and tricyclic ETP systems was achieved using 
RCM reactions. We anticipated that the same principle could be applied to access 
dimeric ETP molecules by CM between an already built monomeric ETPs possessing 
one allyl substituent.
286
 This idea was envisioned for two distinct classes of molecules: 
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di and tri-substituted ETPs. The first class would allow the synthesis of mono-
substituted dimeric ETPs while the second class formed by tri-substituted ETPs would 
render disubstituted dimeric ETPs (Scheme 141). 
 
Scheme 141 – Model for the synthesis of dimeric ETPs using Grubbs catalysed reactions 
We first started with the synthesis of the dimeric product formed by coupling two 
molecules of (±)-(1S,4S)-2-allyl-5-benzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-
dione 7-sulfide (416). Using different conditions, we were able to achieve the mono-
substituted dimeric ETP (516) that presented the same type of polarity when compared 
to previously synthesised dimeric molecules (Table 12). Optimal conditions that 
enabled the synthesis of (516) involved the use of a microwave reaction at 150 °C for 2 
hours and Grubbs second generation or Grubbs-Hoveyda second-generation catalysts. 
 
  Conditions  
CM catalyst Entry Temperature (°C) Time Yield (%) 
Grubbs second generation 1 120 (Reflux) 24h 0 
Grubbs second generation 2 70 (MW) 15min 0 
Table 12 – Continues next page 
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Grubbs second generation 3 100 (MW) 20min 0 
Grubbs second generation 4 120 (MW) 30min 0 
Grubbs second generation 5 150 (MW) 2h 47 
Grubbs-Hoveyda second-generation 6 120 (Reflux) 24h 0 
Grubbs-Hoveyda second-generation 7 70 (MW) 15min 0 
Grubbs-Hoveyda second-generation 8 100 (MW) 20min 0 
Grubbs-Hoveyda second-generation 9 120 (MW) 30min 0 
Grubbs-Hoveyda second-generation 10 150 (MW) 2h 22 
Table 12 – Conditions for (±)-(1S,1'S,4S,4'S)-5,5'-((E)-but-2-ene-1,4-diyl)bis(2-benzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide) synthesis 
Synthesis of (516) showed the feasibility of the initial idea of using olefin metathesis to 
synthesise dimeric ETP molecules. In order to overcome the solubility problems 
encountered from previously produced dimeric compounds we decided to take the same 
coupling approach towards tri-substituted ETPs. The same conditions used to promote 
the cross coupling of two molecules of compound (416) to the desired prospect (516) 
were tried for monomeric ETP (471). By using Grubbs-Hoveyda second-generation 
catalyst under microwave conditions (150 °C for two hours), we were able to synthesise 
dimeric ETP (517) in 18% yield (Scheme 142). This product (517) already showed 
different solubility since purification was achievable under less polar conditions with 
the use of a petroleum spirit / ethyl acetate gradient; when compare to dichloromethane / 
methanol system used for other dimeric ETPs. 
 
Scheme 142 – (±)-(1S,1'S,4S,4'S)-2,2'-((E)-but-2-ene-1,4-diyl)bis(1,5-dibenzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide) synthesis 
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The same methodology was used to obtain dimeric ETP (518) by reacting two 
molecules of tri-substituted ETP (464). However, after several trials the product was not 
achieved. TLC, NMR and MS analysis only showed the presence of starting material 
after the same type of reaction conditions listed for the synthesis of compound (517) 
(Scheme 143). 
 
Scheme 143 – Model for (±)-(1S,1'S,4S,4'S)-5,5'-((E)-but-2-ene-1,4-diyl)bis(1,2-dibenzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide) synthesis 
Our unique approach for the synthesis of dimeric ETPs using olefin metathesis again 
proved successful for carbon allyl tri-substituted ETP (455), to give dimeric compound 
(519) in 25% yield (Scheme 144). By using Grubbs-Hoveyda second-generation 
catalyst and microwave assisted reaction conditions (150 °C for two hours), dimeric 
ETP (519) was synthesised showing the potential of this approach. The polarity was 
similar to that presented for compound (517) demonstrating the correlation in between 
both molecular entities. 
 
Scheme 144 – (±)-(1S,1'S,4S,4'S)-1,1'-((E)-but-2-ene-1,4-diyl)bis(2,5-dibenzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide) synthesis 
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3.5 Biological assays 
Following on from the development of novel synthetic routes to both monomeric and 
dimeric ETPs cores where we could vary four substituents, we next turned our attention 
towards the testing of the biological effects of these newly synthesised molecules. To 
achieve this, we worked closely with a number of different research groups to explore 
the scope of our ETP project in a number of areas that included: microbiology, 
biochemistry and virology. 
In each specific area I would like first to express my deepest regards for the resources 
and time expended to obtain the data shown below in this chapter. 
For this I would like to thank Professor Peter Taylor from the Pharmaceutics 
Department at School of Pharmacy UCL for providing the facilities and expertise to 
develop all the microbiological work. I would also like to express my gratitude to 
Doctor João Moreira from Professor Taylor’s group who took the task of investigating 
the ETPs microbiological activity against different strains of resistant bacteria. All the 
work shown below in section 3.5.1 was carried out in Professor Peter Taylor’s 
laboratory in collaboration with Doctor João Moreira. 
3.5.1 ETPs Antibacterial assays 
The antibacterial activity of ETPs was first reported in the early 1950' as demonstrated 
by Kidd and co-workers.
290
 Gliotoxin (1) is perhaps the most well studied example of 
the ETP family of natural products and was tested against a wide range of resistant 
bacteria cell cultures which included: Staphylococcus aureus, Streptococcus viridians 
and different strains of Mycobacterium tuberculosis. All results gave minimal inhibitory 
concentrations (MIC) below 32 µg/mL which made gliotoxin (1) a suitable candidate 
for further exploration of its antibacterial activity.
290
 The MIC is defined as the lowest 
concentration of drug that inhibits any visual bacterial growth after 16 to 20 hours.
291
  
In order to test the antibacterial activity of our newly synthesised ETPs, four different 
strains of bacteria were chosen: one strain of methicillin-resistant Staphylococcus 
aureus (MRSA) – EMRSA-16, two clinical isolates from the Royal Free Hospital UCL 
of vancomycin-resistant Enterococcus (VRE) strains – VRE-1 and VRE-10 – and a 
surrogate for tuberculosis infection, Mycobacterium aurum – M. aurum A+. Selection 
of these strains was closely related to the importance that MRSA and VRE have in 
nosocomial infections and the emergence of resistance to new antibiotic treatments.
292
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The use of a Mycobacterium sp. strain in the study is linked to a disease responsible for 
a high human mortality rate worldwide, tuberculosis. Mycobacterium aurum provides a 
surrogate for the infectious pathogen Mycobacterium tuberculosis in a less hazardous 
and more economic approach for the primary screening of new tuberculostatic drugs.
293
 
Using the Clinical and Laboratory Standards Institute (CLSI) guidelines, ETPs were 
analysed by one of two protocols for susceptibility testing, involving broth dilution: the 
microdilution procedure. This method was performed in a 96-well plate and required a 
small volume of 0.1 mL of each test compound. This technique guarantees a fast, 
reliable and high-throughput screening for different compounds. The CLSI also suggest 
the Mueller Hinton Broth (MHB) as the standard medium for susceptibility testing, 
since it shows good reproducibility between different batches and contains no 
sulfonamide, trimethoprim and tetracycline inhibitors.
291
  
With the above requirements, MICs for different ETPs were determined using U-shaped 
96-well microtitre plates as shown below (Figure 70).  
 
Figure 70 – Schematic representation of the U-shaped 96-well plate for MIC determinations. Increasing 
concentrations of the test drug are added from column 2 (0 mg/L) to column 12 (32 mg/L). M represents the sterility 
control for the medium used; D represents the test drug mixed with the medium used and C represents a standard 
antibiotic known to inhibit growth of the bacteria in study. Red arrows represent the MIC for the examples depicted. 
In way of example, increasing concentrations of drug one, shown in blue, and two, 
represented in green, were tested from columns two to twelve against one bacterial 
isolate in quadruplicate. Controls for this procedure were included in column one. M 
referred to 200 µL of MHB and D for 200 µL of the tested drug in the absence of 
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bacteria. Wells C contained 100 µL of a conventional antibiotic in a concentration 
known to kill the bacteria in study while red arrows indicate the MIC in mg/L. Bacterial 
growth can be visualised in the form of bacterial clumps at the bottom of the well or by 
observation of turbidity. A clear well indicated inhibition of growth. 
Stock solutions of ETPs (425), (426), (427), (430), (434), (437) and (459) (Table 13) 
were prepared at a concentration of 3.2 mg/mL in 100% DMSO and stored at -20 °C 
until required. For each experiment, stock solutions were diluted to 64 mg/L in an 
appropriate volume of MHB and 200 µL dispensed into each well on column twelve. 
100 µL of MHB were dispensed in all remaining wells. Two-fold serial dilutions of test 
compounds were prepared from columns twelve to three, for final concentrations 
between 32 and 0.0625 mg/L, and the remaining 100 µL were discarded. The initial 
range of drug concentrations tested was adjusted for the following technical replicates. 
Compound Structure 
425 
 
426 
 
427 
 
430 
 
434 
 
437 
 
459 
 
Table 13 – ETP structures for microbiological assays 
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Bacterial suspensions were prepared using CLSI guidelines; bacteria were grown to a 
density equivalent to 0.5 McFarland (BioMérieux SA, Marcy l’Etoile, France) at 37 °C 
and then diluted in MHB to a final concentration of 3-7x10
5
 colony-forming units per 
mL (CFU/mL). This bacterial suspension was added to all wells to a final volume of 
200 µL. The plates were sealed with a plastic cover, shaken gently on an orbital shaker 
(Bibby Scientific, Stone, UK) to ensure proper re-suspension of the bacteria and 
incubated at 37 °C. 
The MIC procedure for ETPs against Mycobacterium aurum was performed in a similar 
fashion to that described above, with the exception of the preparation of the bacterial 
suspension. The method used was based on that described by Seidel and Taylor.
294
 
MHB supplemented with 20 - 25 mg of Ca
2+
 and 10 - 12.5 mg of Mg
2+
 per litre (cation 
adjusted-MHB), was used as growth medium. Mycobacterial strains were plated on to 
MHA plates and incubated at 37 C until colonies were visible. Bacterial suspensions 
were prepared by suspending colonies in a 0.9% saline solution. Glass beads (4 mm 
diameter, Sigma-Aldrich) were added and the suspensions shaken vigorously to disrupt 
clumps. Supernatants were adjusted to a 0.5 McFarland standard corresponding to 
OD600 of 0.08 - 0.1 and a bacterial concentration of 5x10
5
 CFU/mL. Mycobacterial 
suspension was then added to all wells to a final volume of 200 µL. Column number 
one was maintained for control as described before. The incubation period for M. aurum 
A+ was five days. After incubation, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) dye was added to facilitate MIC visualisation. 
Metabolically active cells reduce this tetrazolium dye to water-insoluble MTT formazan 
and converts the initial yellow colour of the dye to dark blue/purple. Bacterial growth 
was detected by addition of 20 µL of MTT methanol solution (5 g/L) to each well. 
Plates were incubated at 37 C for a further 20 – 50 minutes and the MIC value was 
determined by visual observation. Eight examples of synthesised ETPs were used for 
these biological assays which included seven disubstituted ETPs (434, 430, 437, 426, 
427 and 425) and one tri-substituted ETP (459). Test results are shown below (Table 
14). 
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Compound Structure 
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434 
 
32 >32 >32 8 79 >79 >79 20 
430 
 
32 >32 >32 8 90 >90 >90 22 
437 
 
16 >32 8 16 78 >157 39 78 
426 
 
32 >32 >32 32 81 >81 >81 81 
427 
 
32 >32 >32 16 87 >87 >87 44 
425 
 
16 >32 >32 16 42 >84 >84 42 
459 
 
16 >32 >32 8 36 >72 >72 18 
Table 14 – MIC’s for the ETPs microbiological assays using four different strains of resistant bacteria: EMRSA-16, 
VRE-1, VRE-10 and M. aurum A+ 
Our results showed that compounds (437), (425) and (459) demonstrate relevant activity 
against EMRSA-16 strain with values ranging to half the concentration needed to 
prevent bacterial growth when compared to the other tested examples. However, all 
compounds excluding (437) do not exhibit any significant antibacterial activity against 
both strains of VRE. This can be taken as a positive outcome, since specificity towards 
a single bacterial strain is crucial in antibacterial drug discovery. Excellent results were 
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obtained when ETPs were tested against the tuberculosis surrogate (M. aurum A+), with 
compound (426) showing the only result above 16 µg/mL for the MIC. All other tested 
molecules achieved values in the range of 16 to 8 µg/mL (MIC). In terms of structure 
relationship activity (SRA) for the tuberculosis assay, compounds that have longer 
chain substituents as (426), (427) and (425) show less activity (16 µg/mL) when 
compared to molecules with short length substituents (i.e. 430). However, ETPs (434), 
(430) and (459) that both have bulkier built-in substituents (i. e. benzyl and naphthyl) 
showed better antimycobacterial outcomes (8 µg/mL) when compared to other 
molecules with only one benzylic substituent (eg. 427). ETPs that contain more 
aromatic groups proved to have better antibacterial activity against M. aurum A+ than 
others with only aliphatic substituents (eg. 437). Lipophilicity of the tested molecules 
was shown to be a relevant characteristic for SRA since a decrease in hydrophilicity was 
translated in an increase of antibacterial activity. Examples of this occurrence are 
demonstrated for compound (437) with a partition coefficient (CLogP) of 0.27 and a 16 
µg/mL MIC when compared to compounds (430), (434) and (459) with 8 µg/mL MICs 
with CLogP values ranging between 3 – 5,  as shown below (Figure 71). 
 
Figure 71 – CLogP of different ETPs tested against resistant bacteria 
Molarity values showed by these molecules regarding their MICs are quite encouraging 
for antibacterial activity since they range from 22 µM (430) to 18 µM (459).
295, 296, 297 
 
 
 
3.5.2 ETPs Anticancer assays 
For this I would like to thank Doctor Andy Wilderspin from the Pharmaceutical & 
Biological Chemistry Department at School of Pharmacy UCL for allowing me the use 
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of his laboratory and developed assays to explore the anticancer testing of ETPs. I 
would also like to express my gratefulness to Andreia Guimarães from Doctor 
Wilderspin’s group who took the effort and skills to investigate the anticancer activity of 
our ETPs using an in-house assay. All the work shown below in section 3.5.2 was 
developed in Doctor Andy Wilderspin’s laboratory in collaboration with Andreia 
Guimarães. 
The widespread reported biological activity of the ETP family of natural products was 
first demonstrated by the anticancer associated activity of gliotoxin in 1936.
4
 Since 
then, ETPs have proven to be potent anticancer agents with both the natural and 
synthetic examples reported.
258, 112
 
In order to interpret the biological activity of the synthesised ETPs a homogeneous 
assay based on fluorescence resonance energy transfer (FRET) was used.
298
 This assay 
developed by Doctor Andy Wilderspin’s group detected protein-protein interactions 
associated with the locus where ETPs express their biological activity – the HIF-1α C-
terminal activation (C-TAD) and the cysteine-histidine rich 1 (CH1) domains of the 
p300 co-activator. These two proteins were tagged with fluorescent markers. HIF-1α C-
TAD was marked with a cyan fluorescent protein (CFPTEV HIF-1α C-TAD) and the 
p300 CH1 tagged with a yellow fluorescent protein (YFPTEV p300 CH1). The 
interaction between these two provided a FRET signal indicative of the proximity of 
both proteins.
299
 
The assay consisted in a 1:1 ratio of CFPTEV HIF-1α C-TAD and YFPTEV p300 CH1 
using a 96-well flat-bottom non-binding plate (Corning™) to form the complex. The 
apparatus used for measurements was a PerkinElmer EnVision 2101 Multilable reader 
(excitation 405 nm, emission 535 nm). Stock solutions of a small library of ETPs: (18), 
(425), (426), (427), (429), (431), (432), (433), (437), (459), (483) and (488) (Table 15); 
were prepared in 10% methanol / 90% water and stored at -20 °C until required. DMSO 
was not used as a solvent since it interfered with the test results due to an intense colour 
change by the solution that was formed. For each experiment, stock solutions were 
diluted to 1000, 500, 300, 100, 50, 30, 10, 5, 3 and 1 µM in an appropriate volume of 
water. 
Compound Structure Compound Structure 
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437 
 
426 
 
433 
 
425 
 
432 
 
427 
 
429 
 
18 
 
431 
 
483 
 
459 
 
488 
 
Table 15 – ETP structures for anticancer assay 
The monitoring of this complex formation was carried out by FRET analysis enabling 
the fast screening of potential molecular inhibitors. Any hits from the screen were 
expected to disrupt the FRET signal by binding to the YFPTEV p300 CH1 domain, 
disabling the protein complex in this manner. Initial measurements from the screening 
corresponded to those from each of the isolated proteins: YFPTEV p300 CH1 and 
CFPTEV HIF-1α C-TAD; and the resulting protein-protein interaction complex, 
CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 (Chart 2). 
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Chart 2 – FRET measurements for YFPTEV p300 CH1, CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex 
and CFPTEV HIF-1α C-TAD in RFU 
As shown above (Chart 2), YFPTEV p300 CH1 presented 21,776 relative fluorescence 
units (RFU) compare to CFPTEV HIF-1α C-TAD with 25,263 RFU, setting the value 
for the experimental threshold. The complex CFPTEV HIF-1α C-TAD / YFPTEV p300 
CH1 resulted in 58,803 RFU that provided an end limit for the assay in a 1:1 ratio 
experiment with both labelled proteins. 
Using these average values as the start and end points for our research, we next tested a 
small library of ETPs by applying the same methodology. All twelve ETPs used during 
this experiment were first mixed separately with each labelled protein (YFPTEV p300 
CH1 and CFPTEV HIF-1α C-TAD) to demonstrate that no variation from the initial 
setup values was seen, providing us with a range of standards during the course of the 
tests. The outcomes were expressed by percentage of inhibition of the CFPTEV HIF-1α 
C-TAD / YFPTEV p300 CH1 interaction as shown below.  
3.5.2.1 Compound 437 
Results for ETP (437) clearly show an inhibition of 48% of the CFPTEV HIF-1α C-
TAD / YFPTEV p300 CH1 complex at 500 µM concentration. Results decrease to 7% 
in the lowest concentration tested of 1 µM (Chart 3).  
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Chart 3 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (compound 437) 
3.5.2.2 Compound 433 
Significant changes were seen in compound (433) since 1000 µM of the ETP inhibited 
77% of protein-protein interaction whereas using half this concentration (500 µM) only 
41% inhibition occurred. Values were kept in a small range of variation between 500 
and 30 µM (14%) with a decline in activity from the 10 µM tested concentration with 
10% inhibition of the complex (Chart 4). 
 
Chart 4 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (compound 433) 
3.5.2.3 Compound 432 
Compound (432) showed a key decrease in activity from 500 to 300 µM concentration 
with a 26% drop. However, the most significant loss of inhibition of the CFPTEV HIF-
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1α C-TAD / YFPTEV p300 CH1 complex came with the 10 µM assay (11%) where the 
previous tested concentration (30 µM) showed results of 28% (Chart 5).  
 
Chart 5 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (compound 432) 
3.5.2.4 Compound 429 
ETP (429) showed a linear increase of activity from 1 µM (12%) to 1000 µM (77%) 
concentration. The highest decrease in inhibition of protein-protein interaction was seen 
between 300 µM (62%) and 100 µM (44%) (Chart 6).  
 
Chart 6 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (compound 429) 
3.5.2.5 Compound 431 
This asymmetric disubstituted ETP (431) showed promising results when compared to 
the previously tested molecules, since inhibition of the CFPTEV HIF-1α C-TAD / 
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YFPTEV p300 CH1 complex at 1 µM concentration was 38%. Results were maintained 
from an 80% inactivation of protein binding at 1000 µM to 77% at 500 µM. In the range 
of 300 to 50 µM a short reduction in activity was seen with a difference of 3% between 
the tests performed (Chart 7).  
 
Chart 7 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (compound 431) 
3.5.2.6 Compound 459 
Tri-benzyl substituted ETP (459) gave the best results from this small library of 
compounds. The values for protein-protein inhibition ranged from 99 to 78%. Data 
shown below (Chart 8) illustrates the potency of this analogue since dilution from 1000 
to 1 µM in concentration only decreased the outcome of the assay by 19%, highlighting 
the potential of this compound to inhibit the binding of HIF-1α with p300.  
 
Chart 8 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (compound 459) 
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3.5.2.7 Compound 426 
ETPs with different length carbon chain esters were also synthesised using the newly 
developed base catalysed approach. One of the examples – compound (426) – was 
tested and the inhibition of protein binding ranged between similar values to that seen 
before: 53% (1000 µM) and 16% (1 µM), respectively (Chart 9).  
 
Chart 9 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (compound 426) 
3.5.2.8 Compound 425 
One of the other tested ETP substituted esters (426) showed similar results to compound 
(425). CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 inhibition was achieved at a 
maximum value of 52% at 1000 µM concentration. A significant decrease in activity 
was observed between 50 µM (30%) and 30 µM (20%) (Chart 10).  
 
Chart 10 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (compound 425) 
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3.5.2.9 Compound 427 
Compound (427) gave a similar profile in its protein-protein inhibition rate at 1000 µM 
(55%) as its ester substituted ETP congeners. This compound showed low activity from 
30 µM (10%) to 1 µM (4%) concentration (Chart 11).  
 
Chart 11 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (compound 427) 
3.5.2.10 Compound 18 (Hyalodendrin) 
Hyalodendrin (18) was the only natural product used in the assay and gave results 
ranging from 53% (1000 µM) to 1% (1 µM) inhibition of the CFPTEV HIF-1α C-TAD / 
YFPTEV p300 CH1 complex. This compound showed a significant loss of activity 
between 300 µM (41%) and 100 µM (20%) (Chart 12).  
 
Chart 12 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (compound 18) 
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3.5.2.11 Compound 483 
Tri-substituted ETP (483) showed percentages of protein inhibition in a range of 52% 
(1000 µM) to 4% (1 µM). Analogous to hyalodendrin (18), this compound also gave a 
decrease in activity between the 300 µM (42%) and 100 µM (25%) concentration values 
used for the assay (Chart 13).  
 
Chart 13 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (compound 483) 
3.5.2.12 Compound 488 
Tetra-substituted ETP (488) gave initial constant CFPTEV HIF-1α C-TAD / YFPTEV 
p300 CH1 complex inhibition results for concentrations 1000 µM (52%), 500 µM 
(49%) and 300 µM (49%). However, this last value declined to 25% for 100 µM 
concentration and a steady state was reached at 4% total activity at 1 µM (Chart 14).  
 
Chart 14 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (compound 488) 
Bruno Sil                                                                                                 Results and Discussion 
 
185 
 
Results from the FRET CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex 
inhibition assay clearly showed the dominance of compound (459) when compared to 
other tested compounds with an average of 78% inhibition at a 1 µM range (Chart 15). 
 
Chart 15 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (ETPs anticancer assay summary) 
When compared to only aliphatic disubstituted ETP (437), compound (459) clearly 
highlighted the importance of aromatic substituents around the ETP core since 
inhibition of protein-protein interaction for (437) gave an average value of 7% at 1 µM 
concentration. The same low range of inhibition was also shown by hyalodendrin (18), 
the only ETP natural product tested, having the same core structure as (437) with 
variations on the remaining 3- and 6-positions of the ETP ring (Figure 72). 
 
Figure 72 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (correlation between compounds 
459, 437 and 18) 
Compounds (433), (429) and (431) with percentage inhibitions above 75% at 1000 µM 
proved to be very good candidates at an initial stage. However, the values dropped to 
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significant lower percentages below 15% when the concentrations were lowered to 1 
µM for both aliphatic saturated substituted ETPs (i. e. 433, 429). The same occurred for 
compound (432) which possessed similar molecular saturated features. A 38% 
inhibition of the CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex was achieved 
at 1 µM concentration for compound (431) proving the importance of the unsaturated 
carbon ETP substituent when compare to different saturated carbon chains of 
disubstituted ETPs (433), (429) and (432) (Figure 73). 
 
Figure 73 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (correlation between compounds 
431, 429, 432 and 433) 
Based on these findings we decided to test different synthesised compounds that 
contained more unsaturated carbons in the core structure. ETPs (483) and (488) were 
chosen for this testing since both contained more than one allyl substituent. However, 
results indicated the absence of a correlation between ETPs with greater number of 
unsaturated carbons and an increase in protein-protein interaction inhibition as shown 
below (Figure 74). 
 
Figure 74 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (correlation between compounds 
431, 483 and 488) 
ETPs containing different ester substituents (426, 425 and 427) showed that the length 
of the carbon chain had some influence on the outcome of the assay. The values for 
inhibition of protein-protein interaction were similar for the three tested compounds 
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until dilution reached 300 µM concentration where considerable changes in inhibition 
were seen. Shorter carbon chain ester compound (427) showed a reduction in activity 
from 42 to 25% when diluted from 300 to 100 µM concentration. Compounds (426) and 
(425) also showed significant decreases in activity from 50 to 30 µM concentration. 
However, the percentages of complex inhibition for these molecules clearly show the 
correlation between the lengths of the carbon chains associated with the ester 
substituents at these concentrations. Longer carbon chain ester ETP (427) gave a higher 
percentage of activity (16%) at 1 µM concentration that disubstituted ETP (425) (12%), 
which showed a higher percentage of inhibition when compared to a shorter carbon 
chain ester ETP (426) (4%) at the same tested concentration  (Figure 75). 
 
Figure 75 – Inhibition of CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex (correlation between compounds 
426, 425 and 427) 
3.5.3 ETPs Antiviral assay 
For this I would like to thank Professor Doctor Hofmann-Lehmann, Doctor M. L. Meli
 
and T. Meili from the Clinical Laboratory, Vetsuisse Faculty, University of Zürich 
(Switzerland); Professor Antti Poso and Doctor J. T. Laitinen from the School of 
Pharmacy, Faculty of Health Sciences, University of Eastern Finland (Finland); and, 
Doctor K. Allenspach from Veterinary Clinical Sciences, Royal Veterinary College 
(United Kingdom) for providing the services and knowledge to develop all the virology 
work. I would also like to express my appreciation to Christopher Asquith from Doctor 
Stephen Hilton’s group that took the task of investigating the ETPs antiviral activity. All 
the work shown below in section 3.5.3 was developed in Professor Doctor Hofmann-
Lehmann laboratory in collaboration with Christopher Asquith. 
As described before, retroviral nucleocapsid proteins contain two zinc finger motifs that 
mediate genomic RNA packaging into virions. As demonstrated for the p300 CH1 rich 
domain, ETPs have the ability to bind to zinc disabling its protein interactions.
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the same principle to target the RNA transcription stage could provide an alternative in 
the fight against HIV.
300, 301, 302
 
Therapeutic resistance to anti-viral drugs via mutation is a major challenge affecting 
both human and veterinary medicine. Since its discovery in 1984, just one single species 
disease - human immunodeficiency virus (HIV) has caused 25 million deaths and 34 
million infected worldwide with 2.6 million new infections in 2009. This clearly 
highlights the unique challenge in this research area. Amongst non-human vertebrates, 
feline immunodeficiency virus (FIV) infection is perhaps the closest biological model of 
HIV infection with an analogous late-stage AIDS-type progression.
303
 
FIV infection primarily occurs through biting and during mating with about 44 million 
cats currently infected worldwide. Targeting the mutation resistant nucleocapsid protein 
in FIV that performs the same role as the NCp7 protein in HIV can determine a new 
therapeutic approach towards HIV treatment.
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3.5.3.1 Cytotoxicity for different cell lines  
To test the cytotoxicity of ETPs, treatment of Crandell Rees feline kidney (CRFK) cell 
line was carried out using three higher level concentrations (100 µM, 10 µM and 1 µM) 
of compounds: (Gliotoxin (1)), (Hyalodendrin (18)), (Chaetocin A (42)), (425), (426), 
(427), (429), (430), (431), (432), (433), (434), (435), (455), (459), (464), (471), (483), 
(487), (488), (499),  (516) and (517) (Table 16). 
Compound Structure Compound Structure 
433 
 
426 
 
425 
 
432 
 
427 
 
429 
 
18 
 
431 
 
483 
 
Table 16 – Continues next page 
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459 
 
488 
 
435 
 
1 
 
487 
 
464 
 
471 
 
430 
 
434 
 
517 
 
455 
 
499 
 
516 
 
42 
 
Table 16 – ETP structures for antiviral assays 
A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used 
to determine the compounds’ toxicity and viability of cells by MTT dye reduction. 
First 10,000 CRFK cells were eluted with Roswell Park Memorial Institute (RPMI) 
1640 medium supplemented with 10% fetal bovine serum 100 M/mL Glutamine and 
1% v/v antibiotic antimycotic (Ab/Am) (total volume 200 µL) onto 96-well plates and 
incubated for 24 hours (37 ºC, 5% CO2). The medium was then removed by vacuum 
and replaced with the specific dilution of the compounds to test (200 µL). Compounds 
were suspended in 2% DMSO and RPMI 1640 medium supplemented with 10% fetal 
bovine serum 100 M/mL Glutamine and 1% v/v antibiotic / antimycotic (Ab/Am) and 
diluted to the desired concentrations. After 24 hours, the wells were observed and the 
medium removed. 
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The cells were then suspended in RPMI 1640 phenol red-free medium (180 µL) and 
MTT (3 mg/mL) (20 µL) and incubated 4 hours at (37 ºC, 5% CO2). The medium was 
then removed by vacuum and the cells were lyse with methanol (200 µL) to reveal a 
bright purple formazan product. The methanol-formazan absorbance was then 
determined at 570 nm using a BioTek Synergy HT plate reader with KC4 software. 
Data was expressed as the percentage of viability (normalised to cells with no exposure) 
of compound-treated wells compared to that of untreated control wells. The same 
procedure was also carried out for the feline lymphoblastoid cell line 4 (FL-4) using six 
higher level concentrations (100 µM, 10 µM, 1 µM, 100 nM, 10 nM and 1 nM) of the 
previously reported compounds. In the FL-4 cell line, 50% of cytotoxic concentration 
(CC50) is defined as the concentration of drug at which the tissue viability was reduced 
to 50% of the drug-free control value. Compounds that passed the initial 24 hours 
exposure test with a toxicity of less than 25% were then screened against FIV. The 
MTT assay is a colorimetric assay and that can be used for measuring the viability 
living cells. The mitochondrial reductase enzymes reduce the tetrazolium salt by 
cleavage of the central core to produce an insoluble formazan which gives a purple 
colour. This assay measures the cellular metabolic activity via nicotinamide adenine 
dinucleotide phosphate-oxidase (NADPH) dependent cellular oxidoreductase enzymes. 
The amount of formazan dye is directly proportional to the amount of viable cells or 
cytotoxicity.
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ETP synthetic analogues showed that even after longer term exposure, it was possible to 
have compounds containing the ETP core that were non-toxic (Table 17). This was 
significant since it highlighted the potential for further development and clearly showed 
the limitation of the harmful effects previously associated with ETPs. In contrast, 
natural products containing the ETP core showed high toxicity when tested. Gliotoxin 
(1) caused complete cell lysis at a concentration as low as 1 µM in CRFK cells and 
produced no detectable results on the MTT assay. Hyalodendrin (18) only showed 
significant results at 1 µM concentration. 
All other monomeric synthetic ETPs were followed up for additional analysis apart 
from compounds (430) and (431). Remarkably, compound (434) showed no toxic 
effects even when tested at the limiting concentration of 100 µM in CRFK cell line. 
Chaetocin A (42) also showed heavy toxicity along with some of the dimeric ETPs 
tested: (499) and (516). However, dimeric ETP (517) showed good results at 10 µM 
Bruno Sil                                                                                                 Results and Discussion 
 
191 
 
concentration leading to further testing. CC50 results for compounds (433), (427), (426), 
(483), (464) and (517) clearly showed the importance of synthetic analogues when 
compared to the homologous natural products.
253
 The different toxicity profiles meant 
that the compounds were exposed to the cells and had significant pharmokinetic 
properties. 
 
Table 17 – Toxicity results from Initial CRFK Kidney cell line and from the subsequent FL-4 (FIV) Lymphocyte cell 
line.  Toxic concentrations are shown in red, while mild/non-toxic are shown in green. The CC50 values correspond to 
the FL-4 (FIV) cell line. 
The second stage of testing involved the testing of compounds at six concentrations 
(100 µM, 10 µM, 1 µM, 100 nM, 10 nM and 1 nM) unless otherwise determined by the 
24 hours assay. The cells were exposed to the compounds for 7 days and sampled every 
day for each concentration. This cell supernatant sample was then extracted in a total 
nucleic acid (TNA) 
304
 extraction and subsequently used to determine the viral load by a 
polymerase chain reaction (PCR) for FIV RNA. The DNA and albumin were also tested 
as controls (results not shown) to detect any interferences. If the compound was active it 
should show a decrease in the detection value Ct (threshold cycle). After the 7 day 
screen, the cells were also checked for their viability to rule out any toxicity effects and 
validate the PCR result.
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3.5.3.2 FIV Ct values 
To calculate Ct values, 10,000 FL-4 (FIV) cells were eluted with RPMI 1640 medium 
supplemented with 10% fetal bovine serum 100 M/mL Glutamine and 1% v/v antibiotic 
/ antimycotic (Ab/Am) (total volume: 200 µL) onto 96-well plates and incubated for 24 
hours (37 ºC, 5% CO2). Compounds were suspended in 2% DMSO and RPMI 1640 
medium supplemented with 10% fetal bovine serum 100 M/mL Glutamine and 1% v/v 
antibiotic antimycotic (Ab/Am) and diluted to the desired concentrations. On day zero 
the plate was first centrifuged (150 g, 5 minutes) and 100 µL of supernatant was 
removed from each well and replaced with twice the concentrated compound dilution in 
horizontal triplicate. Day 1 – 6 follow the same procedure but at the normal 
concentration; the 100 µL supernatant was pooled to create a 300 µL batch that was 
frozen immediately at -20 ºC.  
The total nucleic acids were extracted as previously reported from 200 μL of 
supernatant and 300 μL lysis buffer using MagNA Pure LC Total Nucleic Acid (TNA) 
isolation kit and a MagNA Pure LC instrument (Roche Diagnostics, Rotkreuz, 
Switzerland), according to the manufacturer's recommendations. The elution volume 
was 90 μL. Extracted samples were stored at -80 ºC until analysis. Negative controls 
were used in all extractions and consisted of 200 µL phosphate-buffer saline solution 
prepared concurrently with each batch of samples to monitor for cross-contamination. 
All TNA samples were tested by TaqMan® real-time PCR for the presence and load 
FIV RNA and FIV DNA on an ABI PRISM 7700/7500 Sequence Detection System 
(Applied Biosystems, Rotkreuz, Switzerland). PCR runs were performed with 
concurrent negative controls of RNA free water. 
The PCR was performed in a reaction volume of 25 μL, using of master mix (12.5 μL) 
(Eurogentec), Primer FIV 552f (800 nM, 1 μL) (Microsynth, Switzerland), Primer 
FIV672r (800 nM, 1 μL) (Microsynth, Switzerland), Probe FIV 582p (160 nM, 0.4 μL) 
(Microsynth, Switzerland), Euroscript Reverse Transcriptase enzyme (0.125 μL) 
(Eurogentec) and RNA free water (4.975 μL) or RNA free water (5.1 μL) for RNA or 
DNA, respectively, followed by TNA (5 μL). The preparation was pipetted on ice at 0 
ºC. The PCR cycle was ran with the following cycle parameters: 2 minutes at 50 ºC or 
30 minutes 48 ºC for RNA and DNA, respectively, and 10 minutes at 95 ºC; followed 
by 45 cycles of 95 ºC for 15 seconds, 60 ºC for 1 min. 
Bruno Sil                                                                                                 Results and Discussion 
 
193 
 
On Day 7 the final 100 µL was collected and pooled so medium RPMI 1640 (Phenol-
Red free) (100 µL) could be added to each well, followed by MTT (3 mg/mL) (20 µL) 
and incubated 4 hours at (37 ºC, 5% CO2). The medium was then removed by vacuum 
and the cells were lysied with methanol (200 µL) to reveal a dark purple formazan 
product. The methanol-formazan absorbance was then determined at 570 nm (Bio-Tek 
Synergy HT plate reader with KC4 software). Data was expressed as the percentage of 
viability (normalised to cells with no exposure) of compound-treated wells compared to 
that of untreated control wells. The 50% cytotoxic concentration (CC50) is defined as 
before.
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We observed a full spectrum of results from inactive/toxic compounds at high 
concentration to highly active compounds at low concentration. The FIV screening 
assay measured the viral loading with a constant level of compound to see if there was a 
reduction or stabilization. Since Ct value is the detection limit of the virus by PCR, the 
longer it took for the virus to be detected the less virus was shed from the cells and 
hence the lower the viral load in the supernatant. Day one and seven (Table 18) showed 
a marked progression towards higher Ct values and hence more virus was shed as the 
cells multiplied. 
 
Table 18 – Primary Ct Values on day one and day seven after exposure to the compounds 
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There were two disruptions to this pathway, one was that the cells were destroyed by 
the compound and hence Ct values remained static or increased as the virus was 
incubated and became denatured with no fresh supply (these results are shown in red). 
The other option was that the compound could actively reduce the amount of virus 
shedded from the cells without toxicity and increasing significantly the replication of 
the virus. Relative to the non-treated cells (these are shown in blue), compounds of this 
series have shown very good efficacy (Table 19). 
 
Table 19 - Difference in Ct values from the control untreated cells. Day seven shows the most active compounds 
highlighted in blue 
ETP (459) showed a reduction of almost 10-fold reduction in viral loading at 10 nM and 
5-fold at 1 nM. Compounds (426) and (464) also showed reductions of around 5-fold at 
10 µM and ETP (427) showed a 4-fold reduction at 100 nM. This was shown to be very 
encouraging data for further clinical development of the ETPs as antiviral agents, but 
due to time constrains, we were unable to test any other members of this class of 
compounds. Nevertheless, the data clearly shows that the toxicity previously associated 
with the ETP can be abrogated and activity maintained. 
 
Bruno Sil                                                                                         Summary and Future Work 
 
195 
 
 
 
  
4. Summary 
& 
Future Work 
Bruno Sil                                                                                         Summary and Future Work 
 
196 
 
Despite widespread interest in the ETP family of natural products as a result of their 
potent biological activities, a comprehensive medicinal chemistry analysis of their 
potential has yet to be realised. However, in our approach to these compounds, we have 
clearly developed a number of synthetic strategies to enable ready access to both the 
natural products and synthetic analogues as shown below (Scheme 145). 
 
Scheme 145 – Different synthetic strategies developed to achieve ETPs 
Our approach differs from others since it uses a short number of steps to achieve the 
fully functionalised ETP core. In section 3.3.1 a four step approach towards monomeric 
disubstituted ETPs was shown to be effective for all given examples. The introduction 
of sulfur at an initial stage combined with possible differentiation between symmetric 
and asymmetrical ETPs highlighted the well-designed method developed by ourselves. 
Our new base catalysed cyclisation reaction to form monomeric protected ETPs 
described in section 3.2.1 proved to be of use by increasing final reaction yields for 
previously synthesised compounds or by enabling us to access new examples of the 
ETP family of synthetic analogues such as the mono-substituted esters. This new 
methodology also led to the development of the first four-step synthetic reaction to 
achieve dimeric ETPs 3.4.2. Using these new insights we were able to develop new 
ways of attaining the ETP core, as seen in section 4.4.1, and this led to different 
examples of dimeric ETPs. 
However, the increased polarity of these dimeric molecules and poor solubility rendered 
them ineffective for use in biological assays. This fortunately led us to the development 
of tri and tetra-substituted ETPs (Sections 3.3.2 and 3.3.3). Our initial idea was to create 
a synthetic pathway in which every possible functionalisation of the ETP core could be 
achieved. The introduction of a methoxy diacetate cyclisation derivative proved to be 
successful, as it enabled the synthesis of various tri-substituted ETP analogues. 
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The same approach used to achieve tri-substituted ETPs permitted the synthesis of a 
bicyclic ETP system (Section 3.3.2.1). We expected to use the knowledge acquired 
from this synthetic route to develop new examples of synthetic analogues since 
members of the ETP family of natural products show numerous examples of bicyclic 
systems fused at the central molecular core. We were also able to synthesise tetra-
substituted ETPs (Section 3.3.3) in an analogous manner to the tricyclic ETP system 
(Section 3.3.3.1). Nevertheless, in the future we plan to revise our approach to tetra-
substituted ETPs by using a similar pathway as for tri-substituted ETPs (Scheme 146). 
By using the same methodology to achieve alkylation of the methoxy intermediate 
(444), a tetra-substituted protected ETP intermediate (520) with different substituents at 
all four substitution points can readily be obtained. 
 
Scheme 146 – Model for the synthesis of tetrasubstituted ETPs 
As described previously, mono-substituted dimeric ETPs showed weak solubility and 
therefore were not able to be used in most of the biological assays. The synthesis of 
disubstituted dimeric ETPs (Section 3.4.3) had a very important impact on the solubility 
of the dimeric series of molecules. Using the same principles as for the synthesis of tri-
substituted ETPs, here we were able to combine two monomeric tri-substituted ETP 
molecules into one disubstituted dimeric ETP. The addition of more aromatic 
substituents to the ETP core changed the solubility of the final molecules which will 
therefore be able to explore their biological potential. 
Using the same approach as for the tetra-substituted ETPs, intermediate (520) could be 
formed using two different stages of alkylation with different substituents. By coupling 
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two of these tetra-substituted ETPs (521), a new tri-substituted dimeric ETP can be 
obtained (522) (Scheme 147). 
 
Scheme 147 – Model for the synthesis of trisubstituted dimeric ETPs (1) 
Following the potent activity displayed by compound (459), one of the first examples 
that should be synthesised for this class of molecules should comprise two ETPs with 
tribenzyl substituents into one single dimeric molecule using the chemistry outlined in 
sections 3.3.2 and 3.4.3 (Scheme 148). 
 
Scheme 148 – Model for the synthesis of trisubstituted dimeric ETPs (2) 
The biological results presented in section 3.5 clearly demonstrate the potential that 
these newly synthesised molecules have for the treatment of hypoxic cancer, specific 
strains of bacteria and antiviral activity. Exceptional results were obtained with ETP 
(459) in every assay carried out. It showed specificity in the microbiological testing for 
M. aurum A+ (MIC: 18 µM) as well as inhibition of the CFPTEV HIF-1α C-TAD / 
YFPTEV p300 CH1 complex by 78% at 1 µM concentration. A preliminary structure 
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relationship activity (SRA) was achieved for results shown in section 3.5.1 since ETPs 
which contain more aromatic and cyclic substituents gave the best outcomes. Testing of 
a large number of compounds that would include dimeric ETPs should be performed to 
demonstrate the validity of this SRA. 
It was clearly shown that ETPs containing longer aliphatic chain substituents had better 
biological activities when compared to small chain aliphatic substituted ETPs. Mono 
ester substituted ETPs also demonstrated this, since longer chain ester mono-substituted 
ETPs gave a higher inhibition of protein-protein interaction. However, an increase of 
unsaturated carbon substituents also diminished activity. With results as high as 38% for 
inhibition of the CFPTEV HIF-1α C-TAD / YFPTEV p300 CH1 complex at 1 µM for 
compound (431), the introduction of more allylic groups decreased inhibition of protein 
/ protein interaction to an average of 4%. This clearly demonstrates the importance of a 
balance between both unsaturated and aromatic substituents surrounding the ETP core. 
Preliminary antiviral studies (Section 3.5.3) clearly showed significant differences in 
toxicity between the three tested natural products and all other synthetic ETPs for both 
cell lines. Ct values also highlighted the promise of synthetic ETP analogues when 
compared to their parent natural products. 
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5.1 General details 
All reactions requiring the use of dry conditions were carried out under an atmosphere 
of nitrogen and all glassware was pre-dried in an oven (110 C) and cooled under 
nitrogen prior to use. Stirring was by internal magnetic follower unless otherwise stated. 
Microwave heated reactions were carried out in a Biotage™ Initiator 2.5. All reactions 
were followed by TLC and organic phases extracted were dried with anhydrous 
magnesium sulfate or sodium sulfate as required. 
TLC analysis was carried out using Merck aluminium-backed plates coated with silica 
gel 60 F254. Components were visualised using combinations of ultraviolet light, iodine 
and ceric ammonium molybdate stain. 
All anhydrous solvents and reagents were purchased from Sigma-Aldrich and Fisher 
Scientific chemical companies and used with Oxford sure/seal valves attached to a 
standard Schlenk line for solvent removal. 
Purification of compounds was carried out using two different methodologies: flash 
column chromatography (FCC) as reported by Still,
305
 or by automatic column 
chromatography (ACC). Silica gel used for FCC was Merck 60 (230-400 mesh). ACC 
was carried out using a Biotage™ Horizon High Performance Flash Chromatography 
(HPFC). The use of this automated system required different pre-packed silica columns 
supported by the system and supplied by Biotage™. Columns used were: Flash 12+S, 
Flash 12+M, Flash 25+S, Flash 25+M, SNAP 10 g, SNAP 25 g, SNAP 50 g, SNAP 100 
g, ZIP 5 g, ZIP 10 g, ZIP 30 g and ZIP 45 g cartridges. In order to simplify the use of 
ACC a series of tests were made using the different types of columns described above. 
These assessments led to the creation of an internal protocol that enabled the 
standardization of product purification. The outcome of our in-house procedure was a 
spreadsheet that aided in the selection of different solvent gradients which allowed the 
purification of the chosen product. Figure 76 shows the designed spreadsheet where 
Entry 1 represents the TLC analysis used for product separation. Rf values were 
collected with the solvent system used for elution of the reaction from the TLC plate, 
along with the mass of product to separate and entered into this section which provides 
automatic information to the remaining segments (Entries 2, 3 and 4, figure 76). Entry 2 
indicates the evaluation of the separation according to the values entered in Entry 1 in 
three different grades: difficult, typical and easy. Part 3 of the spreadsheet shows the 
columns highlighted in green that should be used for separation from the given product 
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information reported in entry 1. More information can be found in this section regarding 
the steps that should be input into the Biotage™ Horizon purification system along with 
the flow rates to be used so that the product could be readily separated. Entry 4 shows a 
visual breakdown of the solvent gradient for purification in a visible chart. 
 
Figure 76 – Biotage™ Horizon HPFC purification guide 
As an typical example of separation, 0.54 g of compound (425) gave an Rf value of 0.37 
from TLC analysis for the product with impurities of 0.89 and 0.01 Rf above and below, 
respectively, using a 3 : 1 (petroleum ether / ethyl acetate) solvent system. Following 
entry of these values, the first section of our designed spreadsheet was populated 
accordingly (Figure 77). 
 
Figure 77 – Biotage™ Horizon HPFC purification guide (Entry 1) 
Value
Rf of Compound 0.37
Rf of Impurity Above 0.89
Rf of Impurity Below 0.01
Strong Solvent ethyl acetate
Weak Solvent petroleum spirit
% Strong Solvent 25
% Weak Solvent 75
Mass of Compound in g 0.535
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Following the data loaded into these fields, Entry 2 of the above spreadsheet (Figure 76) 
enables the user to evaluate the separation using the defined 3 : 1 (petroleum ether / 
ethyl acetate) solvent system and as can be seen, it suggested that this is an easy 
purification (Figure 78). 
 
Figure 78 – Biotage™ Horizon HPFC purification guide (Entry 2) 
Column choice for compound (452) is linked to the TLC analysis with the most suitable 
suggestion being the Flash 25+S, Flash 25+M and SNAP 50 g cartridges (Figure 79). 
Each of these columns could be used to separate the molecule required with information 
for the setup of Biotage™ Horizon shown in every row of the chosen purification 
column (i. e. column volume (CV), segments in CV per strong solvent percentage (6.25 
and 50% ethyl acetate) and flow rates (mL/min)). 
 
Figure 79 – Biotage™ Horizon HPFC purification guide (Entry 3) 
CV of Compound
CV of Impurity Above
CV of Impurity Below
DCV Above
DCV Below
DCV For Column Selection
Difficult DCV = 1 Typical  DCV = 2 Easy  DCV = 6
1.579
97.297
1.58
Calculated Value
2.70
1.12
100.00
Segment 1 - 1CV Segment 3 - 4CV
Cartridge Sample (g) Column Volume 6.25 6.25 50 50 Flow Rates (mL/min)
FLASH 12+S 0.075 6 6 24 2.5 – 12
FLASH 12+M 0.15 12 12 48 2.5 – 12
FLASH 25+S 0.375 24 24 96 10 – 25
FLASH 25+M 0.75 48 48 192 10 – 25
FLASH 40+S 0.825 66 66 264 25 – 50
FLASH 40+M 1.65 132 132 528 25 – 50
FLASH 65i 6 470 470 1880 65 – 85
FLASH 75S 3.5 300 300 1200 100 – 250
FLASH 75M 6 500 500 2000 100 – 250
FLASH 75L 11.7 1000 1000 4000 100 – 250
FLASH 150M 46.9 4.3 4.3 17.2 500 – 1000
FLASH 150L 93.8 8.6 8.6 34.4 500 – 1000
FLASH 400M 330 38 38 152 7000
FLASH 400L 670 76 76 304 7000
SNAP 10g 0.15 15 15 60 10-20
SNAP 25g 0.15 33 33 132 20-40
SNAP 50g 0.825 66 66 264 30-50
SNAP 100g 1.5 132 132 528 31 - 50
SNAP 340g 6 470 470 1880 65 - 1005640
Segment 2 to 3  - 12CV
Purification in % Strong Solvent
456
912
180
396
792
1584
5640
3600
6000
12000
51.6
103.2
72
144
288
576
792
1584
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Graphical analysis (Figure 80) allowed confirmation of the methodology calculated for 
the purification of compound (452), facilitating the visualization of the steps required 
for the separation of impurities. 
 
Figure 80 – Biotage™ Horizon HPFC purification guide (Entry 4) 
Analytical Reversed-Phase HPLC was performed on a Waters Atlantis C18 column (250 
mm x 4.6 mm). Separation was achieved using a linear gradient at a flow rate of 1.2 mL 
min
-1
 effected by a Waters 600S controller and 616 pump running solvent A [0.1% (v/v) 
TFA in H2O], solvent B [0.16% (v/v) TFA in 90% MeCN]; 0% B to 100% B over 20 
min then 100% B for 5 min then 100% B to 0% B over 7 min (System A). All data was 
managed using Millennium version 2.15 software. 
Semi-preparative reverse phase – HPLC (RP-HPLC) (<20 mg material) was achieved 
using a Waters Atlantis Prep LC C18 column (250.0 mm x 6.0 mm) at a flow rate of 5 
mL min
-1
. Preparative RP-HPLC (>20 mg material) was achieved using a Waters 
Atlantis Prep LC C18 column (250 mm x 19 mm) at a flow rate of 20.4 mL min
-1
. Two 
Applied Biosystems 200 solvent Delivery System pumps were used, running 0% B to 
100% B over 40 min then 100% B for 10 min then 100% B to 0% B over 7 min (System 
B). Semi-preparative and preparative RP-HPLC was also achieved using a Waters 600E 
Multi Solvent Delivery System: Waters Applied Biosystems 783A Programmable 
Absorbance Detector and Waters 2847 dual λ Absorbance Detector also using System 
B. Separation was monitored at 214 nm, 254 nm and 340 nm by Waters Millennium 
Chromatography Manager Software and Empower2 Pro Chromatography software. 
Fractions were collected using a Waters Fraction Collector III, and data managed using 
Empower2 Pro Software. 
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Infrared spectra were recorded on a Bruker Alpha FT-IR spectrophotometer using NaCl 
plates. 
1
H NMR and 
13
C NMR were recorded using either a Bruker AM400 
spectrometer operating at 400 MHz for proton and 101 MHz for carbon or a Bruker 
AM500 spectrometer operating at 500 MHz for proton and 126 MHz for carbon. 
Chemical shifts (H and C) are quoted as parts per million downfield from 0.  The 
multiplicity of a 
1
H NMR signal is designated by one of the following abbreviations: s = 
singlet, d = doublet, t = triplet, q = quartet, br = broad and m = multiplet. Coupling 
constants (J) are expressed in Hertz. 
High-resolution mass spectra were carried out using either a Kratos MS89MS with 
Kratos DS90 software or a Jeol AX505W with Jeol complement data system.  Samples 
were ionised electronically (EI), with an accelerating voltage of 6kV or by low 
resolution fast atom bombardment (FAB) in a thioglycerol matrix.  High-resolution fast 
atom bombardment was carried out at the ULIRS mass spectrometry facility at UCL 
School of Pharmacy. 
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5.2 Ethyl-2-(benzylamino)-2-((4-methoxybenzyl)thio)acetate (258)217 
 
Benzylamine (2.76 mL, 25.2 mmol) (255) was added to a solution of ethyl glyoxalate 
(5.00 mL of a 50% solution in toluene, 25.2 mmol) (256) in toluene (20.0 mL) at room 
temperature (RT) and stirred for 2 minutes, whereupon para-methoxybenzyl mercaptan 
(3.54 mL, 25.2 mmol) (257) was added and the mixture stirred for 2 hours. Solvent was 
removed under reduced pressure and the residue purified via Biotage™ Horizon (3:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 50 g) to give ethyl-2-(benzylamino)-2-((4-
methoxybenzyl)thio)acetate (7.56 g, 87%) (258) as a colourless oil; max/cm
-1
 3347 (N-
H), 1732 (C=O);  H (400 MHz; CDCl3) 1.31 (3H, t, J 7.2, CO2CH2CH3), 1.88 (1H, br 
s, NH), 3.72 (1H, d, J 13.1, SCH2), 3.75 – 3.77 (2H, m, NHCH2), 3.79 (3H, s, OCH3), 
3.87 (1H, d, J 13.1, SCH2), 4.22 (2H, q, J 7.2, CO2CH2CH3), 4.35 (1H, s, CH), 6.84 
(2H, d, J 8.7, Ar-H), 7.23 – 7.29 (7H, m, Ar-H);  C (101 MHz; CDCl3) 14.15 
(CO2CH2CH3), 33.23 (SCH2), 49.22 (NHCH2), 55.28 (OCH3), 61.41 (CO2CH2CH3), 
63.71 (CH), 114.00 (Ar-C-H), 127.19 (Ar-C-H), 128.41 (Ar-C-H), 128.48 (Ar-C-H), 
130.07 (Ar-C-H), 138.79 (quaternary C), 158.76 (quaternary C), 169.97 (CO2CH2CH3); 
m/z 346 (100%, [M+H]
+
): Found [M+H]
+
 346.1477, C19H24NO3S requires 346.1482. 
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5.3 2-(Benzyl(2-ethoxy-1-(4-methoxybenzylthio)-2-oxoethyl)amino)-2-
oxoethane-1,1-diyl diacetate (259)
1
 
 
A solution of diacetoxyacetyl chloride (5.11 g, 26.3 mmol) (379) in dichloromethane 
(20.0 mL) was added dropwise to a rapidly stirred biphasic mixture of ethyl-2-
(benzylamino)-2-((4-methoxybenzyl)thio)acetate (7.56 g, 21.9 mmol) (258) and sodium 
hydrogen carbonate (12.9 g, 153 mmol) in dichloromethane (150 mL) and water (100 
mL) at RT and the resulting mixture stirred rapidly for 12 hours. The layers were 
separated and the aqueous phase extracted with dichloromethane (2 x 100 mL). The 
combined extracts were dried over MgSO4, filtered and solvent removed under reduced 
pressure to give 2-(benzyl(2-ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-
oxoethane-1,1-diyl diacetate (10.5 g, 95%) (259) as a colourless oil that did not require 
further purification; max/cm
-1
 1770 (C=O), 1739 (C=O), 1685 (C=O);  H (400 MHz; 
CDCl3) 1.15 (3H, t, J 7.1, CH2CH3), 1.95 (3H, s, OC(O)CH3), 1.98 (3H, s, OC(O)CH3), 
3.72 (2H, s, SCH2), 3.75 (3H, s, OCH3), 3.98 – 4.02 (2H, m, CH2CH3), 4.59 (1H, d, J 
17.4, NCH2), 4.86 (1H, d, J 17.4, NCH2), 5.85 (1H, s, CHS), 6.79 (2H, d, J 8.4, Ar-H), 
6.92 (1H, s, CH(OAc)2), 7.16 – 7.27 (7H, m, Ar-H);  C (101 MHz; CDCl3) 13.76 
(CH2CH3), 20.20 (C(O)CH3), 20.25 (C(O)CH3), 35.49 (CH2), 48.68 (CH2), 55.18 
(OCH3), 61.65 (CHS), 62.21 (CH2CH3), 83.99 (CH(OAc)2), 113.97 (Ar-C-H), 126.79 
(Ar-C-H), 127.66 (Ar-C-H), 128.48 (Ar-C-H), 128.65 (quaternary C), 130.21 (Ar-C-
H), 135.72 (quaternary C), 158.87 (quaternary C), 165.76 (CO), 167.16 (CO), 168.34 
(CO), 168.62 (CO); m/z 504 (100%, [M+H]
+
): Found [M+H]
+
 504.1688, C25H30NO8S 
requires 504.1692. 
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5.4 (3S,6S)-1-Benzyl-4-butyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione (373)
1
 
 
5.4.1 Method A: 
n-Butylamine (0.57 mL, 5.72 mmol) (404) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(0.96 g, 1.91 mmol) (259) in acetonitrile (30.0 mL) followed by addition of para-
methoxybenzyl mercaptan (0.40 mL, 2.86 mmol) (257) and the resulting mixture stirred 
for 2 minutes. TFA (0.15 mL, 1.91 mmol) was added and the resulting mixture heated at 
reflux for 16 hours, cooled to RT and solvent removed under reduced pressure. The 
residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 25 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give (3S,6S)-1-benzyl-4-butyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione (0.70 g, 65%) (373) as a colourless solid; 
m.p. 134-135 C; max/cm
-1
 1670 (C=O);  H (400 MHz; CDCl3) 0.75 – 0.79 (3H, m, 
NCH2(CH2)2CH3), 0.97 – 1.13 (4H, m, NCH2(CH2)2CH3), 2.54 – 2.57 (1H, m, 
NCH2(CH2)2CH3), 3.54 – 3.57 (2H, m, NCH2(CH2)2CH3 & NCH2-Ph), 3.77 (1H, s, 
SCH2), 3.80 (3H, s, OCH3), 3.83 (3H, s, OCH3), 3.87 (1H, s, SCH2), 3.94 (1H, d, J 13.9, 
SCH2), 4.00 (1H, d, J 13.9, SCH2), 4.28 (1H, s, CHS), 4.42 (1H, s, CHS), 5.14 (1H, d, J 
14.5, NCH2-Ph), 6.67 (2H, d, J 7.4, Ar-H), 6.84 – 6.91 (4H, m, Ar-H), 7.10 – 7.19 (3H, 
m, Ar-H), 7.33 – 7.41 (4H, m, Ar-H);  C (101 MHz; CDCl3) 13.51 (CH2CH3), 19.86 
(CH2), 28.75 (CH2), 36.17 (CH2), 36.71 (CH2), 43.40 (CH2), 46.01 (CH2), 55.22 
(OCH3), 57.25 (CHS), 58.79 (CHS), 113.97 (Ar-C-H), 114.00 (Ar-C-H), 127.79 (Ar-
C-H), 128.54 (Ar-C-H), 128.69 (quaternary C), 128.85 (quaternary C), 130.69 (Ar-C-
H), 130.77 (Ar-C-H), 134.94 (quaternary C), 159.06 (quaternary C), 164.94 (CO), 
165.32 (CO); m/z 565 (100%, [M+H]
+
): Found [M+H]
+
 565.2175, C31H37N2O4S2 
requires 565.2195.  
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5.4.2 Method B: 
n-Butylamine (0.18 mL, 1.82 mmol) (404) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(259) (0.31 g, 0.61 mmol) in acetonitrile (30.0 mL) followed by addition of para-
methoxybenzyl mercaptan (0.13 mL, 0.91 mmol) (257) and the resulting mixture stirred 
for 2 minutes. DMAP (0.04 g, 0.30 mmol) was added in a single portion and the 
resulting mixture heated at reflux for 16 hours, cooled to RT and solvent removed under 
reduced pressure. The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 
40-60 °C: ethyl acetate; snap 25 g) and further purified by recrystallisation (petroleum 
spirit 40-60 °C: ethyl acetate) to give (3S,6S)-1-benzyl-4-butyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione (0.28 g, 81%) (373) as a colourless solid; 
identical spectroscopic data to that obtained previously for (373). 
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5.5 Diacetoxyacetyl chloride (379)285 
 
A solution of glyoxylic acid monohydrate (16.0 g, 174 mmol) in acetic anhydride (49.2 
mL, 521 mmol) and acetic acid (29.9 mL, 521 mmol) was heated at 150 C for 3 hours 
and then allowed to cool to RT over 1 hour. Excess reactants were removed under 
azeotropic distillation (toluene 2 x 100 mL) under reduced pressure. The residue was 
taken up in dichloromethane (200 mL) followed by sequential addition of thionyl 
chloride (25.4 mL, 348 mmol) and dimethylformamide (0.03 mL, 0.35 mmol). The 
mixture was heated under reflux conditions (50 °C) for varying time periods (Table 1) 
until diacetoxyacetyl chloride was formed. Solvent and excess thionyl chloride were 
removed under reduced pressure and the crude product purified by distillation under 
reduced pressure (64-65 C/ 1.0 mmHg) to give diacetoxyacetyl chloride (25.0 g, 75%) 
(379) as a colourless oil; max/cm
-1
 1763 (C=O), 1376 (CH3), 1200 (C-C(O)-C), 718 (C-
Cl);  H (500 MHz; CDCl3) 2.09 (6H, s, CH(OC(O)CH3)2), 6.79 (1H, s, CH);  C (126 
MHz; CDCl3) 20.48 (CH3), 88.03 (CH(OAc)2), 167.67 (CO), 168.21 (CO); m/z 195 
(100%, [M+H]
+
): Found [M+H]
+
 195.5805, C6H8ClO5 requires 195.5801. 
 
 
  H (400 MHz; CDCl3) 
Time period (hours) COOH CH(OC(O)CH3)2 CH(OC(O)CH3)2 
1.5 10.81 (1 H, s) 6.74 (1 H, s) 2.03 – 2.04 (6 H, s) 
3.0 10.62 (0.5 H, s) 6.78 (1 H, s) 2.08 – 2.10 (6 H, s) 
5.0 - 6.79 (1 H, s) 2.09 (6 H, s) 
Table 20 – Diacetoxyacetyl chloride synthesis 
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5.6 Ethyl-2-(allylamino)-2-(4-methoxybenzylthio)acetate (388) 
 
Allylamine (1.90 mL, 25.2 mmol) (387) was added to a solution of ethyl glyoxalate 
(5.00 mL of a 50% solution in toluene, 25.2 mmol) (256) in toluene (30.0 mL) at room 
temperature (RT) and the solution stirred for 2 minutes, whereupon para-
methoxybenzyl mercaptan (3.51 mL, 25.22 mmol) (257) was added and the mixture 
stirred for 2 hours. Solvent was removed under reduced pressure and the residue 
purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 50 g) 
to give ethyl-2-(allylamino)-2-(4-methoxybenzylthio)acetate (6.00 g, 81%) (388) as a 
colourless oil; max/cm
-1
 3344 (N-H), 1732 (C=O);  H (400 MHz; CDCl3) 1.27 (3H, t, J 
7.1, CH2CH3), 1.89 (1H, br s, NH), 3.11 (1H, dd, J 13.9 & 6.4, NCH2), 3.28 (1H, dd, J 
13.9 & 6.6, NCH2), 3.69 (2H, s, SCH2), 3.74 (3H, s, OCH3), 4.18 (2H, q, J 7.1, 
CH2CH3), 4.32 (1H, s, CHS), 5.06 – 5.10 (2H, m, CH=CH2), 5.72 – 5.77 (1H, m, 
CH=CH2), 6.80 (2H, d, J 8.6, Ar-H), 7.23 (2H, d, J 8.6, Ar-H);  C (101 MHz; CDCl3) 
13.89 (CH2CH3), 32.85 (CH2), 47.59 (CH2), 54.99 (OCH3), 61.09 (CH2), 63.36 (CHS), 
113.66 (Ar-C-H), 116.64 (CH=CH2), 129.72 (quaternary C), 129.78 (Ar-C-H), 135.07 
(CH=CH2), 158.46 (quaternary C), 169.68 (CO); m/z 296 (100%, [M+H]
+
): Found 
[M+H]
+
 296.1322, C15H22NO3S requires 296.1320. 
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5.7 Ethyl-2-(cyclopropylamino)-2-(4-methoxybenzylthio)acetate (391) 
 
Cyclopropylamine (1.76 mL, 25.2 mmol) (389) was added to a solution of ethyl 
glyoxalate (5.00 mL of a 50% solution in toluene, 25.2 mmol) (256) in toluene (25.0 
mL) at RT and stirred for 2 minutes, whereupon para-methoxybenzyl mercaptan (3.51 
mL, 25.2 mmol) (257) was added and the mixture stirred for 2 hours. Solvent was 
removed under reduced pressure and the residue purified via Biotage™ Horizon (3:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 50 g) to give ethyl-2-(cyclopropylamino)-
2-(4-methoxybenzylthio)acetate (5.07 g, 68%) (391) as a colourless oil; max/cm
-1
 3342 
(N-H), 1732 (C=O);  H (400 MHz; CDCl3) 0.29 – 0.32 (1H, m, cyclopropyl-CH2), 
0.38 – 0.42 (1H, m, cyclopropyl-CH2), 0.48 – 0.50 (2H, m, cyclopropyl-CH2), 1.32 (3H, 
t, J 6.5, CO2CH2CH3), 2.34 – 2.37 (1H, m, cyclopropyl-CH), 2.50 (1H, br s, NH), 3.82 
– 3.93 (5H, m, SCH2 & OCH3), 4.23 (2H, q, J 6.5, CO2CH2CH3), 4.42 (1H, s, CH), 6.88 
(2H, d, J 8.4, Ar-H), 7.31 (2H, d, J 8.4, Ar-H);  C (101 MHz; CDCl3) 5.99 (CH2), 6.52 
(CH2), 14.09 (CO2CH2CH3), 26.74 (NHCH-CH2CH2), 33.56 (SCH2), 55.26 (OCH3), 
61.26 (CO2CH2CH3), 64.35 (CH), 113.94 (Ar-C-H), 129.86 (quaternary C), 130.05 
(Ar-C-H), 158.77 (quaternary C), 170.08 (CO2CH2CH3); m/z 296 (100%, [M+H]
+
): 
Found [M+H]
+
 296.1236, C15H22NO3S requires 296.1237. 
  
Bruno Sil                                                                                                                 Experimental 
 
213 
 
5.8 Ethyl-2-((4-methoxybenzyl)thio)-2-(methylamino)acetate (392)217 
 
Methylamine (10.2 mL of a 2M solution in tetrahydrofuran, 20.4 mmol) (390) was 
added to a solution of ethyl glyoxalate (4.20 mL of a 50% solution in toluene, 22.3 
mmol) (256) in toluene (50.0 mL) at RT and stirred for 2 minutes, whereupon para-
methoxybenzyl mercaptan (3.10 mL, 22.3 mmol) (257) was added and the mixture 
heated to reflux under Dean and Stark water removal conditions for 5 hours. Solvent 
was removed under reduced pressure and the residue purified via Biotage™ Horizon 
(3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 50 g) to give ethyl-2-((4-
methoxybenzyl)thio)-2-(methylamino)acetate (2.04 g, 37%) (392) as a colourless oil; 
max/cm
-1
 3358 (N-H), 1735 (C=O);  H (400 MHz; CDCl3) 1.29 (3H, t, J 7.2, 
CO2CH2CH3), 1.76 (1H, br s, NH), 2.33 (3H, s, NHCH3), 3.71 (2H, s, SCH2), 3.78 (3H, 
s, OCH3), 4.20 (2H, q, J 7.2, CO2CH2CH3), 4.23 (1H, s, CH), 6.83 (2H, d, J 8.6, Ar-H), 
7.25 (2H, d, J 8.6, Ar-H);  C (101 MHz; CDCl3) 14.13 (CO2CH2CH3), 32.19 (NCH3), 
33.14 (SCH2), 55.27 (OCH3), 61.33 (CO2CH2CH3), 66.22 (CH), 113.91 (Ar-C-H), 
129.92 (quaternary C), 130.03 (Ar-C-H), 158.72 (quaternary C), 169.99 (CO); m/z 270 
(100%, [M+H]
+
): Found [M+H]
+
 270.1162, C13H20NO3S requires 270.1164. 
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5.9 2-(Allyl(2-ethoxy-1-(4-methoxybenzylthio)-2-oxoethyl)amino)-2-
oxoethane-1,1-diyl diacetate (395) 
 
A solution of diacetoxyacetyl chloride (4.74 g, 24.4 mmol) (379) in dichloromethane 
(15.0 mL) was added dropwise to a rapidly stirred biphasic mixture of ethyl-2-
(allylamino)-2-(4-methoxybenzylthio)acetate (6.00 g, 20.3 mmol) (388) and sodium 
hydrogen carbonate (11.9 g, 142 mmol) in dichloromethane (200 mL) and water (100 
mL) at RT and the resulting mixture stirred rapidly for 12 hours. The layers were 
separated and the aqueous phase extracted with dichloromethane (2 x 100 mL). The 
combined organic extracts were dried over MgSO4, filtered and solvent removed under 
reduced pressure to give 2-(allyl(2-ethoxy-1-((4-methoxybenzyl)thio)-2-
oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate (8.93 g, 97%) (395) as a colourless oil 
that did not require further purification; max/cm
-1
 1770 (C=O), 1743 (C=O), 1681 
(C=O);  H (400 MHz; CDCl3) 1.20 (3H, t, J 7.1, CH2CH3), 1.95 (3H, s, OC(O)CH3), 
2.11 (3H, s, OC(O)CH3), 3.67 (2H, s, SCH2), 3.73 (3H, s, OCH3), 3.99 (1H, dd, J 17.7 
& 5.4, NCH2), 4.09 (2H, d, J 7.1, CH2CH3), 4.25 (1H, dd, J 17.7 & 5.5, NCH2), 5.19 – 
5.23 (2H, m, CH=CH2), 5.84 – 5.89 (1H, m, CH=CH2), 6.08 (1H, s, CHS), 6.80 (2H, d, 
J 8.6, Ar-H), 7.03 (1H, s, CH(OAc)2), 7.19 (2H, d, J 8.6, Ar-H);  C (101 MHz; CDCl3) 
13.70 (CH2CH3), 20.29 (C(O)CH3), 34.90 (CH2), 47.12 (CH2), 54.99 (OCH3), 60.77 
(CHS), 62.08 (CH2), 83.86 (CH(OAc)2), 113.80 (Ar-C-H), 117.56 (CH=CH2), 128.48 
(quaternary C), 130.02 (Ar-C-H), 133.22 (CH=CH2), 158.73 (quaternary C), 165.41 
(CO), 167.14 (CO), 168.37 (CO), 168.69 (CO); m/z 454 (100%, [M+H]
+
): Found 
[M+H]
+
 454.1539, C21H28NO8S requires 454.1536. 
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5.10 2-(Cyclopropyl(2-ethoxy-1-(4-methoxybenzylthio)-2-oxoethyl) 
amino)-2-oxoethane-1,1-diyl diacetate (396) 
 
A solution of diacetoxyacetyl chloride (3.95 g, 20.3 mmol) (379) in dichloromethane 
(20.0 mL) was added dropwise to a rapidly stirred biphasic mixture of ethyl 2-
(cyclopropylamino)-2-(4-methoxybenzylthio)acetate (5.00 g, 16.9 mmol) (391) and 
sodium hydrogen carbonate (9.95 g, 118 mmol) in dichloromethane (200 mL) and water 
(100 mL) at room temperature and the resulting mixture stirred rapidly for 12 hours.  
The layers were separated and the aqueous phase extracted with dichloromethane (2 x 
100 mL). The combined organic extracts were dried over MgSO4, filtered and solvent 
removed under reduced pressure to give 2-(cyclopropyl(2-ethoxy-1-(4-
methoxybenzylthio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate (6.02 g, 78%) 
(396) as a colourless oil that did not require further purification; max/cm
-1
 1768 (C=O), 
1743 (C=O), 1693 (C=O);  H (400 MHz; CDCl3) 0.82 – 0.89 (3H, m, cyclopropyl-
CH2), 1.06 – 1.11 (1H, m, cyclopropyl-CH2), 1.26 (3H, t, J 7.1, CO2CH2CH3), 2.17 (3H, 
s, OC(O)CH3), 2.18 (3H, s, OC(O)CH3), 2.70 – 2.77 (1H, m, cyclopropyl-CH), 3.79 
(3H, s, OCH3), 3.83 (2H, s, SCH2), 4.13 – 4.23 (2H, m, CH2CH3), 5.61 (1H, s, CHS), 
6.85 (2H, d, J 8.7, Ar-H), 7.26 (2H, d, J 8.7, Ar-H), 7.55 (1H, s, CH(OAc)2);  C (101 
MHz; CDCl3) 8.11 (CH2), 8.49 (CH2), 13.83 (COCH2CH3), 20.37 (C(O)CH3), 20.41 
(C(O)CH3), 29.01 (CH), 35.91 (SCH2), 55.12 (OCH3), 62.21 (COCH2CH3), 62.46 
(CHS), 83.82 (CH(OAc)2), 113.86 (Ar-C-H), 128.79 (quaternary C), 130.12 (Ar-C-H), 
158.78 (quaternary C), 166.60 (CO), 168.10 (CO), 168.69 (CO), 168.74 (CO); m/z 454 
(100%, [M+H]
+
): Found [M+H]
+
 454.1564, C21H28NO8S requires 454.1536. 
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5.11 2-((2-Ethoxy-1-((4-methoxybenzyl)thio)-2-
oxoethyl)(methyl)amino)-2-oxoethane-1,1-diyl diacetate (397) 
 
A solution of diacetoxyacetyl chloride (2.53 g, 13.0 mmol) (379) in dichloromethane 
(20.0 mL) was added dropwise to a rapidly stirred biphasic mixture of ethyl-2-((4-
methoxybenzyl)thio)-2-(methylamino)acetate (3.50 g, 13.0 mmol) (392) and sodium 
hydrogen carbonate (1.09 g, 13.0 mmol) in dichloromethane (150 mL) and water (80.0 
mL) at room temperature and the resulting mixture stirred rapidly for 12 hours. The 
layers were separated and the aqueous phase extracted with dichloromethane (2 x 100 
mL). The combined organic extracts were dried over MgSO4, filtered and solvent 
removed under reduced pressure to give 2-((2-ethoxy-1-((4-methoxybenzyl)thio)-2-
oxoethyl)(methyl)amino)-2-oxoethane-1,1-diyl diacetate (5.41 g, 97%) (397) as a 
colourless oil that did not require further purification; max/cm
-1
 1774 (C=O), 1739 
(C=O), 1685 (C=O);  H (400 MHz; CDCl3) 1.21 (3H, t, J 7.2, OCH2CH3), 2.15 (6H, s, 
CH(OC(O)CH3)2), 3.03 (3H, s, NCH3), 3.59 (1H, d, J 13.4, SCH2), 3.66 (1H, d, J 13.4, 
SCH2), 3.74 (3H, s, OCH3), 4.11 – 4.15 (2H, m, OCH2CH3), 6.35 (1H, s, CHS), 6.80 
(2H, d, J 8.6, Ar-H), 7.11 (1H, s, CH(OAc)2), 7.18 (2H, d, J 8.6, Ar-H);  C (101 MHz; 
CDCl3) 13.85 (CH2CH3), 20.34 (CH(OC(O)CH3)2), 30.28 (NCH3), 34.90 (SCH2), 
55.06 (OCH3), 60.53 (CHS), 62.18 (CH2CH3), 83.81 (CH(OAc)2), 113.85 (Ar-C-H), 
128.58 (quaternary C), 130.01 (Ar-C-H), 158.76 (quaternary C), 164.81 (CO), 167.05 
(CO), 168.39 (CO), 168.70 (CO); m/z 428 (100%, [M+H]
+
): Found [M+H]
+
 428.1312, 
C19H26NO8S requires 428.1301. 
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5.12 (3S,6S)-1-Benzyl-4-(3-chlorobenzyl)-3,6-bis((4-methoxybenzyl) 
thio)piperazine-2,5-dione (410)
1
 
 
5.12.1 Method A: 
3-Chlorobenzylamine (0.04 mL, 0.45 mmol) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(0.11 g, 0.21 mmol) (410) in acetonitrile (30.0 mL) followed by addition of para-
methoxybenzyl mercaptan (0.04 mL, 0.32 mmol) (257) and the resulting mixture stirred 
for 2 minutes. TFA (0.01 mL, 0.15 mmol) was added and the resulting mixture heated at 
reflux for 16 hours, cooled to RT and solvent removed under reduced pressure. The 
residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 25 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give (3S,6S)-1-benzyl-4-(3-chlorobenzyl)-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione (0.06 g, 60%) (410) as a colourless solid; 
m.p. 159-161 °C; max/cm
-1
 1670 (C=O), 736 (C-Cl);  H (400 MHz; CDCl3) 3.53 (1H, 
d, J 14.7, NCH2), 3.58 (1H, d, J 14.6, NCH2), 3.80 – 3.83 (2H, m, SCH2), 3.84 (3H, s, 
OCH3), 3.85 (3H, s, OCH3), 3.95 – 4.02 (2H, m, SCH2), 4.35 (1H, s, CHS), 4.38 (1H, s, 
CHS), 5.02 (1H, d, J 14.7, NCH2), 5.14 (1H, d, J 14.6, NCH2), 6.53 (1H, d, J 7.6, Ar-
H), 6.65 – 6.71 (3H, m, Ar-H), 6.87 – 6.91 (4H, m, Ar-H), 7.06 (1H, m, Ar-H), 7.14 – 
7.25 (4H, m, Ar-H), 7.34 – 7.38 (4H, m, Ar-H);  C (101 MHz; CDCl3) 36.30 (SCH2), 
36.36 (SCH2), 45.73 (NCH2), 46.10 (NCH2), 55.22 (OCH3), 55.25 (OCH3), 57.32 
(CHS), 57.87 (CHS), 114.14 (Ar-C-H), 126.53 (Ar-C-H), 127.85 (Ar-C-H), 128.11 
(Ar-C-H), 128.15 (Ar-C-H), 128.41 (Ar-C-H), 128.61 (Ar-C-H), 128.69 (quaternary 
C), 129.79 (Ar-C-H), 130.70 (Ar-C-H), 130.77 (Ar-C-H), 134.44 (quaternary C), 
134.80 (quaternary C), 137.07 (quaternary C), 159.13 (quaternary C), 159.14 
(quaternary C), 164.93 (CO), 165.01 (CO); m/z 655.1494 (100%, [M+Na]
+
), 656.1428 
(53.3%, [M+Na]
+
), 657.1417 (58.0%, [M+Na]
+
), 658.1183 (123.6%, [M+Na]
+
), 
659.1173 (82.5%, [M+Na]
+
), C34H33ClN2O4S2Na requires 655.1468.  
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5.12.2 Method B: 
3-Chlorobenzylamine (0.18 mL, 1.48 mmol) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(0.25 g, 0.49 mmol) (259) in acetonitrile (15.0 mL) followed by addition of para-
methoxybenzyl mercaptan (0.10 mL, 0.74 mmol) (257) and the resulting mixture stirred 
for 2 minutes. DMAP (0.03 g, 0.25 mmol) was added and the resulting mixture heated 
at reflux for 16 hours, cooled to RT and solvent removed under reduced pressure. The 
residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 25 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give (3S,6S)-1-benzyl-4-(3-chlorobenzyl)-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione (0.23 g, 75%) (410) as a colourless solid; 
identical spectroscopic data to that obtained previously for (410). 
5.12.3 Method C:  
3-Chlorobenzylamine (0.30 mL, 2.44 mmol) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(0.41 g, 0.81 mmol) (259) in acetonitrile (5.00 mL) followed by addition of para-
methoxybenzyl mercaptan (0.17 mL, 1.22 mmol) (257) and the resulting mixture stirred 
for 2 minutes. TFA (0.03 mL, 0.41 mmol) was added and the mixture heated in the 
microwave at 150 C for 5 minutes, allowed to cool to room temperature and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (3:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) and further purified by 
recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (3S,6S)-1-benzyl-4-
(3-chlorobenzyl)-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.27 g, 51%) 
(410) as a colourless solid; identical spectroscopic data to that obtained previously for 
(410). 
5.12.4 Method D: 
3-Chlorobenzylamine (0.13 mL, 1.07 mmol) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(0.18 g, 0.36 mmol) (259) in acetonitrile (5.00 mL) followed by addition of para-
methoxybenzyl mercaptan (0.07 mL, 0.53 mmol) (257) and the resulting mixture stirred 
for 2 minutes. DMAP (0.02 g, 0.18 mmol) was added and the mixture heated in the 
microwave at 150 C for 5 minutes, allowed to cool to room temperature and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (3:1, 
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petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) and further purified by 
recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (3S,6S)-1-benzyl-4-
(3-chlorobenzyl)-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.15 g, 68%) 
(410) as a colourless solid; identical spectroscopic data to that obtained previously for 
(410).  
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5.13 Ethyl-4-((2S,5S)-4-benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-
dioxopiperazin-1-yl)butanoate (411) 
 
5.13.1 Method A: 
Ethyl-4-aminobutanoate hydrochloride (0.24 g, 1.40 mmol) was added to a solution of 
2-(benzyl(2-ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl 
diacetate (0.24 g, 0.47 mmol) (259)  in acetonitrile (15.0 mL) followed by addition of 
triethylamine (0.26 mL, 1.87 mmol) and para-methoxybenzyl mercaptan (0.10 mL, 
0.70 mmol) (257) and the resulting mixture stirred for 2 minutes. DMAP (0.03 g, 0.23 
mmol) was added and the resulting mixture heated at reflux for 16 hours, cooled to RT 
and solvent removed under reduced pressure. The residue was purified via Biotage™ 
Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) and further purified 
by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give ethyl 4-((2S,5S)-4-
benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-dioxopiperazin-1-yl)butanoate (0.20 g, 
70%) (411) as a colourless solid; m.p. 105-107 °C; max/cm
-1
 2931 (C-H), 1730 (C=O), 
1674 (C=O), 833 (C-H), 733 (C-H);  H (400 MHz, CDCl3) 1.13 (3H, t, J 7.1, 
OCH2CH3), 1.31 – 1.51 (2H, m, CH2CO2CH2CH3), 1.93 – 2.02 (2H, m, NCH2CH2), 
2.54 – 2.66 (1H, m, NCH2CH2), 3.41– 3.54 (2H, m, NCH2-Ph), 3.70 (1H, d, J 12.2, 
SCH2), 3.73 (3H, s, OCH3), 3.76 (3H, s, OCH3), 3.78 – 3.83 (1H, m, SCH2), 3.85 (1H, 
d, J 13.9, SCH2), 3.90 – 4.01 (3H, m, CO2CH2CH3 & SCH2), 4.39 (1H, s, CHS), 4.21 
(1H, s, CHS), 5.08 (1H, d, J 14.5, NCH2), 6.61 – 6.65 (2H, m, Ar-H), 6.77 – 6.81 (2H, 
m, Ar-H), 6.80 – 6.84 (2H, m, Ar-H), 7.03 – 7.09 (2H, m, Ar-H), 7.11 – 7.13 (1H, m, 
Ar-H), 7.23 – 7.27 (2H, m, Ar-H), 7.30 – 7.34 (2H, m, Ar-H);  C (101 MHz, CDCl3) 
14.04 (CO2CH2CH3), 21.95 (CH2), 31.29 (CH2), 36.10 (SCH2), 36.80 (SCH2), 43.13 
(CH2), 46.00 (CH2), 55.14 (OCH3), 55.15 (OCH3), 57.23 (CHS), 59.26 (CHS), 60.24 
(CO2CH2CH3), 113.96 (Ar-C-H), 114.01 (Ar-C-H), 127.72 (Ar-C-H), 128.46 (Ar-C-
H), 128.52 (Ar-C-H), 128.56 (quaternary C), 128.73 (quaternary C), 130.60 (Ar-C-H), 
130.67 (Ar-C-H), 134.84 (quaternary C), 159.01 (quaternary C), 159.03 (quaternary C), 
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164.92 (CO), 165.07 (CO), 172.26 (CO2CH2); m/z 645 (100%, [M+Na]
+
): Found 
[M+Na]
+
 645.2069, C33H38N2O6S2Na requires 645.2069. 
5.13.2 Method B: 
Ethyl 4-aminobutanoate hydrochloride (0.10 g, 0.61 mmol) was added to a solution of 
2-(benzyl(2-ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl 
diacetate (0.24 g, 0.47 mmol) (259)  in acetonitrile (3.00 mL) followed by addition of 
triethylamine (0.34 mL, 2.45 mmol) and para-methoxybenzyl mercaptan (0.10 mL, 
0.73 mmol) (257) and the resulting mixture stirred for 2 minutes. DMAP (0.04 g, 0.31 
mmol) was added and the mixture heated in the microwave at 130 C for 35 minutes, 
allowed to cool to room temperature and solvent removed under reduced pressure. The 
residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 25 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give ethyl 4-((2S,5S)-4-benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-
dioxopiperazin-1-yl)butanoate (0.11 g, 28%) (411) as a colourless solid; identical 
spectroscopic data to that obtained previously for (411). 
  
Bruno Sil                                                                                                                 Experimental 
 
222 
 
5.14 Methyl 6-((2S,5S)-4-benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-
dioxopiperazin-1-yl)hexanoate (412) 
 
5.14.1 Method A: 
Aminocaproic methyl ester (0.23 g, 1.58 mmol) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(0.27 g, 0.53 mmol) (259)  in acetonitrile (15.0 mL) followed by addition of 
triethylamine (0.29 mL, 2.11 mmol) and para-methoxybenzyl mercaptan (0.11 mL, 
0.79 mmol) (257) and the resulting mixture stirred for 2 minutes. DMAP (0.03 g, 0.26 
mmol) was added and the resulting mixture heated at reflux for 16 hours, cooled to RT 
and solvent removed under reduced pressure. The residue was purified via Biotage™ 
Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) and further purified 
by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give methyl 6-((2S,5S)-
4-benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-dioxopiperazin-1-yl)hexanoate (0.26 g, 
76%) (412) as a colourless solid; m.p. 109-112 °C; max/cm
-1
 1641 (C=O), 1452 (C-H), 
1174 (C-O);  H (400 MHz, CDCl3) 0.96 – 1.13 (3H, m, NCH2(CH2)3CH2CO), 1.14 – 
1.26 (1H, m, NCH2(CH2)3CH2CO), 1.42 – 1.55 (2H, m, NCH2(CH2)3CH2CO), 2.24 
(2H, t, J 2.3, NCH2(CH2)3CH2CO), 2.58 – 2.65  (1H, m, NCH2(CH2)3CH2CO), 3.47 – 
3.55 (1H, m, NCH2(CH2)3CH2CO), 3.59 (1H, d, J 14.5, NCH2-Ph), 3.68 (3H, s, 
CO2CH3), 3.83 (3H, s, OCH3), 3.80 (1H, d, J 13.9, SCH2), 3.85 – 3.92 (4H, m, SCH2 & 
OCH3), 3.96 (1H, d, J 13.9, SCH2), 4.03 (1H, d, J 13.9, SCH2), 4.31 (1H, s, CHS), 4.43 
(1H, s, CHS), 5.17 (1H, d, J 14.5, NCH2-Ph), 6.71 (2H, d, J 7.0, Ar-H), 6.85 – 6.96 (4H, 
m, Ar-H), 7.12 – 7.19 (2H, m, Ar-H), 7.19 – 7.25 (1H, m, Ar-H), 7.32 – 7.39 (2H, m, 
Ar-H), 7.39 – 7.45 (2H, m, Ar-H);  C (101 MHz, CDCl3) 24.34 (CH2), 26.12 (CH2), 
26.39 (CH2), 33.68 (CH2), 36.18 (CH2), 36.70 (CH2), 43.52 (CH2), 46.04 (CH2), 51.36 
(CO2CH3),55.18 (OCH3), 55.21 (OCH3), 57.32 (CHS), 58.90 (CHS), 113.96 (Ar-C-H), 
114.06 (Ar-C-H), 127.78 (Ar-C-H), 128.52 (Ar-C-H), 128.66 (quaternary C), 128.81 
(quaternary C), 130.68 (Ar-C-H), 130.72 (Ar-C-H), 134.91 (quaternary C), 159.06 
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(quaternary C), 159.07 (quaternary C), 164.91 (CO), 165.22 (CO), 173.69 (CO2CH3); 
m/z 637 (100%, [M+H]
+
): Found [M+H]
+
 637.2441, C34H41N2O6S2 requires 637.2406. 
5.14.2 Method B: 
Aminocaproic methyl ester (0.26 g, 1.79 mmol) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(0.30 g, 0.60 mmol) (259) in acetonitrile (3.00 mL) followed by addition of 
triethylamine (0.34 mL, 2.38 mmol) and para-methoxybenzyl mercaptan (0.09 mL, 
0.66 mmol) (257) and the resulting mixture stirred for 2 minutes. DMAP (0.04 g, 0.30 
mmol) was added and the mixture heated in the microwave at 130 C for 25 minutes, 
allowed to cool to room temperature and solvent removed under reduced pressure. The 
residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 25 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give methyl 6-((2S,5S)-4-benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-
dioxopiperazin-1-yl)hexanoate (0.17 g, 46%) (412) as a colourless solid; identical 
spectroscopic data to that obtained previously for (412). 
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5.15 Ethyl-3-((2S,5S)-4-benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-
dioxopiperazin-1-yl)propanoate (413) 
 
Ethyl-3-aminopropanoate hydrochloride (0.08 g, 0.52 mmol) was added to a solution of 
2-(benzyl(2-ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl 
diacetate (0.26 g, 0.52 mmol) (259) in acetonitrile (15.0 mL) followed by addition of 
triethylamine (0.29 mL, 2.07 mmol) and para-methoxybenzyl mercaptan (0.11 mL, 
0.77 mmol) (257) and the resulting mixture stirred for 2 minutes. DMAP (0.03 g, 0.26 
mmol) was added and the resulting mixture stirred for 16 hours, cooled to RT and 
solvent removed under reduced pressure. The residue was purified via Biotage™ 
Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) and further purified 
by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give ethyl-3-((2S,5S)-4-
benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-dioxopiperazin-1-yl)propanoate (0.19 g, 
61%) (413) as a light yellow solid; m.p. 127-131 °C; max/cm
-1
 1732 (C=O), 1672 
(C=O), 1451 (C-H);  H (400 MHz, CDCl3) 1.11 (3H, t, J 7.1, CO2CH2CH3), 2.24 – 
2.38 (2H, m, CH2CO2CH2CH3), 2.90 – 3.06 (1H, m, NCH2CH2), 3.48 (1H, d, J 14.5, 
NCH2Ph), 3.55 (1H, m, NCH2CH2), 3.67 – 3.76 (4H, m, SCH2 & OCH3), 3.77 (3H, s, 
OCH3), 3.83 – 3.86 (2H, m, SCH2), 3.95 – 3.98 (3H, m, CO2CH2CH3 & SCH2), 4.22 
(1H, s, CHS), 4.55 (1H, s, CHS), 5.08 – 5.10 (1H, m, Ar-H), 6.56 – 6.69 (2H, m, Ar-H), 
6.75 – 6.88 (4H, m, Ar-H), 7.03 – 7.09 (2H, m, Ar-H), 7.12 – 7.14 (1H, m, Ar-H), 7.26 
(2H, d, J 8.6, Ar-H), 7.32 (2H, d, J 8.6, Ar-H);  C (101 MHz, CDCl3) 13.98 (CH2CH3) 
31.77 (CH2), 36.14 (CH2), 36.91 (CH2), 40.80 (CH2), 46.02 (CH2), 55.16 (OCH3), 
55.18 (OCH3), 57.21 (CHS), 60.44 (CHS), 60.51 (CO2CH2), 114.03 (Ar-C-H), 127.75 
(Ar-C-H), 128.47 (Ar-C-H), 128.50 (Ar-C-H), 128.71 (quaternary C), 130.51 (Ar-C-
H), 130.69 (Ar-C-H), 134.88 (quaternary C), 159.05 (quaternary C), 164.96 (CO), 
165.00 (CO), 170.64 (CO2CH2); m/z 609 (100%, [M+H]
+
): Found [M+H]
+
 609.2103, 
C32H37N2O6S2 requires 609.2093.  
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5.16 Methyl 5-((2S,5S)-4-benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-
dioxopiperazin-1-yl)pentanoate (414) 
 
Aminovaleric methyl ester (0.16 g, 1.22 mmol) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(0.20 g, 0.41 mmol) (259)  in acetonitrile (15.0 mL) followed by addition of 
triethylamine (0.23 mL, 1.62 mmol) and para-methoxybenzyl mercaptan (0.09 mL, 
0.61 mmol) (257) and the resulting mixture stirred for 2 minutes. DMAP (0.03 g, 0.20 
mmol) was added and the resulting mixture heated at reflux for 16 hours, cooled to RT 
and solvent removed under reduced pressure. The residue was purified via Biotage™ 
Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) and further purified 
by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give methyl 5-((2S,5S)-
4-benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-dioxopiperazin-1-yl)pentanoate (0.20 g, 
78%) (414) as a colourless solid; m.p. 94-96 °C; max/cm
-1
 1732 (C=O), 1663 (C=O), 
731 (C-H);  H (400 MHz; CDCl3) 1.08 – 1.36 (4H, m, NCH2(CH2)2CH2CO), 2.00 – 
2.15 (2H, m, NCH2(CH2)2CH2CO), 2.46 – 2.60 (1H, m, NCH2(CH2)2CH2CO), 3.38 – 
3.45 (1H, m, NCH2(CH2)2CH2CO), 3.49 (1H, d, J 14.5, NCH2-Ph), 3.58 (3H, d, J 5.0, 
CO2CH3), 3.67 – 3.72 (1H, m, SCH2), 3.73 (3H, s, OCH3), 3.75 – 3.82 (4H, m, SCH2 & 
OCH3), 3.83 – 3.88 (1H, m, SCH2), 3.93 (1H, d, J 13.1, SCH2), 4.22 (1H, s, CHS), 4.35 
(1H, s, CHS), 5.07 (1H, d, J 14.5, NCH2-Ph), 6.59 – 6.64 (2H, m, Ar-H), 6.76 – 6.85 
(5H, m, Ar-H), 7.03 – 7.14 (3H, m, Ar-H), 7.25 – 7.27 (1H, m, Ar-H), 7.30 – 7.34 (2H, 
m, Ar-H);  C (101 MHz, CDCl3) 21.87 (CH2), 26.11 (CH2), 33.25 (CH2), 36.13 
(SCH2), 36.69 (SCH2), 43.26 (CH2), 46.01 (CH2), 51.36 (OCH3), 55.13 (OCH3), 55.16 
(CHS), 57.28 (CHS), 58.93 (CO2CH3), 113.94 (Ar-C-H), 114.02 (Ar-C-H), 127.73(Ar-
C-H), 128.48 (Ar-C-H), 128.74 (Ar-C-H), 130.63 (quaternary C), 130.68 (Ar-C-H), 
134.84 (Ar-C-H), 159.02 (quaternary C), 159.05 (quaternary C), 164.89 (CO), 165.16 
(CO), 173.26 (CO2CH3); m/z 645 (100%, [M+Na]
+
): Found [M+Na]
+
 645.2101, 
C33H38N2O6S2Na requires 645.2069.  
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5.17 1,4-Dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione 
(415)
253
 
 
5.17.1 Method A: 
Benzylamine (0.66 mL, 5.99 mmol) (255) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(1.01 g, 1.99 mmol) (259) in acetonitrile (30.0 mL) followed by addition of para-
methoxybenzyl mercaptan (0.42 mL, 2.99 mmol) (257) and the resulting mixture stirred 
for 2 minutes. TFA (0.05 mL, 0.07 mmol) was added and the resulting mixture heated at 
reflux for 16 hours, cooled to RT and solvent removed under reduced pressure. The 
residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 25 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give 1,4-dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione 
(0.76 g, 64%) (415) as a colourless solid; m.p. 205-206 °C; max/cm
-1
 3231 (N-H), 1664 
(C=O), 1504 (C=O);  H (400 MHz; CDCl3) 3.58 (2H, d, J 14.6, NCH2), 3.83 (2H, d, J 
14.0, SCH2), 3.86 (6H, s, OCH3), 3.99 (2H, d, J 14.0, SCH2), 4.38 (2H, s, CHS), 5.13 
(2H, d, J 14.6, NCH2), 6.65 (4H, d, J 6.8, Ar-H), 6.89 (4H, d, J 8.6, Ar-H), 7.11 – 7.21 
(6H, m, Ar-H), 7.36 (4H, d, J 8.6, Ar-H);  C (101 MHz; CDCl3) 36.30 (CH2), 46.01 
(CH2), 55.25 (OCH3), 57.37 (CHS), 114.11 (Ar-C-H), 127.80 (Ar-C-H), 128.47 (Ar-C-
H), 128.56 (Ar-C-H), 128.81 (quaternary C), 130.80 (Ar-C-H), 134.86 (quaternary C), 
159.09 (quaternary C), 165.00 (CO); m/z 599 (100%, [M+H]
+
): Found [M+H]
+
 
599.2065, C34H35N2O4S2 requires 599.2038. 
5.17.2 Method B: 
Benzylamine (0.08 mL, 0.72 mmol) (255) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(0.12 g, 0.24 mmol) (259) in acetonitrile (5.00 mL) followed by addition of para-
methoxybenzyl mercaptan (0.05 mL, 0.72 mmol) (257) and the resulting mixture stirred 
for 2 minutes. TFA (0.03 mL, 0.41 mmol) was added and the mixture heated in the 
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microwave at 150 C for 5 minutes, allowed to cool to room temperature and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (3:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 10 g) and further purified by 
recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give 1,4-dibenzyl-3,6-
bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.09 g, 60%) (415) as a colourless 
solid; identical spectroscopic data to that obtained previously for (415). 
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5.18 1,4-Dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione 
(415)  
 
5.18.1 Method A: 
DMAP (0.08 g, 0.61 mmol) was added to a solution of ethyl-2-(benzylamino)-2-((4-
methoxybenzyl)thio)acetate (0.30 g, 0.87 mmol) (258) in acetonitrile (1.50 mL) and the 
mixture stirred for 10 minutes at RT and then heated in the microwave at 160 °C for 30 
minutes. Solvent was removed under reduced pressure and the residue purified via 
Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 10 g) and further 
purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give 1,4-
dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.02 g, 8%) (415) as a 
colourless solid; identical spectroscopic data to that obtained previously for (415). 
5.18.2 Method B: 
TFA (0.05 mL, 0.66 mmol) was added to a solution of ethyl-2-(benzylamino)-2-((4-
methoxybenzyl)thio)acetate (0.33 g, 0.94 mmol) (258) in acetonitrile (1.50 mL) and the 
mixture stirred for 10 minutes at RT and then heated in the microwave at 160 °C for 30 
minutes. Solvent was removed under reduced pressure and the residue purified via 
Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 10 g) and further 
purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give 1,4-
dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.05 g, 17%) (415) as a 
colourless solid; identical spectroscopic data to that obtained previously for (415). 
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5.19 (3S,6S)-1-Allyl-4-benzyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione (416)
253
 
 
5.19.1 Method A: 
Allylamine (0.44 mL, 5.84 mmol) (387) was added to a solution of 2-(benzyl(2-ethoxy-
1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate (0.98 g, 
1.95 mmol) (259) in acetonitrile (30.0 mL) followed by addition of para-
methoxybenzyl mercaptan (0.41 mL, 2.92 mmol) (257) and the resulting mixture stirred 
for 2 minutes. TFA (0.06 mL, 0.78 mmol) was added and the solution stirred for 16 
hours, cooled to RT and solvent removed under reduced pressure. The residue was 
purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) 
and further purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to 
give (3S,6S)-1-allyl-4-benzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.58 
g, 54%) (416) as a light yellow solid; m.p. 123-128 °C; max/cm
-1
 3030 (N-H), 1664 
(C=C), 1608 (C=O);  H (400 MHz, CDCl3) 3.05 (1H, d, J 15.0  SCH2), 3.46 – 3.52 
(1H, m, SCH2), 3.68 – 3.73 (4H, m, SCH2 & OCH3), 3.77 – 3.83 (4H, m, SCH2 & 
OCH3), 3.85 – 3.87 (1H, m, NCH2), 3.91 – 3.97 (2H, m, NCH2), 4.26 (1H, s, CHS), 
4.32 – 4.34 (1H, m, NCH2), 4.41 (1H, s, CHS), 4.88 (1H, d, J 10.1, NCH2CH=CH2), 
5.03 – 5.13 (1H, m, NCH2CH=CH2), 5.35 – 5.37 (1H, m, NCH2CH=CH2), 6.61 – 6.65 
(2H, m, Ar-H), 6.74 – 6.84 (4H, m, Ar-H), 7.08 – 7.12 (3H, m, Ar-H), 7.23 – 7.32 (4H, 
m, Ar-H);  C (101 MHz, CDCl3) 36.46 (CH2), 36.76 (CH2), 45.78 (CH2), 46.28 (CH2), 
55.45 (OCH3), 55.52 (OCH3), 57.56 (CHS), 58.27 (CHS), 114.26 (Ar-C-H), 114.32 
(Ar-C-H), 119.63 (CH2), 128.03(Ar-C-H), 128.77 (Ar-C-H), 129.02 (quaternary C), 
130.87 (Ar-C-H), 131.00 (Ar-C-H), 135.17 (quaternary C), 159.32 (quaternary C), 
164.96 (CO), 165.24 (CO); m/z 549 (100%, [M+H]
+
); Found [M+H]
+
 549.1874, 
C30H33N2O4S2 requires 549.1882. 
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5.19.2 Method B: 
Allylamine (0.09 mL, 1.15 mmol) (387) was added to a solution of 2-(benzyl(2-ethoxy-
1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate (0.19 g, 
0.52 mmol) (259) in acetonitrile (15.0 mL) followed by addition para-methoxybenzyl 
mercaptan (0.08 mL, 0.58 mmol) (257) and the resulting mixture stirred for 2 minutes. 
DMAP (0.02 g, 0.19 mmol) was added and the resulting mixture stirred for 16 hours, 
cooled to RT and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) and further 
purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (3S,6S)-1-
allyl-4-benzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.11 g, 53%) (416) 
as a light yellow solid; identical spectroscopic data to that obtained previously for (416). 
5.19.3 Method C: 
Allylamine (0.18 mL, 2.33 mmol) (387) was added to a solution of 2-(benzyl(2-ethoxy-
1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate (0.59 g, 
1.17 mmol) (259) in acetonitrile (4.00 mL) followed by addition para-methoxybenzyl 
mercaptan (0.41 mL, 2.91 mmol) (257) and the resulting mixture stirred for 2 minutes. 
DMAP (0.07 g, 0.58 mmol) was added and the mixture heated in the microwave at 140 
C for 30 minutes, allowed to cool to room temperature and solvent removed under 
reduced pressure. The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 
40-60 °C: ethyl acetate; snap 25 g) and further purified by recrystallisation (petroleum 
spirit 40-60 °C: ethyl acetate) to give (3S,6S)-1-allyl-4-benzyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione (0.49 g, 76%) (416) as a light yellow solid; 
identical spectroscopic data to that obtained previously for (416). 
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5.20 (3S,6S)-1-Benzyl-4-isopropyl-3,6-bis((4-methoxybenzyl)thio) 
piperazine-2,5-dione (417)
217
 
 
Isopropylamine (0.51 mL, 6.02 mmol) was added to a solution of 2-(benzyl(2-ethoxy-1-
((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate (1.01 g, 
1.99 mmol) (259)  in acetonitrile (30.0 mL) followed by addition of para-
methoxybenzyl mercaptan (0.42 mL, 2.99 mmol) (257) and the resulting mixture stirred 
for 2 minutes. TFA (0.05 mL, 0.07 mmol) was added and the resulting solution heated 
at reflux for 16 hours, cooled to RT and solvent removed under reduced pressure. The 
residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 25 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give (3S,6S)-1-benzyl-4-isopropyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione (0.76 g, 64%) (417) as a colourless solid; 
m.p. 119-121 °C; max/cm
-1
 1662 (C=O);  H (400 MHz; CDCl3) 0.89 (3H, d, J 6.8, 
CH(CH3)2), 1.12 (3H, d, J 6.8, CH(CH3)2), 3.53 (1H, d, J 14.5, NCH2), 3.77 – 3.84 (8H, 
m, 2 x OCH3 & SCH2), 3.93 – 4.09 (3H, m, SCH2 & CH(CH3)2), 4.30 (1H, s, CHS), 
4.58 (1H, s, CHS), 5.10 (1H, d, J 14.5, NCH2), 6.67 (2H, d, J 7.2, Ar-H), 6.84 – 6.90 
(4H, m, Ar-H), 7.10 – 7.19 (3H, m, Ar-H), 7.33 (2H, d, J 8.6, Ar-H), 7.40 (2H, d, J 8.6, 
Ar-H);  C (101 MHz; CDCl3) 18.86 (CH(CH3)2), 20.05 (CH(CH3)2), 36.33 (SCH2), 
36.58 (SCH2), 45.89 (NCH2), 47.92 (CH(CH3)2), 55.21 (OCH3), 55.25 (OCH3), 56.02 
(CHS), 58.10 (CHS), 113.88 (Ar-C-H), 114.06 (Ar-C-H), 127.72 (Ar-C-H), 128.49 
(Ar-C-H), 128.62 (quaternary C), 128.95 (quaternary C), 130.76 (Ar-C-H), 130.78 (Ar-
C-H), 135.03 (quaternary C), 158.93 (quaternary C), 159.04 (quaternary C), 164.75 
(CO), 165.10 (CO); m/z 551 (100%, [M+H]
+
): Found [M+H]
+
 551.2029, C30H35N2O4S2 
requires 551.2038.  
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5.21 (3S,6S)-1-Benzyl-3,6-bis((4-methoxybenzyl)thio)-4-
methylpiperazine -2,5-dione (418)
217
 
 
Methylamine (4.60 mL of a 2M solution in tetrahydrofuran, 9.17 mmol) (390) was 
added to a solution of 2-(benzyl(2-ethoxy-1-((4-methoxybenzyl)thio)-2-
oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate (1.54 g, 3.06 mmol) (259) in 
acetonitrile (30.0 mL) followed by addition of para-methoxybenzyl mercaptan (6.64 
mL, 4.60 mmol) (257) and the resulting mixture stirred for 2 minutes. TFA (0.05 mL, 
0.07 mmol) was added and the resulting mixture heated at reflux for 16 hours, cooled to 
RT and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (1:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) and further 
purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (3S,6S)-1-
benzyl-3,6-bis((4-methoxybenzyl)thio)-4-methylpiperazine-2,5-dione (0.53 g, 33%) 
(418) as a colourless solid; m.p. 127-129 °C; max/cm
-1
 1674 (C=O);  H (400 MHz; 
CDCl3) 2.63 (3H, s, NCH3), 3.54 (1H, d, J 14.5, NCH2-Ph), 3.79 – 3.81 (4H, m, OCH3 
& SCH2), 3.83 (3H, s, OCH3), 3.88 (1H, d, J 13.9, SCH2), 3.95 (1H, d, J 13.9, SCH2), 
4.01 (1H, d, J 13.8, SCH2), 4.29 (1H, s, CHS), 4.39 (1H, s, CHS), 5.16 (1H, d, J 14.5, 
NCH2-Ph), 6.67 (1H, d, J 6.8, Ar-H), 6.86 (2H, d, J 8.6, Ar-H), 6.88 (2H, d, J 8.6, Ar-
H), 7.09 – 7.18 (4H, m, Ar-H), 7.34 (2H, d, J 8.6, Ar-H), 7.38 (2H, d, J 8.6, Ar-H);  C 
(101 MHz; CDCl3) 31.50 (NCH3), 36.22 (CH2), 36.77 (CH2), 46.01 (CH2), 55.27 (2 x 
OCH3), 57.06 (CHS), 61.53 (CHS), 113.98 (Ar-C-H), 114.10 (Ar-C-H), 127.86 (Ar-C-
H), 128.56 (Ar-C-H), 128.63 (Ar-C-H), 128.82 (quaternary C), 130.64 (Ar-C-H), 
130.81 (Ar-C-H), 134.92 (quaternary C), 159.04 (quaternary C), 159.09 (quaternary C), 
165.00 (CO), 165.17 (CO); m/z 523 (100%, [M+H]
+
): Found [M+H]
+
 523.1734, 
C28H31N2O4S2 requires 523.1725.  
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5.22 (3S,6S)-1-Benzyl-3,6-bis((4-methoxybenzyl)thio)-4-(naphthalen-1-
ylmethyl)piperazine-2,5-dione (419)
217
 
 
Naphthylmethylamine (0.67 mL, 4.59 mmol) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(0.77 g, 1.53 mmol) (259)  in acetonitrile (30.0 mL) followed by addition of para-
methoxybenzyl mercaptan (0.32 mL, 2.29 mmol) (257) and the resulting mixture stirred 
for 2 minutes. TFA (0.05 mL, 0.07 mmol) was added and the resulting solution heated 
at reflux for 16 hours, cooled to RT and solvent removed under reduced pressure. The 
residue was purified via Biotage™ Horizon (1:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 25 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give (3S,6S)-1-benzyl-3,6-bis((4-methoxybenzyl)thio)-4-(naphthalen-
1-ylmethyl)piperazine-2,5-dione (0.57 g, 58%) (419) as a colourless solid; m.p. 138-140 
°C; max/cm
-1
 1670 (C=O);  H (400 MHz; CDCl3) 3.55 (1H, d, J 14.9, NCH2), 3.80 – 
3.81 (1H, m, SCH2), 3.82 (3H, s, OCH3), 3.86 (3H, s, OCH3), 3.89 (1H, d, J 13.9, 
SCH2), 3.95 (1H, d, J 13.9, SCH2), 4.04 (1H, d, J 13.9, SCH2), 4.12 (1H, d, J 14.7, 
NCH2), 4.42 (1H, s, CHS), 4.45 (1H, s, CHS), 5.11 (1H, d, J 14.9, NCH2), 5.79 (1H, d, 
J 14.7, NCH2), 6.51 (1H, d, J 6.9, Ar-H), 6.56 (2H, d, J 7.5, Ar-H), 6.81 (2H, d, J 8.5, 
Ar-H), 6.89 (2H, d, J 8.5, Ar-H), 7.08 – 7.23 (3H, m, Ar-H), 7.32 (2H, d, J 8.5, Ar-H), 
7.37 (2H, d, J 8.5, Ar-H), 7.42 – 7.62 (3H, m, Ar-H), 7.74 (1H, d, J 8.2, Ar-H), 7.83 – 
7.86 (2H, m, Ar-H);  C (101 MHz; CDCl3) 36.15 (CH2), 36.67 (CH2), 44.15 (CH2), 
45.75 (CH2), 55.16 (OCH3), 55.23 (OCH3), 56.61 (CHS), 57.97 (CHS), 114.06 (Ar-C-
H), 114.11 (Ar-C-H), 123.29 (Ar-C-H), 100.09 (Ar-C-H), 100.93 (Ar-C-H), 126.61 
(Ar-C-H), 127.64 (Ar-C-H), 127.94 (Ar-C-H), 128.05 (Ar-C-H), 128.49 (Ar-C-H), 
128.65 (Ar-C-H), 128.88 (Ar-C-H), 128.90 (quaternary C), 129.59 (quaternary C), 
130.66 (Ar-C-H), 130.71 (Ar-C-H), 131.37 (quaternary C), 133.76 (quaternary C), 
134.79 (quaternary C), 158.90 (quaternary C), 159.08 (quaternary C), 164.76 (CO), 
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165.26 (CO); m/z 649 (100%, [M+H]
+
): Found [M+H]
+
 649.2203, C38H37N2O4S2 
requires 649.2195.  
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5.23 (3S,6S)-1-Benzyl-4-(4-methoxybenzyl)-3,6-bis((4-methoxybenzyl) 
thio)piperazine-2,5-dione (420)
217
 
 
para-Methoxybenzylamine (0.89 mL, 6.80 mmol) was added to a solution of 2-
(benzyl(2-ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl 
diacetate (1.14 g, 2.27 mmol) (259)  in acetonitrile (30.0 mL) followed by addition of 
para-methoxybenzyl mercaptan (0.47 mL, 3.40 mmol) (257) and the resulting mixture 
stirred for 2 minutes. TFA (0.05 mL, 0.07 mmol) was added and the resulting solution 
heated at reflux for 16 hours, cooled to RT and solvent removed under reduced pressure. 
The residue was purified via Biotage™ Horizon (1:3, petroleum spirit 40-60 °C: ethyl 
acetate; snap 25 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give (3S,6S)-1-benzyl-4-(4-methoxybenzyl)-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione (1.20 g, 84%) (420) as a colourless solid; 
m.p. 141-143 °C; max/cm
-1
 1666 (C=O), 1510 (C-H), 829 (C-H);  H (400 MHz; 
CDCl3) 3.50 – 3.59 (2H, m, NCH2Ar), 3.76 (3H, s, OCH3), 3.79 (1H, s, SCH2), 3.84 
(1H, s, SCH2), 3.85 (3H, s, OCH3), 3.86 (3H, s, OCH3), 3.99 (2H, s, SCH2), 4.37 (1H, s, 
CHS), 4.38 (1H, s, CHS), 5.09 (1H, d, J 11.4, NCH2), 5.13 (1H, d, J 11.5, NCH2), 6.56 
(2H, d, J 8.7, Ar-H), 6.65 – 6.67 (4H, m, Ar-H), 6.90 – 6.94 (4H, m, Ar-H), 7.11 – 7.21 
(3H, m, Ar-H), 7.37 – 7.40 (4H, m, Ar-H);  C (101 MHz; CDCl3) 36.15 (SCH2), 36.24 
(SCH2), 45.33 (NCH2), 45.94 (NCH2), 55.07 (OCH3), 55.19 (2 x OCH3), 56.96 (CHS), 
57.42 (CHS), 113.88 (Ar-C-H), 114.06 (Ar-C-H), 126.82 (quaternary C), 127.72 (Ar-
C-H), 128.42 (Ar-C-H), 128.49 (Ar-C-H), 128.78 (quaternary C), 128.85 (quaternary 
C), 129.86 (Ar-C-H), 130.73 (Ar-C-H), 130.79 (Ar-C-H), 134.83 (quaternary C), 
159.04 (quaternary C), 159.10 (quaternary C), 164.85 (CO), 164.91 (CO); m/z 629 
(100%, [M+H]
+
): Found [M+H]
+
 629.2145, C35H37N2O5S2 requires 629.2144.  
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5.24 (3S,6S)-1,4-Diallyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-
dione (421) 
 
Allylamine (0.62 mL, 8.31 mmol) (387) was added to a solution of 2-(allyl(2-ethoxy-1-
((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate (2.09 g, 
4.62 mmol) (395) in acetonitrile (15.0 mL) followed by addition of para-
methoxybenzyl mercaptan (1.29 mL, 9.23 mmol) (257) and the resulting mixture stirred 
for 2 minutes. DMAP (0.28 g, 2.31 mmol) was added and the mixture heated in the 
microwave at 140 C for 30 minutes, allowed to cool to room temperature and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (3:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) and further purified by 
recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (3S,6S)-1,4-diallyl-
3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (1.67 g, 72%) (421) as a colourless 
solid; m.p. 70-71 °C; max/cm
-1
 1675 (C=O), 1609 (C=C), 1465 (CH2), 832 (C-H);  H 
(400 MHz, CDCl3) 3.82 – 3.91 (12H, m, NCH2 & OCH3 & SCH2), 3.98 – 4.02 (2H, m, 
NCH2), 4.45 (2H, s, CHS), 4.62 – 4.68 (2H, m, CH=CH2), 4.99 – 5.05 (2H, m, 
CH=CH2), 5.48 – 5.54 (2H, m, CH=CH2), 6.88 – 6.90 (4H, m, Ar-H), 7.36 – 7.38 (4H, 
m, Ar-H);  C (101 MHz, CDCl3) 36.74 (CH2), 45.85 (CH2), 55.56 (OCH3), 58.20 
(CHS), 114.28 (CH=CH2), 119.78 (CH2), 129.04 (quaternary C), 130.91 (Ar-C-H), 
130.95 (Ar-C-H), 159.36 (quaternary C), 165.09 (CO); m/z 499 (100%, [M+H]
+
); 
Found [M+H]
+
 499.1723, C26H31N2O4S2 requires 499.1725.   
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5.25 (3S,6S)-1-Allyl-4-benzyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione (416)
253
 
 
5.25.1 Method A: 
Benzylamine (0.40 mL, 3.68 mmol) (255) was added to a solution of 2-(allyl(2-ethoxy-
1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate (0.56 g, 
1.23 mmol) (395) in acetonitrile (30.0 mL) followed by addition of para-
methoxybenzyl mercaptan (0.25 mL, 1.79 mmol) (257) and the resulting mixture stirred 
for 2 minutes. TFA (0.05 mL, 0.66 mmol) was added and the resulting mixture stirred 
for 16 hours, cooled to RT and solvent removed under reduced pressure. The residue 
was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 
25 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) 
to give (3S,6S)-1-allyl-4-benzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione 
(0.55 g, 80%) (422) as a light yellow solid; identical spectroscopic data to that obtained 
previously for (416). 
5.25.2 Method B: 
Benzylamine (0.23 mL, 2.07 mmol) (255) was added to a solution of 2-(allyl(2-ethoxy-
1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate (0.63 g, 
1.38 mmol) (395) in acetonitrile (30.0 mL) followed by addition para-methoxybenzyl 
mercaptan (0.39 mL, 2.77 mmol) (257) and the resulting mixture stirred for 2 minutes. 
DMAP (0.08 g, 0.69 mmol) was added and the resulting mixture stirred for 16 hours, 
cooled to RT and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) and further 
purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (3S,6S)-1-
allyl-4-benzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.55 g, 72%) (422) 
as a light yellow solid; identical spectroscopic data to that obtained previously for (416). 
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5.26 (3S,6S)-3,6-Bis((4-methoxybenzyl)thio)-1,4-dimethylpiperazine-
2,5-dione (423) 
 
Methylamine (17.5 mL of a 2M solution in tetrahydrofuran, 35.0 mmol) (390) was 
added to a solution of 2-((2-ethoxy-1-((4-methoxybenzyl)thio)-2-
oxoethyl)(methyl)amino)-2-oxoethane-1,1-diyl diacetate (4.98 g, 12.0 mmol) (259) in 
toluene (100 mL) followed by addition of para-methoxybenzyl mercaptan (2.44 mL, 
17.5 mmol) (257) and the resulting mixture stirred for 2 minutes. TFA (0.05 mL, 0.07 
mmol) was added and the resulting solution stirred for one hour and then heated to 
reflux under Dean and Stark water removal conditions for 24 hours, cooled to RT and 
solvent removed under reduced pressure. The residue was purified via Biotage™ 
Horizon (1:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) and further purified 
by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (3S,6S)-3,6-bis((4-
methoxybenzyl)thio)-1,4-dimethylpiperazine-2,5-dione (3.21 g, 62%) (423) as a 
colourless crystalline solid; m.p. 118-119 °C; max/cm
-1
 1651 (C=O);  H (400 MHz; 
CDCl3) 2.65 (6H, s, NCH3), 3.78 (6H, s, OCH3), 3.83 (2H, d, J 13.6, SCH2), 3.96 (2H, 
d, J 13.6, SCH2), 4.31 (2H, s, CHS), 6.85 (4H, d, J 8.6, Ar-H), 7.34 (4H, d, J 8.6, Ar-
H);  C (101 MHz; CDCl3) 31.51 (NCH3), 36.60 (CH2), 55.21 (OCH3), 61.36 (CHS), 
113.90 (Ar-C-H), 128.55 (quaternary C), 130.57 (Ar-C-H), 158.97 (quaternary C), 
165.14 (CO); m/z 447 (100%, [M+H]
+
): Found [M+H]
+
 447.1353, C22H27N2O4S2 
requires 447.1334. 
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5.27 (±)-(1S,4S)-2-Benzyl-5-(3-chlorobenzyl)-7-thia-2,5-diazabicyclo 
[2.2.1]heptane-3,6-dione 7-sulfide (424)
217
 
 
Boron tribromide (0.21 mL, 2.25 mmol) was added dropwise to a solution of (3S,6S)-1-
benzyl-4-(3-chlorobenzyl)-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.72 g, 
1.12 mmol) (410) in dichloromethane (40.0 mL) at -78 °C. The resulting mixture was 
stirred for 45 minutes whereupon aqueous ammonium chloride (15.0 mL of a saturated 
aqueous solution) was added and the biphasic mixture stirred for 15 minutes until the 
yellow colour had dissipated. The resulting mixture was stirred at room temperature for 
40 minutes, whereupon iodine was added portionwise until the colour due to iodine just 
persisted and stirring was maintained for 2 minutes. A solution of saturated aqueous 
sodium thiosulfate was added, the mixture stirred for 30 minutes and diluted with 
dichloromethane (10.0 mL) and water (20.0 mL). The layers were separated and the 
aqueous phase extracted with dichloromethane (2 x 20.0 mL). The combined organic 
extracts were dried over MgSO4, filtered and solvent removed under reduced pressure. 
The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 10 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give (±)-(1S,4S)-2-benzyl-5-(3-chlorobenzyl)-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide  (0.14 g, 32%) (424) as a pale yellow 
solid; m.p. 147-149 C; max/cm
-1
 1674 (C=O);  H (400 MHz; CDCl3) 4.50 – 4.52 (2H, 
m, NCH2Ar), 4.72 (1H, d, J 11.1, NCH2), 4.84 (1H, d, J 11.9, NCH2), 5.26 (1H, s, 
CHS), 5.27 (1H, s, CHS), 7.18 – 7.19 (1H, m, Ar-H), 7.26 – 7.40 (8H, m, Ar-H);  C 
(101 MHz, CDCl3) 47.24 (NCH2), 47.71 (NCH2), 64.49 (CHS), 64.85 (CHS), 126.30 
(Ar-C-H), 128.36 (Ar-C-H), 128.43 (Ar-C-H), 128.58 (Ar-C-H), 128.74 (Ar-C-H), 
129.14 (Ar-C-H), 130.36 (Ar-C-H), 134.01 (quaternary C), 134.91 (quaternary C), 
136.27 (quaternary C), 163.58 (CO), 163.65 (CO); m/z 391.0853 (100%, [M+H]
+
), 
392.0931 (27.6%, [M+H]
+
), 393.0873 (42.3%, [M+H]
+
), 394.0934 (14.1%, [M+H]
+
), 
395.0991 (13.9%, [M+H]
+
), C18H16ClN2O2S2 requires 391.0842.  
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5.28 Ethyl 4-((±)-(1S,4S)-5-benzyl-3,6-dioxo-7-sulfido-7-thia-2,5-
diazabicyclo [2.2.1]heptan-2-yl)butanoate (425) 
 
Boron tribromide (0.04 mL, 0.39 mmol) was added dropwise to a solution of ethyl 4-
((2S,5S)-4-benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-dioxopiperazin-1-yl)butanoate 
(0.12 g, 0.19 mmol) (411) in dichloromethane (10.0 mL) at -78 °C. The resulting 
mixture was stirred for 30 minutes whereupon sodium hydrogen carbonate (10.0 mL of 
a saturated aqueous solution) was added and the biphasic mixture stirred for 15 minutes 
until the yellow colour had dissipated. The resulting mixture was stirred at room 
temperature for 40 minutes, whereupon iodine was added portionwise until the colour 
due to iodine just persisted and stirring was maintained for 5 minutes. A solution of 
saturated aqueous sodium thiosulfate was added and the mixture stirred for 30 minutes, 
diluted with dichloromethane (10.0 mL) and water (20.0 mL). The layers were 
separated and the aqueous phase extracted with dichloromethane (2 x 20.0 mL). The 
combined organic extracts were dried over MgSO4, filtered and solvent removed under 
reduced pressure. The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 
40-60 °C: ethyl acetate; snap 10 g) and further recrystallisation to give ethyl 4-((±)-
(1S,4S)-5-benzyl-3,6-dioxo-7-sulfido-7-thia-2,5-diazabicyclo[2.2.1]heptan-2-
yl)butanoate (0.05 g, 64%) (425) as a pale yellow solid; m.p. 82-84 C; max/cm
-1
 1498 
(CH2), 1160 (C-C(O)-C);  H (400 MHz; CDCl3) 1.28 (3H, t, J 7.1, OCH2CH3), 1.99 – 
2.09 (2H, m, NCH2CH2CH2CO), 2.40 – 2.43 (2H, m, NCH2CH2CH2CO), 3.52 – 3.67 
(2H, m, NCH2CH2CH2CO), 4.17 – 4.20 (2H, m, OCH2CH3), 4.53 (1H, d, J 12.0, NCH2-
Ph), 4.86 (1H, d, J 12.2, NCH2-Ph), 5.20 (1H, s, CHS), 5.42 (1H, s, CHS), 7.29 – 7.32 
(2H, m, Ar-H), 7.36 – 7.41 (3 H, m, Ar-H);  C (101 MHz, CDCl3) 14.43 (CH3), 23.27 
(CH2), 31.23 (CH2), 44.91 (CH2), 47.96 (CH2), 60.88 (CH2), 64.90 (CHS), 66.07 
(CHS), 128.65 (Ar-C-H), 128.82 (Ar-C-H), 129.38 (Ar-C-H), 134.30 (quaternary C), 
163.85 (CO), 164.10 (CO), 172.70 (CO); m/z 403 (100%, [M+Na]
+
): Found [M+Na]
+
 
403.1341, C17H20N2O4S2Na requires 403.0762.  
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5.29 Methyl 6-((±)-(1S,4S)-5-benzyl-3,6-dioxo-7-sulfido-7-thia-2,5-
diazabicyclo[2.2.1]heptan-2-yl)hexanoate (426) 
 
Boron tribromide (0.03 mL, 0.35 mmol) was added dropwise to a solution of methyl 6-
((2S,5S)-4-benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-dioxopiperazin-1-yl)hexanoate 
(0.15 g, 0.24 mmol) (412) in dichloromethane (10.0 mL) at -78 °C. The resulting 
mixture was stirred for 30 minutes whereupon sodium hydrogen carbonate (10.0 mL of 
a saturated aqueous solution) was added and the biphasic mixture stirred for 15 minutes 
until the yellow colour had dissipated. The resulting mixture was stirred at room 
temperature for 40 minutes, whereupon iodine was added portionwise until the colour 
due to iodine just persisted and stirring was maintained for 5 minutes. A solution of 
saturated aqueous sodium thiosulfate was added and the mixture stirred for 30 minutes, 
diluted with dichloromethane (10.0 mL) and water (20.0 mL). The layers were 
separated and the aqueous phase extracted with dichloromethane (2 x 20.0 mL). The 
combined organic extracts were dried over MgSO4, filtered and solvent removed under 
reduced pressure. The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 
40-60 °C: ethyl acetate; snap 10 g) and further purified by recrystallisation (petroleum 
spirit 40-60 °C: ethyl acetate) to give methyl 6-((±)-(1S,4S)-5-benzyl-3,6-dioxo-7-
sulfido-7-thia-2,5-diazabicyclo[2.2.1]heptan-2-yl)hexanoate (0.07 g, 75%) (426) as a 
pale yellow solid; m.p. 85-88 C; max/cm
-1
 2933 (C-H), 1734 (C=O), 1674 (C=O), 1451 
(CH2), 733 (C-H);  H (400 MHz; CDCl3) 1.36 – 1.42 (2H, m, NCH2(CH2)3CH2CO), 
2.34 (2H, t, J 7.4, NCH2(CH2)3CH2CO), 3.53 (2H, t, J 7.3, NCH2(CH2)3CH2CO), 3.68 – 
3.69 (5H, m, CH2CO2CH3), 3.73 – 3.80 (2H, m, NCH2(CH2)3CH2CO), 4.52 (1H, d, J 
12.0, NCH2-Ph), 4.85 (1H, d, J 12.0, NCH2-Ph), 5.20 (1H, s, CHS), 5.37 (1H, s, CHS), 
7.30 (2H, d, J 7.7, Ar-H), 7.37 – 7.40 (3H, m, Ar-H);  C (101 MHz, CDCl3) 24.55 
(CH2), 26.31 (CH2), 27.64 (CH2), 33.95 (CH2), 45.26 (CH2), 47.94 (CH2), 51.74 (CH3), 
64.93 (CHS), 65.84 (CHS), 128.59 (Ar-C-H), 128.78 (Ar-C-H), 129.34 (Ar-C-H), 
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134.32 (quaternary C), 163.77 (CO), 164.16 (CO), 174.01 (CO); m/z 417 (100%, 
[M+Na]
+
): Found [M+Na]
+
 417.0939, C18H22N2O4S2Na requires 417.0919.  
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5.30 Ethyl 3-((±)-(1S,4S)-5-benzyl-3,6-dioxo-7-sulfido-7-thia-2,5-
diazabicyclo [2.2.1]heptan-2-yl)propanoate (427) 
 
Boron tribromide (0.05 mL, 0.56 mmol) was added dropwise to a solution of ethyl 3-
((2S,5S)-4-benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-dioxopiperazin-1-yl)propanoate 
(0.17 g, 0.28 mmol) (413) in dichloromethane (10.0 mL) at -78 °C. The resulting 
mixture was stirred for 30 minutes whereupon sodium hydrogen carbonate (10.0 mL of 
a saturated aqueous solution) was added and the biphasic mixture stirred for 15 minutes 
until the yellow colour had dissipated. The resulting mixture was stirred at room 
temperature for 40 minutes, whereupon iodine was added portionwise until the colour 
due to iodine just persisted and stirring was maintained for 5 minutes. A solution of 
saturated aqueous sodium thiosulfate was added and the mixture stirred for 30 minutes, 
diluted with dichloromethane (10.0 mL) and water (20.0 mL). The layers were 
separated and the aqueous phase extracted with dichloromethane (2 x 20.0 mL). The 
combined organic extracts were dried over MgSO4, filtered and solvent removed under 
reduced pressure. The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 
40-60 °C: ethyl acetate; snap 10 g) and further purified by recrystallisation (petroleum 
spirit 40-60 °C: ethyl acetate) to give ethyl 3-((±)-(1S,4S)-5-benzyl-3,6-dioxo-7-sulfido-
7-thia-2,5-diazabicyclo[2.2.1]heptan-2-yl)propanoate (0.05 g, 51%) (427) as a pale 
yellow solid; m.p. 100-104 C; max/cm
-1 
1670 (C=O), 1496 (C-H);  H (400 MHz; 
CDCl3) 1.30 (3H, t, J 7.1, OCH2CH3), 2.71 (2H, t, J 6.2, NCH2), 3.79 – 3.84 (2H, m, 
NCH2CH2), 4.22 (2H, q, J 7.1, OCH2CH3), 4.50 (1H, d, J 15.0, NCH2), 4.86 (1H, d, J 
15.0, NCH2), 5.19 (1H, s, CHS), 5.67 (1H, s, CHS), 7.28 – 7.29 (1H, m, Ar-H), 7.30 
(1H, d, J 2.0, Ar-H), 7.38 (2H, t, J 2.1, Ar-H), 7.39 – 7.40 (1H, m, Ar-H);  C (101 
MHz; CDCl3) 14.39 (CH3), 33.04 (CH2), 41.88 (CH2), 47.85 (CH2), 61.45 (CH2), 64.80 
(CHS), 66.98 (CHS), 128.64 (Ar-C-H), 128.78 (Ar-C-H), 129.35 (Ar-C-H), 134.35 
(quaternary C), 163.64 (CO), 164.12 (CO), 171.66 (CO); m/z 389 (100%, [M+Na]
+
): 
Found [M+Na]
+
 389.0622, C16H18N2O4S2Na requires 389.0606.  
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5.31 Ethyl 3-((±)-(1S,4S)-5-benzyl-3,6-dioxo-7-sulfido-7-thia-2,5-
diazabicyclo [2.2.1]heptan-2-yl)propanoate (428) 
 
Boron tribromide (0.02 mL, 0.21 mmol) was added dropwise to a solution of methyl 5-
((2S,5S)-4-benzyl-2,5-bis((4-methoxybenzyl)thio)-3,6-dioxopiperazin-1-yl)pentanoate 
(0.07 g, 0.11 mmol) (414) in dichloromethane (10.0 mL) at -78 °C. The resulting 
mixture was stirred for 45 minutes whereupon sodium hydrogen carbonate (10.0 mL of 
a saturated aqueous solution) was added and the biphasic mixture stirred for 15 minutes 
until the yellow colour had dissipated. The resulting mixture was stirred at room 
temperature for 40 minutes, whereupon iodine was added portionwise until the colour 
due to iodine just persisted and stirring was maintained for 3 minutes. A solution of 
saturated aqueous sodium thiosulfate was added and the mixture stirred for 30 minutes, 
diluted with dichloromethane (10.0 mL) and water (20.0 mL). The layers were 
separated and the aqueous phase extracted with dichloromethane (2 x 20.0 mL). The 
combined organic extracts were dried over MgSO4, filtered and solvent removed under 
reduced pressure. The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 
40-60 °C : ethyl acetate; snap 10 g) and further purified by recrystallisation (petroleum 
spirit 40-60 °C: ethyl acetate) to give methyl 5-((±)-(1S,4S)-5-benzyl-3,6-dioxo-7-
sulfido-7-thia-2,5-diazabicyclo[2.2.1]heptan-2-yl)pentanoate (0.01 g, 29%) (428) as a 
pale yellow solid; m.p. 93-96 C; max/cm
-1
 1732 (C=O), 1672 (C=O), 1453 (CH2), 734 
(C-H), 700 (C-H);  H (400 MHz; CDCl3) 1.28 – 1.31 (2H, m, NCH2(CH2)2CH2CO), 
2.39 (2H, t, J 6.9, NCH2(CH2)2CH2CO), 3.55 (2H, t, J 6.6, NCH2(CH2)3CH2CO), 3.70 
(4H, s, CH2CO2CH3), 3.82 – 3.84 (1H, m, CH2CO2CH3), 4.53 (1H, d, J 11.0, NCH2-
Ph), 4.87 (1H, d, J 10.0, NCH2-Ph), 5.20 (1H, s, CHS), 5.36 (1H, s, CHS), 7.29 (2H, d, 
J 4.2, Ar-H), 7.38 – 7.43 (3H, m, Ar-H);  C (101 MHz, CDCl3) 22.14 (CH2), 27.40 
(CH2), 33.52 (CH2), 45.04 (CH2), 47.98 (CH2), 51.86 (CH3), 64.91 (CHS), 65.85 
(CHS), 128.64 (Ar-C-H), 128.84 (Ar-C-H), 129.40 (Ar-C-H), 134.29 (quaternary C), 
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163.82 (CO), 164.14 (CO), 173.67 (CO); m/z 403 (100%, [M+Na]
+
): Found [M+Na]
+
 
403.1341, C17H20N2O4S2Na requires 403.0762.  
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5.32 (±)-(1S,4S)-2-Benzyl-5-butyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (429)
217
 
 
Boron tribromide (0.11 mL, 1.12 mmol) was added dropwise to a solution of (3S,6S)-1-
benzyl-4-butyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.25 g, 0.45 mmol) 
(373) in dichloromethane (15.0 mL) at -78 °C. The resulting mixture was stirred for 30 
minutes whereupon aqueous hydrochloric acid (15.0 mL of a 0.5M solution) was added 
and the biphasic mixture stirred for 15 minutes until the yellow colour had dissipated. 
The resulting mixture was stirred at room temperature for 40 minutes, whereupon iodine 
was added portionwise until the colour due to iodine just persisted and stirring was 
maintained for 15 minutes. A solution of saturated aqueous sodium thiosulfate was 
added and the mixture stirred for 30 minutes, diluted with dichloromethane (10.0 mL) 
and water (20.0 mL). The layers were separated and the aqueous phase extracted with 
dichloromethane (2 x 20.0 mL). The combined organic extracts were dried over MgSO4, 
filtered and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (2:1, petroleum spirit 40-60 °C: ethyl acetate; snap 10 g) and further 
purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (±)-
(1S,4S)-2-benzyl-5-butyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide 
(0.08 g, 54%) (429) as a pale yellow solid; m.p. 119-121 C; max/cm
-1
 1681 (C=O);  H 
(400 MHz; CDCl3) 0.95 (3H, t, J 7.3, NCH2(CH2)2CH3), 1.29 – 1.37 (2H, m, 
NCH2(CH2)2CH3), 1.61 – 1.72 (2H, m, NCH2(CH2)2CH3), 3.42 – 3.59 (2H, m, 
NCH2(CH2)2CH3), 4.51 (1H, d, J 14.9, NCH2-Ph), 4.84 (1H, d, J 14.9, NCH2-Ph), 5.18 
(1H, s, CHS), 5.34 (1H, s, CHS), 7.26 – 7.29 (2H, m, Ar-H), 7.31 – 7.38 (3H, m, Ar-H); 
 C (101 MHz; CDCl3) 13.65 (CH3), 19.90 (CH2), 29.75 (CH2), 44.90 (CH2), 47.65 
(CH2), 64.69 (CHS), 65.55 (CHS), 128.36 (Ar-C-H), 128.56 (Ar-C-H), 129.12 (Ar-C-
H), 134.08 (quaternary C), 163.53 (CO), 163.99 (CO); m/z 323 (100%, [M+H]
+
): Found 
[M+H]
+
 323.0900, C15H19N2O2S2 requires 323.0888. 
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5.33 (±)-(1S,4S)-2,5-Dibenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-
dione 7-sulfide (430)
217
 
 
Boron tribromide (0.07 mL, 0.69 mmol) was added dropwise to a solution of (3S,6S)-
1,4-dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.21 g, 0.34 mmol) 
(415) in dichloromethane (5.00 mL) at -78 °C. The resulting mixture was stirred for 45 
minutes whereupon aqueous ammonium chloride (15.0 mL of a saturated aqueous 
solution) was added and the biphasic mixture stirred for 15 minutes until the yellow 
colour had dissipated. The resulting mixture was stirred at room temperature for 40 
minutes, whereupon iodine was added portionwise until the colour due to iodine just 
persisted and stirring was maintained for 2 minutes. A solution of saturated aqueous 
sodium thiosulfate was added and the mixture stirred for 30 minutes, diluted with 
dichloromethane (10.0 mL) and water (20.0 mL). The layers were separated and the 
aqueous phase extracted with dichloromethane (2 x 20.0 mL). The combined organic 
extracts were dried over MgSO4, filtered and solvent removed under reduced pressure. 
The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 10 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give (±)-(1S,4S)-2,5-dibenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-
3,6-dione 7-sulfide (0.10 g, 85%) (430) as a pale yellow solid; m.p. 166-188 C; 
max/cm
-1
 1685 (C=O);  H (400 MHz; CDCl3) 4.63 (2H, d, J 12.0, CH2Ar), 4.99 (2H, d, 
J 12.0 Hz, CH2Ar), 5.39 (2H, s, CHS), 7.40 – 7.54 (10H, m, Ar-H);  C (101 MHz, 
CDCl3) 48.14 (CH2), 65.14 (CH), 128.85 (Ar-C-H), 129.03 (Ar-C-H), 129.59 (Ar-C-
H), 134.54 (quaternary C), 164.19 (CO); m/z 357 (100%, [M+H]
+
): Found [M+H]
+
 
357.0651, C18H17N2O2S2 requires 357.0653.  
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5.34 (±)-(1S,4S)-2-Allyl-5-benzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-
3,6-dione 7-sulfide (431)
253
 
 
Boron tribromide (0.03 mL, 0.36 mmol) was added dropwise to a solution of (3S,6S)-1-
allyl-4-benzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.10 g, 0.18 mmol) 
(416) in dichloromethane (10.0 mL) at -78 °C. The resulting mixture was stirred for 45 
minutes whereupon aqueous ammonium chloride (15 mL of a saturated aqueous 
solution) was added and the biphasic mixture stirred for 15 minutes until the yellow 
colour had dissipated. The resulting mixture was stirred at room temperature for 40 
minutes, whereupon iodine was added portionwise until the colour due to iodine just 
persisted and stirring was maintained for 2 minutes. A solution of saturated aqueous 
sodium thiosulfate was added and the mixture stirred for 30 minutes, diluted with 
dichloromethane (10.0 mL) and water (20.0 mL). The layers were separated and the 
aqueous phase extracted with dichloromethane (2 x 20.0 mL). The combined organic 
extracts were dried over MgSO4, filtered and solvent removed under reduced pressure. 
The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 10 g) and further recrystallisation to give (±)-(1S,4S)-2-allyl-5-benzyl-7-
thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide  (0.03 g, 60%) (431) as a pale 
yellow solid; m.p. 116-118 C; max/cm
-1
 1685 (C=O);  H (400 MHz; CDCl3) 3.96 
(1H, dd, J 15.4 & 8.6, NCH2CH=CH2), 4.25 (1H, dd, J 15.4 & 7.6, NCH2CH=CH2), 
4.49 (1H, d, J 11.7, NCH2), 4.85 (1H, d, J 11.9, NCH2), 5.22 (1H, s, CHS), 5.33 – 5.34 
(2H, m, CH=CH2), 5.36 (1H, s, CHS), 5.38 – 5.42 (1H, m, CH=CH2), 7.26 – 7.29 (2H, 
m, Ar-H), 7.32 – 7.39 (3H, m, Ar-H);  C (101 MHz, CDCl3) 46.38 (CH2), 47.52 
(CH2), 64.36 (CHS), 64.55 (CHS), 120.65 (CHCH2), 128.33 (Ar-C-H), 128.49 (Ar-C-
H), 129.07 (Ar-C-H), 130.74 (CH=CH2), 134.05 (quaternary C), 163.38 (CO), 163.82 
(CO); m/z 307 (100%, [M+H]
+
): Found [M+H]
+
 307.0484, C14H15N2O2S2 requires 
307.0497.  
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5.35 (±)-(1S,4S)-2-Benzyl-5-isopropyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (432)
217
 
 
Boron tribromide (0.50 mL, 0.50 mmol, 1M solution in dichloromethane) was added 
dropwise to a solution of (3S,6S)-1-benzyl-4-isopropyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione (0.11 g, 0.20 mmol) (417) in dichloromethane 
(2.00 mL) at -78 °C and stirred for 15 minutes. The resulting mixture was stirred for 30 
minutes whereupon aqueous hydrochloric acid (15.0 mL of a 0.5M solution) was added 
and the biphasic mixture stirred for 15 minutes until the yellow colour had dissipated. 
The resulting mixture was stirred at room temperature for 40 minutes, whereupon iodine 
was added portionwise until the colour due to iodine just persisted and stirring was 
maintained for 5 minutes. A solution of saturated aqueous sodium thiosulfate was added 
and the mixture stirred for 30 minutes, diluted with dichloromethane (10.0 mL) and 
water (20.0 mL). The layers were separated and the aqueous phase extracted with 
dichloromethane (2 x 20.0 mL). The combined organic extracts were dried over MgSO4, 
filtered and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 10 g) and further 
purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (±)-
(1S,4S)-2-benzyl-5-isopropyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide 
(0.04 g, 65%) (432) as a pale yellow solid; m.p. 177-180 C; max/cm
-1 
1662 (C=O), 
1609 (C=C), 1434 (C-H), 731 (C-H);  H (400 MHz; CDCl3) 1.35 (6H, dd, J 12.9 & 
6.8, CH(CH3)2), 1.61 (1H, s, CH(CH3)2), 4.53 (1H, d, J 12.6, NCH2-Ph), 4.83 (1H, d, J 
12.9, NCH2-Ph), 5.19 (1H, s, CHS), 5.48 (1H, s, CHS), 7.30 (3H, d, J 10.0, Ar-H), 7.39 
(2H, d, J 7.4, Ar-H);  C (101 MHz, CDCl3) 19.78 (CH3), 20.74 (CH3), 46.63 (CH), 
47.95 (CH2), 61.03 (CHS), 65.29 (CHS), 128.62 (Ar-C-H), 128.76 (Ar-C-H), 129.33 
(Ar-C-H), 134.35 (quaternary C), 163.02 (CO), 164.26 (CO); m/z 331 (100%, 
[M+Na]
+
): Found [M+Na]
+
 331.0569, C14H16N2O2S2Na requires 331.0551. 
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5.36 (±)-(1S,4S)-2-Benzyl-5-methyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (433)
217
 
 
Boron tribromide (0.05 mL, 0.57 mmol) was added dropwise to a solution of (3S,6S)-1-
benzyl-3,6-bis((4-methoxybenzyl)thio)-4-methylpiperazine-2,5-dione (0.15 g, 0.29 
mmol) (418) in dichloromethane (8.00 mL) at -78 °C. The resulting mixture was stirred 
for 45 minutes whereupon aqueous ammonium chloride (15.0 mL of a saturated 
aqueous solution) was added and the biphasic mixture stirred for 15 minutes until the 
yellow colour had dissipated. The resulting mixture was stirred at room temperature for 
40 minutes, whereupon iodine was added portionwise until the colour due to iodine just 
persisted and stirring was maintained for 2 minutes. A solution of saturated aqueous 
sodium thiosulfate was added and the mixture stirred for 30 minutes, diluted with 
dichloromethane (10.0 mL) and water (20.0 mL). The layers were separated and the 
aqueous phase extracted with dichloromethane (2 x 20.0 mL). The combined organic 
extracts were dried over MgSO4, filtered and solvent removed under reduced pressure. 
The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 10 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give (±)-(1S,4S)-2-benzyl-5-methyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (0.07 g, 65%) (433) as a pale yellow 
solid; m.p. 109-111 C; max/cm
-1
 1699 (C=O);  H (400 MHz; CDCl3) 3.12 (3H, s, 
NCH3), 4.49 (1H, d, J 12.9, NCH2), 4.90 (1H, d, J 12.9, NCH2), 5.20 (1H, s, CHS), 5.32 
(1H, s, CHS), 7.28 – 7.39 (5H, m, Ar-H);  C (101 MHz, CDCl3) 31.40 (NCH3), 47.48 
(CH2), 64.34 (CHS), 67.53 (CHS), 128.39 (Ar-C-H), 128.58 (Ar-C-H), 129.15 (Ar-C-
H), 134.04 (quaternary C), 163.85 (CO), 163.99 (CO); m/z 281 (100%, [M+H]
+
): Found 
[M+H]
+
 281.0415, C12H13N2O2S2 requires 281.0418.  
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5.37 (±)-(1S,4S)-2-Benzyl-5-(naphthalen-1-ylmethyl)-7-thia-2,5-
diazabicyclo [2.2.1]heptane-3,6-dione 7-sulfide (434)
217
 
 
Boron tribromide (0.10 mL, 1.02 mmol) was added dropwise to a solution of (3S,6S)-1-
benzyl-3,6-bis((4-methoxybenzyl)thio)-4-(naphthalen-1-ylmethyl)piperazine-2,5-dione 
(0.33 g, 0.51 mmol) (419) in dichloromethane (7.00 mL) at -78 °C. The resulting 
mixture was stirred for 45 minutes whereupon aqueous ammonium chloride (15.0 mL of 
a saturated aqueous solution) was added and the biphasic mixture stirred for 15 minutes 
until the yellow colour had dissipated. The resulting mixture was stirred at room 
temperature for 40 minutes, whereupon iodine was added portionwise until the colour 
due to iodine just persisted and stirring was maintained for 2 minutes. A solution of 
saturated aqueous sodium thiosulfate was added and the mixture stirred for 30 minutes, 
diluted with dichloromethane (10.0 mL) and water (20.0 mL). The layers were 
separated and the aqueous phase extracted with dichloromethane (2 x 20.0 mL). The 
combined organic extracts were dried over MgSO4, filtered and solvent removed under 
reduced pressure. The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 
40-60 °C: ethyl acetate; snap 10 g) to give ((±)-(1S,4S)-2-benzyl-5-(naphthalen-1-
ylmethyl)-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (0.18 g, 85%) (434) 
as a pale yellow solid; m.p. 161-163 C; max/cm
-1
 1685 (C=O);  H (400 MHz; CDCl3) 
4.40 (1H, d, J 12.6, NCH2), 4.79 – 4.84 (3H, m, NCH2), 5.24 (1H, s, CHS), 5.30 (1H, s, 
CHS), 7.20 – 7.25 (2H, m, Ar-H), 7.34 – 7.39 (3H, m, Ar-H), 7.44 – 7.47 (2H, m, Ar-
H), 7.53 – 7.58 (2H, m, Ar-H), 7.88 – 7.92 (2H, m, Ar-H), 7.95 – 8.00 (1H, m, Ar-H);  
C (101 MHz, CDCl3) 45.09 (CH2), 47.31 (CH2), 63.36 (CHS), 64.64 (CHS), 123.05 
(Ar-C-H), 100.10 (Ar-C-H), 126.32 (Ar-C-H), 126.94 (Ar-C-H), 128.13 (Ar-C-H), 
128.35 (Ar-C-H), 128.39 (Ar-C-H), 128.82 (Ar-C-H), 128.98 (Ar-C-H), 129.48 
(quaternary C), 129.88 (Ar-C-H), 131.48 (quaternary C), 133.84 (quaternary C), 134.11 
(quaternary C), 163.43 (CO), 163.48 (CO); m/z 407 (100%, [M+H]
+
): Found [M+H]
+
 
407.0791, C22H19N2O2S2 requires 407.0810.  
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5.38 (±)-(1S,4S)-2-Benzyl-5-(4-methoxybenzyl)-7-thia-2,5-
diazabicyclo[2.2.1] heptane-3,6-dione 7-sulfide (435)
217
 
 
Boron tribromide (0.11 mL, 1.22 mmol) was added dropwise to a solution of (3S,6S)-1-
benzyl-4-(4-methoxybenzyl)-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.38 
g, 0.61 mmol) (420) in dichloromethane (8.00 mL) at -78 °C. The resulting mixture was 
stirred for 45 minutes whereupon aqueous ammonium chloride (15.0 mL of a saturated 
aqueous solution) was added and the biphasic mixture stirred for 15 minutes until the 
yellow colour had dissipated. The resulting mixture was stirred at room temperature for 
40 minutes, whereupon iodine was added portionwise until the colour due to iodine just 
persisted and stirring was maintained for 2 minutes. A solution of saturated aqueous 
sodium thiosulfate was added and the mixture stirred for 30 minutes, diluted with 
dichloromethane (10.0 mL) and water (20.0 mL). The layers were separated and the 
aqueous phase extracted with dichloromethane (2 x 20.0 mL). The combined organic 
extracts were dried over MgSO4, filtered and solvent removed under reduced pressure. 
The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 10 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give (±)-(1S,4S)-2-benzyl-5-(4-methoxybenzyl)-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (0.11 g, 48%) (435) as a pale yellow 
solid; m.p. 146-148 C; max/cm
-1
 2991 (C-H), 1681 (C=O);  H (400 MHz; CDCl3) 
3.80 (3H, s, OCH3), 4.43 (1H, d, J 12.7, CH2), 4.48 (1H, d, J 13.0, CH2), 4.75 (1H, d, J 
12.7, CH2), 4.82 (1H, d, J 13.0, CH2), 5.25 (1H, s, CHS), 5.26 (1H, s, CHS), 6.90 (2H, 
d, J 8.6, Ar-H), 7.21 (2H, d, J 8.6, Ar-H), 7.27 – 7.29 (2H, m, Ar-H), 7.35 – 7.36 (3H, 
m, Ar-H);  C (101 MHz, CDCl3) 47.09 (CH2), 47.55 (CH2), 55.20 (OCH3), 64.27 
(CHS), 64.67 (CHS), 114.45 (Ar-C-H), 100.84 (quaternary C), 128.31 (Ar-C-H), 
128.47 (Ar-C-H), 129.05 (Ar-C-H), 129.86 (Ar-C-H), 134.10 (quaternary C), 159.72 
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(quaternary C), 163.64 (CO), 163.77 (CO); m/z 387 (100%, [M+H]
+
): Found [M+H]
+
 
387.0833, C19H19N2O3S2 requires 387.0837.  
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5.39 (±)-(1S,4S)-2-Allyl-5-benzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-
3,6-dione 7-sulfide (436)
253
 
 
Boron tribromide (0.09 mL, 0.94 mmol) was added dropwise to a solution of (3S,6S)-1-
allyl-4-benzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.26 g, 0.47 mmol) 
(416) in dichloromethane (7.00 mL) at -78 °C. The resulting mixture was stirred for 45 
minutes whereupon aqueous ammonium chloride (15 mL of a saturated aqueous 
solution) was added and the biphasic mixture stirred for 15 minutes until the yellow 
colour had dissipated. The resulting mixture was stirred at room temperature for 40 
minutes, whereupon iodine was added portionwise until the colour due to iodine just 
persisted and stirring was maintained for 2 minutes. A solution of saturated aqueous 
sodium thiosulfate was added and the mixture stirred for 30 minutes, diluted with 
dichloromethane (10.0 mL) and water (20.0 mL). The layers were separated and the 
aqueous phase extracted with dichloromethane (2 x 20.0 mL). The combined organic 
extracts were dried over MgSO4, filtered and solvent removed under reduced pressure. 
The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 10 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give (±)-(1S,4S)-2-allyl-5-benzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (0.10 g, 67%) (436) as a pale yellow 
solid; identical spectroscopic data to that obtained previously for (431). 
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5.40 (±)-(1S,4S)-2,5-Dimethyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-
3,6-dione 7-sulfide (437) 
 
Boron tribromide (0.10 mL, 1.03 mmol) was added dropwise to a solution of (3S,6S)-
3,6-bis((4-methoxybenzyl)thio)-1,4-dimethylpiperazine-2,5-dione (0.23 g, 0.52 mmol) 
(423) in dichloromethane (8.00 mL) at -78 °C. The resulting mixture was stirred for 45 
minutes whereupon aqueous ammonium chloride (15.0 mL of a saturated aqueous 
solution) was added and the biphasic mixture stirred for 15 minutes until the yellow 
colour had dissipated. The resulting mixture was stirred at room temperature for 40 
minutes, whereupon iodine was added portionwise until the colour due to iodine just 
persisted and stirring was maintained for 2 minutes. A solution of saturated aqueous 
sodium thiosulfate was added and the mixture stirred for 30 minutes, diluted with 
dichloromethane (10.0 mL) and water (20.0 mL). The layers were separated and the 
aqueous phase extracted with dichloromethane (2 x 20.0 mL). The combined organic 
extracts were dried over MgSO4, filtered and solvent removed under reduced pressure. 
The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 10 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give (±)-(1S,4S)-2,5-dimethyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-
3,6-dione 7-sulfide (0.07 g, 68%) (437) as a pale yellow solid; m.p. 202-205 C; 
max/cm
-1
 1686 (C=O), 1390 (CH3);  H (400 MHz; CDCl3) 3.05 (6H, s, NCH3), 5.15 
(2H, s, CHS);  C (101 MHz, CDCl3) 31.59 (NCH3), 67.60 (CHS), 164.32 (CO); m/z 
202 (100%, [M-H]
-
): Found [M-H]
-
 202.9957, C6H7N2O2S2 requires 202.9949. 
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5.41 1,4-Dibenzyl-3-isopropoxy-6-((4-methoxybenzyl)thio)piperazine-
2,5-dione (446) 
 
Benzylamine (0.18 mL, 1.67 mmol) (255) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(0.70 g, 1.39 mmol) (259) in iso-propanol (15.0 mL) and the resulting mixture stirred 
for 2 minutes. DMAP (0.09 g, 0.70 mmol) was added and the resulting mixture stirred 
for 24 hours at RT and solvent removed under reduced pressure. The residue was 
purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) 
to give 1,4-dibenzyl-3-isopropoxy-6-((4-methoxybenzyl)thio)piperazine-2,5-dione (0.42 
g, 60%) (446) as a colourless oil; max/cm
-1
 3031 (C-H), 1677 (C=O), 1359 (CH3), 1206 
(C-C(O)-C), 1002 (C-C(O)-C), 733 (C-H), 700 (C-H);  H (400 MHz, CDCl3) 1.09 (3H, 
d, J 6.0, OCH(CH3)2), 1.28 (3H, d, J 6.2, OCH(CH3)2), 3.36 – 3.39 (1H, m, 
OCH(CH3)2), 3.75 (3H, s, OCH3), 3.75 (2H, s, SCH2), 4.33 (2H, d, J 4.2, NCH2), 4.36 – 
4.43 (2H, m, NCH2), 4.69 (1H, s, CHS), 5.42 (1H, s, CHO), 6.78 (2H, d, J 1.2, Ar-H), 
6.79 – 6.80 (2H, m, Ar-H), 7.11 – 7.13 (5H, m, Ar-H), 7.25 – 7.27 (5H, m, Ar-H);  C 
(101 MHz, CDCl3) 21.50 (CH3), 23.08 (CH3), 36.44 (CH2), 47.73 (CH2), 49.81 (CH2), 
55.47 (OCH3), 57.09 (CHS), 58.05 (CHO), 71.37 (OCH(CH3)2), 128.24 (Ar-C-H), 
128.61 (Ar-C-H), 128.68 (Ar-C-H), 128.84 (Ar-C-H), 129.04 (Ar-C-H), 129.12 (Ar-C-
H), 130.88 (Ar-C-H), 130.93 (Ar-C-H), 134.49 (quaternary C), 135.24 (quaternary C), 
135.93 (quaternary C), 139.02 (quaternary C), 165.28 (CO), 166.92 (CO); m/z 505 
(100%, [M+H]
+
); Found [M+H]
+
 505.2163, C29H33N2O4S requires 505.2161. 
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5.42 1,4-Dibenzyl-3-ethoxy-6-((4-methoxybenzyl)thio)piperazine-2,5-
dione (447)
217
 
 
Benzylamine (0.14 mL, 1.26 mmol) (255) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(0.53 g, 1.05 mmol) (259) in ethanol (15.0 mL) and the resulting mixture stirred for 2 
minutes. DMAP (0.06 g, 0.53 mmol) was added and the resulting mixture stirred for 24 
hours at RT and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) to give 1,4-
dibenzyl-3-ethoxy-6-((4-methoxybenzyl)thio)piperazine-2,5-dione (0.38 g, 74%) (447) 
as a colourless oil; max/cm
-1
 1683 (C=O), 729 (C-H);  H (400 MHz, CDCl3) 1.26 (3H, 
t, J 7.0, OCH2CH3), 3.64 (2H, d, J 6.7, SCH2), 3.87 – 3.89 (7H, m, NCH2 & OCH3), 
4.07 – 4.12 (2H, m, OCH2CH3), 4.47 (1H, s, CHS), 4.77 (1H, s, CHO), 6.76 – 6.82 (3H, 
m, Ar-H), 6.91 – 6.93 (3H, m, Ar-H), 7.18 – 7.22 (3H, m, Ar-H), 7.37 – 7.40 (5H, m, 
Ar-H);  C (101 MHz, CDCl3) 15.17 (OCH2CH3), 36.35 (CH2), 45.95 (CH2), 48.08 
(CH2), 55.41 (CH3), 57.87 (CHS), 65.63 (CH2), 84.15 (CHO), 114.31 (Ar-C-H), 128.13 
(Ar-C-H), 128.43 (Ar-C-H), 128.64 (Ar-C-H), 128.76 (Ar-C-H), 128.81 (Ar-C-H), 
128.99 (Ar-C-H), 130.90 (Ar-C-H), 135.09 (quaternary C), 135.53 (quaternary C), 
159.28 (quaternary C), 163.27 (quaternary C), 165.24 (CO), 166.51 (CO); m/z 491 
(100%, [M+H]
+
); Found [M+H]
+
 491.1992, C28H31N2O4S requires 491.2004.  
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5.43 1,4-Dibenzyl-3-methoxy-6-((4-methoxybenzyl)thio)piperazine-2,5-
dione (448) 
 
Benzylamine (0.21 mL, 1.93 mmol) (255) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(0.65 g, 1.29 mmol) (259) in methanol (15.0 mL) and the resulting mixture stirred for 2 
minutes. DMAP (0.08 g, 0.64 mmol) was added and the resulting mixture stirred for 5 
hours at RT and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) and further 
purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give 1,4-
dibenzyl-3-methoxy-6-((4-methoxybenzyl)thio)piperazine-2,5-dione (0.49 g, 79%) 
(448) as a colourless solid; m.p. 85-88 °C; max/cm
-1
 3030 (C-H), 3005 (C-H), 1671 
(C=O), 1357 (CH3), 1002 (C-O-C), 832 (C-H);  H (400 MHz, CDCl3) 3.53 (3H, s, 
OCH3), 3.62 (1H, d, J 14.5, NCH2), 3.87 – 3.90 (4H, m, SCH2 & OCH3), 4.09 (1H, d, J 
13.8, SCH2), 4.25 (1H, d, J 14.9, NCH2), 4.66 (1H, s, CHO), 4.45 (1H, s, CHS), 5.18 
(2H, d, J 14.7, NCH2), 6.91 – 6.95 (2H, m, Ar-H), 7.16 – 7.29 (6H, m, Ar-H), 7.36 (6H, 
dd, J 16.4 & 9.2, Ar-H);  C (101 MHz, CDCl3) 36.29 (CH2), 45.93 (CH2), 48.07 
(CH2), 55.39 (OCH3), 57.66 (OCH3), 85.50 (CHS), 114.29 (CHO), 128.03 (Ar-C-H), 
128.19 (Ar-C-H), 128.53 (Ar-C-H), 128.66 (Ar-C-H), 128.75 (Ar-C-H), 129.01 (Ar-C-
H), 130.88 (Ar-C-H), 134.98 (quaternary C), 135.30 (quaternary C), 159.27 (quaternary 
C), 162.73 (CO), 166.29 (CO); m/z 477 (100%, [M+H]
+
); Found [M+H]
+
 477.1841, 
C27H29N2O4S requires 477.1848.  
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5.44 1,4-Dibenzyl-3-hydroxy-6-((4-methoxybenzyl)thio)piperazine-2,5-
dione (450) 
 
Benzylamine (0.11 mL, 1.03 mmol) (255) was added to a solution of 2-(benzyl(2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate 
(0.43 g, 0.85 mmol) (259) in tert-butanol (15.0 mL) and the resulting mixture stirred for 
2 minutes. DMAP (0.05 g, 0.43 mmol) was added and the resulting mixture stirred for 
24 hours at RT and solvent removed under reduced pressure. The residue was purified 
via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) which 
further recrystallisation did not give 1,4-dibenzyl-3-(tert-butoxy)-6-((4-
methoxybenzyl)thio)piperazine-2,5-dione (449) but gave 1,4-dibenzyl-3-hydroxy-6-((4-
methoxybenzyl)thio)piperazine-2,5-dione (0.23 g, 59%) (450) as a colourless solid; 
m.p. 99-100 °C; max/cm
-1
 3322 (OH), 3030 (C-H), 1672 (C=O), 1001 (C-O), 832 (C-
H), 731 (C-H), 699 (C-H);  H (400 MHz, CDCl3) 2.52 (1H, br s, OH), 3.88 – 3.95 (5H, 
m, OCH3 & SCH2), 4.12 (2H, d, J 7.5, NCH2), 4.16 (2H, d, J 7.6, NCH2), 4.46 (1H, s, 
CHS), 4.56 (1H, s, CHO), 6.77 – 6.82 (2H, m, Ar-H), 6.92 – 6.94 (2H, m, Ar-H), 7.32 – 
7.42 (10H, m, Ar-H);  C (101 MHz, CDCl3) 46.23 (CH2), 46.46 (CH2), 49.80 (CH2), 
55.46 (OCH3), 57.08 (CHS), 69.13 (CHO), 127.57 (Ar-C-H), 127.89 (Ar-C-H), 128.16 
(Ar-C-H), 128.32 (Ar-C-H), 128.67 (Ar-C-H), 128.83 (Ar-C-H), 129.11(Ar-C-H), 
130.92 (Ar-C-H), 135.06 (quaternary C), 135.93 (quaternary C), 139.02 (quaternary C), 
159.34 (quaternary C), 165.27 (CO), 165.16 (CO); m/z 485 (100%, [M+Na]
+
); Found 
[M+Na]
+
 485.1494, C26H26N2O4SNa requires 485.1511. 
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5.45 3-Allyl-1,4-dibenzyl-6-methoxy-3-((4-
methoxybenzyl)thio)piperazine -2,5-dione (453) 
 
5.45.1 Method A: 
LiHMDS (0.34 mL of a 1M solution in tetrahydrofuran, 0.34 mmol) was added 
dropwise to a solution of 1,4-dibenzyl-3-methoxy-6-((4-
methoxybenzyl)thio)piperazine-2,5-dione (0.08 g, 0.17 mmol) (448) and allyl bromide 
(0.07 mL, 0.84 mmol) (452) in tetrahydrofuran (2.00 mL) at -78 °C and the resulting 
mixture stirred at this temperature for 1 hour and 1.5 hours at 0 °C. Saturated aqueous 
sodium hydrogen carbonate (10.0 mL) was added and solvent removed under reduced 
pressure. The residue was partitioned between water (10.0 mL) and dichloromethane 
(20.0 mL). The aqueous phase was extracted with dichloromethane (2 x 10.0 mL) and 
the combined extracts were dried (MgSO4), filtered and solvent removed under reduced 
pressure. The residue was purified via Biotage™ Horizon (4:1, petroleum spirit 40-60 
°C: ethyl acetate; snap 10 g) to give 3-allyl-1,4-dibenzyl-6-methoxy-3-((4-
methoxybenzyl)thio)piperazine-2,5-dione (0.07 g, 79%) (453) as a pale yellow oil; 
max/cm
-1
 2934 (C-H), 1670 (C=O), 1610 (C=C), 1249 (C-O-C), 834 (C-H), 727 (C-H); 
 H (400 MHz, CDCl3) 2.62 (1H, dd, J 14.3 & 6.3, CH2CH=CH), 3.03 (1H, dd, J 14.2 
& 7.7, CH2CH=CH), 3.50 (3H, s, OCH3), 3.53 – 3.57 (1H, m, SCH2), 3.69 (3H, s, 
OCH3), 3.70 – 3.74 (1H, m, SCH2), 4.06 (2H, d, J 14.5, NCH2), 4.57 (1H, s, CHO), 4.74 
(2H, d, J 14.5, NCH2), 4.82 – 4.88 (2H, m, CH=CH2), 4.98 – 5.09 (1H, m, CH=CH2), 
6.69 – 6.72 (2H, m, Ar-H), 6.95 – 6.98 (2H, m, Ar-H), 7.20 – 7.25 (8H, m, Ar-H), 7.34 
– 7.37 (2H, m, Ar-H);  C (101 MHz, CDCl3) 34.45 (CH2), 42.10 (CH2), 47.05 (CH2), 
47.51 (CH2), 55.45 (OCH3), 58.51 (OCH3), 75.34 (quaternary C), 83.71 (CHO), 114.13 
(CH=CH2), 121.55 (CH2), 127.65 (Ar-C-H), 127.77 (quaternary C), 128.32 (Ar-C-H), 
128.61 (Ar-C-H), 128.99 (Ar-C-H), 129.01 (Ar-C-H), 129.21 (Ar-C-H), 129.86 (Ar-C-
H), 130.58 (Ar-C-H), 135.26 (quaternary C), 137.65 (quaternary C), 159.06 (quaternary 
C), 164.25 (CO), 165.30 (CO); m/z 517 (100%, [M+H]
+
); Found [M+H]
+
 517.2172, 
C30H33N2O4S requires 517.2161. 
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5.45.2 Method B: 
LDA (0.13 mL of a 2M solution in tetrahydrofuran /heptane/ethylbenzene, 0.25 mmol) 
was added dropwise to a solution of 1,4-dibenzyl-3-methoxy-6-((4-
methoxybenzyl)thio)piperazine-2,5-dione (0.10 g, 0.21 mmol) (448) and allyl bromide 
(0.04 mL, 0.42 mmol) (452) in tetrahydrofuran (2.00 mL) at -78 °C and the resulting 
mixture stirred at this temperature for 1 hour and 1.5 hours at 0 °C. Saturated aqueous 
sodium hydrogen carbonate (10.0 mL) was added and solvent removed under reduced 
pressure. The residue was partitioned between water (10.0 mL) and dichloromethane 
(20.0 mL). The aqueous phase was extracted with dichloromethane (2 x 10.0 mL) and 
the combined extracts were dried (MgSO4), filtered and solvent removed under reduced 
pressure. The residue was purified via Biotage™ Horizon (4:1, petroleum spirit 40-60 
°C: ethyl acetate; snap 10 g) to give 3-allyl-1,4-dibenzyl-6-methoxy-3-((4-
methoxybenzyl)thio)piperazine-2,5-dione (0.04 g, 32%) (453) as a pale yellow oil; 
identical spectroscopic data to that obtained previously for (453). 
5.45.3 Method C: 
NaH (0.01 g, 0.24 mmol) was added dropwise to a solution of 1,4-dibenzyl-3-methoxy-
6-((4-methoxybenzyl)thio)piperazine-2,5-dione (0.10 g, 0.20 mmol) (448) and allyl 
bromide (0.03 mL, 0.40 mmol) (452) in tetrahydrofuran (2.00 mL) at -78 °C and the 
resulting mixture stirred at this temperature for 1 hour and 1.5 hours at 0 °C. Saturated 
aqueous sodium hydrogen carbonate (10.0 mL) was added and solvent removed under 
reduced pressure. The residue was partitioned between water (10.0 mL) and 
dichloromethane (20.0 mL). The aqueous phase was extracted with dichloromethane (2 
x 10.0 mL) and the combined extracts were dried (MgSO4), filtered and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (4:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 10 g) to give 3-allyl-1,4-dibenzyl-6-
methoxy-3-((4-methoxybenzyl)thio)piperazine-2,5-dione (0.02 g, 22%) (453) as a pale 
yellow oil; identical spectroscopic data to that obtained previously for (453). 
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5.46 3-Allyl-1,4-dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-
dione (454) 
 
TFA (0.71 mL, 9.17 mmol) was added to a solution of 3-allyl-1,4-dibenzyl-6-methoxy-
3-((4-methoxybenzyl)thio)piperazine-2,5-dione (0.32 g, 0.61 mmol) (453) in 
dichloromethane (10.0 mL) at RT followed by the addition of para-methoxybenzyl 
mercaptan (0.13 mL, 0.92 mmol) (257) and the resulting mixture stirred at this 
temperature for 18 hours. After, the solution was diluted in dichloromethane (10.0 mL) 
and washed with saturated aqueous sodium hydrogen carbonate (10.0 mL). The aqueous 
phase was extracted with dichloromethane (2 x 10.0 mL) and the combined extracts 
were dried (MgSO4), filtered and solvent removed under reduced pressure. The residue 
was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 
25 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) 
to give 3-allyl-1,4-dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.32 
g, 83%) (454) as a pale yellow solid; m.p. 124-127 °C; max/cm
-1
 1667 (C=O), 1610 
(C=C), 1001 (C-O-C), 843 (C-H), 725 (C-H), 701 (C-H);  H (400 MHz, CDCl3) 3.36 – 
3.40 (1H, m, CH2CH=CH2), 3.49 – 3.53 (1H, m, CH2CH=CH2), 3.79 (3H, s, OCH3), 
3.81 (2H, s, SCH2), 3.87 (3H, s, OCH3), 3.89 (2H, d, J 5.9, SCH2), 3.93 (1H, d, J 7.9, 
NCH2), 4.03 – 4.07 (1H, m, NCH2), 4.54 (1H, s, CHS), 5.20 – 5.25 (2H, m, CH=CH2), 
5.31 (1H, d, J 14.5, NCH2), 5.43 (1H, d, J 14.2, NCH2), 5.79 (1H, t, J 1.4, CH=CH2), 
6.75 – 6.78 (2H, m, Ar-H), 6.83 – 6.87 (2H, m, Ar-H), 6.91 – 6.94 (5H, m, Ar-H), 7.16 
– 7.20 (5H, m, Ar-H), 7.35 – 7.37 (4H, m, Ar-H);  C (101 MHz, CDCl3) 34.13 (CH2), 
34.83 (CH2), 35.77 (CH2), 41.00 (CH2), 47.20 (CH2), 55.43 (OCH3), 55.52 (OCH3), 
58.50 (CHS), 68.84 (quaternary C), 114.36 (Ar-C-H), 121.60 (CH=CH), 123.27 
(CH=CH), 128.43 (Ar-C-H), 128.72 (Ar-C-H), 128.79 (Ar-C-H), 128.98 (Ar-C-H), 
129.33 (Ar-C-H), 130.19 (Ar-C-H), 130.54 (Ar-C-H), 130.85 (Ar-C-H), 131.00 (Ar-C-
H), 135.42 (quaternary C), 158.99 (quaternary C), 159.07 (quaternary C), 159.33 
(quaternary C), 163.47 (quaternary C), 165.49 (quaternary C), 165.61 (CO), 166.14 
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(CO); m/z 661 (100%, [M+Na]
+
); Found [M+Na]
+
 661.2162, C37H38N2O4S2Na requires 
661.2170.   
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5.47 (±)-(1S,4S)-1-Allyl-2,5-dibenzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (455) 
 
Boron tribromide (0.27 mL, 2.81 mmol) was added dropwise to a solution of 3-allyl-
1,4-dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.90 g, 1.40 mmol) 
(455) in dichloromethane (20.0 mL) at -78 °C. The resulting mixture was stirred for 15 
minutes whereupon sodium hydrogen carbonate (10.0 mL of a saturated aqueous 
solution) was added and the biphasic mixture stirred for 15 minutes until the yellow 
colour had dissipated. The resulting mixture was stirred at room temperature for 10 
minutes, whereupon iodine was added portionwise until the colour due to iodine just 
persisted and stirring was maintained for 2 minutes. Sodium thiosulfate was added and 
the mixture stirred for 10 minutes, diluted with dichloromethane (10.0 mL) and water 
(20.0 mL). The layers were separated and the aqueous phase extracted with 
dichloromethane (2 x 20.0 mL). The combined organic extracts were dried over MgSO4, 
filtered and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (4:1, petroleum spirit 40-60 °C: ethyl acetate; snap 10 g) and further 
purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (±)-
(1S,4S)-1-allyl-2,5-dibenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide 
(0.13 g, 24%) (455) as a pale yellow solid; m.p. 63-65 °C; max/cm
-1
 1687 (C=O, C=C), 
1453 (CH2), 730 (C-H), 697 (C-H);  H (400 MHz, CDCl3) 3.07 – 3.14 (1H, m, 
CH2CH=CH2), 3.25 – 3.31 (1H, m, CH2CH=CH2), 4.53 – 4.58 (1H, m, NCH2-Ph), 4.63 
– 4.68 (1H, m, NCH2-Ph), 4.95 (1H, d, J 15.9, NCH2-Ph), 5.13 (1H, d, J 16.1, NCH2-
Ph), 5.28 – 5.35 (2H, m, CH=CH2), 5.41 (1H, s, CHS), 6.16 – 6.20 (1H, m, CH=CH2), 
7.27 – 7.30 (3H, m, Ar-H), 7.32 – 7.36 (4H, m, Ar-H), 7.39 – 7.43 (3H, m, Ar-H);  C 
(101 MHz, CDCl3) 36.35 (CH2), 45.35 (CH2), 48.66 (CH2), 64.24 (CHS), 75.21 
(quaternary C), 120.89 (CH2), 127.10 (Ar-C-H), 128.00 (Ar-C-H), 128.65 (Ar-C-H), 
128.73 (Ar-C-H), 128.93 (Ar-C-H), 129.31 (Ar-C-H), 131.60 (CH=CH2), 134.52 
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(quaternary C), 136.08 (quaternary C), 164.61 (CO), 165.14 (CO); m/z 419 (100%, 
[M+Na]
+
); Found [M+Na]
+
 419.0852, C21H20N2O2S2Na requires 419.0864. 
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5.48 1,3,4-Tribenzyl-6-methoxy-3-((4-methoxybenzyl)thio)piperazine-
2,5-dione (457) 
 
LiHMDS (0.50 mL of a 1M solution in tetrahydrofuran, 0.50 mmol) was added 
dropwise to a solution of 1,4-dibenzyl-3-methoxy-6-((4-
methoxybenzyl)thio)piperazine-2,5-dione (0.20 g, 0.41 mmol) (448) and benzyl 
bromide (0.05 mL, 0.41 mmol) (456) in tetrahydrofuran (2.00 mL) at -78 °C and the 
resulting mixture stirred at this temperature for 1.5 hours and 1 hour at 0 °C. Saturated 
aqueous sodium hydrogen carbonate (10.0 mL) was added and solvent removed under 
reduced pressure. The residue was partitioned between water (10.0 mL) and 
dichloromethane (20.0 mL). The aqueous phase was extracted with dichloromethane (2 
x 10.0 mL) and the combined extracts were dried (MgSO4), filtered and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (3:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 10 g) to give 1,3,4-tribenzyl-6-methoxy-
3-((4-methoxybenzyl)thio)piperazine-2,5-dione (0.14 g, 59%) (457) as a pale yellow oil; 
max/cm
-1
 3004 (C-H), 1670 (C=O), 1453 (CH2), 1357 (CH3), 1000 (C-O-C);  H (400 
MHz, CDCl3) 3.18 (1H, d, J 10.9, CH2), 3.32 (1H, d, J 14.2, CH2), 3.38 (1H, d, J 8.8, 
SCH2), 3.44 (3H, s, OCH3), 3.73 (1H, d, J 9.1, SCH2), 3.78 (3H, s, OCH3), 4.05 (1H, d, 
J 14.2, NCH2), 4.13 (1H, s, CHO), 4.65 (1H, d, J 14.7, NCH2), 4.75 (1H, d, J 14.7, 
NCH2), 5.30 (1H, d, J 14.7, NCH2), 7.01 (6H, dd, J 11.5 & 4.5, Ar-H), 7.14 – 7.17 (3H, 
m, Ar-H), 7.29 – 7.33 (8H, m, Ar-H), 7.54 – 7.57 (2H, m, Ar-H);  C (101 MHz, 
CDCl3) 34.61 (CH2), 43.51 (CH2), 47.21 (CH2), 47.91 (CH2), 55.41 (OCH3), 82.93 
(OCH3), 113.98 (CHO), 127.63 (Ar-C-H), 128.13 (Ar-C-H), 128.36 (Ar-C-H), 128.60 
(Ar-C-H), 128.82 (Ar-C-H), 129.03 (Ar-C-H), 129.39 (Ar-C-H), 129.56 (Ar-C-H), 
130.19 (Ar-C-H), 130.48 (Ar-C-H), 130.65 (Ar-C-H), 133.87 (quaternary C), 134.70  
(quaternary C), 135.44 (quaternary C), 137.89 (quaternary C), 159.02 (quaternary C), 
164.23 (quaternary C), 165.06 (CO), 166.07 (CO); m/z 589 (100%, [M+Na]
+
); Found 
[M+Na]
+
 589.2107, C34H34N2O4SNa requires 589.2137.  
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5.49 (3S,6S)-1,3,4-Tribenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-
2,5-dione (458) 
 
TFA (1.00 mL, 13.0 mmol) was added to a solution of 1,3,4-tribenzyl-6-methoxy-3-((4-
methoxybenzyl)thio)piperazine-2,5-dione (0.18 g, 0.32 mmol) (457) in dichloromethane 
(5.00 mL) at RT followed by the addition of para-methoxybenzyl mercaptan (0.13 mL, 
0.95 mmol) (257) and the resulting mixture stirred at this temperature for 18 hours. 
After, the solution was diluted in dichloromethane (10.0 mL) and washed with saturated 
aqueous sodium hydrogen carbonate (10.0 mL). The aqueous phase was extracted with 
dichloromethane (2 x 10.0 mL) and the combined extracts were dried (MgSO4), filtered 
and solvent removed under reduced pressure. The residue was purified via Biotage™ 
Horizon (4:1, petroleum spirit 40-60 °C: ethyl acetate; snap 10 g) to give (3S,6S)-1,3,4-
tribenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.20 g, 91%) (458) as a 
pale yellow oil; max/cm
-1
 3032 (C-H), 3005 (C-H), 1666 (C=O), 1356 (CH3), 1001 (C-
O-C), 833 (C-H), 730 (C-H);  H (400 MHz, CDCl3) 3.77 – 3.78 (2H, m, CH2), 3.79 
(3H, s, OCH3), 3.84 (3H, s, OCH3), 3.87 – 3.89 (4H, m, SCH2 & NCH2), 3.97 – 4.06 
(2H, m, SCH2), 4.27 (1H, s, CHS), 4.62 (1H, d, J 15.1, NCH2), 5.28 (1H, d, J 15.1, 
NCH2), 6.51 – 6.54 (3H, m, Ar-H), 6.75 – 6.81 (4H, m, Ar-H), 6.84 – 6.88 (4H, m, Ar-
H), 7.00 – 7.05 (4H, m, Ar-H), 7.13 – 7.20 (4H, m, Ar-H), 7.27 – 7.31 (2H, m, Ar-H), 
7.59 – 7.63 (2H, m, Ar-H);  C (101 MHz, CDCl3) 35.31 (CH2), 36.93 (CH2), 43.44 
(CH2), 46.98 (CH2), 47.70 (CH2), 55.38 (OCH3), 58.20 (OCH3), 75.78 (quaternary C), 
113.96 (CHS), 127.84 (Ar-C-H), 128.50 (Ar-C-H), 128.58 (Ar-C-H), 128.62 (Ar-C-H), 
128.81 (Ar-C-H), 128.90 (Ar-C-H), 129.17 (Ar-C-H), 129.86 (Ar-C-H), 130.35 (Ar-C-
H), 130.65 (Ar-C-H), 130.74 (Ar-C-H), 130.81 (Ar-C-H), 130.96 (Ar-C-H), 133.96 
(quaternary C), 134.27 (quaternary C), 134.41 (quaternary C), 135.74 (quaternary C), 
137.79 (quaternary C), 158.96 (quaternary C), 159.17 (quaternary C), 163.98 (CO), 
165.99 (CO); m/z 711 (100%, [M+Na]
+
); Found [M+Na]
+
 711.2355, C41H40N2O4S2Na 
requires 711.2327.  
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5.50 (±)-(1S,4S)-1,2,5-Tribenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-
3,6-dione 7-sulfide (459) 
 
Boron tribromide (0.70 mL of a 1M solution in dichloromethane, 0.70 mmol) was added 
dropwise to a solution of (3S,6S)-1,3,4-tribenzyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione (0.12 g, 0.17 mmol) (458) in dichloromethane 
(2.00 mL) at -78 °C. The resulting mixture was stirred for 15 minutes whereupon 
aqueous sodium hydrogen carbonate (10.0 mL of a saturated aqueous solution) and 
methanol (1.00 mL) were added and the biphasic mixture stirred for 15 minutes until the 
yellow colour had dissipated. The resulting mixture was stirred at room temperature for 
10 minutes, whereupon iodine was added portionwise until the colour due to iodine just 
persisted and stirring was maintained for 2 minutes. Sodium thiosulfate was added and 
the mixture stirred for 10 minutes, diluted with dichloromethane (10.0 mL) and water 
(20.0 mL). The layers were separated and the aqueous phase extracted with 
dichloromethane (2 x 20.0 mL). The combined organic extracts were dried over MgSO4, 
filtered and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 10 g), followed 
by HPLC separation and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give (±)-(1S,4S)-1,2,5-tribenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-
3,6-dione 7-sulfide (0.04 g, 50%) (459) as a colourless solid; m.p. 122-124 C; 
max/cm
-1
 1641 (C=O), 1438 (CH2), 749 (C-H);  H (400 MHz; CDCl3) 3.62 – 3.68 (1H, 
m, CH2), 3.73 – 3.79 (1H, m, CH2), 4.23 (1H, d, J 15.2, NCH2), 4.34 (1H, d, J 15.0, 
NCH2), 4.86 (1H, d, J 14.9, NCH2), 5.12 (1H, d, J 15.0, NCH2), 5.26 (1H, s, CHS), 7.12 
– 7.24 (15H, m, Ar-H);  C (101 MHz; CDCl3) 36.39 (CH2), 46.11 (CH2), 48.78 (CH2), 
64.13 (CHS), 76.53 (quaternary C), 127.38 (Ar-C-H), 127.98 (Ar-C-H), 128.17 (Ar-C-
H), 128.68 (Ar-C-H), 128.74 (Ar-C-H), 128.80 (Ar-C-H), 128.98 (Ar-C-H), 129.40 
(Ar-C-H), 130.42 (Ar-C-H), 133.96 (quaternary C), 134.54 (quaternary C), 136.00 
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(quaternary C), 164.83 (CO), 165.31 (CO); m/z 469 (100%, [M+Na]
+
): Found [M+Na]
+
 
469.1097, C25H22N2O2S2Na requires 469.1101.  
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5.51 1-Allyl-4-benzyl-6-methoxy-3-((4-methoxybenzyl)thio)piperazine-
2,5-dione (461) 
 
Allylamine (0.78 mL, 10.4 mmol) (387) was added to a solution of 2-(benzyl(2-ethoxy-
1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate (3.50 g, 
6.94 mmol) (259) in methanol (25.0 mL) and the resulting mixture stirred for 2 minutes. 
DMAP (0.42 g, 3.47 mmol) was added and the resulting mixture stirred for 5 hours at 
RT and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 50 g) to give 1-
allyl-4-benzyl-6-methoxy-3-((4-methoxybenzyl)thio)piperazine-2,5-dione (2.26 g, 76%) 
(461) as a colourless oil; max/cm
-1
 1654 (C=O), 1458 (C=C), 1121 (C-O-C);  H (400 
MHz, CDCl3) 3.48 (3H, s, OCH3), 3.80 – 3.88 (5H, m, SCH2 & OCH3), 4.09 (1H, d, J 
13.7, NCH2), 4.22 (1H, d, J 14.8, NCH2), 4.40 (2H, d, J 14.9, NCH2), 4.54 (1H, s, 
CHS), 4.60 (1H, s, CHO), 4.68 (1H, d, J 15.0, CH=CH2), 5.01 – 5.04 (1H, m, 
CH=CH2), 5.23 – 5.26 (1H, m, J 14.8, CH=CH2), 6.90 (2H, d, J 8.7, Ar-H), 7.30 – 7.32 
(3H, m, Ar-H), 7.34 – 7.39 (4H, m, Ar-H);  C (101 MHz, CDCl3) 36.49 (CH2), 45.46 
(CH2), 48.03 (CH2), 55.46 (OCH3), 57.60 (OCH3), 58.24 (CHS), 85.38 (CHO), 114.23 
(Ar-C-H), 119.79 (CH=CH2), 128.22 (Ar-C-H), 128.63 (Ar-C-H), 129.03 (Ar-C-H), 
130.74 (CH=CH2), 130.78 (Ar-C-H), 135.38 (quaternary C), 159.27 (quaternary C), 
162.48 (CO), 166.33 (CO); m/z 449 (100%, [M+Na]
+
); Found [M+Na]
+
 449.1512, 
C23H26N2O4SNa requires 449.1511.   
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5.52 1-Allyl-3,4-dibenzyl-6-methoxy-3-((4-
methoxybenzyl)thio)piperazine -2,5-dione (462) 
 
LiHMDS (6.35 mL of a 1M solution in tetrahydrofuran, 6.35 mmol) was added 
dropwise to a solution of 1-allyl-4-benzyl-6-methoxy-3-((4-
methoxybenzyl)thio)piperazine-2,5-dione (2.26 g, 5.29 mmol) (461) and benzyl 
bromide (0.94 mL, 7.94 mmol) (456) in tetrahydrofuran (2.00 mL) at -78 °C and the 
resulting mixture stirred at this temperature for 1.5 hours and 1 hour at 0 °C. Saturated 
aqueous sodium hydrogen carbonate (10.0 mL) was added and solvent removed under 
reduced pressure. The residue was partitioned between water (10.0 mL) and 
dichloromethane (20.0 mL). The aqueous phase was extracted with dichloromethane (2 
x 10.0 mL) and the combined extracts were dried (MgSO4), filtered and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (3:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) to give 1-allyl-3,4-dibenzyl-6-
methoxy-3-((4-methoxybenzyl)thio)piperazine-2,5-dione (1.33 g, 49%) (462) as a pale 
yellow oil; max/cm
-1
 3031 (C-H), 1671 (C=O), 1609 (C=C), 1000 (C-O-C), 834 (C-H), 
748 (C-H), 700 (C-H);  H (400 MHz, CDCl3) 3.15 (1H, d, J 14.0, CH2-Ph), 3.21 (1H, 
d, J 14.8, CH2-Ph), 3.33 (3H, s, OCH3), 3.44 – 3.47 (2H, m, SCH2), 3.63 (3H, s, OCH3), 
4.01 (1H, s, CHO), 4.49 – 4.54 (1H, m, NCH2), 4.60 – 4.64 (1H, m, NCH2), 4.94 (1H, d, 
J 17.1, NCH2), 5.02 (1H, d, J 17.1, NCH2), 5.08 – 5.12 (1H, m, CH=CH2), 5.18 – 5.22 
(1H, m, CH=CH2), 5.35 – 5.40 (1 H, m, CH=CH2), 6.58 – 6.72 (6H, m, Ar-H), 7.12 – 
7.15 (4H, m, Ar-H), 7.19 – 7.23 (4H, m, Ar-H);  C (101 MHz, CDCl3) 34.64 (CH2), 
43.79 (CH2), 46.71 (CH2), 47.98 (CH2), 55.44 (OCH3), 57.18 (OCH3), 83.22 (CHO), 
113.98 (CH=CH2), 119.92 (CH2), 127.27 (quaternary C), 127.52 (Ar-C-H), 128.03 (Ar-
C-H), 128.64 (Ar-C-H), 128.83 (Ar-C-H), 129.03 (Ar-C-H), 129.48 (Ar-C-H), 130.32 
(Ar-C-H), 130.68 (Ar-C-H), 133.85 (quaternary C), 138.00 (quaternary C), 138.13 
(quaternary C), 159.05 (quaternary C), 164.34 (CO), 164.65 (CO); m/z 517 (100%, 
[M+H]
+
); Found [M+H]
+
 517.2155, C30H33N2O4S requires 517.2161.  
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5.53 1-Allyl-3,4-dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-
dione (463) 
 
TFA (2.96 mL, 38.5 mmol) was added to a solution of 1-allyl-3,4-dibenzyl-6-methoxy-
3-((4-methoxybenzyl)thio)piperazine-2,5-dione (1.33 g, 2.56 mmol) (462) in 
dichloromethane (20.0 mL) at RT followed by the addition of para-methoxybenzyl 
mercaptan (0.54 mL, 3.85 mmol) (257) and the resulting mixture stirred at this 
temperature for 18 hours. After, the solution was diluted in dichloromethane (10.0 mL) 
and washed with saturated aqueous sodium hydrogen carbonate (10.0 mL). The aqueous 
phase was extracted with dichloromethane (2 x 10.0 mL) and the combined extracts 
were dried (MgSO4), filtered and solvent removed under reduced pressure. The residue 
was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 
25 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) 
to give 1-allyl-3,4-dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (1.33 
g, 81%) (463) as a pale yellow solid; m.p. 124-126 °C; max/cm
-1
 1665 (C=O), 1609 
(C=C), 1000 (C-O-C), 833 (C-H), 728 (C-H), 699 (C-H);  H (400 MHz, CDCl3) 3.33 – 
3.39 (2H, m, CH2-Ph), 3.47 (2H, s, SCH2), 3.77 (6H, s, OCH3), 3.81 (2H, s, SCH2), 3.82 
– 3.84 (2H, m, NCH2CH=CH), 4.15 (1H, s, CHS), 4.57 – 4.65 (2H, m, NCH2-Ph), 5.31 
– 5.37 (2H, m, CH=CH2), 5.43 – 5.54 (1H, m, CH=CH2), 6.72 – 6.90 (11H, m, Ar-H), 
7.07 – 7.15 (3H, m, Ar-H), 7.33 – 7.37 (4H, m, Ar-H);  C (101 MHz, CDCl3) 34.64 
(CH2), 35.23 (CH2), 37.10 (CH2), 43.80 (CH2), 46.71 (CH2), 55.45 (OCH3), 58.62 
(OCH3), 76.70 (quaternary C), 83.23 (CHS), 114.01 (CH=CH2), 119.96 (CH=CH2), 
127.52 (Ar-C-H), 128.65 (Ar-C-H), 128.83 (Ar-C-H), 129.04 (Ar-C-H), 130.19 (Ar-C-
H), 130.32 (Ar-C-H), 130.52 (Ar-C-H), 130.69 (Ar-C-H), 130.93 (Ar-C-H), 131.28 
(Ar-C-H), 133.86 (quaternary C), 134.21 (quaternary C), 138.00 (quaternary C), 159.05 
(quaternary C), 159.29 (quaternary C), 163.72 (quaternary C), 164.65 (CO), 166.18 
(CO); m/z 661 (100%, [M+Na]
+
); Found [M+Na]
+
 661.2159, C37H38N2O4S2Na requires 
661.2170.   
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5.54 (±)-(1S,4S)-5-Allyl-1,2-dibenzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (464) 
 
Boron tribromide (0.34 mL, 4.170 mmol) was added dropwise to a solution of 1-allyl-
3,4-dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (1.33 g, 2.09 mmol) 
(463) in dichloromethane (30.0 mL) at -78 °C. The resulting mixture was stirred for 15 
minutes whereupon sodium hydrogen carbonate (10.0 mL of a saturated aqueous 
solution) was added and the biphasic mixture stirred for 15 minutes until the yellow 
colour had dissipated. The resulting mixture was stirred at room temperature for 10 
minutes, whereupon iodine was added portionwise until the colour due to iodine just 
persisted and stirring was maintained for 2 minutes. Sodium thiosulfate was added and 
the mixture stirred for 10 minutes, diluted with dichloromethane (10.0 mL) and water 
(20.0 mL). The layers were separated and the aqueous phase extracted with 
dichloromethane (2 x 20.0 mL). The combined organic extracts were dried over MgSO4, 
filtered and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (4:1, petroleum spirit 40-60 °C: ethyl acetate; snap 10 g) and further 
purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (±)-
(1S,4S)-5-allyl-1,2-dibenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide 
(0.19 g, 23%) (464) as a pale yellow solid; m.p. 62-64 °C; max/cm
-1
 1685 (C=O), 1628 
(C=C), 734 (C-H), 697 (C-H);  H (400 MHz, CDCl3) 3.84 (2H, s, CH2-Ph), 3.86 – 3.90 
(1H, m, NCH2CH=CH2), 4.00 – 4.05 (1H, m, NCH2CH=CH2), 4.09 (1H, d, J 15.0, 
NCH2-Ph), 4.64 (1H, s, CHS), 4.75 (1 H, d, J 17.1, CH=CH2), 5.03 (1H, d, J 17.1, 
CH=CH2), 5.22 (1H, d, J 15.0, NCH2-Ph), 5.55 – 5.67 (1H, m, CH=CH2), 6.89 – 6.92 
(4H, m, Ar-H), 7.36 – 7.42 (6H, m, Ar-H);  C (101 MHz, CDCl3) 35.94 (CH2), 46.05 
(CH2), 48.00 (CH2), 55.58 (CHS), 59.30 (CH=CH2), 114.35 (Ar-C-H), 119.50 
(CH=CH2), 123.94 (Ar-C-H), 127.70 (Ar-C-H), 128.71 (Ar-C-H), 129.66 (Ar-C-H), 
130.78 (Ar-C-H), 133.97 (quaternary C), 136.45 (quaternary C), 159.40 (quaternary C), 
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163.57 (CO), 165.65 (CO); m/z 397 (100%, [M+H]
+
); Found [M+H]
+
 397.1078, 
C21H21N2O2S2 requires 397.1045.  
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5.55 1-Allyl-4-benzyl-3-methoxy-6-((4-methoxybenzyl)thio)piperazine-
2,5-dione (468) 
 
Benzylamine (1.42 mL, 13.0 mmol) (255) was added to a solution of 2-(allyl(2-ethoxy-
1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate (3.92 g, 
8.65 mmol) (395) in methanol (40.0 mL) and the resulting mixture stirred for 2 minutes. 
DMAP (0.53 g, 4.33 mmol) was added and the resulting mixture stirred for 12 hours at 
RT and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 50 g) to give 1-
allyl-4-benzyl-3-methoxy-6-((4-methoxybenzyl)thio)piperazine-2,5-dione (3.14 g, 85%) 
(468) as a colourless oil; max/cm
-1
 1654 (C=O), 1458 (C=C), 1121 (C-O-C);  H (400 
MHz, CDCl3) 3.48 (3H, s, OCH3), 3.80 – 3.88 (5H, m, SCH2 & OCH3), 4.09 (1H, d, J 
13.7, NCH2), 4.22 (1H, d, J 14.8, NCH2), 4.40 (2H, d, J 14.9, NCH2), 4.54 (1H, s, 
CHS), 4.60 (1H, s, CHO), 4.68 (1H, d, J 15.0, CH=CH2), 5.01 – 5.04 (1H, m, 
CH=CH2), 5.23 – 5.26 (1H, m, J 14.8, CH=CH2), 6.90 (2H, d, J 8.7, Ar-H), 7.30 – 7.32 
(3H, m, Ar-H), 7.34 – 7.39 (4H, m, Ar-H);  C (101 MHz, CDCl3) 36.49 (CH2), 45.46 
(CH2), 48.03 (CH2), 55.46 (OCH3), 57.60 (OCH3), 58.24 (CHS), 85.38 (CHO), 114.23 
(Ar-C-H), 119.79 (CH=CH2), 128.22 (Ar-C-H), 128.63 (Ar-C-H), 129.03 (Ar-C-H), 
130.74 (CH=CH2), 130.78 (Ar-C-H), 135.38 (quaternary C), 159.27 (quaternary C), 
162.48 (CO), 166.33 (CO); m/z 449 (100%, [M+Na]
+
); Found [M+Na]
+
 449.1512, 
C23H26N2O4SNa requires 449.1511.  
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5.56 4-Allyl-1,3-dibenzyl-6-methoxy-3-((4-
methoxybenzyl)thio)piperazine -2,5-dione (469) 
 
LiHMDS (8.62 mL of a 1M solution in tetrahydrofuran, 8.62 mmol) was added 
dropwise to a solution of 1-allyl-4-benzyl-3-methoxy-6-((4-
methoxybenzyl)thio)piperazine-2,5-dione (3.06 g, 7.18 mmol) (468) and benzyl 
bromide (1.28 mL, 10.8 mmol) (456) in tetrahydrofuran (30.0 mL) at -78 °C and the 
resulting mixture stirred at this temperature for 1.5 hours and 1 hour at 0 °C. Saturated 
aqueous sodium hydrogen carbonate (10.0 mL) was added and solvent removed under 
reduced pressure. The residue was partitioned between water (10.0 mL) and 
dichloromethane (20.0 mL). The aqueous phase was extracted with dichloromethane (2 
x 10.0 mL) and the combined extracts were dried (MgSO4), filtered and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (3:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) to give 4-allyl-1,3-dibenzyl-6-
methoxy-3-((4-methoxybenzyl)thio)piperazine-2,5-dione (2.89 g, 78%) (469) as a pale 
yellow oil; max/cm
-1
 3032 (C-H), 1669 (C=O), 1609 (C=C), 1000 (C-O-C), 746 (C-H), 
701 (C-H);  H (400 MHz, CDCl3) 3.03 – 3.07 (1H, d, J 14.3, CH2-Ph), 3.26 (3H, s, 
OCH3), 3.46 (1H, d, J 14.1, CH2-Ph), 3.63 (2H, s, SCH2), 3.64 (3H, s, OCH3), 3.65 – 
3.66 (1H, m, NCH2CH=CH), 3.83 – 3.87 (1H, m, NCH2CH=CH), 3.96 (1H, s, CHO), 
4.93 – 5.06 (2H, m, NCH2-Ph), 5.23 – 5.33 (2H, m, CH=CH2), 5.89 – 5.97 (1H, m, 
CH=CH2), 6.64 – 6.68 (2H, m, Ar-H), 6.86 – 6.95 (4H, m, Ar-H), 7.05 – 7.10 (8H, m, 
Ar-H);  C (101 MHz, CDCl3) 34.55 (CH2), 43.27 (CH2), 46.96 (CH2), 47.56 (CH2), 
55.50 (OCH3), 57.57 (OCH3), 76.43 (quaternary C), 82.68 (CHO), 114.23 (CH=CH2), 
119.28 (CH2), 128.68 (Ar-C-H), 128.85 (Ar-C-H), 129.16 (Ar-C-H), 129.65 (Ar-C-H), 
130.28 (Ar-C-H), 130.62 (Ar-C-H), 130.84 (Ar-C-H), 133.02 (Ar-C-H), 133.24 
(quaternary C), 134.14 (quaternary C), 134.65 (quaternary C), 159.16 (quaternary C), 
163.26 (CO), 165.00 (CO); m/z 517 (100%, [M+H]
+
); Found [M+H]
+
 517.2171, 
C30H33N2O4S requires 517.2161.   
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5.57 4-Allyl-1,3-dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-
dione (470) 
 
TFA (6.45 mL, 84.0 mmol) was added to a solution of 4-allyl-1,3-dibenzyl-6-methoxy-
3-((4-methoxybenzyl)thio)piperazine-2,5-dione (2.89 g, 5.58 mmol) (469) in 
dichloromethane (20.0 mL) at RT followed by the addition of para-methoxybenzyl 
mercaptan (1.17 mL, 8.38 mmol) (257) and the resulting mixture stirred at this 
temperature for 18 hours. After, the solution was diluted in dichloromethane (10.0 mL) 
and washed with saturated aqueous sodium hydrogen carbonate (10.0 mL). The aqueous 
phase was extracted with dichloromethane (2 x 10.0 mL) and the combined extracts 
were dried (MgSO4), filtered and solvent removed under reduced pressure. The residue 
was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 
25 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) 
to give 4-allyl-1,3-dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (2.94 
g, 82%) (470) as a pale yellow solid; m.p. 124-126 °C; max/cm
-1
 3004 (C-H), 1665 
(C=O), 1609 (C=C), 1001 (C-O-C), 833 (C-H), 747 (C-H), 701 (C-H);  H (400 MHz, 
CDCl3) 3.42 (2H, d, J 16.5, CH2-Ph), 3.79 (2H, s, SCH2), 3.82 – 3.84 (6H, m, OCH3), 
3.84 (2H, s, SCH2), 3.86 – 3.93 (2H, m, NCH2), 4.00 – 4.07 (2H, m, NCH2), 4.22 (1H, 
s, CHS), 4.39 – 4.51 (2H, m, CH=CH2), 6.10 – 6.20 (1H, m, CH=CH2), 6.76 – 6.84 (4H, 
m, Ar-H), 7.10 – 7.21 (6H, m, Ar-H), 7.26 – 7.33 (8H, m, Ar-H);  C (101 MHz, 
CDCl3) 34.04 (CH2), 35.43 (CH2), 37.04 (CH2), 43.23 (CH2), 47.48 (CH2), 55.44 
(OCH3), 55.48 (OCH3), 57.94 (CHS), 74.92 (quaternary C), 114.25 (CH=CH2), 118.65 
(CH=CH2), 128.62 (Ar-C-H), 128.74 (Ar-C-H), 128.82 (Ar-C-H), 129.22 (Ar-C-H), 
129.99 (Ar-C-H), 130.33 (Ar-C-H), 130.67 (Ar-C-H), 130.97 (Ar-C-H), 133.14 (Ar-C-
H), 133.90 (Ar-C-H), 134.13 (quaternary C), 134.57 (quaternary C), 135.80 (quaternary 
C), 159.16 (quaternary C), 159.25 (quaternary C), 163.95 (quaternary C), 165.52 (CO), 
165.65 (CO); m/z 661 (100%, [M+Na]
+
); Found [M+Na]
+
 661.2168, C37H38N2O4S2Na 
requires 661.2170.  
Bruno Sil                                                                                                                 Experimental 
 
278 
 
5.58 (±)-(1S,4S)-2-Allyl-1,5-dibenzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (471) 
 
Boron tribromide (0.87 mL, 9.20 mmol) was added dropwise to a solution of 4-allyl-
1,3-dibenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (2.94 g, 4.60 mmol) 
(470) in dichloromethane (50.0 mL) at -78 °C. The resulting mixture was stirred for 15 
minutes whereupon sodium hydrogen carbonate (10.0 mL of a saturated aqueous 
solution) was added and the biphasic mixture stirred for 15 minutes until the yellow 
colour had dissipated. The resulting mixture was stirred at room temperature for 10 
minutes, whereupon iodine was added portionwise until the colour due to iodine just 
persisted and stirring was maintained for 2 minutes. Sodium thiosulfate was added and 
the mixture stirred for 10 minutes, diluted with dichloromethane (10.0 mL) and water 
(20.0 mL). The layers were separated and the aqueous phase extracted with 
dichloromethane (2 x 20.0 mL). The combined organic extracts were dried over MgSO4, 
filtered and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (4:1, petroleum spirit 40-60 °C: ethyl acetate; snap 10 g) and further 
purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (±)-
(1S,4S)-2-allyl-1,5-dibenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide 
(0.38 g, 21%) (471) as a pale yellow solid; m.p. 63-64 °C; max/cm
-1
 1672 (C=O), 1627 
(C=C), 832 (C-H), 698 (C-H);  H (400 MHz, CDCl3) 3.84 (2H, s, CH2-Ph), 3.87 – 3.91 
(2H, m, NCH2CH=CH2), 4.04 (1H, d, J 6.9, NCH2-Ph), 4.65 (1H, s, CHS), 4.73 (1H, d, 
J 10.1, CH=CH2), 5.04 (1H, d, J 10.0, CH=CH2), 5.21 (1H, d, J 7.1, NCH2-Ph), 5.56 – 
5.70 (1H, m, CH=CH2), 6.85 – 6.90 (2H, m, Ar-H), 6.91 – 6.97 (4H, m, Ar-H), 7.37 – 
7.40 (4H, m, Ar-H);  C (101 MHz, CDCl3) 44.00 (CH2), 45.99 (CH2), 47.92 (CH2), 
55.52 (CHS), 59.25 (CH=CH2), 119.43 (CH=CH2), 123.87 (Ar-C-H), 127.64 (Ar-C-H), 
128.65 (Ar-C-H), 128.84 (Ar-C-H), 129.60 (Ar-C-H), 130.72 (Ar-C-H), 133.90 
(quaternary C), 136.39 (quaternary C), 159.33 (quaternary C), 163.50 (CO), 165.58 
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(CO); m/z 419 (100%, [M+Na]
+
); Found [M+Na]
+
 419.0973, C21H20N2O2S2Na requires 
419.0864.  
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5.59 3,4-Diallyl-1-benzyl-6-methoxy-3-((4-
methoxybenzyl)thio)piperazine -2,5-dione (479) 
 
LiHMDS (7.73 mL of a 1M solution in tetrahydrofuran, 7.73 mmol) was added 
dropwise to a solution of 1-allyl-4-benzyl-3-methoxy-6-((4-
methoxybenzyl)thio)piperazine-2,5-dione (2.75 g, 6.45 mmol) (468) and allyl bromide 
(0.84 mL, 9.67 mmol) (452) in tetrahydrofuran (30.0 mL) at -78 °C and the resulting 
mixture stirred at this temperature for 1.5 hours and 1 hour at 0 °C. Saturated aqueous 
sodium hydrogen carbonate (10.0 mL) was added and solvent removed under reduced 
pressure. The residue was partitioned between water (10.0 mL) and dichloromethane 
(20.0 mL). The aqueous phase was extracted with dichloromethane (2 x 10.0 mL) and 
the combined extracts were dried (MgSO4), filtered and solvent removed under reduced 
pressure. The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 
°C: ethyl acetate; snap 10 g) to give 3,4-diallyl-1-benzyl-6-methoxy-3-((4-
methoxybenzyl)thio)piperazine-2,5-dione (2.05 g, 68%) (479) as a colourless oil; 
max/cm
-1
 2933 (C-H), 1671 (C=O, C=C), 1357 (CH3), 1249 (C-O-C), 835 (C-H);  H 
(400 MHz, CDCl3) 2.60 (1H, dd, J 14.2 & 6.1, CH2CH=CH2), 3.05 (1H, dd, J 14.2 & 
7.2, CH2CH=CH2), 3.49 (3H, s, OCH3), 3.64 (1H, d, J 11.9, SCH2), 3.70 (3H, s, OCH3), 
3.74 (1H, d, J 11.5, SCH2), 3.99 (2H, d, J 10.7, NCH2), 4.09 (1H, d, J 10.5, NCH2), 4.48 
(1H, s, CHO), 5.01 – 5.09 (1H, m, NCH2), 5.11 – 5.18 (2H, m, CH=CH2), 5.26 (1H, d, J 
14.2, CH=CH2), 5.32 (1H, d, J 14.5, CH=CH2), 5.35 – 5.44 (1H, m, CH=CH2), 5.92 – 
5.94 (1H, m, CH=CH2), 7.12 (2H, d, J 8.7, Ar-H), 7.18 – 7.27 (7H, m, Ar-H);  C (101 
MHz, CDCl3) 34.22 (CH2), 41.74 (CH2), 46.67 (CH2), 47.28 (CH2), 55.41 (OCH3), 
58.47 (OCH3), 74.69 (quaternary C), 83.30 (CHO), 114.13 (CH=CH2), 118.82 
(CH=CH2), 121.64 (CH=CH2), 127.90 (CH=CH2), 128.29 (quaternary C), 128.94 (Ar-
C-H), 129.14 (Ar-C-H), 130.13 (Ar-C-H), 130.48 (Ar-C-H), 133.12 (quaternary C), 
135.12 (Ar-C-H), 159.00 (quaternary C), 163.27 (CO), 165.22 (CO); m/z 467 (100%, 
[M+H]
+
); Found [M+H]
+
 467.2023, C26H31N2O4S requires 467.2004.  
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5.60 3,4-Diallyl-1-benzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-
dione (480) 
 
TFA (1.00 mL, 13.0 mmol) was added to a solution of 3,4-diallyl-1-benzyl-6-methoxy-
3-((4-methoxybenzyl)thio)piperazine-2,5-dione (0.24 g, 0.51 mmol) (479) in 
dichloromethane (3.00 mL) at RT followed by the addition of para-methoxybenzyl 
mercaptan (0.22 mL, 1.54 mmol) (257) and the resulting mixture stirred at this 
temperature for 18 hours. After, the solution was diluted in dichloromethane (10.0 mL) 
and washed with saturated aqueous sodium hydrogen carbonate (10.0 mL). The aqueous 
phase was extracted with dichloromethane (2 x 10.0 mL) and the combined extracts 
were dried (MgSO4), filtered and solvent removed under reduced pressure. The residue 
was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl acetate; snap 
10 g) to give 3,4-diallyl-1-benzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione 
(0.23 g, 76%) (480) as a pale yellow oil; max/cm
-1
 3004 (C-H), 1666 (C=O), 1609 
(C=C), 1442 (CH2), 834 (C-H), 750 (C-H);  H (400 MHz, CDCl3) 2.65 – 2.76 (2H, m, 
CH2CH=CH2), 2.96 – 3.03 (2H, m, SCH2), 3.29 – 3.42 (2H, m, SCH2), 3.73 – 3.76 (2H, 
m, NCH2), 3.79 (3H, s, OCH3), 3.86 – 3.87 (2H, m, NCH2), 3.88 (3H, s, OCH3), 4.00 – 
4.34 (4H, m, CH=CH2), 4.47 (1H, s, CHS), 5.82 – 5.94 (1H, m, CH=CH2), 5.97 – 6.11 
(1H, m, CH=CH2), 6.72 (2H, d, J 7.0, Ar-H), 6.75 – 6.78 (2H, m, Ar-H), 6.88 (2H, d, J 
3.2, Ar-H), 6.93 – 6.97 (3H, m, Ar-H), 7.35 – 7.38 (2H, m, Ar-H), 7.39 – 7.43 (2H, m, 
Ar-H);  C (101 MHz, CDCl3) 34.03 (CH2), 35.29 (CH2), 37.07 (CH2), 41.36 (CH2), 
46.99 (CH2), 55.49 (OCH3), 57.65 (OCH3), 58.08 (CHS), 73.50 (quaternary C), 114.46 
(CH=CH2), 118.22 (CH=CH2), 121.57 (CH=CH2), 128.35 (CH=CH2), 129.33 (Ar-C-
H), 130.15 (Ar-C-H), 130.61 (Ar-C-H), 130.89 (Ar-C-H), 131.07 (Ar-C-H), 133.11 
(quaternary C), 133.51 (quaternary C), 135.22 (Ar-C-H), 135.83 (Ar-C-H), 159.14 
(quaternary C), 159.44 (quaternary C), 164.18 (quaternary C), 165.11 (CO), 166.01 
(CO); m/z 611 (100%, [M+Na]
+
); Found [M+Na]
+
 611.1988, C33H36N2O4S2Na requires 
611.2014.  
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5.61 2-Benzyl-3,9a-bis((4-methoxybenzyl)thio)-2,3,9,9a-tetrahydro-1H-
pyrido[1,2-a]pyrazine-1,4(6H)-dione (481) 
 
A solution of 3,4-diallyl-1-benzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione 
(0.09 g, 0.15 mmol) (480) in dichloromethane (5.00 mL) was degassed and taken under 
nitrogen atmosphere. To this (1,3-bis(2,4,6-trimethylphenyl)-2-
imidazolidinylidene)dichloro(phenylmethylene) (tricyclohexylphosphine) ruthenium 
(Grubbs second-generation catalyst) (0.01 g, 0.02 mmol) was added  and the resulting 
mixture heated at reflux for 16 hours, cooled to RT and solvent removed under reduced 
pressure. The residue was purified via Biotage™ Horizon (4:1, petroleum spirit 
40-60 °C: ethyl acetate; snap 10 g) and further purified by recrystallisation (petroleum 
spirit 40-60 °C: ethyl acetate) to give 2-benzyl-3,9a-bis((4-methoxybenzyl)thio)-
2,3,9,9a-tetrahydro-1H-pyrido[1,2-a]pyrazine-1,4(6H)-dione (0.03 g, 40%) (481 – (1)) 
and 2-benzyl-3-((4-methoxybenzyl)thio)-2,3-dihydro-1H-pyrido[1,2-a]pyrazine-
1,4(6H)-dione (0.01 g, 3%) (482 – (2)) as pale yellow solids; Data for 481 – (1): m.p. 
112-115 °C; max/cm
-1
 3033 (C-H), 2934 (C-H), 2836 (C-H), 1665 (C=O), 834 (C-H), 
734 (C-H);  H (400 MHz, CDCl3) 3.36 – 3.40 (1H, m, CH2CH=CH), 3.49 – 3.53 (1H, 
m, CH2CH=CH), 3.79 (3H, s, OCH3), 3.81 (2H, d, J 5.7, SCH2), 3.87 (3H, s, OCH3), 
3.89 (2H, d, J 5.9, SCH2), 3.93 (1H, d, J 7.9, NCH2), 4.03 – 4.07 (1H, m, NCH2), 4.54 
(1H, s, CHS), 5.31 (1H, d, J 14.5, NCH2CH=CH), 5.43 (1H, d, J 14.2, NCH2CH=CH), 
5.79 (2H, d, J 1.4, CH=CH), 6.75 – 6.78 (2H, m, Ar-H), 6.83 – 6.87 (2H, m, Ar-H), 
6.91 – 6.94 (4H, m, Ar-H), 7.16 – 7.20 (3H, m, Ar-H), 7.35 – 7.37 (2H, m, Ar-H);  C 
(101 MHz, CDCl3) 34.13 (CH2), 34.83 (CH2), 35.77 (CH2), 41.00 (CH2), 47.20 (CH2), 
55.43 (OCH3), 55.52 (OCH3), 58.50 (CHS), 68.84 (quaternary C), 114.36 (Ar-C-H), 
121.60 (CH=CH), 123.27 (CH=CH), 128.43 (Ar-C-H), 128.79 (Ar-C-H), 128.98 (Ar-
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C-H), 129.33 (Ar-C-H), 130.19 (Ar-C-H), 130.85 (Ar-C-H), 135.42 (quaternary C), 
159.07 (quaternary C), 159.33 (quaternary C), 163.47 (quaternary C), 165.61 
(quaternary C), 165.61 (CO), 166.14 (CO); m/z 583 (100%, [M+Na]
+
); Found [M+Na]
+
 
583.1694, C31H32N2O4S2Na requires 583.1701; Data for 381 – (2): m.p. 92-95 °C; 
max/cm
-1
 2932 (C-H), 1680 (C=O), 1639 (C=C), 1609 (C=C), 834 (C-H), 734 (C-H), 
701 (C-H);  H (400 MHz, CDCl3) 3.65 – 3.67 (1H, d, J 5.0, SCH2), 3.70 (1H, d, J 5.0, 
SCH2), 3.72 – 3.74 (1H, m, NCH2), 3.76 (3H, s, OCH3), 3.81 – 3.85 (1H, m, NCH2), 
4.00 (1H, d, J 12.6, NCH2), 4.46 (1H, s, CHS), 4.76 (1H, d, J 12.5, NCH2), 5.81 – 5.85 
(1H, m, CH=CH), 6.01 – 6.04 (1H, m, CH=CH), 6.38 (1H, d, J 5.9, CH-CH), 6.77 – 
6.81 (4H, m, Ar-H), 7.13 – 7.16 (2H, m, Ar-H), 7.22 – 7.26 (3H, m, Ar-H);  C (101 
MHz, CDCl3) 35.09 (CH2), 43.30 (CH2), 46.20 (CH2), 55.50 (OCH3), 58.71 (CHS), 
113.44 (CH-CH), 114.30 (Ar-C-H), 121.99 (CH=CH), 100.69 (CH=CH), 127.20 
(quaternary C), 128.23 (Ar-C-H), 128.58 (quaternary C), 128.93 (Ar-C-H), 129.06 (Ar-
C-H), 130.64 (Ar-C-H), 135.00 (quaternary C), 158.97 (quaternary C), 159.27 (CO), 
162.73 (CO); m/z 429 (100%, [M+Na]
+
); Found [M+Na]
+
 429.1237, C23H22N2O3SNa 
requires 429.1249.  
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5.62 (±)-(3S,9aS)-2-Benzyl-2,3-dihydro-3,9a-epithiopyrido[1,2-
a]pyrazine-1,4(6H,9H)-dione 10-sulfide (482) 
 
Boron tribromide (0.24 mL of a 1M solution in dichloromethane, 0.24 mmol) was added 
dropwise to a solution of 2-benzyl-3,9a-bis((4-methoxybenzyl)thio)-2,3,9,9a-tetrahydro-
1H-pyrido[1,2-a]pyrazine-1,4(6H)-dione (0.03 g, 0.06 mmol) (481 – (1)) in 
dichloromethane (2.00 mL) at -78 °C. The resulting mixture was stirred for 15 minutes 
whereupon aqueous sodium hydrogen carbonate (5.00 mL of a saturated aqueous 
solution) and methanol (2.00 mL) were added and the biphasic mixture stirred for 15 
minutes until the yellow colour had dissipated. The resulting mixture was stirred at 
room temperature for 10 minutes, whereupon iodine was added portionwise until the 
colour due to iodine just persisted and stirring was maintained for 2 minutes. Sodium 
thiosulfate was added and the mixture stirred for 10 minutes, diluted with 
dichloromethane (10.0 mL) and water (20.0 mL). The layers were separated and the 
aqueous phase extracted with dichloromethane (2 x 20.0 mL). The combined organic 
extracts were dried over MgSO4, filtered and solvent removed under reduced pressure. 
The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 10 g) which did not give (3S,9aS)-2-benzyl-2,3-dihydro-3,9a-
epithiopyrido[1,2-a]pyrazine-1,4(6H,9H)-dione 10-sulfide (482). 
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5.63 (±)-(3S,9aS)-2-Benzyl-2,3-dihydro-3,9a-epithiopyrido[1,2-
a]pyrazine-1,4(6H,9H)-dione 10-sulfide (482) 
 
5.63.1 Method A: 
A solution of 3,4-diallyl-1-benzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione 
(0.05 g, 0.15 mmol) (483) in dichloromethane (2.00 mL) was degassed and taken under 
nitrogen atmosphere. To this (1,3-bis(2,4,6-trimethylphenyl)-2-
imidazolidinylidene)dichloro(phenylmethylene) (tricyclohexylphosphine)ruthenium 
(Grubbs second-generation catalyst) (0.01 g, 0.02 mmol) was added and the resulting 
mixture heated at 80 °C for 30 minutes in the microwave, cooled to RT and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (4:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 10 g) and further purified by 
recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (3S,9aS)-2-benzyl-
2,3-dihydro-3,9a-epithiopyrido[1,2-a]pyrazine-1,4(6H,9H)-dione 10-sulfide (0.01 g, 
8%) (482) as a colourless solid; m.p. 119-121 °C; max/cm
-1
 1682 (C=O), 1639 (C=C), 
746 (C-H);  H (400 MHz, CDCl3) 2.57 – 2.65 (2H, m, CH2), 3.40 (2H, dd, J 13.4 & 
5.8, NCH2), 4.44 (1H, d, J 14.9, NCH2), 4.88 (1H, d, J 14.9, NCH2), 5.19 (1H, s, CHS), 
5.93 (2H, ddd, J 6.9 & 4.3 & 2.2, CH=CH), 7.24 (2H, d, J 2.1, Ar-H), 7.29 – 7.32 
(3H, m, Ar-H);  C (101 MHz, CDCl3) 28.64 (CH2), 41.64 (CH2), 48.61 (CH2), 64.59 
(CHS), 70.72 (quaternary C), 114.24 (Ar-C-H), 121.41 (CH=CH), 122.59 (CH=CH), 
128.74 (Ar-C-H), 129.38 (Ar-C-H), 130.58 (quaternary C), 190.40 (CO), 193.85 (CO); 
m/z 341 (100%, [M+Na]
+
); Found [M+Na]
+
 341.0520, C15H14N2O2S2Na requires 
341.0515. 
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5.63.2 Method B: 
A solution of 3,4-diallyl-1-benzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione 
(0.05 g, 0.15 mmol) (483) in dichloromethane (2.00 mL) was degassed and taken under 
nitrogen atmosphere. To this (1,3-bis-(2,4,6-trimethylphenyl)-2-
imidazolidinylidene)dichloro(o-isopropoxyphenylmethylene) ruthenium (Grubbs-
Hoveyda second-generation catalyst) (0.01 g, 0.02 mmol) was added and the resulting 
mixture heated at 80 °C for 30 minutes in the microwave, cooled to RT and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (4:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 10 g) and further purified by 
recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (3S,9aS)-2-benzyl-
2,3-dihydro-3,9a-epithiopyrido[1,2-a]pyrazine-1,4(6H,9H)-dione 10-sulfide (0.03 g, 
40%) (482) as a colourless solid; identical spectroscopic data to that obtained previously 
for (482). 
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5.64 (±)-(1S,4S)-1,2-Diallyl-5-benzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (483) 
 
Boron tribromide (0.52 mL, 5.43 mmol) was added dropwise to a solution of 3,4-
diallyl-1-benzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (1.60 g, 2.72 
mmol) (480) in dichloromethane (40.0 mL) at -78 °C. The resulting mixture was stirred 
for 15 minutes whereupon sodium hydrogen carbonate (10.0 mL of a saturated aqueous 
solution) was added and the biphasic mixture stirred for 15 minutes until the yellow 
colour had dissipated. The resulting mixture was stirred at room temperature for 10 
minutes, whereupon iodine was added portionwise until the colour due to iodine just 
persisted and stirring was maintained for 2 minutes. Sodium thiosulfate was added and 
the mixture stirred for 10 minutes, diluted with dichloromethane (10.0 mL) and water 
(20.0 mL). The layers were separated and the aqueous phase extracted with 
dichloromethane (2 x 20.0 mL). The combined organic extracts were dried over MgSO4, 
filtered and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (4:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) to give 
((±)-(1S,4S)-1,2-diallyl-5-benzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-
sulfide (0.266 g, 28%) (483) as a pale yellow oil; max/cm
-1
 1674 (C=O), 1609 (C=C), 
833 (C-H), 735 (C-H), 701 (C-H);  H (400 MHz, CDCl3) 3.23 – 3.29 (1H, m, 
CH2CH=CH2), 3.90 – 3.99 (1H, m, CH2CH=CH2), 4.41 – 4.48 (2H, m, NCH2), 4.82 
(1H, d, J 14.9, NCH2), 5.15 (1H, d, J 14.5, NCH2), 5.21 (1H, s, CHS), 5.22 – 5.27 (2H, 
m, CH=CH2), 5.30 – 5.33 (2H, m, CH=CH2), 5.76 – 5.85 (1H, m, CH=CH2), 6.07 – 
6.12 (1H, m, CH=CH2), 7.21 – 7.24 (2H, m, Ar-H), 7.27 – 7.31 (3H, m, Ar-H);  C (101 
MHz, CDCl3) 36.16 (CH2), 44.96 (CH2), 48.62 (CH2), 64.28 (CHS), 75.25 (quaternary 
C), 118.20 (CH2), 120.82 (CH2), 128.68 (CH), 128.74 (Ar-C-H), 129.32 (CH), 131.71 
(Ar-C-H), 131.91 (Ar-C-H), 134.48 (quaternary C), 164.52 (CO), 164.66 (CO); m/z 
369 (100%, [M+Na]
+
); Found [M+Na]
+
 369.0726, C17H18N2O2S2Na requires 369.0707.  
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5.65 (3S,6S)-1,3,4,6-Tetraallyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione (485) 
 
LiHMDS (4.14 mL of a 1M solution in tetrahydrofuran, 4.14 mmol) was added 
dropwise to a solution of (3S,6S)-1,4-diallyl-3,6-bis((4-methoxybenzyl)thio)piperazine-
2,5-dione (0.83 g, 1.65 mmol) (421) and allyl bromide (0.43 mL, 4.96 mmol) (452) in 
tetrahydrofuran (20.0 mL) at -78 °C and the resulting mixture stirred at this temperature 
for 1 hour and 1.5 hours at 0 °C. Saturated aqueous sodium hydrogen carbonate (10.0 
mL) was added and solvent removed under reduced pressure.  The residue was 
partitioned between water (10.0 mL) and dichloromethane (20.0 mL). The aqueous 
phase was extracted with dichloromethane (2 x 10.0 mL) and the combined extracts 
were dried (MgSO4), filtered and solvent removed under reduced pressure. The residue 
was purified via Biotage™ Horizon (4:1, petroleum spirit 40-60 °C: ethyl acetate; snap 
10 g) to give (3S,6S)-1,3,4,6-tetraallyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-
dione (0.53 g, 55%) (485) as a pale yellow oil; max/cm
-1
 1656 (C=O), 1610 (C=C), 
1001 (C-O-C), 835 (C-H);  H (400 MHz, CDCl3) 2.69 (2H, d, J 14.2, CH2CH=CH2), 
3.21 (2H, d, J 14.1, CH2CH=CH2), 3.79 (6H, s, OCH3), 3.94 – 3.99 (2H, m, SCH2), 4.05 
– 4.09 (2H, m, SCH2), 4.23 – 4.27 (4H, m, NCH2), 5.13 – 5.22 (2H, m, CH=CH2), 5.25 
(4H, dd, J 10.2 & 1.2, CH=CH2), 5.40 (2H, dd, J 10.3 & 1.4, CH=CH2), 5.52 – 5.63 
(2H, m, CH=CH2), 6.02 – 6.07 (2H, m, CH=CH2), 6.81 – 6.85 (4H, m, Ar-H), 7.20 – 
7.24 (4H, m, Ar-H);  C (101 MHz, CDCl3) 35.66 (CH2), 41.66 (CH2), 47.69 (CH2), 
55.42 (OCH3), 73.15 (quaternary C), 114.20 (CH=CH2), 118.63 (CH2), 121.15 (CH2), 
128.06 (quaternary C), 130.53 (CH=CH2), 131.28 (Ar-C-H), 133.62 (Ar-C-H), 159.05 
(quaternary C), 164.94 (CO); m/z 601 (100%, [M+Na]
+
); Found [M+Na]
+
 601.2176, 
C32H38N2O4S2Na requires 601.2170.  
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5.66 6a,12a-Bis((4-methoxybenzyl)thio)-1,6a,7,12a-tetrahydrodipyrido 
[1,2-a:1',2'-d]pyrazine-6,12(4H,10H)-dione (486) 
 
A solution of (3S,6S)-1,3,4,6-tetraallyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-
dione (0.20 g, 0.35 mmol) (485) in toluene (2.00 mL) was degassed and taken under 
nitrogen atmosphere. To this (1,3-bis(2,4,6-trimethylphenyl)-2-
imidazolidinylidene)dichloro(phenylmethylene) (tricyclohexylphosphine)ruthenium 
(Grubbs second-generation catalyst) (0.06 g, 0.07 mmol) was added and the resulting 
mixture heated at reflux for 16 hours, cooled to RT and solvent removed under reduced 
pressure. The residue was purified via Biotage™ Horizon (4:1, petroleum spirit 
40-60 °C: ethyl acetate; snap 10 g) to give 6a,12a-bis((4-methoxybenzyl)thio)-
1,6a,7,12a-tetrahydrodipyrido[1,2-a:1',2'-d]pyrazine-6,12(4H,10H)-dione (0.05 g, 28%) 
(486) as a pale yellow oil; max/cm
-1
 3001 (C-H), 2934 (C-H), 2836 (C-H), 1659 (C=O), 
1609 (C=C), 835 (C-H);  H (400 MHz, CDCl3) 2.56 – 2.66 (2H, m, CH2CH=CH), 2.88 
– 2.97 (2H, m, CH2CH=CH), 3.78 (6H, s, OCH3), 3.85 – 3.92 (2H, m, SCH2), 3.92 – 
3.96 (2H, m, SCH2), 4.02 – 4.06 (2H, m, NCH2), 4.61 – 4.73 (2H, m, NCH2), 5.72 – 
5.78 (2H, m, CH=CH), 5.79 – 5.87 (2H, m, CH=CH), 6.79 – 6.82 (4H, m, Ar-H), 7.20 – 
7.24 (4H, m, Ar-H);  C (101 MHz, CDCl3) 34.71 (CH2), 35.91 (CH2), 41.26 (CH2), 
55.43 (OCH3), 65.70 (quaternary C), 114.12 (Ar-C-H), 121.02 (CH=CH2), 123.12 
(CH=CH2), 128.13 (quaternary C), 130.56 (Ar-C-H), 159.00 (quaternary C), 165.66 
(CO); m/z 545 (100%, [M+Na]
+
); Found [M+Na]
+
 545.1529, C28H30N2O4S2Na requires 
545.1545.  
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5.67 (±)-(6aS,12aS)-7,10-Dihydro-6a,12a-epithiodipyrido[1,2-a:1',2'-d] 
pyrazine-6,12(1H,4H)-dione 13-sulfide (487) 
 
Boron tribromide (0.86 mL of a 1M solution in dichloromethane, 0.86 mmol) was added 
dropwise to a solution of 6a,12a-bis((4-methoxybenzyl)thio)-1,6a,7,12a-
tetrahydrodipyrido[1,2-a:1',2'-d]pyrazine-6,12(4H,10H)-dione (0.15 g, 0.29 mmol) 
(486) in dichloromethane (2.00 mL) at -78 °C. The resulting mixture was stirred for 15 
minutes whereupon aqueous sodium hydrogen carbonate (5.00 mL of a saturated 
aqueous solution) and methanol (2.00 mL) were added and the biphasic mixture stirred 
for 15 minutes until the yellow colour had dissipated. The resulting mixture was stirred 
at room temperature for 10 minutes, whereupon iodine was added portionwise until the 
colour due to iodine just persisted and stirring was maintained for 2 minutes. Sodium 
thiosulfate was added and the mixture stirred for 10 minutes, diluted with 
dichloromethane (10.0 mL) and water (20.0 mL). The layers were separated and the 
aqueous phase extracted with dichloromethane (2 x 20.0 mL). The combined organic 
extracts were dried over MgSO4, filtered and solvent removed under reduced pressure. 
The residue was purified via Biotage™ Horizon (3:1, petroleum spirit 40-60 °C: ethyl 
acetate; snap 10 g) which did not give (6aS,12aS)-7,10-dihydro-6a,12a-
epithiodipyrido[1,2-a:1',2'-d]pyrazine-6,12(1H,4H)-dione 13-sulfide (487). 
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5.68 (±)-(6aS,12aS)-7,10-Dihydro-6a,12a-epithiodipyrido[1,2-a:1',2'-d] 
pyrazine-6,12(1H,4H)-dione 13-sulfide (487) 
 
5.68.1 Method A: 
A solution of (±)-(1S,4S)-1,2,4,5-tetraallyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-
dione 7-sulfide (0.04 g, 0.12 mmol) (488) in dichloromethane (2.00 mL) was degassed 
and taken under nitrogen atmosphere. To this (1,3-bis-(2,4,6-trimethylphenyl)-2-
imidazolidinylidene)dichloro(o-isopropoxyphenylmethylene)ruthenium (Grubbs-
Hoveyda second-generation catalyst) (0.01 g, 0.01 mmol) was added and the resulting 
mixture heated at 80 °C for 30 minutes in the microwave, cooled to RT and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (4:1, 
petroleum spirit 40-60 °C: ethyl acetate; pipette column) and further purified by 
recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (6aS,12aS)-7,10-
dihydro-6a,12a-epithiodipyrido[1,2-a:1',2'-d]pyrazine-6,12(1H,4H)-dione 13-sulfide 
(0.01 g, 39%) (487) as a colourless solid; m.p. 135-137 °C; max/cm
-1
 1683 (C=O, C=C), 
1351 (C-H), 1321 (C-H);  H (400 MHz, CDCl3) 2.60 – 2.72 (2H, m, CH2CH=CH), 
3.29 – 3.40 (2H, m, CH2CH=CH), 3.87 – 4.08 (4H, m, NCH2), 5.86 – 5.97 (4H, m, 
CH=CH);  C (101 MHz, CDCl3) 28.60 (CH2), 42.30 (CH2), 70.29 (quaternary C), 
121.14 (CH=CH), 122.32 (CH=CH), 165.15 (CO); m/z 303 (100%, [M+Na]
+
); Found 
[M+Na]
+
 303.0253, C12H12N2O2S2Na requires 303.0238. 
5.68.2 Method B: 
A solution of (±)-(1S,4S)-1,2,4,5-tetraallyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-
dione 7-sulfide (0.04 g, 0.13 mmol) (488) in dichloromethane (2.00 mL) was degassed 
and taken under nitrogen atmosphere. To this (1,3-bis(2,4,6-trimethylphenyl)-2-
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imidazolidinylidene)dichloro (phenylmethylene)(tricyclohexylphosphine)ruthenium 
(Grubbs second-generation catalyst) (0.01 g, 0.01 mmol) was added and the resulting 
mixture heated at 80 °C for 30 minutes in the microwave, cooled to RT and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (4:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 5 g) and further purified by 
recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (6aS,12aS)-7,10-
dihydro-6a,12a-epithiodipyrido[1,2-a:1',2'-d]pyrazine-6,12(1H,4H)-dione 13-sulfide 
(0.01 g, 7%) (487) as a colourless solid; identical spectroscopic data to that obtained 
previously for (487).  
Bruno Sil                                                                                                                 Experimental 
 
293 
 
5.69 (±)-(1S,4S)-1,2,4,5-Tetraallyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (488) 
 
Boron tribromide (0.14 mL, 1.50 mmol) was added dropwise to a solution of 1,3,4,6-
tetraallyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.44 g, 0.75 mmol) 
(485) in dichloromethane (20.0 mL) at -78 °C. The resulting mixture was stirred for 15 
minutes whereupon Rochelle’s salt (20.0 mL of a saturated aqueous solution) was added 
and the biphasic mixture stirred for 15 minutes until the yellow colour had dissipated. 
The resulting mixture was stirred at room temperature for 10 minutes, whereupon iodine 
was added portionwise until the colour due to iodine just persisted and stirring was 
maintained for 2 minutes. Sodium thiosulfate was added and the mixture stirred for 10 
minutes, diluted with dichloromethane (10.0 mL) and water (20.0 mL). The layers were 
separated and the aqueous phase extracted with dichloromethane (2 x 20.0 mL). The 
combined organic extracts were dried over MgSO4, filtered and solvent removed under 
reduced pressure. The residue was purified via Biotage™ Horizon (4:1, petroleum spirit 
40-60 °C: ethyl acetate; snap 10 g) and further purified by recrystallisation (petroleum 
spirit 40-60 °C: ethyl acetate) to give (±)-(1S,4S)-1,2,4,5-tetraallyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (0.10 g, 41%) (488) as a colourless 
solid; m.p. 180-182 °C; max/cm
-1
 1639 (C=O, C=C), 1462 (CH2), 749 (CH2);  H (400 
MHz, CDCl3) 3.20 – 3.27 (2H, m, CH2CH=CH), 3.28 – 3.36 (2H, m, CH2CH=CH), 
4.04 (2H, dd, J 16.4 & 6.8, NCH2), 4.62 (2H, dd, J 16.2 & 4.8, NCH2), 5.21 – 5.41 (8H, 
m, CH=CH2), 5.89 – 5.94 (2H, m, CH=CH2), 6.12 – 6.17 (2H, m, CH=CH2);  C (101 
MHz, CDCl3) 36.44 (CH2), 45.46 (CH2), 74.50 (quaternary C), 118.31 (CH=CH2), 
120.60 (CH=CH2), 131.74 (CH=CH2), 132.01 (CH=CH2), 165.02 (CO); m/z 337 
(100%, [M+H]
+
); Found [M+H]
+
 337.1456, C16H21N2O2S2 requires 337.1448.  
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5.70 Ethyl 2-((6-((2-ethoxy-1-((4-methoxybenzyl)thio)-2-
oxoethyl)amino) hexyl)amino)-2-((4-methoxy benzyl)thio)acetate 
(491) 
 
1,6-Diaminohexane (0.59 g, 5.07 mmol) (490) was added to a solution of ethyl 
glyoxalate (2.00 mL of a 50% solution in toluene, 10.1 mmol) (256) in toluene (20.0 
mL) at RT and stirred for 2 minutes, whereupon para-methoxybenzyl mercaptan (1.41 
mL, 10.1 mmol) (257) was added and the mixture stirred for 2 hours. Solvent was 
removed under reduced pressure and the residue purified via Biotage™ Horizon (3:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 50 g) to give ethyl 2-((6-((2-ethoxy-1-((4-
methoxybenzyl)thio)-2-oxoethyl)amino)hexyl)amino)-2-((4-methoxybenzyl)thio)acetate 
(1.73 g, 58%) (491) as a colourless oil; max/cm
-1
 2953 (C-H), 2858 (C-H), 1736 (C=O), 
1644 (C=O), 1463 (CH2), 730 (CH2);  H (400 MHz; CDCl3) 1.17 – 1.29 (8H, m, 
NHCH2(CH2)4CH2NH), 1.32 (6H, t, J 7.1, OCH2CH3), 1.67 – 1.77 (2H, m, NH), 2.37 – 
2.45 (2H, m, NHCH2(CH2)4CH2NH), 2.68 – 2.74 (2H, m, NHCH2(CH2)4CH2NH), 3.74 
(4H, d, J 1.9, SCH2), 3.79 (6H, s, OCH3), 4.23 (4H, q, J 7.2, OCH2CH3), 4.34 (2H, s, 
CHS), 6.82 – 6.87 (4H, m, Ar-H), 7.25 – 7.31 (4H, m, Ar-H);  C (101 MHz; CDCl3) 
14.29 (CH3), 27.24 (CH2), 29.55 (CH2), 33.36 (CH2), 45.61 (CH2), 55.43 (OCH3), 
61.47 (CH2), 64.71 (CHS), 114.06 (Ar-C-H), 130.14 (Ar-C-H), 130.27 (quaternary C), 
158.86 (quaternary C), 170.18 (CO); m/z 593 (100%, [M+H]
+
): Found [M+H]
+
 
593.5126, C30H45N2O6S2 requires 593.5102.  
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5.71 Diethyl 2,2'-((1,4-phenylenebis(methylene))bis(azanediyl))bis(2-
((4-methoxybenzyl)thio)acetate) (493) 
 
p-Xylylenediamine (0.69 g, 5.04 mmol) (492) was added to a solution of ethyl 
glyoxalate (2.00 mL of a 50% solution in toluene, 10.1 mmol) (256) in toluene (20.0 
mL) at RT and stirred for 2 minutes, whereupon para-methoxybenzyl mercaptan (1.41 
mL, 10.1 mmol) (257) was added and the mixture stirred for 2 hours. Solvent was 
removed under reduced pressure and the residue purified via Biotage™ Horizon (3:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 50 g) to give diethyl 2,2'-((1,4-
phenylenebis(methylene))bis(azanediyl))bis(2-((4-methoxybenzyl)thio)acetate) (2.43 g, 
79%) (493) as a colourless oil; max/cm
-1
 2983 (C-H), 1729 (C=O), 1644 (N-H), 1176 
(C-C(O)-C), 1108 (C-N), 832 (C-H);  H (400 MHz; CDCl3) 1.21 (6H, t, J 7.2, 
OCH2CH3), 2.04 (2H, br s, NH), 3.56 – 3.61 (2H, m, NHCH2), 3.65 (4H, d, J 2.4, 
SCH2), 3.69 (6H, d, J 0.8, OCH3), 3.71 – 3.76 (2H, m, NHCH2), 4.12 (4H, q, J 7.1, 
OCH2CH3), 4.24 (2H, s, CHS), 6.71 – 6.76 (4H, m, Ar-H), 7.06 – 7.09 (4H, m, Ar-H), 
7.15 – 7.19 (4H, m, Ar-H);  C (101 MHz; CDCl3) 14.26 (CH3), 33.33 (CH2), 49.03 
(CH2), 55.42 (OCH3), 61.52 (CH2), 63.82 (CHS), 114.11 (Ar-C-H), 128.63 (Ar-C-H), 
130.17 (Ar-C-H), 137.85 (quaternary C), 158.88 (quaternary C), 170.06 (CO); m/z 613 
(100%, [M+H]
+
): Found [M+H]
+
 613.2413, C32H41N2O6S2 requires 613.2406. 
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5.72 (5,14-Bis((4-methoxybenzyl)thio)-4,15-dioxo-3,16-dioxa-6,13-
diazaoctadecane-6,13-diyl)bis(2-oxoethane-2,1,1-triyl) tetraacetate 
(494) 
 
A solution of diacetoxyacetyl chloride (1.36 g, 7.00 mmol) (379) in dichloromethane 
(20.0 mL) was added dropwise to a rapidly stirred biphasic mixture of ethyl 2-((6-((2-
ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)hexyl)amino)-2-((4-
methoxybenzyl)thio) acetate (1.73 g, 2.92 mmol) (491) and sodium hydrogen carbonate 
(0.98 g, 11.7 mmol) in dichloromethane (200 mL) and water (100 mL) at RT and the 
resulting mixture stirred rapidly for 3 hours. The layers were separated and the aqueous 
phase extracted with dichloromethane (2 x 100 mL). The combined extracts were dried 
over MgSO4, filtered and solvent removed under reduced pressure to give (5,14-bis((4-
methoxybenzyl)thio)-4,15-dioxo-3,16-dioxa-6,13-diazaoctadecane-6,13-diyl)bis(2-
oxoethane-2,1,1-triyl) tetraacetate (2.40 g, 90%) (494) as a colourless oil that did not 
require further purification; max/cm
-1
 1736 (C=O), 1664 (C=O), 1463 (CH2), 1374 
(CH3), 1248 (C-C(O)-C), 733 (C-H);  H (400 MHz; CDCl3) 1.28 (6H, t, J 7.1, 
OCH2CH3), 2.12 – 2.16 (8H, m, NCH2(CH2)4CH2N), 3.57 – 3.60 (4H, m, SCH2), 3.72 – 
3.83 (22H, m, 2 x OC(O)CH3 & OCH3 & NCH2), 4.15 (4H, q, J 7.3, OCH2CH3), 5.06 
(2H, s, CHS), 6.86 – 6.90 (4H, m, Ar-H), 6.92 (2H, s, CH(OAc)2), 7.23 – 7.25 (4H, m, 
Ar-H);  C (101 MHz; CDCl3) 14.13 (CH3), 14.19 (CH3), 15.41 (CH3), 21.26 (CH2), 
26.37 (CH2), 34.94 (CH2), 36.84 (CH2), 42.94 (OCH3), 55.45 (CH2), 66.33 (CHS), 
72.53 (CH(OAc)2), 114.13 (quaternary C), 130.21 (Ar-C-H), 130.31 (Ar-C-H), 130.34 
(quaternary C), 158.72 (CO), 159.82 (CO), 171.20 (CO), 175.77 (CO); m/z 909 (100%, 
[M+H]
+
): Found [M+H]
+
 909.8103, C42H57N2O16S2 requires 909.8123.  
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5.73 ((1,4-Phenylenebis(methylene))bis((2-ethoxy-1-((4-
methoxybenzyl)thio)-2-oxoethyl)azanediyl))bis(2-oxoethane-2,1,1-
triyl) tetraacetate (495) 
 
A solution of diacetoxyacetyl chloride (1.45 g, 7.44 mmol) (379) in dichloromethane 
(20.0 mL) was added dropwise to a rapidly stirred biphasic mixture of diethyl 2,2'-((1,4-
phenylenebis(methylene))bis(azanediyl))bis(2-((4-methoxybenzyl)thio)acetate) (1.90 g, 
3.10 mmol) (493) and sodium hydrogen carbonate (1.04 g, 12.4 mmol) in 
dichloromethane (200 mL) and water (100 mL) at RT and the resulting mixture stirred 
rapidly for 3 hours. The layers were separated and the aqueous phase extracted with 
dichloromethane (2 x 100 mL). The combined extracts were dried over MgSO4, filtered 
and solvent removed under reduced pressure to give ((1,4-
phenylenebis(methylene))bis((2-ethoxy-1-((4-methoxybenzyl)thio)-2-
oxoethyl)azanediyl))bis(2-oxoethane-2,1,1-triyl) tetraacetate (2.45 g, 85%) (495) as a 
colourless oil that did not require further purification; max/cm
-1
 1739 (C=O), 1639 
(C=O), 1371 (CH3), 1246 (C-C(O)-C);  H (400 MHz; CDCl3) 1.22 (6H, t, J 7.0, 
OCH2CH3), 2.01 – 2.16 (12H, m, CH(C(O)CH3)2), 3.82 – 3.85 (10H, m, OCH3 & 
OCH2CH3), 3.99 – 4.10 (4H, m, SCH2), 4.56 – 4.65 (2H, m, NCH2), 4.86 – 4.95 (2H, m, 
NCH2), 5.85 (2H, s, CHS), 6.84 – 6.88 (4H, m, Ar-H), 6.96 (2H, s, CH(OAc)2), 7.21 – 
7.29 (8H, m, Ar-H);  C (101 MHz; CDCl3) 14.08 (CH3), 20.54 (CH3), 27.51 (CH3), 
35.91 (CH2), 48.51 (CH2), 55.50 (OCH3), 61.86 (CH2), 62.50 (CHS), 84.24 
(CH(OAc)2), 85.52 (Ar-C-H), 114.34 (Ar-C-H), 127.29 (quaternary C), 128.91 
(quaternary C), 130.49 (Ar-C-H), 159.24 (quaternary C), 160.76 (CO), 168.64 (CO), 
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167.45 (CO), 168.88 (CO); m/z 951 (100%, [M+Na]
+
): Found [M+Na]
+
 951.2670, 
C44H52N2O16S2Na requires 951.2656. 
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5.74 (3S,3'S,6S,6'S)-4,4'-(1,4-Phenylenebis(methylene))bis(1-benzyl-
3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione) (496) 
 
A mixture of 2-(benzyl(2-ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-
oxoethane-1,1-diyl diacetate (0.40 g, 0.79 mmol) (259), p-xylylenediamine (0.06 g, 0.47 
mmol) (492), para-methoxybenzyl mercaptan (0.16 mL, 1.18 mmol) (257) and DMAP 
(0.02 g, 0.20 mmol) in acetonitrile (3.00 mL) was stirred at room temperature for 10 
minutes and heated at 130 °C for 30 minutes in the microwave. The residue was 
purified via Biotage™ Horizon (2:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) 
and further purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to 
give (3S,3'S,6S,6'S)-4,4'-(1,4-phenylenebis(methylene))bis(1-benzyl-3,6-bis((4-
methoxybenzyl)thio) piperazine-2,5-dione) (0.04 g, 18%) (496) as a colourless solid; 
m.p. 63-65 C; max/cm
-1
 1672 (C=O), 830 (C-H), 730 (C-H);   H (400 MHz, CDCl3) 
3.49 (2H, d, J 12.3, SCH2), 3.63 (2H, d, J 8.6, SCH2), 3.80 (10H, d, J 6.2, SCH2 & 
OCH3), 3.87 (10H, d, J 4.5, NCH2 & OCH3), 4.01 (2H, d, J 13.9, NCH2), 4.41 (2H, s, 
CHS), 4.53 (2H, s, CHS), 5.15 (2H, d, J 12.5, NCH2), 6.88 – 6.93 (12H, m, Ar-H), 7.08 
(4H, d, J 8.5, Ar-H), 7.13 – 7.19 (6H, m, Ar-H), 7.29 (8H, d, J 5.7, Ar-H);  C (101 
MHz, CDCl3) 36.57 (CH2), 36.68 (CH2), 46.05 (CH2), 46.36 (CH2), 55.34 (OCH3), 
55.53 (OCH3), 57.68 (CHS), 58.15 (CHS), 114.40 (Ar-C-H), 128.08 (Ar-C-H), 128.78 
(Ar-C-H), 128.88 (Ar-C-H), 129.08 (quaternary C), 130.91 (Ar-C-H), 131.05 (Ar-C-
H), 134.72 (quaternary C), 135.16 (quaternary C), 159.41 (quaternary C), 165.05 (CO), 
165.27 (CO); m/z 1142 (100%, [M+Na]
+
): Found [M+Na]
+
 1143.4436, 
C62H62N4O8S4Na requires 1143.4410.  
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5.75 (3S,3'S,6S,6'S)-4,4'-(1,4-Phenylenebis(methylene))bis(1-benzyl-
3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione) (496) 
 
5.75.1 Method A: 
Benzylamine (0.15 mL, 1.41 mmol) (255) was added to a solution of ((1,4-
phenylenebis(methylene))bis((2-ethoxy-1-((4-methoxybenzyl)thio)-2-
oxoethyl)azanediyl))bis(2-oxoethane-2,1,1-triyl) tetraacetate  (0.29 g, 0.31 mmol) (495) 
in acetonitrile (15.0 mL) followed by addition of para-methoxybenzyl mercaptan (0.13 
mL, 0.94 mmol) (257) and the resulting mixture stirred for 2 minutes. DMAP (0.02 g, 
0.15 mmol) was added and the resulting mixture heated at reflux for 16 hours, cooled to 
RT and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (2:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) and further 
purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give 
(3S,3'S,6S,6'S)-4,4'-(1,4-phenylenebis(methylene))bis(1-benzyl-3,6-bis((4-
methoxybenzyl)thio) piperazine-2,5-dione) (0.15 g, 43%) (496) as a colourless solid; 
identical spectroscopic data to that obtained previously for (496). 
5.75.2 Method B: 
Benzylamine (0.10 mL, 0.92 mmol) (255) was added to a solution of ((1,4-
phenylenebis(methylene))bis((2-ethoxy-1-((4-methoxybenzyl)thio)-2-
oxoethyl)azanediyl))bis(2-oxoethane-2,1,1-triyl) tetraacetate (0.19 g, 0.21 mmol) (495) 
in acetonitrile (3.00 mL) followed by addition para-methoxybenzyl mercaptan (0.09 
mL, 0.61 mmol) (257) and the resulting mixture stirred for 2 minutes. DMAP (0.01 g, 
0.10 mmol) was added and the mixture heated in the microwave 130 C for 30 minutes, 
allowed to cool to room temperature and solvent removed under reduced pressure. The 
residue was purified via Biotage™ Horizon (2:1, petroleum spirit 40-60 °C: ethyl 
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acetate; snap 25 g) and further purified by recrystallisation (petroleum spirit 40-60 °C: 
ethyl acetate) to give (3S,3'S,6S,6'S)-4,4'-(1,4-phenylenebis(methylene))bis(1-benzyl-
3,6-bis((4-methoxybenzyl)thio) piperazine-2,5-dione) (0.11 g, 48%) (496) as a 
colourless solid; identical spectroscopic data to that obtained previously for (496). 
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5.76 (3S,3'S,6S,6'S)-4,4'-(Hexane-1,6-diyl)bis(1-benzyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione) (497) 
 
A mixture of 2-(benzyl(2-ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-
oxoethane-1,1-diyl diacetate (0.22 g, 0.43 mmol) (259), 1,6-diaminohexane (0.05 g, 
0.43 mmol) (490), para-methoxybenzyl mercaptan (0.18 mL, 1.29 mmol) (257) and 
DMAP (0.03 g, 0.21 mmol) in acetonitrile (3.00 mL) was stirred at room temperature 
for 10 minutes and heated at 130 °C for 30 minutes in the microwave. The residue was 
purified via Biotage™ Horizon (2:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) 
and further purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to 
give (3S,3'S,6S,6'S)-4,4'-(hexane-1,6-diyl)bis(1-benzyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione) (0.08 g, 33%) (497) as a colourless solid; 
m.p. 101-104 C; max/cm
-1
 3003 (C-H), 1673 (C=O), 1451 (CH2), 733 (CH2);   H (400 
MHz, CDCl3) 1.64 – 1.66 (2H, m, NCH2(CH2)4CH2N), 2.53 – 2.62 (2H, m, 
NCH2(CH2)4CH2N), 3.42 – 3.52 (2H, m, NCH2(CH2)4CH2N), 3.60 – 3.63 (2H, m, 
NCH2(CH2)4CH2N), 3.73 (4H, d, J 7.5, SCH2), 3.80 (8H, d, J 12.9, OCH3 & SCH2), 
3.88 – 3.94 (10H, m, SCH2 & NCH2 & OCH3), 3.97 (2H, d, J 12.9, NCH2), 4.04 (2H, d, 
J 13.8, NCH2), 4.32 (2H, s, CHS), 4.44 (2H, s, CHS), 5.17 (2H, d, J 13.6, NCH2), 6.72 
(4H, d, J 7.6, Ar-H), 6.89 (10H, d, J 8.6, Ar-H), 7.37 – 7.42 (12H, m, Ar-H);  C (101 
MHz, CDCl3) 26.55 (CH2), 26.98 (CH2), 36.49 (SCH2), 37.01 (SCH2), 44.03 (CH2), 
46.36 (CH2), 55.52 (OCH3), 57.67 (CHS), 59.37 (CHS), 114.26 (Ar-C-H), 114.37 (Ar-
C-H), 128.83 (Ar-C-H), 129.14 (quaternary C), 130.94 (Ar-C-H),  131.04 (Ar-C-H), 
135.24 (quaternary C), 159.36 (quaternary C), 165.12 (CO), 165.47 (CO); m/z 1121 
(100%, [M+Na]
+
): Found [M+Na]
+
 1121.3680, C60H66N4O8S4Na requires 1121.3661.  
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5.77 (3S,3'S,6S,6'S)-4,4'-(Hexane-1,6-diyl)bis(1-benzyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione) (497) 
 
5.77.1 Method A: 
Benzylamine (0.11 mL, 1.04 mmol) (255) was added to a solution of (5,14-bis((4-
methoxybenzyl)thio)-4,15-dioxo-3,16-dioxa-6,13-diazaoctadecane-6,13-diyl)bis(2-
oxoethane-2,1,1-triyl) tetraacetate  (0.21 g, 0.23 mmol) (494) in acetonitrile (15.0 mL) 
followed by addition of para-methoxybenzyl mercaptan (0.10 mL, 0.69 mmol) (257) 
and the resulting mixture stirred for 2 minutes. DMAP (0.01 g, 0.12 mmol) was added 
and the resulting mixture heated at reflux for 16 hours, cooled to RT and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (2:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) and further purified by 
recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (3S,3'S,6S,6'S)-4,4'-
(hexane-1,6-diyl)bis(1-benzyl-3,6-bis((4-methoxybenzyl)thio) piperazine-2,5-dione) 
(0.13 g, 50%) (497) as a colourless solid; identical spectroscopic data to that obtained 
previously for (497). 
5.77.2 Method B: 
Benzylamine (0.10 mL, 0.94 mmol) (255) was added to a solution of (5,14-bis((4-
methoxybenzyl)thio)-4,15-dioxo-3,16-dioxa-6,13-diazaoctadecane-6,13-diyl)bis(2-
oxoethane-2,1,1-triyl) tetraacetate (0.19 g, 0.21 mmol) (494) in acetonitrile (3.00 mL) 
followed by addition para-methoxybenzyl mercaptan (0.09 mL, 0.63 mmol) (257) and 
the resulting mixture stirred for 2 minutes. DMAP (0.01 g, 0.11 mmol) was added and 
the mixture heated in the microwave 130 C for 30 minutes, allowed to cool to room 
temperature and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (2:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) and further 
purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give 
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(3S,3'S,6S,6'S)-4,4'-(hexane-1,6-diyl)bis(1-benzyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione) (0.11 g, 47%) (497) as a colourless solid; 
identical spectroscopic data to that obtained previously for (497). 
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5.78 (±)-(1S,1'S,4S,4'S)-5,5'-(1,4-Phenylenebis(methylene))bis(2-
benzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide) 
(498) 
 
Boron tribromide (0.03 mL, 0.36 mmol) was added dropwise to a solution of 
(3S,3'S,6S,6'S)-4,4'-(1,4-phenylenebis(methylene))bis(1-benzyl-3,6-bis((4-
methoxybenzyl)thio) piperazine-2,5-dione) (0.10 g, 0.09 mmol) (492) in 
dichloromethane (3.00 mL) at -78 °C. The resulting mixture was stirred for 15 minutes 
whereupon Rochelle’s salt (10.0 mL of a saturated aqueous solution) and methanol 
(2.00 mL) were added and the biphasic mixture stirred for 15 minutes until the yellow 
colour had dissipated. The resulting mixture was stirred at room temperature for 10 
minutes, whereupon iodine was added portionwise until the colour due to iodine just 
persisted and stirring was maintained for 2 minutes. Sodium thiosulfate was added and 
the mixture stirred for 10 minutes, diluted with dichloromethane (10.0 mL) and water 
(20.0 mL). The layers were separated and the aqueous phase extracted with 
dichloromethane (2 x 20.0 mL). The combined organic extracts were dried over MgSO4, 
filtered and solvent removed under reduced pressure. The residue was purified via 
Biotage™ Horizon (9:1, dichloromethane: methanol; snap 10 g), followed by HPLC 
separation and further purified by recrystallisation (petroleum spirit 40-60 °C: ethyl 
acetate) to give (1S,1'S,4S,4'S)-5,5'-(1,4-phenylenebis(methylene))bis(2-benzyl-7-thia-
2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide) (0.01 g, 23%) (498) as a colourless 
solid; m.p. 148-151 C; max/cm
-1
 2919 (C-H), 1678 (C=O);  H (500 MHz; CDCl3) 
4.44 – 4.54 (8H, m, NCH2), 5.23 (4H, s, CHS), 6.45 – 6.46 (2H, m, Ar-H), 6.48 – 6.49 
(2H, m, Ar-H), 7.02 – 7.03 (10H, m, Ar-H); m/z 657 (100%, [M+Na]+): Found [M+Na]+ 
657.3334, C30H26N4O4S4Na requires 657.0735. 
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5.79 (±)-(1S,1'S,4S,4'S)-5,5'-(Hexane-1,6-diyl)bis(2-benzyl-7-thia-2,5-
diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide) (499) 
 
Boron tribromide (0.68 mL of a 1M solution in dichloromethane, 0.68 mmol) was added 
dropwise to a solution of (3S,3'S,6S,6'S)-4,4'-(hexane-1,6-diyl)bis(1-benzyl-3,6-bis((4-
methoxybenzyl) thio)piperazine-2,5-dione) (0.10 g, 0.11 mmol) (497) in 
dichloromethane (20.0 mL) at -78 °C. The resulting mixture was stirred for 15 minutes 
whereupon aqueous sodium hydrogen carbonate (10.0 mL of a saturated aqueous 
solution) and methanol (10.0 mL) were added and the biphasic mixture stirred for 15 
minutes until the yellow colour had dissipated. The resulting mixture was stirred at 
room temperature for 10 minutes, whereupon iodine was added portionwise until the 
colour due to iodine just persisted and stirring was maintained for 2 minutes. Sodium 
thiosulfate was added and the mixture stirred for 10 minutes, diluted with 
dichloromethane (10.0 mL) and water (20.0 mL). The layers were separated and the 
aqueous phase extracted with dichloromethane (2 x 20.0 mL). The combined organic 
extracts were dried over MgSO4, filtered and solvent removed under reduced pressure. 
The residue was purified via Biotage™ Horizon (9:1, dichloromethane: methanol; snap 
10 g), followed by HPLC separation and further purified by recrystallisation (petroleum 
spirit 40-60 °C: ethyl acetate) to give (1S,1'S,4S,4'S)-5,5'-(hexane-1,6-diyl)bis(2-
benzyl-7-thia-2,5-diazabicyclo[2.2.1] heptane-3,6-dione 7-sulfide) (0.04 g, 50%) (499) 
as a colourless solid; m.p. 175-178 C; max/cm
-1
 2092 (C-H), 1642 (C=O);  H (500 
MHz; CDCl3) 2.01 – 2.17 (2H, m, NCH2(CH2)4CH2N), 2.40 – 2.42 (2H, m, 
NCH2(CH2)4CH2N), 3.52 – 3.55 (6H, m, NCH2 & NCH2(CH2)4CH2N), 3.80 – 3.82 (2H, 
m, NCH2), 4.54 (2H, d, J 14.8, NCH2), 4.86 (2H, d, J 14.9, NCH2), 5.20 (2H, s, CHS), 
5.36 (2H, s, CHS), 7.38 – 7.45 (10H, m, Ar-H); m/z 613 (100%, [M-H]-): Found [M-H]- 
613.2100, C28H29N4O4S4 requires 613.1072. 
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5.80 (8S,10a)-9-Benzyl-8-((4-methoxybenzyl)thio) 
octahydropyrazino[1,2-a][1,3] diazepine-7,10-dione (504) & (505) 
 
A solution of 2-(benzyl(2-ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-
oxoethane-1,1-diyl diacetate (0.20 g, 0.40 mmol) (259), 1,4-diaminobutane (0.04 mL, 
0.40 mmol) (502), para-methoxybenzyl mercaptan (0.08 mL, 0.60 mmol) (257) and 
DMAP (0.02 g, 0.20 mmol) in acetonitrile (3.00 mL) was stirred at room temperature 
for 10 minutes and heated at 130 °C for 25 minutes in the microwave. Solvent was 
removed under reduced pressure and the residue purified via Biotage™ Horizon (2:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 10 g) and further purified by 
recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (8S,10aR)-9-benzyl-
8-((4-methoxybenzyl)thio)octahydropyrazino[1,2-a][1,3]diazepine-7,10-dione (0.06 g, 
36%) (504) and (8S,10aS)-9-benzyl-8-((4-methoxybenzyl)thio) octahydropyrazino[1,2-
a][1,3]diazepine-7,10-dione (0.02 g, 12%) (505) both as colourless solids; Data for 
(504): m.p. 122-123 C; max/cm
-1
 3424 (NH), 1663 (C=O), 1511 (NH), 1249 (C-C(O)-
C), 1080 (C-N), 732 (CH2);  H (400 MHz, CDCl3) 1.59 – 1.77 (4H, m, 
NCH2(CH2)2CH2NH), 2.81 – 2.97 (3H, m, NHCH2 & NCH2(CH2)2CH2NH), 3.70 – 3.80 
(2H, m, SCH2), 3.64 (1H, d, J 13.2, NCH2(CH2)2CH2NH), 3.86 (3H, s, OCH3), 3.91 
(1H, d, J 13.1, NCH2(CH2)2CH2NH), 3.99 (1H, d, J 13.8, NCH2-Ph), 4.43 (1H, s, CHS), 
4.84 (1H, s, CHNH), 5.19 (1H, d, J 13.5, NCH2-Ph), 6.78 (1H, d, J 1.4, Ar-H), 6.79 – 
6.80 (1H, m, Ar-H), 6.87 – 6.89 (1H, m, Ar-H), 6.89 – 6.91 (1H, m, Ar-H), 7.16 – 7.21 
(2H, m, Ar-H), 7.24 – 7.25 (1H, m, Ar-H), 7.34 – 7.39 (2H, m, Ar-H);  C (101 MHz, 
CDCl3) 27.43 (CH2), 30.58 (CH2), 34.81 (SCH2), 42.43 (CH2), 46.81 (CH2), 47.58 
(CH2), 55.18 (OCH3), 58.08 (CHS), 72.06 (CHN), 113.98 (Ar-C-H), 127.82 (Ar-C-H), 
128.43 (Ar-C-H), 128.57 (Ar-C-H), 128.60 (quaternary C), 130.60 (Ar-C-H), 134.73 
(quaternary C), 158.99 (quaternary C), 163.50 (CO), 166.86 (CO); m/z 426 (100%, 
[M+H]
+
): Found [M+H]
+
 426.1850, C23H28N3O3S requires 426.1852; Data for (505): 
m.p. 121-123 C; max/cm
-1
 3425 (NH), 1658 (C=O), 1511 (NH), 1249 (C-C(O)-C), 
1032 (C-N);  H (400 MHz, CDCl3) 1.63 – 1.98 (4H, m, NCH2(CH2)2CH2NH), 2.02 – 
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2.16 (1H, m, NCH2(CH2)2CH2NH), 2.89 – 2.91 (1H, m, NCH2(CH2)2CH2NH), 2.99 – 
3.09 (1H, m, NCH2(CH2)2CH2NH), 3.26 (1H, d, J 13.2, SCH2), 3.59 (1H, d, J 13.1, 
SCH2), 3.80 – 3.85 (1H, m, NCH2(CH2)2CH2NH), 3.86 (3H, s, OCH3), 4.10 (1H, d, J 
13.7, NCH2(CH2)2CH2NH), 4.24 (1H, d, J 12.9, NCH2-Ph), 4.38 (1H, s, CHS), 4.67 
(1H, s, CHNH), 5.19 (1H, d, J 13.0, NCH2-Ph), 6.76 (2H, d, J 7.2, Ar-H), 6.89 (2H, d, J 
8.6, Ar-H), 7.15 (1H, d, J 6.6, Ar-H), 7.18 (1H, d, J 6.0, Ar-H), 7.21 – 7.30 (1H, m, Ar-
H), 7.37 (2H, d, J 8.6, Ar-H);  C (101 MHz, CDCl3) 25.77 (CH2), 30.08 (CH2), 35.81 
(SCH2), 45.01 (CH2), 46.08 (CH2), 48.25 (CH2), 55.17 (OCH3), 57.02 (CHS), 72.48 
(CHN), 114.02 (Ar-C-H), 127.76 (Ar-C-H), 128.48 (Ar-C-H), 128.56 (Ar-C-H), 128.60 
(quaternary C), 130.64 (Ar-C-H), 134.78 (quaternary C), 159.03(CO), 165.20 (CO); 
m/z 426 (100%, [M+H]
+
): Found [M+H]
+
 426.1836, C23H28N3O3S requires 426.1852. 
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5.81 (3S,3'S,6S,6'S)-4,4'-(Hexane-1,6-diyl)bis(1-cyclopropyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione) (512) 
 
A mixture of 2-(cyclopropyl(2-ethoxy-1-(4-methoxybenzylthio)-2-oxoethyl)amino)-2-
oxoethane-1,1-diyl diacetate (0.40 g, 0.88 mmol) (396), 1,6-diaminohexane (0.10 g, 
0.88 mmol) (490), para-methoxybenzyl mercaptan (0.37 mL, 2.65 mmol) (257) and 
DMAP (0.05 g, 0.44 mmol) in acetonitrile (3.00 mL) was stirred at room temperature 
for 10 minutes and heated at 130 °C for 30 minutes in the microwave. The residue was 
purified via Biotage™ Horizon (2:1, petroleum spirit 40-60 °C: ethyl acetate; snap 25 g) 
and further purified by recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to 
give (3S,3'S,6S,6'S)-4,4'-(hexane-1,6-diyl)bis(1-cyclopropyl-3,6-bis((4-
methoxybenzyl)thio)piperazine-2,5-dione) (0.11 g, 25%) (512) as a colourless solid; 
m.p. 98-102 C; max/cm
-1
 2934 (C-H), 2856 (C-H), 2836 (C-H), 1666 (C=O), 
1464(CH2), 733 (C-H);   H (400 MHz, CDCl3) 0.13 (2H, dt, J 6.8 & 4.3, cyclopropyl-
CH2), 0.23 – 0.38 (2H, m, cyclopropyl-CH2), 0.72 – 0.83 (2H, m, cyclopropyl-CH2), 
0.88 – 0.91 (4H, m, NCH2(CH2)4CH2N), 1.09 (2H, dt, J 6.2 & 4.4, cyclopropyl-CH2), 
1.28 – 1.30 (2H, m, NCH2(CH2)4CH2N), 1.60 – 1.61 (2H, m, cyclopropyl-CH), 2.49 – 
2.58 (2H, m, NCH2(CH2)4CH2N), 2.62 – 2.64 (2H, m, SCH2), 3.44 – 3.57 (2H, m, 
SCH2), 3.78 (6H, s, OCH3), 3.81 – 3.85 (8H, m, SCH2 & OCH3), 3.88 (2H, d, J 2.5, 
SCH2), 4.01 (2H, d, J 8.7, NCH2), 4.05 (2H, d, J 8.8, NCH2), 4.30 (2H, s, CHS), 4.49 
(2H, s, CHS), 6.85 – 6.92 (8H, m, Ar-H), 7.39 – 7.45 (8H, m, Ar-H);  C (101 MHz, 
CDCl3) 4.76 (CH2), 7.94 (CH2), 26.47 (CH2), 26.84 (CH2), 28.39 (CH), 36.98 (SCH2), 
37.10 (SCH2), 43.68 (NCH2), 55.52 (OCH3), 55.57 (OCH3), 59.31 (CHS), 60.76 
(CHS), 114.21 (Ar-C-H), 128.97 (quaternary C), 130.97 (Ar-C-H), 159.28 (quaternary 
C), 165.42 (CO), 167.47 (CO); m/z 999 (100%, [M+H]
+
): Found [M+H]
+
 999.3549, 
C52H63N4O8S4 requires 999.3529. 
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5.82 (±)-(1S,1'S,4S,4'S)-5,5'-(Hexane-1,6-diyl)bis(2-cyclopropyl-7-thia-
2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide) (515) 
 
Boron tribromide (0.74 mL of a 1M solution in dichloromethane, 0.74 mmol) was added 
dropwise to a solution of (3S,3'S,6S,6'S)-4,4'-(hexane-1,6-diyl)bis(1-cyclopropyl-3,6-
bis((4-methoxybenzyl) thio)piperazine-2,5-dione) (0.15 g, 0.15 mmol) (512) in 
dichloromethane (2.00 mL) at -78 °C. The resulting mixture was stirred for 15 minutes 
whereupon aqueous sodium hydrogen carbonate (10.0 mL of a saturated aqueous 
solution) and methanol (2.00 mL) were added and the biphasic mixture stirred for 15 
minutes until the pale yellow colour had dissipated. The resulting mixture was stirred at 
room temperature for 10 minutes, whereupon iodine was added portionwise until the 
colour due to iodine just persisted and stirring was maintained for 2 minutes. Sodium 
thiosulfate was added and the mixture stirred for 10 minutes, diluted with 
dichloromethane (10.0 mL) and water (20.0 mL). The layers were separated and the 
aqueous phase extracted with dichloromethane (2 x 20.0 mL). The combined organic 
extracts were dried over MgSO4, filtered and solvent removed under reduced pressure. 
The residue was purified via Biotage™ Horizon (9:1, dichloromethane: methanol; snap 
10 g), followed by HPLC separation and further purified by recrystallisation (petroleum 
spirit 40-60 °C: ethyl acetate) to give (1S,1'S,4S,4'S)-5,5'-(hexane-1,6-diyl)bis(2-
cyclopropyl-7-thia-2,5-diazabicyclo [2.2.1]heptane-3,6-dione 7-sulfide) (0.02 g, 20%) 
(515) as a colourless solid; m.p. 168-170 C; max/cm
-1
 2924 (C-H), 2853 (C-H), 1684 
(C=O), 1458 (CH2);  H (500 MHz; CDCl3) 0.75 – 0.83 (2H, m, cyclopropyl-CH2), 0.86 
– 0.95 (2H, m, cyclopropyl-CH2), 0.98 – 1.11 (4H, m, cyclopropyl-CH2), 1.38 – 1.39 
(2H, m, cyclopropyl-CH), 1.64 – 1.66 (8H, m, NCH2(CH2)4CH2N), 2.89 (2H, t, J 7.0, 
NCH2), 3.50 (2H, t, J 7.1, NCH2), 5.27 (2H, s, CHS), 5.38 (2H, s, CHS);  C (126 MHz; 
CDCl3) 6.14 (CH2), 7.39 (CH2), 26.25 (CH), 27.78 (CH2), 28.58 (CH2), 45.19 (CH2), 
66.34 (CHS), 67.01 (CHS), 164.05 (CO), 164.81 (CO); m/z 515 (100%, [M+H]
+
): 
Found [M+H]
+
 515.1381, C20H27N4O4S4 requires 515.0915.  
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5.83 (±)-(1S,1'S,4S,4'S)-5,5'-((E)-But-2-ene-1,4-diyl)bis(2-benzyl-7-thia-
2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide) (516) 
 
5.83.1 Method A: 
A solution of (±)-(1S,4S)-2-allyl-5-benzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-
3,6-dione 7-sulfide (0.10 g, 1.20 mmol) (431) in dichloromethane (2.00 mL) was 
degassed and taken under nitrogen atmosphere. To this (1,3-bis(2,4,6-trimethylphenyl)-
2-imidazolidinylidene)dichloro (phenylmethylene)(tricyclohexylphosphine)ruthenium 
(Grubbs second-generation catalyst) (0.01 g, 0.01 mmol) was added and the resulting 
mixture heated at 80 °C for 30 minutes in the microwave, cooled to RT and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (4:1, 
petroleum spirit 40-60 °C: ethyl acetate; pipette column) and further purified by 
recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (1S,1'S,4S,4'S)-5,5'-
((E)-but-2-ene-1,4-diyl)bis(2-benzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-
sulfide) (0.04 g, 47%) (516) as a dark yellow solid; m.p. 198-200 °C; max/cm
-1
 3061 
(CH=CH), 3029 (C-H), 1692 (C=O), 1606 (C=C), 1445 (CH2), 724 (C-H), 699 (C-H);  
H (400 MHz, CDCl3) 4.15 – 4.17 (4H, m, NCH2), 4.54 (2H, d, J 7.4, NCH2), 4.85 (2H, 
d, J 7.2, NCH2), 5.23 (2H, s, CHS), 5.40 (2H, s, CHS), 5.87 – 5.91 (2H, m, CH=CH2), 
7.37 – 7.43 (10H, m, Ar-H); m/z 585 (100%, [M+H]+): Found [M+H]+ 585.0738, 
C26H25N4O4S4 requires 585.0734. 
5.83.2 Method B: 
A solution of (±)-(1S,4S)-2-allyl-5-benzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-
dione 7-sulfide (0.10 g, 0.119 mmol) (431) in dichloromethane (2.00 mL) was degassed 
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and taken under nitrogen atmosphere. To this (1,3-bis-(2,4,6-trimethylphenyl)-2-
imidazolidinylidene)dichloro(o-isopropoxyphenylmethylene)ruthenium (Grubbs-
Hoveyda second-generation catalyst) (0.01 g, 0.01 mmol) was added and the resulting 
mixture heated at 80 °C for 30 minutes in the microwave, cooled to RT and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (4:1, 
petroleum spirit 40-60 °C: ethyl acetate; pipette column) and further purified by 
recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (1S,1'S,4S,4'S)-5,5'-
((E)-but-2-ene-1,4-diyl)bis(2-benzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-
sulfide) (0.02 g, 22%) (516) as a dark yellow solid; identical spectroscopic data to that 
obtained previously for (516). 
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5.84 (±)-(1S,1'S,4S,4'S)-2,2'-((E)-But-2-ene-1,4-diyl)bis(1,5-dibenzyl-7-
thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide) (517) 
 
A solution of (±)-(1S,4S)-2-allyl-1,5-dibenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-
3,6-dione 7-sulfide (0.11 g, 0.28 mmol) (471) in dichloromethane (5.00 mL) was 
degassed and taken under nitrogen atmosphere. To this (1,3-bis-(2,4,6-trimethylphenyl)-
2-imidazolidinylidene)dichloro(o-isopropoxyphenylmethylene)ruthenium (Grubbs-
Hoveyda second-generation catalyst) (0.01 g, 0.02 mmol) was added and the resulting 
mixture heated at 150 °C for 2 hours in the microwave, cooled to RT and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (4:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 5 g) and further purified by 
recrystallisation (petroleum spirit 40-60 °C: ethyl acetate) to give (1S,1'S,4S,4'S)-2,2'-
((E)-but-2-ene-1,4-diyl)bis(1,5-dibenzyl-7-thia-2,5-diazabicyclo [2.2.1]heptane-3,6-
dione 7-sulfide) (0.02 g, 18%) (517) as a colourless solid; m.p. 108-110 °C; max/cm
-1
 
1670 (C=O), 1608 (C=C), 1453 (CH2), 734 (C-H), 699 (C-H);  H (400 MHz, CDCl3) 
3.47 (2H, d, J 14.1, NCH2CH=CH), 3.65 (2H, d, J 13.8, NCH2CH=CH), 3.69 – 3.73 
(2H, m, NCH2-Ph), 3.78 (4H, s, CH2-Ph), 3.89 – 3.95 (2H, m, NCH2-Ph), 4.31 (2H, s, 
CHS), 5.16 – 5.22 (2H, m, CH=CH), 6.61 – 6.64 (4H, m, Ar-H), 6.78 – 6.82 (4H, m, 
Ar-H), 7.05 – 7.10 (4H, m, Ar-H), 7.25 – 7.28 (8H, m, Ar-H);  C (101 MHz, CDCl3) 
36.41 (CH2), 45.70 (CHS), 46.26 (CH2), 50.48 (CH2), 55.53 (quaternary C), 58.27 
(CH=CH), 128.22 (Ar-C-H), 128.62 (Ar-C-H), 128.88 (Ar-C-H), 128.92 (Ar-C-H), 
131.02 (Ar-C-H), 131.29 (Ar-C-H), 135.05 (quaternary C), 159.47 (quaternary C), 
163.41 (CO), 167.21 (CO); m/z 765 (100%, [M+H]
+
); Found [M+H]
+
 765.1645, 
C40H37N4O4S4 requires 765.1629. 
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5.85  (±)-(1S,1'S,4S,4'S)-5,5'-((E)-But-2-ene-1,4-diyl)bis(1,2-dibenzyl-7-
thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide) (518) 
 
A solution of (±)-(1S,4S)-5-allyl-1,2-dibenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-
3,6-dione 7-sulfide (0.03 g, 0.08 mmol) (464) in dichloromethane (5.00 mL) was 
degassed and taken under nitrogen atmosphere. To this (1,3-bis-(2,4,6-trimethylphenyl)-
2-imidazolidinylidene)dichloro(o-isopropoxyphenylmethylene) ruthenium (Grubbs-
Hoveyda second-generation catalyst) (0.01 g, 0.01 mmol) was added and the resulting 
mixture heated at 150 °C for 2 hours in the microwave, cooled to RT and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (4:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 5 g) which did not give (6aS,12aS)-7,10-
dihydro-6a,12a-epithiodipyrido[1,2-a:1',2'-d]pyrazine-6,12(1H,4H)-dione 13-sulfide 
(518). 
  
Bruno Sil                                                                                                                 Experimental 
 
315 
 
5.86 (±)-(1S,1'S,4S,4'S)-1,1'-((E)-But-2-ene-1,4-diyl)bis(2,5-dibenzyl-7-
thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide) (519) 
 
A solution of (±)-(1S,4S)-1-allyl-2,5-dibenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-
3,6-dione 7-sulfide (0.05 g, 0.08 mmol) (455) in dichloromethane (5.00 mL) was 
degassed and taken under nitrogen atmosphere. To this (1,3-bis-(2,4,6-trimethylphenyl)-
2-imidazolidinylidene)dichloro(o-isopropoxyphenylmethylene)ruthenium (Grubbs-
Hoveyda second-generation catalyst) (0.01 g, 0.01 mmol) was added and the resulting 
mixture heated at 150 °C for 2 hours in the microwave, cooled to RT and solvent 
removed under reduced pressure. The residue was purified via Biotage™ Horizon (4:1, 
petroleum spirit 40-60 °C: ethyl acetate; snap 5 g) to give (1S,1'S,4S,4'S)-1,1'-((E)-but-
2-ene-1,4-diyl)bis(2,5-dibenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-
sulfide) (0.01 g, 25%) (519) as a colourless oil; max/cm
-1
 3032 (C-H), 1684 (C=O), 
1609 (C=C), 730 (CH2), 700 (C-H);  H (400 MHz, CDCl3) 2.63 – 2.69 (2H, m, 
CH2CH=CH), 2.75 – 2.81 (2H, m, CH2CH=CH), 3.88 (2H, s, CHS), 4.79 – 4.85 (4H, 
m, NCH2), 4.89 (2H, s, NCH2), 5.03 (2H, s, NCH2), 5.11 – 5.18 (2H, m, CH=CH2), 6.89 
– 6.93 (2H, m, Ar-H), 7.13 – 7.20 (2H, m, Ar-H), 7.30 – 7.47 (16H, m, Ar-H);  C (101 
MHz, CDCl3) 44.41 (CH2), 46.08 (CH2), 46.75 (CH2), 55.33 (CHS), 71.87 (quaternary 
C), 128.21 (Ar-C-H), 128.39 (Ar-C-H), 128.63 (Ar-C-H), 128.79 (Ar-C-H), 129.13 
(Ar-C-H), 129.59 (Ar-C-H), 135.03 (CH=CH2), 156.01 (quaternary C), 159.15 
(quaternary C), 165.06 (CO), 169.88 (CO); m/z 765 (100%, [M+H]
+
); Found [M+H]
+
 
765.1634, C40H37N4O4S4 requires 765.1629. 
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